aspirin has been researched along with Brain Ischemia in 798 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Brain Ischemia: Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Low-dose intravenous tirofiban is superior to intravenous aspirin in avoiding in-stent thrombosis in patients undergoing MT plus carotid stenting in the setting of AIS due to TL." | 9.69 | Safety and efficacy of tirofiban in acute ischemic stroke due to tandem lesions undergoing mechanical thrombectomy: A multicenter randomized clinical trial (ATILA) protocol. ( Aguilar-Pérez, M; Ainz-Gómez, L; Amaya Pascasio, L; Baena-Palomino, P; Bravo Rey, I; Cabezas-Rodríguez, JA; Castellanos Rodrigo, MDM; de Albóniga-Chindurza, A; Delgado-Acosta, F; Díaz Pérez, J; Escudero-Martínez, I; Fernandez Prudencio, L; Freijo Guerrero, MDM; Gamero-García, MÁ; González Díaz, E; González García, A; Hidalgo, C; Jiménez Jorge, S; Jiménez-Gómez, E; Medina-Rodríguez, M; Moniche, F; Montaner, J; Morales Caba, L; Mosteiro, S; Ortega-Quintanilla, J; Oteros Fernández, R; Pardo-Galiana, B; Ramirez Moreno, JM; Rosso Fernández, C; Sanz-Fernandez, G; Vielba-Gomez, I; Zamora, A; Zapata-Arriaza, E, 2023) |
| "Aspirin is recommended for secondary stroke prevention in patients with moderate-to-severe ischaemic stroke but can lead to gastrointestinal intolerance and bleeding." | 9.69 | Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial. ( Bath, PM; Dong, Q; Feng, Y; Huang, X; Jiang, Y; Jin, A; Jing, J; Johnston, SC; Li, H; Li, X; Li, Z; Lin, J; Liu, B; Liu, L; Liu, Q; Meng, X; Pan, Y; Suo, Y; Wang, Y; Xie, X; Xiong, Y; Xu, A; Yang, H; Yuan, B; Zhao, J; Zhao, X; Zhou, Y; Zhu, H, 2023) |
| "Aspirin and unfractionated heparin are often used during endovascular stroke treatment to improve reperfusion and outcomes." | 9.51 | Safety and efficacy of aspirin, unfractionated heparin, both, or neither during endovascular stroke treatment (MR CLEAN-MED): an open-label, multicentre, randomised controlled trial. ( Beenen, LFM; Berkhemer, O; Boiten, J; Bokkers, RPH; Boukrab, I; Chalos, V; Coutinho, JM; de Laat, KF; de Ridder, I; den Hertog, HM; Dippel, DWJ; Elgersma, O; Emmer, BJ; Gerrits, D; Gons, RAR; Hammer, S; Hofmeijer, J; Jenniskens, SFM; Kerkhoff, H; Koudstaal, PJ; Krietemeijer, M; Lingsma, HF; Lycklama, G; Majoie, CBLM; Manschot, S; Martens, J; Meijer, FJA; Nieboer, D; Postma, AA; Remmers, M; Roos, YBWEM; Roosendaal, SD; Roozenbeek, B; Rozeman, A; Schonewille, W; Staals, J; Tolhuisen, M; Truijman, MTB; Tuladhar, AM; Uyttenboogaart, M; van de Graaf, RA; van den Berg, R; van den Wijngaard, I; van der Hoorn, A; van der Lugt, A; van der Schaaf, I; van der Sluijs, PM; van der Steen, W; van der Worp, HB; van Dijk, LC; van Doormaal, PJ; van Es, ACGM; van Hasselt, B; van Oostenbrugge, RJ; van Tuijl, J; van Voorst, H; van Zwam, W; Vos, D; Vos, JA; Wolff, L; Yo, LSF; Yoo, AJ; Zinkstok, S, 2022) |
| "To test whether indobufen is non-inferior to aspirin in reducing the risk of new stroke at 3 months in patients with moderate to severe ischaemic stroke." | 9.51 | Indobufen versus aspirin in acute ischaemic stroke (INSURE): rationale and design of a multicentre randomised trial. ( Bath, PM; Chen, W; Dong, Q; Jiang, Y; Jing, J; Johnston, SC; Li, H; Lin, J; Meng, X; Pan, Y; Wang, Y; Xu, AD, 2022) |
| "The study aimed to evaluate the clinical efficacy of the Huo Xue Hua Yu method combined with aspirin in the treatment of patients with acute cerebral infarction (ACI)." | 9.41 | Clinical Efficacy of the Huo Xue Hua Yu Method Combined with Aspirin in the Treatment of Acute Cerebral Infarction: A Systematic Evaluation and Meta-analysis. ( Chen, C; Liu, X; Ma, F; Tang, Q; Wen, X; Wu, Y, 2023) |
| "Clopidogrel and aspirin are key intervention for acute ischemic stroke (AIS) and transient ischemic attack (TIA)." | 9.41 | Personalized antiplatelet therapy based on clopidogrel/aspirin resistance tests in acute ischemic stroke and transient ischemic attack: Study protocol of a multi-center, single-blinded and randomized controlled trial. ( Chen, J; Gao, P; Han, M; Jia, W; Kuang, J; Peng, C; Starcevich, K; Tu, J; Wang, J; Wu, Y; Yi, Y; Yin, S; Zhang, X, 2021) |
| " Patients with newly diagnosed ischemic stroke who are just about to start Aspirin were assessed for eligibility and inclusion in our trial." | 9.34 | An investigation into the impact of enteric coated of aspirin in patients with newly diagnosed ischemic stroke (ECASIS). ( Abdallah, IM; Ahmed, MS; Ali, M; AlSaud, AE; Danjuma, MI; Elshafei, MN; Imam, Y; Mohamed, MFH; Obeidat, K; Parray, AS; Saeid, R, 2020) |
| "Results show the short-term risk of hemorrhage in treating patients with acute transient ischemic attack (TIA) or minor acute ischemic stroke (AIS) with clopidogrel plus aspirin or aspirin alone." | 9.30 | Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial. ( Barsan, W; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY; Tillman, H, 2019) |
| "Although dual antiplatelet therapy with aspirin and clopidogrel reduces early recurrence of ischaemic stroke, with long-term use this type of therapy is no longer effective and the risk of bleeding increases." | 9.30 | Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial. ( Easton, JD; Hoshino, H; Houkin, K; Isobe, M; Kimura, K; Minematsu, K; Naritomi, H; Okada, Y; Origasa, H; Sakai, N; Tanaka, K; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T, 2019) |
| "Exploratory analyses of 7213 participants in the NAVIGATE ESUS international trial who were randomized to aspirin 100 mg/day or rivaroxaban 15 mg/day and followed for a median of 11 months, during which time there were 309 first recurrent ischemic strokes (4." | 9.30 | Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial. ( Ameriso, SF; Bangdiwala, SI; Berkowitz, SD; Connolly, SJ; Coutts, SB; Czlonkowska, A; Gagliardi, RJ; Hankey, GJ; Hart, RG; Kasner, SE; Lindgren, A; Mundl, H; Ntaios, G; Perera, KS; Peters, G; Sharma, M; Sheridan, P; Shoamanesh, A; Shuaib, A; Toni, D; Veltkamp, RC, 2019) |
| " The trial was halted after 84% of the anticipated number of patients had been enrolled because the data and safety monitoring board had determined that the combination of clopidogrel and aspirin was associated with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin alone at 90 days." | 9.27 | Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. ( Barsan, W; Conwit, RA; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY, 2018) |
| "Rivaroxaban was not superior to aspirin with regard to the prevention of recurrent stroke after an initial embolic stroke of undetermined source and was associated with a higher risk of bleeding." | 9.27 | Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. ( Amarenco, P; Ameriso, SF; Arauz, A; Bangdiwala, SI; Benavente, OR; Bereczki, D; Berkowitz, SD; Bornstein, N; Brouns, R; Connolly, SJ; Cunha, L; Czlonkowska, A; Davalos, A; De Vries Basson, MM; Eckstein, J; Endres, M; Gagliardi, RJ; Hankey, GJ; Hart, RG; Joyner, C; Kasner, SE; Kirsch, B; Lang, W; Lavados, P; Lindgren, A; Mikulik, R; Muir, KW; Mundl, H; Ntaios, G; O'Donnell, MJ; Ozturk, S; Pare, G; Pater, C; Peacock, WF; Peters, G; Shamalov, N; Sharma, M; Sheridan, P; Shoamanesh, A; Swaminathan, B; Tatlisumak, T; Themeles, E; Toni, D; Uchiyama, S; Veltkamp, R; Wang, Y; Weitz, JI; Yoon, BW, 2018) |
| "The PRISMS trial was designed as a 948-patient, phase 3b, double-blind, double-placebo, multicenter randomized clinical trial of alteplase compared with aspirin for emergent stroke at 75 stroke hospital networks in the United States." | 9.27 | Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial. ( Broderick, J; Chatterjee, A; Devenport, J; Devlin, T; Jauch, EC; Khatri, P; Kleindorfer, DO; Levine, SR; Mejilla, J; Pavlov, A; Purdon, B; Romano, JG; Saver, JL; Sawyer, RN; Starr, M; Vagal, A; Yeatts, SD, 2018) |
| "To investigate the short-term time course risks and benefits of clopidogrel with aspirin in minor ischemic stroke or TIA." | 9.24 | Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: Time course analysis of CHANCE. ( Chen, W; Jing, J; Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, D; Wang, Y; Zhao, X, 2017) |
| "In order to evaluate the impact of cilostazol on endothelial function, we compared the changes of flow-mediated dilation (FMD) between aspirin and cilostazol groups in patients with acute cerebral ischemia." | 9.24 | Cilostazol improves endothelial function in acute cerebral ischemia patients: a double-blind placebo controlled trial with flow-mediated dilation technique. ( Choi, MH; Hong, JM; Lee, JS; Lee, SE; Lee, SJ; Shin, DH, 2017) |
| "A total of 14 464 patients (age, 60-85 years) with hypertension, dyslipidemia, and diabetes mellitus participated and were randomized into 2 treatment groups: 100 mg of aspirin or no aspirin." | 9.22 | Aspirin for Stroke Prevention in Elderly Patients With Vascular Risk Factors: Japanese Primary Prevention Project. ( Ando, K; Ikeda, Y; Ishizuka, N; Matsumoto, M; Minematsu, K; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Yamazaki, T; Yokoyama, K, 2016) |
| "In patients with acute ischemic stroke caused by large artery atherosclerosis, clopidogrel plus aspirin versus aspirin alone might be more effective to prevent recurrent cerebral ischemia." | 9.22 | Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone. ( Bae, HJ; Cha, JK; Chang, DI; Cho, KH; Cho, YJ; Choi, JC; Hong, KS; Kang, DW; Kim, DE; Kim, EG; Kim, GM; Kim, HY; Kwon, SU; Lee, J; Lee, KB; Lee, SH; Lee, SJ; Lee, YS; Park, JM; Park, KY; Rha, JH; Sohn, CH; Sohn, SI; Yoon, BW; Yu, KH, 2016) |
| "We analysed the rates of stroke and systemic embolism in 6563 aspirin-treated patients with AF from the ACTIVE-A/AVERROES databases." | 9.20 | Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. ( Alings, M; Avezum, A; Connolly, SJ; Díaz, R; Eikelboom, JW; Hart, RG; Healey, JS; Hohnloser, SH; Lauw, MN; Lewis, BS; Shestakovska, O; Vanassche, T; Wang, J, 2015) |
| "Aspirin is a primary antiplatelet agent for the secondary prevention of ischemic stroke." | 9.20 | Aspirin resistance in the acute stages of acute ischemic stroke is associated with the development of new ischemic lesions. ( Cho, KH; Choi, KH; Choi, MJ; Heo, SH; Kim, BC; Kim, JT; Kim, MK; Lee, JS; Lee, SH; Nam, TS; Park, MS, 2015) |
| "We used data from the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial to assess the relationship of TTR with the WARCEF primary outcome (ischemic stroke, intracerebral hemorrhage, or death), with death alone, ischemic stroke alone, major hemorrhage alone, and net clinical benefit (primary outcome and major hemorrhage combined)." | 9.20 | Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial substudy. ( Anker, SD; Buchsbaum, R; Di Tullio, MR; Estol, CJ; Freudenberger, RS; Graham, S; Homma, S; Labovitz, AJ; Levin, B; Lip, GY; Lok, DJ; Mann, DL; Mohr, JP; Ponikowski, P; Pullicino, PM; Qian, M; Sacco, RL; Teerlink, JR; Thompson, JL; Ye, S, 2015) |
| "This prospective randomized controlled, open-labeled trial, with blinded end point evaluation (PROBE design) tested superiority of aspirin 75 to 150 mg/d plus clopidogrel 75 mg/d (A+C) over warfarin therapy (international normalized ratio 2-3) in patients with ischemic stroke, transient ischemic attack, or peripheral embolism with plaque in the thoracic aorta>4 mm and no other identified embolic source." | 9.19 | Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. ( Amarenco, P; Cohen, AA; Davis, S; Donnan, GA; Heiss, WD; Jones, EF; Kaste, M; Laouénan, C; Macleod, M; Young, D, 2014) |
| "Ancillary analysis of the Apixaban Versus Acetylsalicylic Acid [ASA] to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment (AVERROES) trial, comparing aspirin and apixaban, focused on sex differences." | 9.19 | Modification of outcomes with aspirin or apixaban in relation to female and male sex in patients with atrial fibrillation: a secondary analysis of the AVERROES study. ( Connolly, S; Eikelboom, J; Hart, RG; Lip, GY; Shestakovska, O; Yusuf, S, 2014) |
| "The impact of apixaban versus aspirin on ischemic stroke and major bleeding in relation to the CHADS(2) and CHA(2)DS(2)-VASc stroke risk scores in atrial fibrillation has not been investigated." | 9.17 | Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study. ( Connolly, S; Eikelboom, J; Flaker, G; Hart, R; Lanas, F; Lip, GY; Shestakovska, O; Xavier, D; Yusuf, S, 2013) |
| "Recent randomized trials have shown that cilostazol is superior to aspirin for secondary stroke prevention." | 9.16 | Cilostazol combined with aspirin prevents early neurological deterioration in patients with acute ischemic stroke: a pilot study. ( Nakamura, T; Tsuruta, S; Uchiyama, S, 2012) |
| "The Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study showed no superiority of low-molecular-weight heparin (LMWH) over aspirin for the primary end point (Barthel Index) in acute ischemic stroke due to large artery occlusive disease." | 9.16 | Low-molecular-weight heparin versus aspirin for acute ischemic stroke with large artery occlusive disease: subgroup analyses from the Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study. ( Chen, C; Chen, XY; Han, JH; Leung, TW; Mok, V; Soo, Y; Wang, QS; Wong, KS, 2012) |
| "Dizziness was significantly improved in the cilostazol group versus the aspirin group (P<0." | 9.16 | Cilostazol versus aspirin therapy in patients with chronic dizziness after ischemic stroke. ( Johkura, K; Kudo, Y; Kuroiwa, Y; Momoo, T; Nakae, Y; Yoshida, TN, 2012) |
| "It is unknown whether warfarin or aspirin therapy is superior for patients with heart failure who are in sinus rhythm." | 9.16 | Warfarin and aspirin in patients with heart failure and sinus rhythm. ( Ammon, SE; Anker, SD; Buchsbaum, R; del Valle, ML; Di Tullio, MR; Estol, CJ; Freudenberger, RS; Gabriel, AP; Graham, S; Homma, S; Labovitz, AJ; Levin, B; Lip, GY; Lok, DJ; Mann, DL; Massie, BM; Mejia, V; Mohr, JP; Ponikowski, P; Pullicino, PM; Sacco, RL; Sanford, AR; Teerlink, JR; Thompson, JL, 2012) |
| "Previous studies have suggested that pre-stroke treatment with low-dose aspirin (A) could reduce the severity of acute ischaemic stroke, but less is known on the effect of pre-stroke treatment with a combination of aspirin and dipyridamole (A + D) and post-stroke effects of these drugs." | 9.16 | Comparative evaluation of treatment with low-dose aspirin plus dipyridamole versus aspirin only in patients with acute ischaemic stroke. ( Andersson, B; Arnarsdottir, L; Bokemark, L; Hjalmarsson, C, 2012) |
| "Apixaban reduces stroke with comparable bleeding risks when compared with aspirin in patients with atrial fibrillation who are unsuitable for vitamin k antagonist therapy." | 9.16 | Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K ( Budaj, A; Connolly, SJ; Eikelboom, JW; Flaker, GC; Hart, RG; Husted, S; Kaatz, S; Lip, GY; Shestakovska, O; Yusuf, S, 2012) |
| "Cilostazol increases circulating EPCs and decreases small-dense LDL in diabetic patients with cerebral ischemia." | 9.15 | Comparison of the effect of cilostazol with aspirin on circulating endothelial progenitor cells and small-dense LDL cholesterol in diabetic patients with cerebral ischemia: a randomized controlled pilot trial. ( Emoto, M; Fukumoto, S; Inaba, M; Koyama, H; Mima, Y; Nishizawa, Y; Shoji, T; Tanaka, S; Ueno, H, 2011) |
| "To explore whether triflusal may modulate those pathways in human stroke, evolution of several inflammation markers (pro-inflammatory, adhesion molecules, chemokines, metalloproteinases, apoptosis and angiogenesis-related biomarkers) and neurological outcome were evaluated at baseline, and at days 1, 3, 7 and 90 in a pilot study in which 30 patients with acute ischemic stroke were randomly allocated to receive triflusal or aspirin." | 9.14 | Triflusal and aspirin have different effects on inflammatory biomarkers measured in patients with acute ischemic stroke. ( Alvarez-Sabín, J; García-Bonilla, L; Krupinski, J; Montaner, J; Penalba, A; Quintana, M, 2009) |
| "The antithrombotic, antiplatelet and endothelial activity of terutroban, a specific thromboxane prostaglandin receptor antagonist, was assessed in patients previously treated with aspirin for the prevention of ischemic stroke." | 9.14 | Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke. ( Bal Dit Sollier, C; Bergmann, JF; Bousser, MG; Crassard, I; Drouet, L; Simoneau, G, 2009) |
| "In this double-blind multicenter trial, 244 aspirin users with ischaemic stroke were randomly assigned to receive cilostazol 100 mg twice daily or to placebo." | 9.14 | Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial. ( Cha, JK; Ha, SW; Kwon, SU; Lee, JH; Lee, SJ, 2010) |
| "During the clinical follow-up, ischemic stroke recurred in 2 patients in cilostazol group, while in aspirin group, one case of ischemic stroke recurrence and one case of acute myocardial infarction were found." | 9.14 | Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke. ( Guo, JJ; Lin, QY; Xie, HF; Xu, E; Zeng, GL, 2009) |
| "In spite of the fact that the null hypothesis was not supported by our data, we found results supporting the safety (and potential efficacy) of ASA and tirofiban when used in the first hours of acute ischemic stroke." | 9.14 | Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double-blind randomized trial. ( Boiti, C; Borutti, G; Cazzaniga, M; Falaschi, F; Maestroni, A; Mandelli, C; Manganaro, D; Monzani, V; Rossi, P; Torgano, G; Zecca, B; Zilioli, E, 2010) |
| "The factorial PRoFESS secondary prevention trial assessed antiplatelet and blood pressure-lowering strategies in 20,332 patients, 1360 of whom were randomized within 72 hours of ischemic stroke to combined aspirin (Asp; 25 mg BID) and extended-release dipyridamole (ER-DP; 200 mg BID, n=672) or clopidogrel (75 mg/d, n=688)." | 9.14 | Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis. ( Bath, PM; Cotton, D; Diener, HC; Estol, C; Martin, RH; Palesch, Y; Roberts, R; Sacco, R; Yusuf, S, 2010) |
| "The 160 patients with acute ischemic stroke were divided into two groups randomly: treatment group 85 cases (Songling Xuemaikang + Shuxuetong + Aspirin enterie coated tablets), control group 75 cases (Shuxuetong + Aspirin enterie ccoated tablets)." | 9.14 | [Changes of plasma fibrinogen level among acute ischemic stroke subtypes according to TOAST criteria and effects of Songling Xuemaikang]. ( Chen, Y; Huang, J; Liu, G; Liu, X; Lu, N; Xu, Y; Yang, D, 2010) |
| "Although aspirin (ASA) remains the most popular and accepted agent for secondary stroke prevention, its efficacy does not exceed 25%." | 9.13 | Plasma triglycerides as predictors of platelet responsiveness to aspirin in patients after first ischemic stroke. ( Karepov, V; Kuliczkowski, W; Serebruany, V; Tolpina, G, 2008) |
| "The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel." | 9.13 | Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008) |
| "All patients with acute ischemic stroke or transient ischemic attack within a 10 month period were administered 600 mg clopidogrel bolus if they were already taking aspirin regularly, or had aspirin allergy or intolerance." | 9.13 | Safety and tolerability of 600 mg clopidogrel bolus in patients with acute ischemic stroke: preliminary experience. ( Abdelmoula, MM; Divani, AA; Hussein, HM; Qureshi, AI; Suri, MF, 2008) |
| "Most patients who have had a stroke are given aspirin; however, aspirin-related cerebral haemorrhage is a complication that is currently of concern, particularly in China where there is a high incidence of cerebral haemorrhage in secondary prevention programmes and within the community." | 9.13 | Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. ( Cheng, Y; Ding, M; Fan, D; Gao, X; Hong, Z; Huang, Y; Li, Y; Li, Z; Lu, C; Wong, K; Wu, J; Xiao, J; Xu, E; Yao, C; Zeng, J; Zhang, W, 2008) |
| "Patients experiencing acute ischemic stroke or transient ischemic attack are commonly treated with clopidogrel and/or aspirin (mono- and dual-antiplatelet therapy) to minimize the risk for recurrent stroke." | 9.12 | Efficacy and safety of clopidogrel and/or aspirin for ischemic stroke/transient ischemic attack: An overview of systematic reviews and meta-analysis. ( Huang, Z; Yang, Y; Zhang, X, 2021) |
| "A large number of patients experience ischemic stroke despite treatment with aspirin (acetylsalicylic acid, ASA)." | 9.12 | Variable platelet response to aspirin in patients with ischemic stroke. ( Boucher, M; Hohlfeld, T; Junghans, U; Schrör, K; Schumacher, M; Siebler, M; Weber, AA, 2007) |
| "In the majority of patients with acute ischemic stroke, ASA and acetaminophen are insufficient for reducing an elevated BT to a state of normothermia." | 9.11 | Acetylsalicylic acid and acetaminophen to combat elevated body temperature in acute ischemic stroke. ( De Keyser, J; Elting, JW; Luijckx, GJ; Luyckx, GJ; Maurits, N; Sulter, G, 2004) |
| "The European Stroke Prevention Study showed greater stroke prevention for Aggrenox than either for aspirin or dipyridamole alone." | 9.11 | Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial. ( Atar, D; Hennekens, CH; Jilma, B; Malinin, AI; Sane, DC; Serebruany, VL; Takserman, A, 2004) |
| " Aspirin (A), clopidogrel (C), and dipyridamole (D) were administered singly and in various combinations (A, C, D, AC, AD, CD, ACD), each for two weeks (without washout) to 11 healthy subjects and to 11 patients with previous ischaemic stroke in two randomised multiway crossover trials." | 9.11 | Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke. ( Bath, P; Fletcher, S; Fox, S; Heptinstal, S; Leonardi-Bee, J; May, J; Weaver, C; Willmot, M; Zhao, L, 2005) |
| "Clopidogrel is widely used in patients after recent ischemic stroke; however, its ability to yield additional antiplatelet protection on top of aspirin has never been explored in a controlled study." | 9.11 | Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial. ( Alberts, MJ; Bhatt, DL; Hanley, DF; Malinin, AI; Pokov, AN; Serebruany, VL; Ziai, W, 2005) |
| "This pilot study enrolled ischemic stroke patients within 48 hours and randomized to aspirin 300 mg/d or combination (aspirin 300 mg/d+ standard release dipyridamole 75 mg thrice a day) and followed up for 6 months." | 9.11 | Comparison between aspirin combined with dipyridamole versus aspirin alone within 48 hours after ischemic stroke event for prevention of recurrent stroke and improvement of neurological function: a preliminary study. ( Chairangsarit, P; Nidhinandana, S; Niyasom, S; Sithinamsuwan, P; Suwantamee, J; Udommongkol, C, 2005) |
| "In a case-crossover study, 31 patients with previous atherothrombotic or lacunar stroke who were treated with aspirin (100 to 300 mg/d) received clopidogrel (75 mg/d) and both aspirin and clopidogrel for 4 weeks." | 9.10 | Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study. ( Buggle, F; Grau, AJ; Lichy, C; Reiners, S; Ruf, A, 2003) |
| " In this study, we showed that the combination regimen of clopidogrel with aspirin could downregulate the P-selectin expression on platelets and the plasma concentration of C-reactive protein (CRP) in acute stage of atherosclerotic ischemic stroke." | 9.10 | Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel. ( Bae, HR; Cha, JK; Cheon, SM; Jeong, MH; Lee, KM; Lim, YJ; Park, KW, 2002) |
| "In this study, 591 patients with recent cerebral ischemia of arterial origin were randomly allocated to treatment with aspirin 30 to 325 mg/d or with the combination of aspirin and dipyridamole 400 mg/d in the European/Australian Stroke Prevention in Reversible Ischemia Trial." | 9.10 | Dipyridamole in stroke prevention: effect of dipyridamole on blood pressure. ( De Schryver, EL, 2003) |
| "We performed multivariate logistic regression analysis of 2012 participants given aspirin alone or in combination with low, inefficacious doses of warfarin in the Stroke Prevention in Atrial Fibrillation I-III trials followed for a mean of 2." | 9.09 | Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. ( Asinger, RW; Hart, RG; McBride, R; Pearce, LA; Rothbart, RM, 1999) |
| "Heparin in Acute Embolic Stroke Trial (HAEST) was a multicentre, randomised, double-blind, and double-dummy trial on the effect of low-molecular-weight heparin (LMWH, dalteparin 100 IU/kg subcutaneously twice a day) or aspirin (160 mg every day) for the treatment of 449 patients with acute ischaemic stroke and atrial fibrillation." | 9.09 | Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. ( Abdelnoor, M; Berge, E; Nakstad, PH; Sandset, PM, 2000) |
| " We sought to determine whether clopidogrel compared with aspirin decreases the need for rehospitalization for ischemia and bleeding." | 9.09 | Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. ( Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ, 2000) |
| "We sought to compare different antithrombotic secondary treatments (mainly medium-dose aspirin with low-dose low-molecular-weight heparin [LMWH]) in pediatric patients with a first ischemic stroke onset with regard to the risk of stroke recurrence." | 9.09 | Aspirin versus low-dose low-molecular-weight heparin: antithrombotic therapy in pediatric ischemic stroke patients: a prospective follow-up study. ( Heller, C; Kurnik, K; Luigs, P; Nowak-Göttl, U; Schobess, R; Sträter, R, 2001) |
| "Over two years, we found no difference between aspirin and warfarin in the prevention of recurrent ischemic stroke or death or in the rate of major hemorrhage." | 9.09 | A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. ( Adams, HP; Albers, GW; Furie, KL; Jackson, CM; Kistler, JP; Lazar, RM; Levin, B; Mohr, JP; Pettigrew, LC; Pullicino, P; Sacco, RL; Thompson, JL, 2001) |
| "Aspirin is only modestly effective in the secondary prevention after cerebral ischemia." | 9.08 | A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. ( , 1997) |
| "Background and Purpose- We performed a systematic review and meta-analysis to explore the efficacy and safety of cilostazol as a mono or combination (plus aspirin or clopidogrel) treatments compared to conventional single antiplatelet therapy (SAPT, mainly aspirin) for secondary stroke prevention." | 9.01 | Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis. ( Jung, JM; Kim, BJ; Kim, SM; Kwon, SU; Lee, JS, 2019) |
| "The analysis showed lower risks of major adverse cardiovascular or cerebrovascular events, recurrent stroke, and bleeding events for clopidogrel monotherapy compared to aspirin." | 9.01 | Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis. ( Del Aguila, M; Girotra, S; Hu, B; Ince, B; Jeng, JS; Kutluk, K; Liu, L; Lou, M; Min Han, J; Paciaroni, M; Paek, D; Parfenov, V; Wong, KSL; Zamani, B, 2019) |
| "Background and Purpose- The role of aspirin plus clopidogrel (A+C) therapy compared with aspirin monotherapy in patients presenting with acute ischemic stroke (IS) or transient ischemic attack remains uncertain." | 9.01 | Optimal Duration of Aspirin Plus Clopidogrel After Ischemic Stroke or Transient Ischemic Attack. ( Hammad, T; Kaluski, E; Khan, SU; Meyer, MA; Nasir, F; Rahman, H, 2019) |
| "To assess the effectiveness and safety of dual agent antiplatelet therapy combining clopidogrel and aspirin to prevent recurrent thrombotic and bleeding events compared with aspirin alone in patients with acute minor ischaemic stroke or transient ischaemic attack (TIA)." | 8.98 | Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis. ( Foroutan, F; Guyatt, G; Hao, Q; O'Donnell, M; Siemieniuk, RA; Tampi, M, 2018) |
| "Aspirin is recommended for secondary prevention after transient ischaemic attack (TIA) or ischaemic stroke on the basis of trials showing a 13% reduction in long-term risk of recurrent stroke." | 8.93 | Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. ( Algra, A; Chen, Z; Diener, HC; Mehta, Z; Norrving, B; Rothwell, PM, 2016) |
| " We found no evidence that the net benefit of aspirin increased with increasing risk of thrombosis, haemorrhage or poor functional outcome in all three trials." | 8.91 | Targeting aspirin in acute disabling ischemic stroke: an individual patient data meta-analysis of three large randomized trials. ( Candelise, L; Chen, Z; Murray, GD; Sandercock, PA; Thompson, DD; Whiteley, WN, 2015) |
| " The effects of cilostazol and aspirin on ischemic stroke prevention and treatment were almost equal (combined odds ratio (OR) 0." | 8.89 | Systematic study of cilostazol on secondary stroke prevention: a meta-analysis. ( Bi, Q; Qian, Y, 2013) |
| "This review examines the role of platelets in ischemic stroke, platelet activation mechanisms, aspirin's rise as an antithrombotic agent, clopidogrel's appearance on the stage, a possible role for combination therapy, antiplatelet resistance, practical considerations, and future directions." | 8.89 | Aspirin and clopidogrel for prevention of ischemic stroke. ( Anderson, DC; Thomson, RM, 2013) |
| "Although several new antithrombotic agents have been developed for stroke prevention in patients with nonvalvular atrial fibrillation (AF), many patients will continue to be treated with warfarin worldwide." | 8.88 | Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. ( Agarwal, S; Hachamovitch, R; Menon, V, 2012) |
| "Aspirin is widely used for secondary prevention after stroke." | 8.87 | Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. ( Husain, MR; Kamal, AK; Khealani, BA; Naqvi, I, 2011) |
| "Aspirin is used to prevent ischemic stroke and other types of cardiovascular disease." | 8.87 | Gender differences in the primary prevention of stroke with aspirin. ( Adelman, EE; Brown, DL; Lisabeth, L, 2011) |
| "The results obtained in the CAPRIE study in 1996 led to the introduction of the clopidogrel as a new antiplatelet drug in the secondary prevention of acute myocardial infarct (AMI), ischemic stroke (IS) and symptomatic peripheral artery disease (PAD)." | 8.84 | Clopidogrel in secondary ischemic stroke prevention. ( Belvís, R; Kulisevsky, J; Pagonabarraga, J; Santamaría, A, 2008) |
| "Individual patient data of patients who received aspirin or placebo after cerebral ischemia were obtained from 9 clinical trials." | 8.82 | Risk of intracerebral hemorrhage in patients with arterial versus cardiac origin of cerebral ischemia on aspirin or placebo: analysis of individual patient data from 9 trials. ( Algra, A; Ariesen, MJ; Koudstaal, PJ; Rothwell, PM; van Walraven, C, 2004) |
| "The study pooled individual data from 2580 participants with nonvalvular AF who were prescribed aspirin in a multicenter trial (Atrial Fibrillation, Aspirin, Anticoagulation I study [AFASAK-1], AFASAK-2, European Atrial Fibrillation Trial, Primary Prevention of Arterial Thromboembolism in patients with nonrheumatic Atrial Fibrillation in primary care study, and Stroke Prevention and Atrial Fibrillation [SPAF]-III high risk or SPAF-III low risk)." | 8.82 | Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. ( Boode, BS; Gage, BF; Hart, RG; Koudstaal, PJ; Pearce, L; Petersen, P; van Walraven, C, 2004) |
| "Results from randomized controlled trials of dipyridamole, given with or without aspirin, for secondary prevention after ischemic stroke or transient ischemic attack (TIA) have given conflicting results." | 8.82 | Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. ( Bath, PM; Bousser, MG; Davalos, A; Dewey, ME; Diener, HC; Guiraud-Chaumeil, B; Leonardi-Bee, J; Sivenius, J; Yatsu, F, 2005) |
| "In the secondary prevention of cardiovascular, cerebrovascular, and ischemic events, the evidence supports that the benefits of aspirin treatment significantly outweigh the risk of a major hemorrhage." | 8.82 | Risk of hemorrhagic stroke with aspirin use: an update. ( Gorelick, PB; Weisman, SM, 2005) |
| "This paper will examine how cerebral perfusion deficits in cocaine abusers may be a target for pharmacotherapy." | 8.80 | Pharmacotherapy of cerebral ischemia in cocaine dependence. ( Kosten, TR, 1998) |
| "A retrospective analysis was performed on 75 patients with cancer and mild to moderate ischemic stroke, 34 of whom received tirofiban treatment and 41 aspirin treatment." | 8.31 | Tirofiban in the treatment of cancer-associated ischemic stroke. ( Lin, ZH; Zhang, ZM; Zhu, GL, 2023) |
| "This prospective, observational study assessed TIA/ischaemic stroke patients before (baseline; N = 60), at 14 ±7 days (14d, N = 39) and ≥ 90 days (90d, N = 31) after adding dipyridamole to aspirin." | 8.12 | Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke. ( Collins, DR; Coughlan, T; Cox, D; Egan, B; Lim, ST; Lim, SY; McCabe, DJH; McCarthy, AJ; Murphy, SJX; Murphy, SM; O'Neill, D; Smith, DR; Tierney, S, 2022) |
| "Patients with diabetes and no obstructive coronary artery disease (CAD) as assessed by coronary angiography (CAG) are frequently treated with aspirin and statins." | 8.12 | Statin but not aspirin treatment is associated with reduced cardiovascular risk in patients with diabetes without obstructive coronary artery disease: a cohort study from the Western Denmark Heart Registry. ( Bøtker, HE; Heide-Jørgensen, U; Maeng, M; Olesen, KKW; Sørensen, HT; Thim, T; Thomsen, RW, 2022) |
| "We investigated (1) the associations of pre-stroke aspirin use with thrombus burden, infarct volume, hemorrhagic transformation, early neurological deterioration (END), and functional outcome, and (2) whether stroke subtypes modify these associations in first-ever ischemic stroke." | 8.02 | Relation of Pre-Stroke Aspirin Use With Cerebral Infarct Volume and Functional Outcomes. ( Bae, HJ; Cha, JK; Cho, YJ; Choi, KH; Han, MK; Hong, KS; Jeong, SW; Kang, K; Kim, BJ; Kim, DE; Kim, DH; Kim, JG; Kim, JT; Lee, BC; Lee, J; Lee, KB; Lee, SJ; Nahrendorf, M; Oh, MS; Park, HK; Park, JM; Park, MS; Park, SS; Park, TH; Ryu, WS; Schellingerhout, D; Yu, KH, 2021) |
| "We recruited 293 ischemic stroke patients, taking aspirin for more than seven days, and performed LTA to classify them." | 8.02 | Serum thromboxane B2 but not soluble P-selectin levels identify ischemic stroke patients with persistent platelet reactivity while on aspirin therapy. ( Chandra, SR; Christopher, R; Ramanujam, N; Sundaravadivel, P, 2021) |
| "Ticagrelor plus aspirin could reduce the risks of major adverse cardiac events in diabetic patients with stable coronary artery disease (SCD), and yet it also increases bleeding risk." | 8.02 | Cost-utility of ticagrelor plus aspirin in diabetic patients with stable coronary artery disease. ( Shi, L; Wu, B, 2021) |
| "Patients with ischemic stroke receiving aspirin (100 mg/day) for three months were recruited for a multicenter, prospective, cohort study." | 8.02 | Safety and efficacy of low-dose aspirin in ischemic stroke patients with different G6PD conditions. ( Chen, Y; Deng, W; Huang, W; Jiang, H; Li, J; Liang, Z; Liu, Q; Ou, Z; Ouyang, F; Wu, Z; Xing, S; Zeng, J; Zhang, Y, 2021) |
| "This study provides supporting evidence that aspirin use is associated with reduced ischaemic events after pneumonia in a primary care setting." | 8.02 | Aspirin reduces cardiovascular events in patients with pneumonia: a prior event rate ratio analysis in a large primary care database. ( Arnold, D; Hamilton, F; Henley, W; Payne, RA, 2021) |
| " Here we assessed the contribution of clopidogrel versus aspirin to the development of pneumonia during an acute ischemic stroke admission." | 8.02 | Clopidogrel increases risk of pneumonia compared with aspirin in acute ischemic minor stroke patients. ( Feng, Q; Fu, J; Jin, X; Shan, B; Shen, R; Yu, Z; Zhou, H; Zhu, H, 2021) |
| " The aim of this study was to assess the safety and efficacy of the p48 MW HPC (phenox, Bochum, Germany) to treat distal intracranial aneurysms under the use of aspirin monotherapy." | 8.02 | Aspirin monotherapy in the treatment of distal intracranial aneurysms with a surface modified flow diverter: a pilot study. ( Abud, DG; Abud, TG; de Castro-Afonso, LH; de Freitas, RK; Monsignore, LM; Nakiri, GS, 2021) |
| " Despite the modified dose, bleeding events were higher among patients receiving low-dose prasugrel than among patients receiving clopidogrel, with no difference in ischemic events between the 2 groups." | 7.96 | Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment. ( Fukuda, K; Heidenreich, PA; Ikemura, N; Kohsaka, S; Numasawa, Y; Sandhu, AT; Sawano, M; Shiraishi, Y; Shoji, S; Suzuki, M; Ueno, K, 2020) |
| "In real-world practice settings, there is insufficient evidence on the efficacy of antiplatelet drugs, including clopidogrel, aspirin, and ticlopidine, in stroke prevention." | 7.96 | Efficacy of aspirin, clopidogrel, and ticlopidine in stroke prevention: A population-based case-cohort study in Taiwan. ( Hsu, YH; Ong, CT; Tsai, CF; Wong, YS, 2020) |
| "Several clinical trials reported that clopidogrel was superior to aspirin in secondary stroke prevention by reducing the risk of major adverse cardiovascular events (MACE)." | 7.91 | Aspirin better than clopidogrel on major adverse cardiovascular events reduction after ischemic stroke: A retrospective nationwide cohort study. ( Chan, L; Chen, YC; Hsu, CY; Hu, CJ; Lin, CL; Muo, CH; Vidyanti, AN; Wu, D, 2019) |
| "This study aimed to investigate the effectiveness of monotherapy acetylsalicylic acid (ASA) and warfarin for stroke prevention in low-risk atrial fibrillation (AF) by using a population- -based cohort study in Taiwan." | 7.91 | Monotherapy of acetylsalicylic acid or warfarin for prevention of ischemic stroke in low-risk atrial fibrillation: A Easter Asian population-based study. ( Chen, HC; Liu, CY, 2019) |
| "To evaluate the effect of prestroke aspirin (PA) use on initial stroke severity, early neurologic deterioration (END), stroke recurrence, hemorrhagic transformation (HT), and functional outcome in patients with ischemic stroke (IS)." | 7.91 | Prestroke Aspirin Use is Associated with Clinical Outcomes in Ischemic Stroke Patients with Atherothrombosis, Small Artery Disease, and Cardioembolic Stroke. ( Han, Z; Lin, J; Luo, H; Yi, X; Zhou, J; Zhou, Q, 2019) |
| "To investigate the association of aspirin resistance (AR) with mortality in a cohort of Chinese patients with acute ischemic stroke (AIS)." | 7.91 | Association of Aspirin Resistance with Increased Mortality in Ischemic Stroke. ( Jing, Y; Li, S; Yang, S; Yue, X, 2019) |
| "High plasma level of HbA1c is involved in enhanced platelet aggregability in acute atherothrombotic stroke patients, and prestroke administration of aspirin may be beneficial to clinical outcomes." | 7.91 | Collagen-Induced Platelet Aggregates, Diabetes, and Aspirin Therapy Predict Clinical Outcomes in Acute Ischemic Stroke. ( Hagii, J; Harima, K; Honda, S; Kitajima, M; Metoki, H; Mikami, K; Osanai, T; Tomisawa, T; Urushizaka, M; Yasujima, M, 2019) |
| "To investigate the associations between CYP2C19 genotypes and early neurological deterioration (END), and to carry out a stratified analysis of the effectiveness of clopidogrel alone and dual antiplatelet therapy with clopidogrel and aspirin for prevention of END according to CYP2C19 genotypes in ischemic stroke (IS) patients." | 7.88 | Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles. ( Chai, Z; Han, Z; Huang, R; Lin, J; Wang, C; Yi, X; Zhou, Q, 2018) |
| "To investigate the prognostic value of aspirin reaction units (ARU) in a 3-month follow-up study in a cohort of Chinese patients with first-ever ischemic stroke." | 7.88 | Aspirin resistance predicts unfavorable functional outcome in acute ischemic stroke patients. ( Fan, YN; He, Y; Hua, QJ; Ji, SB; Liu, YX; Su, LL; Wang, CW; Xi, TT; Yuan, B, 2018) |
| "WHAT IS THE ROLE OF DUAL ANTIPLATELET THERAPY AFTER HIGH RISK TRANSIENT ISCHAEMIC ATTACK OR MINOR STROKE? SPECIFICALLY, DOES DUAL ANTIPLATELET THERAPY WITH A COMBINATION OF ASPIRIN AND CLOPIDOGREL LEAD TO A GREATER REDUCTION IN RECURRENT STROKE AND DEATH OVER THE USE OF ASPIRIN ALONE WHEN GIVEN IN THE FIRST 24 HOURS AFTER A HIGH RISK TRANSIENT ISCHAEMIC ATTACK OR MINOR ISCHAEMIC STROKE? AN EXPERT PANEL PRODUCED A STRONG RECOMMENDATION FOR INITIATING DUAL ANTIPLATELET THERAPY WITHIN 24 HOURS OF THE ONSET OF SYMPTOMS, AND FOR CONTINUING IT FOR 10-21 DAYS CURRENT PRACTICE IS TYPICALLY TO USE A SINGLE DRUG." | 7.88 | Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline. ( Agoritsas, T; Booth, B; Fisch, L; Fobuzi, AC; Fraiz, A; Gorthi, SP; Guyatt, G; Hao, Q; Heen, AF; Horton, E; Jusufovic, M; Katragunta, N; Lytvyn, L; Muller, J; O'Donnell, M; Prasad, K; Rochwerg, B; Siemieniuk, J; Siemieniuk, R; Vandvik, PO, 2018) |
| "Prostaglandin-Endoperoxide Synthase 1 (PTGS1) and smoking may play important roles in aspirin nonresponsiveness, but the effect of their interaction on stroke outcomes remains largely unknown." | 7.85 | Association between PTGS1 polymorphisms and functional outcomes in Chinese patients with stroke during aspirin therapy: Interaction with smoking. ( Cai, B; Cai, H; Cao, L; Davis, SM; Guo, H; Liu, X; Sun, L; Sun, W; Yan, B; Zhang, H; Zhang, Z; Zhou, S, 2017) |
| "Our findings indicate a favorable effect of clopidogrel at discharge compared with aspirin in preventing death, recurrent stroke, and CVD events in diabetic patients with a first-ever noncardioembolic AIS." | 7.85 | Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project. ( Elisaf, M; Manios, E; Milionis, H; Ntaios, G; Papavasileiou, V; Spengos, K; Vemmos, K, 2017) |
| "This study is the largest to investigate platelet aggregation in stable coronary artery disease patients receiving aspirin as single antithrombotic therapy." | 7.85 | Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease. ( Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S; Würtz, M, 2017) |
| "To investigate the prevalent of aspirin resistance (AR) in stroke and its association with recurrent stroke in 214 patients with ischemic stroke who were receiving aspirin before the stroke onset." | 7.85 | Aspirin resistance are associated with long-term recurrent stroke events after ischaemic stroke. ( Wang, Z; Zhang, N; Zhou, L, 2017) |
| "BACKGROUND To investigate the combination of beraprost sodium (BPS) and aspirin in the treatment of acute ischemic stroke (AIS)." | 7.85 | Beneficial Effect of Beraprost Sodium Plus Aspirin in the Treatment of Acute Ischemic Stroke. ( Chen, S; Chen, W; He, W; Li, S; Wei, D; Xie, S, 2017) |
| "Aspirin and statin are recommended for the treatment of acute ischemic stroke." | 7.85 | Statin and Aspirin Pretreatment Are Associated with Lower Neurological Deterioration and Platelet Activity in Patients with Acute Ischemic Stroke. ( Han, Z; Lin, J; Wang, C; Yi, X; Zhou, Q, 2017) |
| "Active smokers with myocardial infarction were shown to have enhanced benefit with clopidogrel compared with aspirin." | 7.85 | Clopidogrel and ischemic stroke outcomes by smoking status: Smoker's paradox? ( Cao, Q; Dong, K; Feng, W; Hou, C; Huang, X; Ji, X; Ovbiagele, B; Song, H; Wang, M; Wang, Y; Zhang, Q, 2017) |
| "Admission National Institutes of Health Stroke Scale (NIHSS) score, ischemic lesion volumes on diffusion-weighted imaging (DWI), and in vitro aspirin resistance, in addition to other pertinent stroke features, were determined in a series of ischemic stroke patients." | 7.83 | The Interplay between Stroke Severity, Antiplatelet Use, and Aspirin Resistance in Ischemic Stroke. ( Agayeva, N; Arsava, EM; Topcuoglu, MA, 2016) |
| "We measured serum levels of proinflammatory/prothrombotic markers P-selectin, CD40L, matrix metalloproteinase 9 (MMP-9), intracellular adhesion molecule 1 (ICAM-1), and interleukin (IL)-6 in ischemic stroke patients, correlating their levels with the results of aspirin (ASA) and clopidogrel antiplatelet responses, using 3 "point of care" platelet function instruments, thromboelastograph (TEG), Accumetrics (ACU), and impedance aggregometer (IMP)." | 7.83 | Relationship between Inflammation and Aspirin and Clopidogrel Antiplatelet Responses in Acute Ischemic Stroke. ( Ambrus, JL; Chichelli, T; Ching, M; Janicke, D; Munschauer, F; Sawyer, R; Sternberg, D; Sternberg, Z; Yu, J, 2016) |
| "Selecting among different antiplatelet strategies when patients experience a new ischemic stroke while taking aspirin is a common clinical challenge, currently addressed by a paucity of data." | 7.83 | Different Antiplatelet Strategies in Patients With New Ischemic Stroke While Taking Aspirin. ( Bae, HJ; Cha, JK; Cho, KH; Cho, YJ; Choi, JC; Choi, KH; Han, MK; Hong, KS; Kang, K; Kim, BJ; Kim, DE; Kim, DH; Kim, JG; Kim, JT; Kim, WJ; Ko, YC; Lee, BC; Lee, J; Lee, JS; Lee, KB; Lee, SJ; Nah, HW; Oh, MS; Park, JM; Park, MS; Park, SS; Park, TH; Ryu, WS; Saver, JL; Shin, DI; Yeo, MJ; Yu, KH, 2016) |
| "The effect of prestroke aspirin use on initial severity, hemorrhagic transformation, and functional outcome of ischemic stroke is uncertain." | 7.83 | Comparative Effectiveness of Prestroke Aspirin on Stroke Severity and Outcome. ( Bae, HJ; Cha, JK; Cho, YJ; Choi, JC; Gorelick, PB; Han, MK; Hong, KS; Kang, K; Kim, DE; Kim, DH; Kim, JT; Ko, Y; Lee, BC; Lee, J; Lee, JS; Lee, KB; Lee, SJ; Park, JM; Park, TH; Yu, KH, 2016) |
| " Among these 397 patients, 69 were receiving monotherapy with clopidogrel prior to stroke, 69 were receiving monotherapy with aspirin and 236 patients were not on any antiplatelet treatment." | 7.83 | Treatment with Clopidogrel Prior to Acute Non-Cardioembolic Ischemic Stroke Attenuates Stroke Severity. ( Angelopoulou, SM; Bouziana, SD; Giampatzis, V; Hatzitolios, AI; Kostaki, S; Papadopoulou, M; Savopoulos, C; Spanou, M; Tsopozidi, M; Tziomalos, K, 2016) |
| "To investigate whether aspirin resistance is associated with initial stroke severity and infarct volume, using diffusion-weighted imaging (DWI) in patients with acute ischemic stroke that occurred while taking aspirin." | 7.83 | Aspirin resistance is associated with increased stroke severity and infarct volume. ( Jang, MU; Jung, S; Kim, C; Lee, BC; Lee, J; Lee, JH; Oh, MS; Yu, KH, 2016) |
| "A higher loading dose of aspirin (160-325 mg) can be beneficial in treating acute ischemic stroke, although there is an increased risk of minor bleeding." | 7.83 | To Load or Not to Load? Aspirin Loading in Acute Ischemic Stroke: A Study of Clinical Outcomes. ( Chan, YL; Lee, JD; Lee, M; Lee, TH; Lin, LC; Su, TH; Wen, YW, 2016) |
| "miR-145 is involved in the anti-proliferation and anti-inflammation effects of aspirin on VSMCs by inhibiting the expression of CD40." | 7.83 | miR-145 mediated the role of aspirin in resisting VSMCs proliferation and anti-inflammation through CD40. ( Chen, M; Guo, R; Guo, X; Peng, X; Wu, T; Yu, L; Zhang, B, 2016) |
| "Aspirin is known to reduce stroke risk; however, its role in reducing severity of ischemic syndrome is not clear." | 7.83 | Antecedent Aspirin Use Is Associated with Less Severe Symptoms on Admission for Ischemic Stroke. ( Cloonan, L; Fitzpatrick, KM; Furie, KL; Kanakis, AS; Nelson, S; Perilla, AS; Rost, NS; Shideler, KI, 2016) |
| "Aspirin resistance has an incidence of 5%-65% in patients with ischemic stroke, who receive the standard dose of aspirin, but the platelet function is inadequately inhibited, thereby leading to thrombotic events." | 7.83 | Associations of MDR1, TBXA2R, PLA2G7, and PEAR1 genetic polymorphisms with the platelet activity in Chinese ischemic stroke patients receiving aspirin therapy. ( Cai, YF; Chen, LY; Chen, XM; Huang, M; Jin, J; Li, JL; Peng, LL; Zhao, M; Zhao, YQ; Zhou, ZY, 2016) |
| "A significant proportion of ischemic strokes occur while using aspirin and therefore can be considered as clinical aspirin resistance." | 7.81 | Pathophysiologic, rather than laboratory-defined resistance drives aspirin failure in ischemic stroke. ( Agayeva, N; Arsava, EM; Gungor, L; Topcuoglu, MA, 2015) |
| " Therefore, we sought to evaluate the time-dependent changes in platelet reactivity to aspirin during the acute stage after ischemic stroke and the clinical implications of variable patient responses to aspirin in acute ischemic stroke." | 7.81 | Clinical Implications of Changes in Individual Platelet Reactivity to Aspirin Over Time in Acute Ischemic Stroke. ( Cho, KH; Choi, KH; Choi, SM; Heo, SH; Kim, BC; Kim, JT; Kim, MK; Lee, SH; Nam, TS; Park, MS; Saver, JL, 2015) |
| "Some patients with a recent ischemic stroke who are being treated with aspirin as an antiaggregant suffer a new ischemic stroke." | 7.80 | Aspirin resistant patients with recent ischemic stroke. ( Castilla-Guerra, L; Fernández-Moreno, MC; Navas-Alcántara, MS, 2014) |
| "This study was designed to test the pre-treatment doses of guggulipid (50 mg/kg), aspirin (100 mg/kg) per orally and co-administration of both drugs for 28 days followed by middle cerebral artery occlusion - a model of focal cerebral ischemia in rats." | 7.80 | Neuroprotective effect of guggulipid alone and in combination with aspirin on middle cerebral artery occlusion (MCAO) model of focal cerebral ischemia in rats. ( Ahmad, MA; Akhtar, M; Mujeeb, M; Najmi, AK, 2014) |
| "Our objective was to investigate the association between recurrent stroke risk and headache induced by extended-release dipyridamole (ER-DP) when administered alone or with low-dose aspirin (ASA+ER-DP)." | 7.80 | Dipyridamole-induced headache and lower recurrence risk in secondary prevention of ischaemic stroke: a post hoc analysis. ( Bath, PM; Cotton, D; Davidai, G; Diener, HC; Gorelick, P; Lipton, RB; Sacco, R, 2014) |
| "To analyze the potential impact of aspirin therapy for long-term secondary prevention after stroke of undetermined etiology in resource-limited settings without access to neuroimaging to distinguish ischemic stroke from intracerebral hemorrhage (ICH)." | 7.80 | Aspirin for secondary prevention after stroke of unknown etiology in resource-limited settings. ( Berkowitz, AL; Bianchi, MT; Chou, SH; Westover, MB, 2014) |
| "Aspirin resistance is common in the population of patients with hemodynamic cerebral ischemia scheduled for cerebral revascularization." | 7.79 | Aspirin resistance in patients with hemodynamic cerebral ischemia undergoing extracranial-intracranial bypass surgery. ( Horn, P; Jussen, D; Vajkoczy, P, 2013) |
| "A prospective study included 35 patients admitted with ischemic stroke and commenced on 300 mg aspirin." | 7.79 | "Aspirin resistance" in ischemic stroke: insights using short thrombelastography. ( Curzen, N; Englyst, N; Radhakrishnan, A; Sambu, N; Weir, N, 2013) |
| "The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial found no difference between warfarin and aspirin in patients with low ejection fraction in sinus rhythm for the primary outcome: first to occur of 84 incident ischemic strokes (IIS), 7 intracerebral hemorrhages or 531 deaths." | 7.79 | Stroke in heart failure in sinus rhythm: the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial. ( Anker, SD; Di Tullio, MR; Diek, M; Freudenberger, RS; Graham, S; Haddad, H; Homma, S; Labovitz, AJ; Lok, DJ; Mann, DL; Mohr, JP; Ponikowski, P; Pullicino, PM; Qian, M; Sacco, RL; Sanford, AR; Teerlink, JR; Thompson, JL, 2013) |
| "Among patients with stroke, the phenomenon of resistance to treatment with low-dose aspirin acetylsalicylic acid (ASA) is quite common." | 7.79 | Factors influencing multiplate whole blood impedance platelet aggregometry measurements, during aspirin treatment in acute ischemic stroke: a pilot study. ( Chełstowski, K; Clark, J; Jastrzębska, M; Nowacki, P; Siennicka, A; Wódecka, A, 2013) |
| "The prognostic value of occurrence of ischemic stroke in a patient despite aspirin treatment (aspirin treatment failure) is not known." | 7.79 | Aspirin treatment failure and the risk of recurrent stroke and death among patients with ischemic stroke. ( Adams, HP; Cordina, SM; Georgiadis, AL; Lakshminarayan, K; Qureshi, AI; Suri, MF; Tariq, N; Vazquez, G, 2013) |
| "This study evaluated the antiplatelet effects of clopidogrel (CPG) in patients sustaining acute ischemic stroke who were already receiving chronic outpatient aspirin therapy (81-325 mg/day)." | 7.79 | Clopidogrel responsiveness in stroke patients on a chronic aspirin regimen. ( Chichelli, T; Ching, M; Farooq, O; Janicke, D; Li, F; Mehta, B; Munschauer, FE; Radovic, V; Sawyer, RN; Sternberg, Z, 2013) |
| "Of the 82 patients with recurrent cerebral ischemia included in this study, 37 (45%) patients were poor compliant with aspirin." | 7.79 | Clinical and biochemical aspirin resistance in patients with recurrent cerebral ischemia. ( Abu-Hegazy, M; Azzam, H; El-Mitwalli, A; Gomaa, M; Wasel, Y, 2013) |
| "Randomized trials suggested superior stroke prevention with extended-release dipyridamole (ERD) in combination with low-dose aspirin than either with aspirin or dipyridamole alone." | 7.78 | Effects of extended-release dipyridamole in vitro on thrombin indices measured by calibrated automated thrombography in poststroke survivors. ( Fong, A; Hanley, D; Pokov, I; Sani, Y; Schevchuck, A; Serebruany, V; Thevathasan, L, 2012) |
| "The widespread use of aspirin-driven vascular prevention strategies does not impede the occurrence of first and recurrent ischemic strokes in numerous subjects." | 7.78 | Ischemic stroke in patients receiving aspirin. ( Ameriso, S; Ameriso, SF; Povedano, GP; Pujol Lereis, VA, 2012) |
| "Aspirin is the most commonly used antiplatelet drug for treatment of a serious vascular event, most notably myocardial infarction and stroke." | 7.78 | Association of C3435T multi drug resistance gene-1 polymorphism with aspirin resistance in ischemic stroke and its subtypes. ( Al-Hazzani, A; Dadheech, S; Jyothy, A; Kaul, S; Munshi, A; Prabha, TS; Rao, PP; Sharma, V, 2012) |
| " In this study, the authors assess the incidence of stroke or transient ischemic attack (TIA) following discontinuation of a 6-week course of clopidogrel in patients with cerebral aneurysms treated with stent-assisted techniques." | 7.78 | Incidence of cerebral ischemic events after discontinuation of clopidogrel in patients with intracranial aneurysms treated with stent-assisted techniques. ( Abel, TJ; Chalouhi, N; Hasan, DM; Jabbour, PM; Kung, DK; Rossen, JD; Thomas, J; Wassef, SN, 2012) |
| "A rapid and sustained reduction in the frequency of aspirin+clopidogrel use in ischemic stroke and transient ischemic attack was observed after publication of the MATCH trial in the absence of MATCH-specific GWTG-Stroke initiatives and preceding an American Heart Association guideline update." | 7.76 | Rapid change in prescribing behavior in hospitals participating in get with the guidelines-stroke after release of the management of atherothrombosis with clopidogrel in high-risk patients (MATCH) clinical trial results. ( Ellrodt, G; Fonarow, GC; Frankel, MR; Hernandez, AF; Labresh, KA; Liang, L; Menon, BK; Schwamm, LH; Smith, EE, 2010) |
| "In patients with AF, all combinations of warfarin, aspirin, and clopidogrel are associated with increased risk of nonfatal and fatal bleeding." | 7.76 | Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. ( Abildstrøm, SZ; Andersen, SS; Clausen, MT; Fog-Petersen, ML; Folke, F; Gadsbøll, N; Gislason, GH; Hansen, ML; Køber, L; Poulsen, HE; Raunsø, J; Schramm, TK; Sørensen, R; Torp-Pedersen, C, 2010) |
| "A considerable proportion of patients discontinue dipyridamole therapy because of headache." | 7.75 | Risk indicators for development of headache during dipyridamole treatment after cerebral ischaemia of arterial origin. ( Algra, A; Halkes, PH; Kappelle, LJ; Koudstaal, PJ; van Gijn, J, 2009) |
| "There are very limited data on the influence of pretreatment with aspirin (ASA) on the etiology of subsequent first-ever ischemic stroke." | 7.75 | Pretreatment with aspirin and etiology of first-ever ischemic stroke in young and middle-aged patients. ( Kouperberg, E; Sprecher, E; Telman, G; Yarnitsky, D, 2009) |
| " We tested the hypothesis that combined pre-treatment with aspirin and clopidogrel is a risk factor for thrombolysis-related symptomatic intracerebral hemorrhage (sICH)." | 7.75 | Combined anti-platelet therapy with aspirin and clopidogrel: risk factor for thrombolysis-related intracerebral hemorrhage in acute ischemic stroke? ( Dzialowski, I; Gahn, G; Hermann, A; Koch, R, 2009) |
| "Aspirin is an important therapeutic regimen to prevent the recurrent ischemic events or death after acute ischemic stroke." | 7.74 | ADP-induced platelet aggregation in acute ischemic stroke patients on aspirin therapy. ( Cha, JK; Jeon, HW; Kang, MJ, 2008) |
| "The results suggest that triflusal and aspirin appear to be equally neuroprotective against middle cerebral artery occlusion-induced cerebral ischemia." | 7.74 | Effects of triflusal and aspirin in a rat model of cerebral ischemia. ( Allen, GV; Bayona, NA; Cechetto, DF; Cheng, G; Hachinski, VC; Whitehead, SN, 2007) |
| "To report a case of cerebral ischemia in a patient receiving oral isotretinoin for severe acne." | 7.74 | Cerebral ischemia probably related to isotretinoin. ( Laroche, ML; Macian-Montoro, F; Merle, L; Vallat, JM, 2007) |
| "The present study was carried out to investigate the effect of the combination of an endothelin antagonist TAK-044 and an antiinflammatory agent aspirin in middle cerebral artery (MCA) occlusion model of acute ischemic stroke in rats." | 7.74 | Effect of combination of endothelin receptor antagonist (TAK-044) and aspirin in middle cerebral artery occlusion model of acute ischemic stroke in rats. ( Briyal, S; Gulati, A; Gupta, YK, 2007) |
| "A total of 88 patients taking aspirin daily for the secondary prevention of stroke were included." | 7.74 | Can aspirin resistance be clinically predicted in stroke patients? ( Bang, OY; Choi, YJ; Huh, K; Joo, IS; Lee, PH; Seok, JI; Yoon, JH, 2008) |
| "We aimed to study the timing of aspirin prescription in ischaemic stroke comparing patients admitted to an acute stroke unit (ASU) directly or via a general medical ward." | 7.73 | Timing of aspirin and secondary preventative therapies in acute stroke: support for use of stroke units. ( MacLeod, MJ; Reid, J; Williams, D, 2005) |
| "To study the discontinuation of aspirin therapy as a risk factor for ischemic stroke (IS)." | 7.73 | Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. ( Bezerra, DC; Bogousslavsky, J; Maulaz, AB; Michel, P, 2005) |
| "We studied outpatients of 5 neurological ambulatory centers in an urban city, Valencia, all with a history of ischemic stroke who had received aspirin for at least 6 months." | 7.73 | Adherence to aspirin in secondary prevention of ischemic stroke. ( Ferrer, JM; Lago, A; Pareja, A; Ponz, A; Santos, MT; Tembl, JI; Vallés, J, 2006) |
| "The purpose of this study was to determine safety and tolerability of clopidogrel in children with arterial ischemic stroke (AIS)." | 7.73 | The risks and safety of clopidogrel in pediatric arterial ischemic stroke. ( Allen, A; deVeber, G; Hune, S; MacGregor, D; Rafay, MF; Soman, T, 2006) |
| "Millions of people around the world regularly consume aspirin, but its value in determining stroke severity is still not clear." | 7.73 | Does prior aspirin use reduce stroke mortality? ( Demirkaya, M; Karlikaya, G; Orken, C; Tireli, H; Varlbas, F, 2006) |
| "The authors describe course and outcome of eight patients with ischemic stroke as the first thrombotic manifestation of antiphospholipid syndrome who received low-dose aspirin as prophylactic treatment." | 7.72 | Low dose aspirin after ischemic stroke associated with antiphospholipid syndrome. ( de Groot, PG; Derksen, RH; Kappelle, LJ, 2003) |
| "To investigate the protective effects and mechanism of action of aspirin on focal cerebral ischemia-reperfusion rats." | 7.72 | [Protective effects and mechanism of action of aspirin on focal cerebral ischemia-reperfusion in rats]. ( Chen, CH; Qiu, LY; Yu, J; Zhou, Y, 2003) |
| "The potential neuroprotective effects of the novel nitro-derivate of aspirin (NCX4016) on permanent focal cerebral ischemia in spontaneously hypertensive rats (SHRs) was investigated." | 7.71 | Nitro-aspirin (NCX4016) reduces brain damage induced by focal cerebral ischemia in the rat. ( Ambrosini, MV; Del Soldato, P; Fredduzzi, S; Mariucci, G; Tantucci, M, 2001) |
| "Large intervention studies suggest that aspirin may reduce mortality when given to patients who present with strokes or transient ischemic attacks." | 7.70 | Does prior use of aspirin affect outcome in ischemic stroke? ( Kalra, L; Perez, I; Smithard, DG; Sulch, D, 2000) |
| "This follow-up study was designed to evaluate whether the use of aspirin either before or after aneurysm rupture affects the occurrence of delayed cerebral ischemia." | 7.69 | Aspirin and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. ( Juvela, S, 1995) |
| "The primary outcome is IS recurrence." | 6.80 | Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial. ( Hoshino, H; Kimura, K; Minematsu, K; Naritomi, H; Origasa, H; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2015) |
| "Despite improvements in treatment, stroke still carries a high death toll and disability in Asia." | 6.76 | The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial. ( Horie, Y; Ikeda, Y; Uchiyama, S; Urano, Y; Yamaguchi, T, 2011) |
| " These results suggest that administration of aspirin and cilostazol is safe for acute ischemic stroke." | 6.76 | Pilot study of the safety of starting administration of low-dose aspirin and cilostazol in acute ischemic stroke. ( Fujita, K; Higuchi, O; Kamezaki, T; Komatsu, Y; Kujiraoka, Y; Matsumura, A; Sato, N; Suzuki, K, 2011) |
| " It is impossible to exclude that long term administration of warfarin in strategy of sinus rhythm maintenance attenuated advantages of normal rhythm in relation of lowering of stroke risk in AFFIRM study and other similar works." | 6.73 | [Prevention of ischemic stroke in middle aged patients with atrial fibrillation. Effect of sinus rhythm maintenance, aspirin, warfarin, and simvastatin]. ( Kanorskiĭ, SG; Shevelev, VI; Zafiraki, VK; Zingilevskiĭ, KB, 2007) |
| "Patients with minor ischemic stroke or transient ischemic attack represent a high-risk population for recurrent stroke." | 6.72 | Ticagrelor vs Clopidogrel in addition to Aspirin in minor ischemic stroke/ transient ischemic attack-Protocol for a systematic review and network meta-analysis. ( Dhaliwal, S; Dowlatshahi, D; Hutton, B; Lun, R; Roy, DC; Shorr, R; Zitikyte, G, 2021) |
| "Recurrent stroke is common immediately following a transient ischemic attack (TIA) or ischemic stroke." | 6.61 | Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials. ( Abdalla, A; Ahmed, S; Al Qasmi, M; Bachuwa, G; Bhatt, DL; Chahine, A; Hassan, M; Haykal, T; Kheiri, B; Osman, M; Swaid, B, 2019) |
| "Stroke is one of the leading causes of death." | 6.55 | Genetic Signatures in Ischemic Stroke: Focus on Aspirin Resistance. ( Chaurasia, P; Munshi, A; Singh, S; Vasudeva, K, 2017) |
| "Aspirin treatment of erythromelalgia in thrombocythemia patients resulted in the disappearance of the erythromelalgic, thrombotic signs and symptoms, correction of the shortened platelet survival times, and a significant reduction of the increased levels of beta-TG, PF4, TM and urinary TxB2 excretion to normal." | 6.42 | Platelet-mediated microvascular inflammation and thrombosis in thrombocythemia vera: a distinct aspirin-responsive arterial thrombophilia, which transforms into a bleeding diathesis at increasing platelet counts. ( Michiels, JJ, 2003) |
| "To assess the balance of benefits and risks of aspirin in particular categories of patient with acute stroke (eg, the elderly, those without a CT scan, or those with atrial fibrillation), a prospectively planned meta-analysis is presented of the data from 40 000 individual patients from both trials on events that occurred in the hospital during the scheduled treatment period (4 weeks in CAST, 2 weeks in IST), with 10 characteristics used to define 28 subgroups." | 6.19 | Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. ( Chen, ZM; Collins, R; Counsell, C; Liu, LS; Pan, HC; Peto, R; Sandercock, P; Warlow, C; Xie, JX, 2000) |
| "A review is given on the clinical studies performed with aspirin in patients with chronic vascular occlusions of the limbs and on studies in cerebral ischemia using aspirin and sulfinpyrazone." | 6.14 | Use of platelet inhibitor drugs in peripheral and cerebral vascular disorders. ( Breddin, K, 1977) |
| "Low-dose intravenous tirofiban is superior to intravenous aspirin in avoiding in-stent thrombosis in patients undergoing MT plus carotid stenting in the setting of AIS due to TL." | 5.69 | Safety and efficacy of tirofiban in acute ischemic stroke due to tandem lesions undergoing mechanical thrombectomy: A multicenter randomized clinical trial (ATILA) protocol. ( Aguilar-Pérez, M; Ainz-Gómez, L; Amaya Pascasio, L; Baena-Palomino, P; Bravo Rey, I; Cabezas-Rodríguez, JA; Castellanos Rodrigo, MDM; de Albóniga-Chindurza, A; Delgado-Acosta, F; Díaz Pérez, J; Escudero-Martínez, I; Fernandez Prudencio, L; Freijo Guerrero, MDM; Gamero-García, MÁ; González Díaz, E; González García, A; Hidalgo, C; Jiménez Jorge, S; Jiménez-Gómez, E; Medina-Rodríguez, M; Moniche, F; Montaner, J; Morales Caba, L; Mosteiro, S; Ortega-Quintanilla, J; Oteros Fernández, R; Pardo-Galiana, B; Ramirez Moreno, JM; Rosso Fernández, C; Sanz-Fernandez, G; Vielba-Gomez, I; Zamora, A; Zapata-Arriaza, E, 2023) |
| "Aspirin is recommended for secondary stroke prevention in patients with moderate-to-severe ischaemic stroke but can lead to gastrointestinal intolerance and bleeding." | 5.69 | Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial. ( Bath, PM; Dong, Q; Feng, Y; Huang, X; Jiang, Y; Jin, A; Jing, J; Johnston, SC; Li, H; Li, X; Li, Z; Lin, J; Liu, B; Liu, L; Liu, Q; Meng, X; Pan, Y; Suo, Y; Wang, Y; Xie, X; Xiong, Y; Xu, A; Yang, H; Yuan, B; Zhao, J; Zhao, X; Zhou, Y; Zhu, H, 2023) |
| "The effects of the glycoprotein IIb/IIIa receptor inhibitor tirofiban in patients with acute ischemic stroke but who have no evidence of complete occlusion of large or medium-sized vessels have not been extensively studied." | 5.69 | Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion. ( Cai, T; Cao, M; Chen, X; Chen, Z; Cheng, D; Geng, W; Guo, C; He, P; He, W; Hu, J; Huang, F; Huang, J; Huang, W; Huang, X; Kong, W; Li, B; Li, F; Li, H; Li, L; Li, Z; Liang, H; Liu, C; Liu, J; Liu, S; Liu, W; Liu, Z; Luo, J; Miao, J; Mu, J; Nogueira, RG; Peng, Y; Qiu, Z; Saver, JL; Shi, Q; Shi, Z; Song, J; Tan, X; Tang, M; Tang, Y; Tian, Y; Wan, Y; Wang, D; Wang, M; Wang, P; Wu, Y; Xie, S; Xie, W; Yang, D; Yang, J; Yang, Q; Yang, S; Yao, L; Yu, Y; Yu, Z; Yue, C; Zhang, B; Zhao, H; Zheng, J; Zi, W, 2023) |
| "Aspirin and unfractionated heparin are often used during endovascular stroke treatment to improve reperfusion and outcomes." | 5.51 | Safety and efficacy of aspirin, unfractionated heparin, both, or neither during endovascular stroke treatment (MR CLEAN-MED): an open-label, multicentre, randomised controlled trial. ( Beenen, LFM; Berkhemer, O; Boiten, J; Bokkers, RPH; Boukrab, I; Chalos, V; Coutinho, JM; de Laat, KF; de Ridder, I; den Hertog, HM; Dippel, DWJ; Elgersma, O; Emmer, BJ; Gerrits, D; Gons, RAR; Hammer, S; Hofmeijer, J; Jenniskens, SFM; Kerkhoff, H; Koudstaal, PJ; Krietemeijer, M; Lingsma, HF; Lycklama, G; Majoie, CBLM; Manschot, S; Martens, J; Meijer, FJA; Nieboer, D; Postma, AA; Remmers, M; Roos, YBWEM; Roosendaal, SD; Roozenbeek, B; Rozeman, A; Schonewille, W; Staals, J; Tolhuisen, M; Truijman, MTB; Tuladhar, AM; Uyttenboogaart, M; van de Graaf, RA; van den Berg, R; van den Wijngaard, I; van der Hoorn, A; van der Lugt, A; van der Schaaf, I; van der Sluijs, PM; van der Steen, W; van der Worp, HB; van Dijk, LC; van Doormaal, PJ; van Es, ACGM; van Hasselt, B; van Oostenbrugge, RJ; van Tuijl, J; van Voorst, H; van Zwam, W; Vos, D; Vos, JA; Wolff, L; Yo, LSF; Yoo, AJ; Zinkstok, S, 2022) |
| "To test whether indobufen is non-inferior to aspirin in reducing the risk of new stroke at 3 months in patients with moderate to severe ischaemic stroke." | 5.51 | Indobufen versus aspirin in acute ischaemic stroke (INSURE): rationale and design of a multicentre randomised trial. ( Bath, PM; Chen, W; Dong, Q; Jiang, Y; Jing, J; Johnston, SC; Li, H; Lin, J; Meng, X; Pan, Y; Wang, Y; Xu, AD, 2022) |
| "HPR-aspirin was persistent 75days later in 36% patients." | 5.43 | High platelet reactivity on aspirin in patients with acute ST elevation myocardial infarction. ( Dillinger, JG; Drouet, L; Henry, P; Saeed, A; Sideris, G; Silberman, SM; Sollier, CB; Spagnoli, V; Voicu, S, 2016) |
| "The study aimed to evaluate the clinical efficacy of the Huo Xue Hua Yu method combined with aspirin in the treatment of patients with acute cerebral infarction (ACI)." | 5.41 | Clinical Efficacy of the Huo Xue Hua Yu Method Combined with Aspirin in the Treatment of Acute Cerebral Infarction: A Systematic Evaluation and Meta-analysis. ( Chen, C; Liu, X; Ma, F; Tang, Q; Wen, X; Wu, Y, 2023) |
| " We sought to determine whether the presence of carotid stenosis was associated with increased risk of ischemic stroke and whether the addition of clopidogrel to aspirin was associated with more benefit in patients with versus without carotid stenosis." | 5.41 | Carotid Stenosis and Recurrent Ischemic Stroke: A Post-Hoc Analysis of the POINT Trial. ( de Havenon, A; Easton, JD; Furie, KL; Henninger, N; Johnston, SC; Kim, AS; Kvernland, A; Mac Grory, B; Rostanski, S; Yaghi, S, 2021) |
| "In patients with a minor ischaemic stroke or transient ischaemic attack (TIA), separate trials have shown that dual antiplatelet therapy with clopidogrel plus aspirin (clopidogrel-aspirin) or ticagrelor plus aspirin (ticagrelor-aspirin) are more effective than aspirin alone in stroke secondary prevention." | 5.41 | Clopidogrel with aspirin in High-risk patients with Acute Non-disabling Cerebrovascular Events II (CHANCE-2): rationale and design of a multicentre randomised trial. ( Bath, PM; Dong, Q; Jing, J; Johnston, C; Li, H; Li, Z; Meng, X; Pan, Y; Wang, A; Wang, Y; Xie, X; Xu, A; Zhao, X, 2021) |
| "Clopidogrel and aspirin are key intervention for acute ischemic stroke (AIS) and transient ischemic attack (TIA)." | 5.41 | Personalized antiplatelet therapy based on clopidogrel/aspirin resistance tests in acute ischemic stroke and transient ischemic attack: Study protocol of a multi-center, single-blinded and randomized controlled trial. ( Chen, J; Gao, P; Han, M; Jia, W; Kuang, J; Peng, C; Starcevich, K; Tu, J; Wang, J; Wu, Y; Yi, Y; Yin, S; Zhang, X, 2021) |
| "Focal cerebral ischemia was induced by MCA occlusion for 2 hours followed by reperfusion for 22 hours." | 5.37 | Protective effect of irbesartan, an angiotensin II receptor antagonist, alone and in combination with aspirin on middle cerebral artery occlusion model of focal cerebral ischemia in rats. ( Ahmad, SJ; Akhtar, M; Islam, F; Khanam, R; Pillai, KK; Pratap, R, 2011) |
| " Patients with newly diagnosed ischemic stroke who are just about to start Aspirin were assessed for eligibility and inclusion in our trial." | 5.34 | An investigation into the impact of enteric coated of aspirin in patients with newly diagnosed ischemic stroke (ECASIS). ( Abdallah, IM; Ahmed, MS; Ali, M; AlSaud, AE; Danjuma, MI; Elshafei, MN; Imam, Y; Mohamed, MFH; Obeidat, K; Parray, AS; Saeid, R, 2020) |
| " In this study, we compared three major platelet function tests to assess their performance and found better methods for platelet function evaluation after aspirin or clopidogrel treatment in ischemic stroke patients by comparative study." | 5.34 | A comparison of three platelet function tests in ischemic stroke patients with antiplatelet therapy. ( Cheng, Y; Ge, W; Han, Z; Huang, L; Jin, J; Luo, C; Shao, T; Wang, Z; Xu, Y; Yang, D, 2020) |
| "(2) Aspirin has been tested in several placebo-controlled trials and has a positive risk-benefit balance, preventing about 5 deaths per 1000 patients with ischaemic stroke." | 5.33 | Ischaemic stroke: acute-phase drug therapy. Mostly aspirin and heparin. ( , 2005) |
| "Triflusal has demonstrated an efficacy similar to aspirin in the prevention of vascular events in patients with acute myocardial infarction (ΜΙ) and ischaemic stroke but with less bleeding events." | 5.30 | Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial. ( Adamopoulos, D; Asimakopoulos, C; Bourdakis, A; Chantzichristos, VG; Darmanis, P; Dimitriadou, A; Gkiokas, S; Goudevenos, JA; Ipeirotis, K; Kalantzi, KI; Kitikidou, K; Klonaris, I; Kostaki, A; Logothetis, D; Mainas, K; Mais, T; Maragiannis, A; Martiadou, K; Mavronasos, K; Michelongonas, I; Mitropoulos, D; Ntalas, IV; Panagiotakos, DB; Papadimitriou, G; Papadopoulos, A; Papaioakeim, M; Sofillas, K; Stabola, S; Stefanakis, E; Stergiou, D; Thoma, M; Tselepis, AD; Tsoumani, ME; Zenetos, A; Zisekas, S, 2019) |
| " The aim was to assess whether the effect of clopidogrel plus aspirin versus aspirin alone on recurrent stroke would be affected by admission activated partial thromboplastin time (aPTT)." | 5.30 | Effect of dual versus mono antiplatelet therapy on recurrent stroke modulated by activated partial thromboplastin time. ( Laskowitz, DT; Li, H; Liu, L; Meng, X; Miao, Z; Wang, X; Wang, Y; Xie, X; Zhao, X, 2019) |
| "Results show the short-term risk of hemorrhage in treating patients with acute transient ischemic attack (TIA) or minor acute ischemic stroke (AIS) with clopidogrel plus aspirin or aspirin alone." | 5.30 | Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial. ( Barsan, W; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY; Tillman, H, 2019) |
| "Although dual antiplatelet therapy with aspirin and clopidogrel reduces early recurrence of ischaemic stroke, with long-term use this type of therapy is no longer effective and the risk of bleeding increases." | 5.30 | Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial. ( Easton, JD; Hoshino, H; Houkin, K; Isobe, M; Kimura, K; Minematsu, K; Naritomi, H; Okada, Y; Origasa, H; Sakai, N; Tanaka, K; Toyoda, K; Uchiyama, S; Yamaguchi, K; Yamaguchi, T, 2019) |
| "Exploratory analyses of 7213 participants in the NAVIGATE ESUS international trial who were randomized to aspirin 100 mg/day or rivaroxaban 15 mg/day and followed for a median of 11 months, during which time there were 309 first recurrent ischemic strokes (4." | 5.30 | Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial. ( Ameriso, SF; Bangdiwala, SI; Berkowitz, SD; Connolly, SJ; Coutts, SB; Czlonkowska, A; Gagliardi, RJ; Hankey, GJ; Hart, RG; Kasner, SE; Lindgren, A; Mundl, H; Ntaios, G; Perera, KS; Peters, G; Sharma, M; Sheridan, P; Shoamanesh, A; Shuaib, A; Toni, D; Veltkamp, RC, 2019) |
| " The trial was halted after 84% of the anticipated number of patients had been enrolled because the data and safety monitoring board had determined that the combination of clopidogrel and aspirin was associated with both a lower risk of major ischemic events and a higher risk of major hemorrhage than aspirin alone at 90 days." | 5.27 | Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA. ( Barsan, W; Conwit, RA; Easton, JD; Elm, JJ; Farrant, M; Johnston, SC; Kim, AS; Lindblad, AS; Palesch, YY, 2018) |
| "Rivaroxaban was not superior to aspirin with regard to the prevention of recurrent stroke after an initial embolic stroke of undetermined source and was associated with a higher risk of bleeding." | 5.27 | Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source. ( Amarenco, P; Ameriso, SF; Arauz, A; Bangdiwala, SI; Benavente, OR; Bereczki, D; Berkowitz, SD; Bornstein, N; Brouns, R; Connolly, SJ; Cunha, L; Czlonkowska, A; Davalos, A; De Vries Basson, MM; Eckstein, J; Endres, M; Gagliardi, RJ; Hankey, GJ; Hart, RG; Joyner, C; Kasner, SE; Kirsch, B; Lang, W; Lavados, P; Lindgren, A; Mikulik, R; Muir, KW; Mundl, H; Ntaios, G; O'Donnell, MJ; Ozturk, S; Pare, G; Pater, C; Peacock, WF; Peters, G; Shamalov, N; Sharma, M; Sheridan, P; Shoamanesh, A; Swaminathan, B; Tatlisumak, T; Themeles, E; Toni, D; Uchiyama, S; Veltkamp, R; Wang, Y; Weitz, JI; Yoon, BW, 2018) |
| "In patients with ischaemic stroke at high risk of cerebral haemorrhage, cilostazol was non-inferior to aspirin for the prevention of cardiovascular events, but did not reduce the risk of haemorrhagic stroke." | 5.27 | Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial. ( Ahn, SH; Heo, SH; Hong, KS; Hwang, YH; Jung, JM; Kang, DW; Kim, BJ; Kim, YJ; Kwon, JH; Kwon, SU; Lee, EJ; Lee, J; Lee, JH; Lee, JS; Navarro, JC; Park, JH; Park, JM; Rha, JH; Seo, WK; Sohn, SI; Wong, LKS; Yu, S, 2018) |
| "The PRISMS trial was designed as a 948-patient, phase 3b, double-blind, double-placebo, multicenter randomized clinical trial of alteplase compared with aspirin for emergent stroke at 75 stroke hospital networks in the United States." | 5.27 | Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial. ( Broderick, J; Chatterjee, A; Devenport, J; Devlin, T; Jauch, EC; Khatri, P; Kleindorfer, DO; Levine, SR; Mejilla, J; Pavlov, A; Purdon, B; Romano, JG; Saver, JL; Sawyer, RN; Starr, M; Vagal, A; Yeatts, SD, 2018) |
| "Clinical studies results show that policosanol (20 mg/day) + aspirin therapy had benefits versus placebo + aspirin to patients with recent non-cardioembolic ischemic stroke." | 5.27 | Effects of policosanol in the functional recovery of non-cardioembolic ischemic stroke hypertensive patients. ( Fernandez-Dorta, L; Fernandez-Travieso, JC; Illnait-Ferrer, J; Mas-Ferreiro, R; Mendoza-Castano, S; Mesa-Angarica, M; Reyes-Suarez, P; Sanchez-Lopez, J, 2018) |
| "To investigate the short-term time course risks and benefits of clopidogrel with aspirin in minor ischemic stroke or TIA." | 5.24 | Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: Time course analysis of CHANCE. ( Chen, W; Jing, J; Johnston, SC; Li, H; Liu, L; Meng, X; Pan, Y; Wang, D; Wang, Y; Zhao, X, 2017) |
| "In order to evaluate the impact of cilostazol on endothelial function, we compared the changes of flow-mediated dilation (FMD) between aspirin and cilostazol groups in patients with acute cerebral ischemia." | 5.24 | Cilostazol improves endothelial function in acute cerebral ischemia patients: a double-blind placebo controlled trial with flow-mediated dilation technique. ( Choi, MH; Hong, JM; Lee, JS; Lee, SE; Lee, SJ; Shin, DH, 2017) |
| "Antiplatelet therapy with aspirin 160 mg to 300 mg daily, given orally (or by nasogastric tube or per rectum in people who cannot swallow) and started within 48 hours of onset of presumed ischaemic stroke, significantly decreased death and dependency, and reduced the risk of early recurrent ischaemic stroke without a major risk of early haemorrhagic complications; long-term outcomes were improved." | 5.22 | Oral antiplatelet therapy for acute ischaemic stroke. ( Barnes, SC; Beishon, LC; Chithiramohan, T; Clough, RH; Kadicheeni, M; Minhas, JS; Robinson, T; Wang, X, 2022) |
| "It was found that the effectiveness of dual antiplatelet therapy in patients with minor ischaemic stroke or high risk transient ischaemic attack does not significantly differ in patients with prior aspirin exposure; therefore there should be no influence on the decision to use dual antiplatelet therapy." | 5.22 | Does prior use of antiplatelet therapy modify the effect of dual antiplatelet therapy in transient ischaemic attack/minor ischaemic stroke: A systematic review and meta-analysis. ( Clarke, A; Murphy, R; O'Donnell, MJ; Reddin, C, 2022) |
| "A total of 14 464 patients (age, 60-85 years) with hypertension, dyslipidemia, and diabetes mellitus participated and were randomized into 2 treatment groups: 100 mg of aspirin or no aspirin." | 5.22 | Aspirin for Stroke Prevention in Elderly Patients With Vascular Risk Factors: Japanese Primary Prevention Project. ( Ando, K; Ikeda, Y; Ishizuka, N; Matsumoto, M; Minematsu, K; Murata, M; Oikawa, S; Shimada, K; Sugawara, M; Teramoto, T; Uchiyama, S; Yamazaki, T; Yokoyama, K, 2016) |
| "In patients with acute ischemic stroke caused by large artery atherosclerosis, clopidogrel plus aspirin versus aspirin alone might be more effective to prevent recurrent cerebral ischemia." | 5.22 | Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone. ( Bae, HJ; Cha, JK; Chang, DI; Cho, KH; Cho, YJ; Choi, JC; Hong, KS; Kang, DW; Kim, DE; Kim, EG; Kim, GM; Kim, HY; Kwon, SU; Lee, J; Lee, KB; Lee, SH; Lee, SJ; Lee, YS; Park, JM; Park, KY; Rha, JH; Sohn, CH; Sohn, SI; Yoon, BW; Yu, KH, 2016) |
| " In a previous study, we found that the number of MESs is associated with stroke recurrence and that clopidogrel plus aspirin more effectively reduce the number of MESs than does aspirin alone." | 5.22 | The curative effect comparison of two kinds of therapeutic regimens on decreasing the relative intensity of microembolic signal in CLAIR trial. ( Chen, C; Deng, QQ; Fu, JH; Huang, YN; Markus, H; Ratanakorn, D; Tang, J; Wong, KS; Zhao, H, 2016) |
| "We analysed the rates of stroke and systemic embolism in 6563 aspirin-treated patients with AF from the ACTIVE-A/AVERROES databases." | 5.20 | Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES. ( Alings, M; Avezum, A; Connolly, SJ; Díaz, R; Eikelboom, JW; Hart, RG; Healey, JS; Hohnloser, SH; Lauw, MN; Lewis, BS; Shestakovska, O; Vanassche, T; Wang, J, 2015) |
| "Antiplatelet agents such as aspirin, clopidogrel and dipyridamole are effective in reducing the risk of recurrence after a stroke." | 5.20 | Statistical analysis plan for the 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial. ( Bath, PM; Dineen, R; Pocock, S; Robson, K; Sprigg, N; Woodhouse, LJ, 2015) |
| "Aspirin is a primary antiplatelet agent for the secondary prevention of ischemic stroke." | 5.20 | Aspirin resistance in the acute stages of acute ischemic stroke is associated with the development of new ischemic lesions. ( Cho, KH; Choi, KH; Choi, MJ; Heo, SH; Kim, BC; Kim, JT; Kim, MK; Lee, JS; Lee, SH; Nam, TS; Park, MS, 2015) |
| "We used data from the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial to assess the relationship of TTR with the WARCEF primary outcome (ischemic stroke, intracerebral hemorrhage, or death), with death alone, ischemic stroke alone, major hemorrhage alone, and net clinical benefit (primary outcome and major hemorrhage combined)." | 5.20 | Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial substudy. ( Anker, SD; Buchsbaum, R; Di Tullio, MR; Estol, CJ; Freudenberger, RS; Graham, S; Homma, S; Labovitz, AJ; Levin, B; Lip, GY; Lok, DJ; Mann, DL; Mohr, JP; Ponikowski, P; Pullicino, PM; Qian, M; Sacco, RL; Teerlink, JR; Thompson, JL; Ye, S, 2015) |
| "PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage was designed to compare cilostazol and aspirin and to assess the effect of adding probucol, a lipid-lowering and anti-oxidative agent, in patients at high risk of haemorrhagic stroke." | 5.20 | Rationale and design of the PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage (PICASSO) study: A randomized controlled trial. ( Hong, KS; Kim, BJ; Kwon, SU; Lee, JY, 2015) |
| "In this study, patients taking 100 mg aspirin daily (orally) were examined after admittance to the stroke unit due to a stroke or stroke recurrence." | 5.19 | [Acetylsalicylic acid non-responders after ischemic insult in geriatric patients]. ( Kolb, GF; Nosul, M, 2014) |
| "We performed a secondary analysis from the Cilostazol in Acute Ischemic Stroke Treatment (CAIST) trial, which was a double-blinded, randomized, multicenter trial, assessing the noninferiority of cilostazol over aspirin within 48 hours of an acute ischemic stroke." | 5.19 | Homocysteine as a predictor of early neurological deterioration in acute ischemic stroke. ( Bae, HJ; Kang, DW; Kwon, HM; Lee, YS, 2014) |
| "We evaluated the efficacy of low-molecular-weight heparin (LMWH) relative to aspirin in preventing early neurologic deterioration (END), venous thromboembolism (VTE), and outcomes at 6 months." | 5.19 | Low-molecular-weight heparin is more effective than aspirin in preventing early neurologic deterioration and improving six-month outcome. ( Chi, W; Lin, J; Wang, C; Yi, X; Zhang, B, 2014) |
| "This prospective randomized controlled, open-labeled trial, with blinded end point evaluation (PROBE design) tested superiority of aspirin 75 to 150 mg/d plus clopidogrel 75 mg/d (A+C) over warfarin therapy (international normalized ratio 2-3) in patients with ischemic stroke, transient ischemic attack, or peripheral embolism with plaque in the thoracic aorta>4 mm and no other identified embolic source." | 5.19 | Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. ( Amarenco, P; Cohen, AA; Davis, S; Donnan, GA; Heiss, WD; Jones, EF; Kaste, M; Laouénan, C; Macleod, M; Young, D, 2014) |
| "Ancillary analysis of the Apixaban Versus Acetylsalicylic Acid [ASA] to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment (AVERROES) trial, comparing aspirin and apixaban, focused on sex differences." | 5.19 | Modification of outcomes with aspirin or apixaban in relation to female and male sex in patients with atrial fibrillation: a secondary analysis of the AVERROES study. ( Connolly, S; Eikelboom, J; Hart, RG; Lip, GY; Shestakovska, O; Yusuf, S, 2014) |
| " Its aim was to investigate the potential effects of terutroban in patients with atherothrombotic disorders, in comparison to aspirin, on the evolution of magnetic resonance imaging (MRI) lesions after a recent ischemic stroke or transient ischemic attack (TIA)." | 5.17 | Results of the PERFORM magnetic resonance imaging study. ( Bracoud, L; Chabriat, H; Gass, A; Hennerici, M; Maeder, P; Michel, P, 2013) |
| "Aspirin is the most commonly used antiplatelet drug for treatment of a serious vascular event, most notably stroke and myocardial infarction." | 5.17 | Association of COX-2 rs20417 with aspirin resistance. ( Al-Hazzani, A; Alshatwi, AA; Jyothy, A; Kaul, S; Munshi, A; Sharma, V, 2013) |
| "We selected all patients with a CHADS(2) score of 1 from the AVERROES and ACTIVE trials who were treated with acetylsalicylic acid with or without clopidogrel and calculated the incidences of ischaemic or unspecified stroke or systemic embolus (SSE) according to their CHA(2)DS(2)-VASc score." | 5.17 | The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. ( Connolly, SJ; Coppens, M; Dorian, P; Eikelboom, JW; Hart, RG; Lip, GY; Shestakovska, O; Yusuf, S, 2013) |
| "The impact of apixaban versus aspirin on ischemic stroke and major bleeding in relation to the CHADS(2) and CHA(2)DS(2)-VASc stroke risk scores in atrial fibrillation has not been investigated." | 5.17 | Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study. ( Connolly, S; Eikelboom, J; Flaker, G; Hart, R; Lanas, F; Lip, GY; Shestakovska, O; Xavier, D; Yusuf, S, 2013) |
| "Recent randomized trials have shown that cilostazol is superior to aspirin for secondary stroke prevention." | 5.16 | Cilostazol combined with aspirin prevents early neurological deterioration in patients with acute ischemic stroke: a pilot study. ( Nakamura, T; Tsuruta, S; Uchiyama, S, 2012) |
| "The Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study showed no superiority of low-molecular-weight heparin (LMWH) over aspirin for the primary end point (Barthel Index) in acute ischemic stroke due to large artery occlusive disease." | 5.16 | Low-molecular-weight heparin versus aspirin for acute ischemic stroke with large artery occlusive disease: subgroup analyses from the Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study. ( Chen, C; Chen, XY; Han, JH; Leung, TW; Mok, V; Soo, Y; Wang, QS; Wong, KS, 2012) |
| "Dizziness was significantly improved in the cilostazol group versus the aspirin group (P<0." | 5.16 | Cilostazol versus aspirin therapy in patients with chronic dizziness after ischemic stroke. ( Johkura, K; Kudo, Y; Kuroiwa, Y; Momoo, T; Nakae, Y; Yoshida, TN, 2012) |
| "We identified 9 independent risk factors for SICH: baseline National Institutes of Health Stroke Scale, serum glucose, systolic blood pressure, age, body weight, stroke onset to treatment time, aspirin or combined aspirin and clopidogrel, and history of hypertension." | 5.16 | Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score. ( Ahmed, N; Egido, JA; Ford, GA; Lees, KR; Mazya, M; Mikulik, R; Toni, D; Wahlgren, N, 2012) |
| "We analyzed MRI of 133 patients admitted consecutively for intra- and extracranial stenting for symptomatic large artery atherosclerosis who received aspirin and clopidogrel." | 5.16 | Risk of intracerebral hemorrhage in patients with cerebral microbleeds undergoing endovascular intervention. ( Abrigo, J; Ahuja, AT; Leung, TW; Ng, N; Siu, DY; Soo, YO; Wong, LK; Yu, S, 2012) |
| "It is unknown whether warfarin or aspirin therapy is superior for patients with heart failure who are in sinus rhythm." | 5.16 | Warfarin and aspirin in patients with heart failure and sinus rhythm. ( Ammon, SE; Anker, SD; Buchsbaum, R; del Valle, ML; Di Tullio, MR; Estol, CJ; Freudenberger, RS; Gabriel, AP; Graham, S; Homma, S; Labovitz, AJ; Levin, B; Lip, GY; Lok, DJ; Mann, DL; Massie, BM; Mejia, V; Mohr, JP; Ponikowski, P; Pullicino, PM; Sacco, RL; Sanford, AR; Teerlink, JR; Thompson, JL, 2012) |
| "Previous studies have suggested that pre-stroke treatment with low-dose aspirin (A) could reduce the severity of acute ischaemic stroke, but less is known on the effect of pre-stroke treatment with a combination of aspirin and dipyridamole (A + D) and post-stroke effects of these drugs." | 5.16 | Comparative evaluation of treatment with low-dose aspirin plus dipyridamole versus aspirin only in patients with acute ischaemic stroke. ( Andersson, B; Arnarsdottir, L; Bokemark, L; Hjalmarsson, C, 2012) |
| "Apixaban reduces stroke with comparable bleeding risks when compared with aspirin in patients with atrial fibrillation who are unsuitable for vitamin k antagonist therapy." | 5.16 | Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K ( Budaj, A; Connolly, SJ; Eikelboom, JW; Flaker, GC; Hart, RG; Husted, S; Kaatz, S; Lip, GY; Shestakovska, O; Yusuf, S, 2012) |
| "Cilostazol increases circulating EPCs and decreases small-dense LDL in diabetic patients with cerebral ischemia." | 5.15 | Comparison of the effect of cilostazol with aspirin on circulating endothelial progenitor cells and small-dense LDL cholesterol in diabetic patients with cerebral ischemia: a randomized controlled pilot trial. ( Emoto, M; Fukumoto, S; Inaba, M; Koyama, H; Mima, Y; Nishizawa, Y; Shoji, T; Tanaka, S; Ueno, H, 2011) |
| "TAIST was a randomized controlled trial assessing 10 days of treatment with tinzaparin versus aspirin in 1489 patients with acute ischemic stroke (<48 hr) with admission BP of | 5.14 | The relationship between baseline blood pressure and computed tomography findings in acute stroke: data from the tinzaparin in acute ischaemic stroke trial (TAIST). ( Bath, PM; Christensen, H; De Deyn, PP; England, T; Geeganage, C; Gray, LJ; Leys, D; Moulin, T; O'Neill, D; Ringelstein, EB; Sare, GM; Woimant, F, 2009) |
| "We evaluated the location, type (lacunar vs nonlacunar), cause, and severity of stroke in patients who had an ischemic stroke endpoint in the Warfarin Aspirin Symptomatic Intracranial Disease (WASID) trial." | 5.14 | Causes and severity of ischemic stroke in patients with symptomatic intracranial arterial stenosis. ( Chimowitz, MI; Famakin, BM; George, MG; Lynn, MJ; Stern, BJ, 2009) |
| "To explore whether triflusal may modulate those pathways in human stroke, evolution of several inflammation markers (pro-inflammatory, adhesion molecules, chemokines, metalloproteinases, apoptosis and angiogenesis-related biomarkers) and neurological outcome were evaluated at baseline, and at days 1, 3, 7 and 90 in a pilot study in which 30 patients with acute ischemic stroke were randomly allocated to receive triflusal or aspirin." | 5.14 | Triflusal and aspirin have different effects on inflammatory biomarkers measured in patients with acute ischemic stroke. ( Alvarez-Sabín, J; García-Bonilla, L; Krupinski, J; Montaner, J; Penalba, A; Quintana, M, 2009) |
| "The antithrombotic, antiplatelet and endothelial activity of terutroban, a specific thromboxane prostaglandin receptor antagonist, was assessed in patients previously treated with aspirin for the prevention of ischemic stroke." | 5.14 | Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke. ( Bal Dit Sollier, C; Bergmann, JF; Bousser, MG; Crassard, I; Drouet, L; Simoneau, G, 2009) |
| "We present the protocol of a multicenter randomized clinical trial (n = 800) investigating the effects of immediate addition of aspirin to rt-PA on poor outcome (modified Rankin score >2) in ischemic stroke patients." | 5.14 | Antiplatelet therapy in combination with rt-PA thrombolysis in ischemic stroke (ARTIS): rationale and design of a randomized controlled trial. ( de Haan, RJ; Roos, YB; Stam, J; Vermeulen, M; Zinkstok, SM, 2010) |
| "In this double-blind multicenter trial, 244 aspirin users with ischaemic stroke were randomly assigned to receive cilostazol 100 mg twice daily or to placebo." | 5.14 | Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial. ( Cha, JK; Ha, SW; Kwon, SU; Lee, JH; Lee, SJ, 2010) |
| "During the clinical follow-up, ischemic stroke recurred in 2 patients in cilostazol group, while in aspirin group, one case of ischemic stroke recurrence and one case of acute myocardial infarction were found." | 5.14 | Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke. ( Guo, JJ; Lin, QY; Xie, HF; Xu, E; Zeng, GL, 2009) |
| "In spite of the fact that the null hypothesis was not supported by our data, we found results supporting the safety (and potential efficacy) of ASA and tirofiban when used in the first hours of acute ischemic stroke." | 5.14 | Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double-blind randomized trial. ( Boiti, C; Borutti, G; Cazzaniga, M; Falaschi, F; Maestroni, A; Mandelli, C; Manganaro, D; Monzani, V; Rossi, P; Torgano, G; Zecca, B; Zilioli, E, 2010) |
| "The factorial PRoFESS secondary prevention trial assessed antiplatelet and blood pressure-lowering strategies in 20,332 patients, 1360 of whom were randomized within 72 hours of ischemic stroke to combined aspirin (Asp; 25 mg BID) and extended-release dipyridamole (ER-DP; 200 mg BID, n=672) or clopidogrel (75 mg/d, n=688)." | 5.14 | Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis. ( Bath, PM; Cotton, D; Diener, HC; Estol, C; Martin, RH; Palesch, Y; Roberts, R; Sacco, R; Yusuf, S, 2010) |
| " Our objective is to investigate whether immediate addition of aspirin to rt-PA thrombolysis improves functional outcome in ischemic stroke." | 5.14 | A randomised controlled trial of antiplatelet therapy in combination with Rt-PA thrombolysis in ischemic stroke: rationale and design of the ARTIS-Trial. ( de Haan, RJ; Roos, YB; Stam, J; Vermeulen, M; Zinkstok, SM, 2010) |
| "The 160 patients with acute ischemic stroke were divided into two groups randomly: treatment group 85 cases (Songling Xuemaikang + Shuxuetong + Aspirin enterie coated tablets), control group 75 cases (Shuxuetong + Aspirin enterie ccoated tablets)." | 5.14 | [Changes of plasma fibrinogen level among acute ischemic stroke subtypes according to TOAST criteria and effects of Songling Xuemaikang]. ( Chen, Y; Huang, J; Liu, G; Liu, X; Lu, N; Xu, Y; Yang, D, 2010) |
| "Although aspirin (ASA) remains the most popular and accepted agent for secondary stroke prevention, its efficacy does not exceed 25%." | 5.13 | Plasma triglycerides as predictors of platelet responsiveness to aspirin in patients after first ischemic stroke. ( Karepov, V; Kuliczkowski, W; Serebruany, V; Tolpina, G, 2008) |
| "The trial did not meet the predefined criteria for noninferiority but showed similar rates of recurrent stroke with ASA-ERDP and with clopidogrel." | 5.13 | Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. ( Albers, GW; Bath, P; Bornstein, N; Chan, BP; Chen, ST; Cotton, D; Cunha, L; Dahlöf, B; De Keyser, J; Diener, HC; Donnan, GA; Estol, C; Gorelick, P; Gu, V; Hermansson, K; Hilbrich, L; Kaste, M; Lawton, WA; Lu, C; Machnig, T; Martin, RH; Ounpuu, S; Pais, P; Palesch, Y; Roberts, R; Sacco, RL; Skvortsova, V; Teal, P; Toni, D; Vandermaelen, C; Voigt, T; Weber, M; Yoon, BW; Yusuf, S, 2008) |
| "All patients with acute ischemic stroke or transient ischemic attack within a 10 month period were administered 600 mg clopidogrel bolus if they were already taking aspirin regularly, or had aspirin allergy or intolerance." | 5.13 | Safety and tolerability of 600 mg clopidogrel bolus in patients with acute ischemic stroke: preliminary experience. ( Abdelmoula, MM; Divani, AA; Hussein, HM; Qureshi, AI; Suri, MF, 2008) |
| "Thirty chronic ischemic stroke patients taking aspirin alone followed by aspirin-clopidogrel combined therapy had platelet reactivity tests performed over 3 months: ex vivo platelet aggregation, platelet recruitment and urinary 11-dehydro-thromboxane B(2) (11-dhTxB(2))excretion." | 5.13 | Platelet aggregation and recruitment with aspirin-clopidogrel therapy. ( Brace, LD; Cursio, J; Grossi, E; Helgason, CM; Pandey, D; Valika, A, 2008) |
| "Most patients who have had a stroke are given aspirin; however, aspirin-related cerebral haemorrhage is a complication that is currently of concern, particularly in China where there is a high incidence of cerebral haemorrhage in secondary prevention programmes and within the community." | 5.13 | Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. ( Cheng, Y; Ding, M; Fan, D; Gao, X; Hong, Z; Huang, Y; Li, Y; Li, Z; Lu, C; Wong, K; Wu, J; Xiao, J; Xu, E; Yao, C; Zeng, J; Zhang, W, 2008) |
| "Patients experiencing acute ischemic stroke or transient ischemic attack are commonly treated with clopidogrel and/or aspirin (mono- and dual-antiplatelet therapy) to minimize the risk for recurrent stroke." | 5.12 | Efficacy and safety of clopidogrel and/or aspirin for ischemic stroke/transient ischemic attack: An overview of systematic reviews and meta-analysis. ( Huang, Z; Yang, Y; Zhang, X, 2021) |
| " The recently published European/Australasian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT), an open-label randomised controlled study, compared long-term treatment of patients randomised to aspirin 30-325 mg daily with (n = 1363) or without (n = 1376) dipyridamole 200 mg twice daily." | 5.12 | ESPRIT study design and outcomes--a critical appraisal. ( Einhäupl, K, 2007) |
| "A large number of patients experience ischemic stroke despite treatment with aspirin (acetylsalicylic acid, ASA)." | 5.12 | Variable platelet response to aspirin in patients with ischemic stroke. ( Boucher, M; Hohlfeld, T; Junghans, U; Schrör, K; Schumacher, M; Siebler, M; Weber, AA, 2007) |
| "We examined the outcomes of 627 noncardioembolic stroke patients who were double-blindly assigned to either warfarin or aspirin therapy and assessed VaT using transesophageal echocardiography." | 5.12 | Impact of valvular thickness on stroke recurrence in medically treated patients with stroke. ( Abe, Y; Di Tullio, MR; Homma, S; Jin, Z; Mohr, JP; Okajima, K; Sacco, RL; Salameh, MJ; Suzuki, K, 2007) |
| "TAIST was a randomized, controlled trial assessing the safety and efficacy of tinzaparin versus aspirin in 1484 patients with acute ischemic stroke." | 5.12 | Sex differences in quality of life in stroke survivors: data from the Tinzaparin in Acute Ischaemic Stroke Trial (TAIST). ( Bath, PM; Boysen, G; De Deyn, PP; Gray, LJ; Leys, D; O'Neill, D; Ringelstein, EB; Sprigg, N, 2007) |
| "In the majority of patients with acute ischemic stroke, ASA and acetaminophen are insufficient for reducing an elevated BT to a state of normothermia." | 5.11 | Acetylsalicylic acid and acetaminophen to combat elevated body temperature in acute ischemic stroke. ( De Keyser, J; Elting, JW; Luijckx, GJ; Luyckx, GJ; Maurits, N; Sulter, G, 2004) |
| "We studied 18 558 patients with ischemic stroke, myocardial infarction, or peripheral arterial disease who participated in the trial of Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE), a study that compared the occurrence of ischemic stroke, myocardial infarction, or vascular death under randomized treatment with aspirin or clopidogrel." | 5.11 | Leukocyte count as an independent predictor of recurrent ischemic events. ( Boddy, AW; Brandt, T; Buggle, F; Dukovic, DA; Grau, AJ; Hacke, W; Lichy, C, 2004) |
| "The European Stroke Prevention Study showed greater stroke prevention for Aggrenox than either for aspirin or dipyridamole alone." | 5.11 | Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial. ( Atar, D; Hennekens, CH; Jilma, B; Malinin, AI; Sane, DC; Serebruany, VL; Takserman, A, 2004) |
| " Aspirin (A), clopidogrel (C), and dipyridamole (D) were administered singly and in various combinations (A, C, D, AC, AD, CD, ACD), each for two weeks (without washout) to 11 healthy subjects and to 11 patients with previous ischaemic stroke in two randomised multiway crossover trials." | 5.11 | Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke. ( Bath, P; Fletcher, S; Fox, S; Heptinstal, S; Leonardi-Bee, J; May, J; Weaver, C; Willmot, M; Zhao, L, 2005) |
| "Clopidogrel is widely used in patients after recent ischemic stroke; however, its ability to yield additional antiplatelet protection on top of aspirin has never been explored in a controlled study." | 5.11 | Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial. ( Alberts, MJ; Bhatt, DL; Hanley, DF; Malinin, AI; Pokov, AN; Serebruany, VL; Ziai, W, 2005) |
| "This pilot study enrolled ischemic stroke patients within 48 hours and randomized to aspirin 300 mg/d or combination (aspirin 300 mg/d+ standard release dipyridamole 75 mg thrice a day) and followed up for 6 months." | 5.11 | Comparison between aspirin combined with dipyridamole versus aspirin alone within 48 hours after ischemic stroke event for prevention of recurrent stroke and improvement of neurological function: a preliminary study. ( Chairangsarit, P; Nidhinandana, S; Niyasom, S; Sithinamsuwan, P; Suwantamee, J; Udommongkol, C, 2005) |
| "In a case-crossover study, 31 patients with previous atherothrombotic or lacunar stroke who were treated with aspirin (100 to 300 mg/d) received clopidogrel (75 mg/d) and both aspirin and clopidogrel for 4 weeks." | 5.10 | Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study. ( Buggle, F; Grau, AJ; Lichy, C; Reiners, S; Ruf, A, 2003) |
| " In this study, we showed that the combination regimen of clopidogrel with aspirin could downregulate the P-selectin expression on platelets and the plasma concentration of C-reactive protein (CRP) in acute stage of atherosclerotic ischemic stroke." | 5.10 | Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel. ( Bae, HR; Cha, JK; Cheon, SM; Jeong, MH; Lee, KM; Lim, YJ; Park, KW, 2002) |
| "In this study, 591 patients with recent cerebral ischemia of arterial origin were randomly allocated to treatment with aspirin 30 to 325 mg/d or with the combination of aspirin and dipyridamole 400 mg/d in the European/Australian Stroke Prevention in Reversible Ischemia Trial." | 5.10 | Dipyridamole in stroke prevention: effect of dipyridamole on blood pressure. ( De Schryver, EL, 2003) |
| "We performed multivariate logistic regression analysis of 2012 participants given aspirin alone or in combination with low, inefficacious doses of warfarin in the Stroke Prevention in Atrial Fibrillation I-III trials followed for a mean of 2." | 5.09 | Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. ( Asinger, RW; Hart, RG; McBride, R; Pearce, LA; Rothbart, RM, 1999) |
| "Heparin in Acute Embolic Stroke Trial (HAEST) was a multicentre, randomised, double-blind, and double-dummy trial on the effect of low-molecular-weight heparin (LMWH, dalteparin 100 IU/kg subcutaneously twice a day) or aspirin (160 mg every day) for the treatment of 449 patients with acute ischaemic stroke and atrial fibrillation." | 5.09 | Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial. ( Abdelnoor, M; Berge, E; Nakstad, PH; Sandset, PM, 2000) |
| " We sought to determine whether clopidogrel compared with aspirin decreases the need for rehospitalization for ischemia and bleeding." | 5.09 | Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. ( Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ, 2000) |
| " We assessed three schemes for stroke risk stratification in these patients who were treated with aspirin and who did not have prior cerebral ischemia." | 5.09 | Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation. ( Halperin, JL; Hart, RG; Pearce, LA, 2000) |
| "We sought to compare different antithrombotic secondary treatments (mainly medium-dose aspirin with low-dose low-molecular-weight heparin [LMWH]) in pediatric patients with a first ischemic stroke onset with regard to the risk of stroke recurrence." | 5.09 | Aspirin versus low-dose low-molecular-weight heparin: antithrombotic therapy in pediatric ischemic stroke patients: a prospective follow-up study. ( Heller, C; Kurnik, K; Luigs, P; Nowak-Göttl, U; Schobess, R; Sträter, R, 2001) |
| "Over two years, we found no difference between aspirin and warfarin in the prevention of recurrent ischemic stroke or death or in the rate of major hemorrhage." | 5.09 | A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. ( Adams, HP; Albers, GW; Furie, KL; Jackson, CM; Kistler, JP; Lazar, RM; Levin, B; Mohr, JP; Pettigrew, LC; Pullicino, P; Sacco, RL; Thompson, JL, 2001) |
| "To determine the effectiveness of aspirin in preventing ischemic events in patients with asymptomatic carotid stenosis." | 5.08 | Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group. ( Abrahamowicz, M; Battista, RN; Bourque, F; Côté, R; Langlois, Y; Mackey, A, 1995) |
| "Aspirin is only modestly effective in the secondary prevention after cerebral ischemia." | 5.08 | A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. ( , 1997) |
| ") for secondary prevention of cerebral ischemia were compared with the effects of low-dosage aspirin (300 mg/die)." | 5.07 | [Clinical efficacy of picotamide]. ( de Falco, FA; Mastroroberto, G; Montariello, A; Visconti, OS, 1991) |
| "We compared the outcomes of 2,500 patients who suffered from previous cerebrovascular disorders (transient ischemic attacks, reversible ischemic neurologic deficits, or completed strokes) treated with acetylsalicylic acid plus dipyridamole or matched placebo and followed for 2 years." | 5.06 | European Stroke Prevention Study. ESPS Group. ( , 1990) |
| " An updated meta analysis was done to determine the effect of the various dual antiplatelets vs aspirin alone on recurrence rate of ischemic stroke, cardiovascular morbidity and mortality, and its safety profile as reported through major bleeding." | 5.05 | Dual versus mono antiplatelet therapy for acute non- cardio embolic ischemic stroke or transient ischemic attack, an efficacy and safety analysis - updated meta-analysis. ( Albay, CEQ; Cheng, FC; Leyson, FGD, 2020) |
| "Background and Purpose- We performed a systematic review and meta-analysis to explore the efficacy and safety of cilostazol as a mono or combination (plus aspirin or clopidogrel) treatments compared to conventional single antiplatelet therapy (SAPT, mainly aspirin) for secondary stroke prevention." | 5.01 | Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis. ( Jung, JM; Kim, BJ; Kim, SM; Kwon, SU; Lee, JS, 2019) |
| "The analysis showed lower risks of major adverse cardiovascular or cerebrovascular events, recurrent stroke, and bleeding events for clopidogrel monotherapy compared to aspirin." | 5.01 | Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis. ( Del Aguila, M; Girotra, S; Hu, B; Ince, B; Jeng, JS; Kutluk, K; Liu, L; Lou, M; Min Han, J; Paciaroni, M; Paek, D; Parfenov, V; Wong, KSL; Zamani, B, 2019) |
| "Background and Purpose- The role of aspirin plus clopidogrel (A+C) therapy compared with aspirin monotherapy in patients presenting with acute ischemic stroke (IS) or transient ischemic attack remains uncertain." | 5.01 | Optimal Duration of Aspirin Plus Clopidogrel After Ischemic Stroke or Transient Ischemic Attack. ( Hammad, T; Kaluski, E; Khan, SU; Meyer, MA; Nasir, F; Rahman, H, 2019) |
| "To assess the effectiveness and safety of dual agent antiplatelet therapy combining clopidogrel and aspirin to prevent recurrent thrombotic and bleeding events compared with aspirin alone in patients with acute minor ischaemic stroke or transient ischaemic attack (TIA)." | 4.98 | Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis. ( Foroutan, F; Guyatt, G; Hao, Q; O'Donnell, M; Siemieniuk, RA; Tampi, M, 2018) |
| "Aspirin is recommended for secondary prevention after transient ischaemic attack (TIA) or ischaemic stroke on the basis of trials showing a 13% reduction in long-term risk of recurrent stroke." | 4.93 | Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. ( Algra, A; Chen, Z; Diener, HC; Mehta, Z; Norrving, B; Rothwell, PM, 2016) |
| " We found no evidence that the net benefit of aspirin increased with increasing risk of thrombosis, haemorrhage or poor functional outcome in all three trials." | 4.91 | Targeting aspirin in acute disabling ischemic stroke: an individual patient data meta-analysis of three large randomized trials. ( Candelise, L; Chen, Z; Murray, GD; Sandercock, PA; Thompson, DD; Whiteley, WN, 2015) |
| "Antiplatelet therapy with aspirin 160 mg to 300 mg daily, given orally (or by nasogastric tube or per rectum in people who cannot swallow) and started within 48 hours of onset of presumed ischaemic stroke, reduced the risk of early recurrent ischaemic stroke without a major risk of early haemorrhagic complications; long-term outcomes were improved." | 4.90 | Oral antiplatelet therapy for acute ischaemic stroke. ( Cecconi, E; Counsell, C; Sandercock, PA; Tseng, MC, 2014) |
| "Recurrent stroke risk did not differ between patients receiving dual-antiplatelet therapy and those receiving aspirin monotherapy (relative risk [RR], 0." | 4.89 | Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis. ( Hong, KS; Lee, M; Ovbiagele, B; Rao, NM; Saver, JL; Wu, YL, 2013) |
| " The effects of cilostazol and aspirin on ischemic stroke prevention and treatment were almost equal (combined odds ratio (OR) 0." | 4.89 | Systematic study of cilostazol on secondary stroke prevention: a meta-analysis. ( Bi, Q; Qian, Y, 2013) |
| "This review examines the role of platelets in ischemic stroke, platelet activation mechanisms, aspirin's rise as an antithrombotic agent, clopidogrel's appearance on the stage, a possible role for combination therapy, antiplatelet resistance, practical considerations, and future directions." | 4.89 | Aspirin and clopidogrel for prevention of ischemic stroke. ( Anderson, DC; Thomson, RM, 2013) |
| " In comparison with mono antiplatelet therapy, dual therapy (aspirin+dipyridamole and aspirin+clopidogrel) significantly reduced stroke recurrence, dual 58 (3." | 4.88 | Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials. ( Algra, A; Bath, MW; Bath, PM; Chen, C; Dengler, R; Diener, HC; Geeganage, CM; Markus, HS; Topol, EJ, 2012) |
| "Although several new antithrombotic agents have been developed for stroke prevention in patients with nonvalvular atrial fibrillation (AF), many patients will continue to be treated with warfarin worldwide." | 4.88 | Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis. ( Agarwal, S; Hachamovitch, R; Menon, V, 2012) |
| "Aspirin is widely used for secondary prevention after stroke." | 4.87 | Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. ( Husain, MR; Kamal, AK; Khealani, BA; Naqvi, I, 2011) |
| "Aspirin is used to prevent ischemic stroke and other types of cardiovascular disease." | 4.87 | Gender differences in the primary prevention of stroke with aspirin. ( Adelman, EE; Brown, DL; Lisabeth, L, 2011) |
| "To assess the clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole (MRD) alone or with aspirin (ASA) compared with ASA (and each other where appropriate) in the prevention of occlusive vascular events in patients with a history of MI, ischaemic stroke/TIA or established peripheral arterial disease." | 4.87 | Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. ( Bagust, A; Blundell, M; Boland, A; Dickson, R; Dundar, Y; Fisher, M; Greenhalgh, J; Martin Saborido, C; Oyee, J; Proudlove, C, 2011) |
| "In primary prevention trials conducted in low-risk subjects, aspirin is associated with a small reduction in ischemic strokes in women." | 4.85 | Antiplatelet drugs for ischemic stroke prevention. ( Balucani, C; Cordonnier, C; Leys, D, 2009) |
| " Currently, aspirin is generally prescribed for the primary prevention of stroke despite a number of trial results on effectiveness proving inconclusive." | 4.85 | Antithrombotic therapies in cerebrovascular disease: what should we use as secondary prevention in patients with carotid artery disease? ( Beckman, JA, 2009) |
| "The results obtained in the CAPRIE study in 1996 led to the introduction of the clopidogrel as a new antiplatelet drug in the secondary prevention of acute myocardial infarct (AMI), ischemic stroke (IS) and symptomatic peripheral artery disease (PAD)." | 4.84 | Clopidogrel in secondary ischemic stroke prevention. ( Belvís, R; Kulisevsky, J; Pagonabarraga, J; Santamaría, A, 2008) |
| "In this paper, an overview is given of trials with oral anticoagulants and dipyridamole in the secondary prevention after transient ischaemic attack or minor stroke." | 4.84 | Anticoagulants, aspirin and dipyridamole in the secondary prevention of cerebral ischaemia: which is the best for which patient? ( Algra, A; Halkes, PH, 2007) |
| "The current evidence suggests that aspirin is treatment of choice when compared to anticoagulants for patients with non-cardioembolic stroke." | 4.83 | Antithrombotic agents in cerebral ischaemia. ( Bhat, P; Bhattacharjee, M; Dalal, PM; Mishra, NK, 2006) |
| "Individual patient data of patients who received aspirin or placebo after cerebral ischemia were obtained from 9 clinical trials." | 4.82 | Risk of intracerebral hemorrhage in patients with arterial versus cardiac origin of cerebral ischemia on aspirin or placebo: analysis of individual patient data from 9 trials. ( Algra, A; Ariesen, MJ; Koudstaal, PJ; Rothwell, PM; van Walraven, C, 2004) |
| "The study pooled individual data from 2580 participants with nonvalvular AF who were prescribed aspirin in a multicenter trial (Atrial Fibrillation, Aspirin, Anticoagulation I study [AFASAK-1], AFASAK-2, European Atrial Fibrillation Trial, Primary Prevention of Arterial Thromboembolism in patients with nonrheumatic Atrial Fibrillation in primary care study, and Stroke Prevention and Atrial Fibrillation [SPAF]-III high risk or SPAF-III low risk)." | 4.82 | Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin. ( Boode, BS; Gage, BF; Hart, RG; Koudstaal, PJ; Pearce, L; Petersen, P; van Walraven, C, 2004) |
| "Results from randomized controlled trials of dipyridamole, given with or without aspirin, for secondary prevention after ischemic stroke or transient ischemic attack (TIA) have given conflicting results." | 4.82 | Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. ( Bath, PM; Bousser, MG; Davalos, A; Dewey, ME; Diener, HC; Guiraud-Chaumeil, B; Leonardi-Bee, J; Sivenius, J; Yatsu, F, 2005) |
| "In the secondary prevention of cardiovascular, cerebrovascular, and ischemic events, the evidence supports that the benefits of aspirin treatment significantly outweigh the risk of a major hemorrhage." | 4.82 | Risk of hemorrhagic stroke with aspirin use: an update. ( Gorelick, PB; Weisman, SM, 2005) |
| "This paper will examine how cerebral perfusion deficits in cocaine abusers may be a target for pharmacotherapy." | 4.80 | Pharmacotherapy of cerebral ischemia in cocaine dependence. ( Kosten, TR, 1998) |
| "Aspirin has been widely used to prevent myocardial infarction and ischemic stroke but some studies have suggested it increases risk of hemorrhagic stroke." | 4.80 | Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. ( He, J; Klag, MJ; Vu, B; Whelton, PK, 1998) |
| " Aspirin modestly reduces the risk for subsequent ischemic stroke after a transient ischemic attack or initial stroke." | 4.80 | Antithrombotic and thrombolytic therapy for ischemic stroke. ( Fisher, M, 1999) |
| " In primary prevention, the benefit of aspirin has been established only for patients with non-valvular atrial fibrillation and a low risk of cardioembolism, or as an alternative choice of warfarin, and in subjects at high risk of atherosclerosis." | 4.80 | [Prevention of cerebral ischemia: anti-platelet agents]. ( Leys, D, 1999) |
| "A vast consensus exists in defining a narrow range of recommended daily doses of aspirin, ie, 75 to 160 mg, for the prevention of myocardial infarction, stroke, and vascular death in patients with different manifestations of coronary hearth disease." | 4.79 | Aspirin in ischemic cerebrovascular disease. How strong is the case for a different dosing regimen? ( Patrono, C; Roth, GJ, 1996) |
| "Our study aimed to explore the effectiveness and safety of intravenous t-PA compared with dual antiplatelet therapy (DAPT) and aspirin alone for minor stroke with National Institutes of Health Stroke Scale (NIHSS) score ≤5 and large vessel occlusion (LVO)." | 4.31 | Intravenous thrombolysis versus antiplatelet therapy in minor stroke patients with large vessel occlusion. ( Duan, C; Feng, X; Gu, H; Hao, M; Meng, X; Wang, S; Wang, Y; Xiong, Y; Yang, KX; Zhao, X, 2023) |
| "Aspirin is widely used as secondary prophylaxis for acute ischemic stroke." | 4.31 | In-Hospital Aspirin Dose as a Risk Factor for Hemorrhagic Transformation in Patients Not Treated With Thrombolysis. ( Clares de Andrade, JB; de Abreu, GQ; de Carvalho, JJF; Lima, FO; Maia Barros, LC; Mohr, JP; Pontes-Neto, OM; Silva, GS, 2023) |
| "A retrospective analysis was performed on 75 patients with cancer and mild to moderate ischemic stroke, 34 of whom received tirofiban treatment and 41 aspirin treatment." | 4.31 | Tirofiban in the treatment of cancer-associated ischemic stroke. ( Lin, ZH; Zhang, ZM; Zhu, GL, 2023) |
| " OAC prescribing status was explored for patients at risk for stroke and classified into the following: OAC, aspirin only, or no treatment." | 4.12 | Incidence of nonvalvular atrial fibrillation and oral anticoagulant prescribing in England, 2009 to 2019: A cohort study. ( Ajabnoor, AM; Ashcroft, DM; Carr, MJ; Doran, T; Kontopantelis, E; Mamas, MA; Parisi, R; Rutter, MK; Zghebi, SS, 2022) |
| "This prospective, observational study assessed TIA/ischaemic stroke patients before (baseline; N = 60), at 14 ±7 days (14d, N = 39) and ≥ 90 days (90d, N = 31) after adding dipyridamole to aspirin." | 4.12 | Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke. ( Collins, DR; Coughlan, T; Cox, D; Egan, B; Lim, ST; Lim, SY; McCabe, DJH; McCarthy, AJ; Murphy, SJX; Murphy, SM; O'Neill, D; Smith, DR; Tierney, S, 2022) |
| "Patients with diabetes and no obstructive coronary artery disease (CAD) as assessed by coronary angiography (CAG) are frequently treated with aspirin and statins." | 4.12 | Statin but not aspirin treatment is associated with reduced cardiovascular risk in patients with diabetes without obstructive coronary artery disease: a cohort study from the Western Denmark Heart Registry. ( Bøtker, HE; Heide-Jørgensen, U; Maeng, M; Olesen, KKW; Sørensen, HT; Thim, T; Thomsen, RW, 2022) |
| "We investigated (1) the associations of pre-stroke aspirin use with thrombus burden, infarct volume, hemorrhagic transformation, early neurological deterioration (END), and functional outcome, and (2) whether stroke subtypes modify these associations in first-ever ischemic stroke." | 4.02 | Relation of Pre-Stroke Aspirin Use With Cerebral Infarct Volume and Functional Outcomes. ( Bae, HJ; Cha, JK; Cho, YJ; Choi, KH; Han, MK; Hong, KS; Jeong, SW; Kang, K; Kim, BJ; Kim, DE; Kim, DH; Kim, JG; Kim, JT; Lee, BC; Lee, J; Lee, KB; Lee, SJ; Nahrendorf, M; Oh, MS; Park, HK; Park, JM; Park, MS; Park, SS; Park, TH; Ryu, WS; Schellingerhout, D; Yu, KH, 2021) |
| "We recruited 293 ischemic stroke patients, taking aspirin for more than seven days, and performed LTA to classify them." | 4.02 | Serum thromboxane B2 but not soluble P-selectin levels identify ischemic stroke patients with persistent platelet reactivity while on aspirin therapy. ( Chandra, SR; Christopher, R; Ramanujam, N; Sundaravadivel, P, 2021) |
| "Ticagrelor plus aspirin could reduce the risks of major adverse cardiac events in diabetic patients with stable coronary artery disease (SCD), and yet it also increases bleeding risk." | 4.02 | Cost-utility of ticagrelor plus aspirin in diabetic patients with stable coronary artery disease. ( Shi, L; Wu, B, 2021) |
| "Patients with ischemic stroke receiving aspirin (100 mg/day) for three months were recruited for a multicenter, prospective, cohort study." | 4.02 | Safety and efficacy of low-dose aspirin in ischemic stroke patients with different G6PD conditions. ( Chen, Y; Deng, W; Huang, W; Jiang, H; Li, J; Liang, Z; Liu, Q; Ou, Z; Ouyang, F; Wu, Z; Xing, S; Zeng, J; Zhang, Y, 2021) |
| "This study provides supporting evidence that aspirin use is associated with reduced ischaemic events after pneumonia in a primary care setting." | 4.02 | Aspirin reduces cardiovascular events in patients with pneumonia: a prior event rate ratio analysis in a large primary care database. ( Arnold, D; Hamilton, F; Henley, W; Payne, RA, 2021) |
| " Here we assessed the contribution of clopidogrel versus aspirin to the development of pneumonia during an acute ischemic stroke admission." | 4.02 | Clopidogrel increases risk of pneumonia compared with aspirin in acute ischemic minor stroke patients. ( Feng, Q; Fu, J; Jin, X; Shan, B; Shen, R; Yu, Z; Zhou, H; Zhu, H, 2021) |
| " The aim of this study was to assess the safety and efficacy of the p48 MW HPC (phenox, Bochum, Germany) to treat distal intracranial aneurysms under the use of aspirin monotherapy." | 4.02 | Aspirin monotherapy in the treatment of distal intracranial aneurysms with a surface modified flow diverter: a pilot study. ( Abud, DG; Abud, TG; de Castro-Afonso, LH; de Freitas, RK; Monsignore, LM; Nakiri, GS, 2021) |
| "We selected newly diagnosed ischemic stroke patients aged ≥20years who were newly treated with aspirin or clopidogrel from 2003-2010 Korean National Health Insurance Service-National Sample Cohort, a random sample of 2." | 4.02 | Non-persistence with anti-platelet therapy and long-term mortality after ischemic stroke: A nationwide study. ( Cho, B; Choi, HC; Kim, SJ; Kwon, OD; Lee, EJ, 2021) |
| " Despite the modified dose, bleeding events were higher among patients receiving low-dose prasugrel than among patients receiving clopidogrel, with no difference in ischemic events between the 2 groups." | 3.96 | Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment. ( Fukuda, K; Heidenreich, PA; Ikemura, N; Kohsaka, S; Numasawa, Y; Sandhu, AT; Sawano, M; Shiraishi, Y; Shoji, S; Suzuki, M; Ueno, K, 2020) |
| "In real-world practice settings, there is insufficient evidence on the efficacy of antiplatelet drugs, including clopidogrel, aspirin, and ticlopidine, in stroke prevention." | 3.96 | Efficacy of aspirin, clopidogrel, and ticlopidine in stroke prevention: A population-based case-cohort study in Taiwan. ( Hsu, YH; Ong, CT; Tsai, CF; Wong, YS, 2020) |
| "Several clinical trials reported that clopidogrel was superior to aspirin in secondary stroke prevention by reducing the risk of major adverse cardiovascular events (MACE)." | 3.91 | Aspirin better than clopidogrel on major adverse cardiovascular events reduction after ischemic stroke: A retrospective nationwide cohort study. ( Chan, L; Chen, YC; Hsu, CY; Hu, CJ; Lin, CL; Muo, CH; Vidyanti, AN; Wu, D, 2019) |
| "Treatment of patients with stroke presenting with minor deficits remains controversial, and the recent Potential of rtPA for Ischemic Strokes with Mild Symptoms (PRISMS) trial, which randomized patients to thrombolysis vs aspirin, did not show benefit." | 3.91 | MRI-based thrombolytic therapy in patients with acute ischemic stroke presenting with a low NIHSS. ( Benson, RT; Hsia, AW; Kalaria, CP; Latour, LL; Leigh, R; Luby, M; Lynch, JK; Majidi, S; Nadareishvili, Z, 2019) |
| "This study aimed to investigate the effectiveness of monotherapy acetylsalicylic acid (ASA) and warfarin for stroke prevention in low-risk atrial fibrillation (AF) by using a population- -based cohort study in Taiwan." | 3.91 | Monotherapy of acetylsalicylic acid or warfarin for prevention of ischemic stroke in low-risk atrial fibrillation: A Easter Asian population-based study. ( Chen, HC; Liu, CY, 2019) |
| "Of 149 subjects (mean age 57; 48% female; median NIH stroke scale (NIHSS) 19; 46% ischemic stroke; 54% hemorrhagic), implementation of treatments included: dysphagia screening (80%), deep venous thrombosis prophylaxis (0%), aspirin (83%), antihypertensives (89%) and statins (95%)." | 3.91 | Opportunities for intervention: stroke treatments, disability and mortality in urban Tanzania. ( Biseko, MR; Grundy, SJ; Kharal, GA; Klein, JP; Mateen, FJ; Mmbando, TN; Okeng'o, K; Parker, R; Regenhardt, RW; Saadi, A; Shayo, AF; Wibecan, L; Xu, A, 2019) |
| "To evaluate the effect of prestroke aspirin (PA) use on initial stroke severity, early neurologic deterioration (END), stroke recurrence, hemorrhagic transformation (HT), and functional outcome in patients with ischemic stroke (IS)." | 3.91 | Prestroke Aspirin Use is Associated with Clinical Outcomes in Ischemic Stroke Patients with Atherothrombosis, Small Artery Disease, and Cardioembolic Stroke. ( Han, Z; Lin, J; Luo, H; Yi, X; Zhou, J; Zhou, Q, 2019) |
| "To investigate the association of aspirin resistance (AR) with mortality in a cohort of Chinese patients with acute ischemic stroke (AIS)." | 3.91 | Association of Aspirin Resistance with Increased Mortality in Ischemic Stroke. ( Jing, Y; Li, S; Yang, S; Yue, X, 2019) |
| "Background and Purpose- Two large-scale randomized controlled trials of recurrent stroke prevention suggest that dual antiplatelet therapy with clopidogrel plus aspirin is beneficial for prevention of subsequent ischemic events." | 3.91 | Dual Versus Mono Antiplatelet Therapy in Large Atherosclerotic Stroke. ( Bae, HJ; Cha, JK; Cho, YJ; Choi, JC; Choi, KH; Gorelick, PB; Han, MK; Hong, JH; Hong, KS; Kang, K; Kim, BJ; Kim, D; Kim, DE; Kim, DH; Kim, JG; Kim, JT; Kim, WJ; Kwon, JH; Lee, BC; Lee, J; Lee, JS; Lee, KB; Lee, SJ; Nah, HW; Oh, MS; Park, JM; Park, TH; Ryu, WS; Shin, DI; Sohn, SI; Yu, KH, 2019) |
| "High plasma level of HbA1c is involved in enhanced platelet aggregability in acute atherothrombotic stroke patients, and prestroke administration of aspirin may be beneficial to clinical outcomes." | 3.91 | Collagen-Induced Platelet Aggregates, Diabetes, and Aspirin Therapy Predict Clinical Outcomes in Acute Ischemic Stroke. ( Hagii, J; Harima, K; Honda, S; Kitajima, M; Metoki, H; Mikami, K; Osanai, T; Tomisawa, T; Urushizaka, M; Yasujima, M, 2019) |
| " After multivariate logistic regression, 10 variables remained independent predictors of sICH to compose the STARTING-SICH (systolic blood pressure, age, onset-to-treatment time for thrombolysis, National Institutes of Health Stroke Scale score, glucose, aspirin alone, aspirin plus clopidogrel, anticoagulant with INR ≤1." | 3.88 | STARTING-SICH Nomogram to Predict Symptomatic Intracerebral Hemorrhage After Intravenous Thrombolysis for Stroke. ( Bonetti, B; Bovi, P; Cappellari, M; Forlivesi, S; Toni, D; Turcato, G; Zivelonghi, C, 2018) |
| "We used nationwide population-based registries to identify all first-time hospitalizations for stroke and subsequent mortality in patients treated with aspirin and clopidogrel in Denmark during 2004-2012." | 3.88 | Pre-admission use of platelet inhibitors and short-term stroke mortality: a population-based cohort study. ( Christiansen, CF; Grove, EL; Henderson, VW; Horváth-Puhó, E; Schmidt, M; Sørensen, HT; Würtz, M, 2018) |
| "To investigate the associations between CYP2C19 genotypes and early neurological deterioration (END), and to carry out a stratified analysis of the effectiveness of clopidogrel alone and dual antiplatelet therapy with clopidogrel and aspirin for prevention of END according to CYP2C19 genotypes in ischemic stroke (IS) patients." | 3.88 | Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles. ( Chai, Z; Han, Z; Huang, R; Lin, J; Wang, C; Yi, X; Zhou, Q, 2018) |
| "To investigate the prognostic value of aspirin reaction units (ARU) in a 3-month follow-up study in a cohort of Chinese patients with first-ever ischemic stroke." | 3.88 | Aspirin resistance predicts unfavorable functional outcome in acute ischemic stroke patients. ( Fan, YN; He, Y; Hua, QJ; Ji, SB; Liu, YX; Su, LL; Wang, CW; Xi, TT; Yuan, B, 2018) |
| "WHAT IS THE ROLE OF DUAL ANTIPLATELET THERAPY AFTER HIGH RISK TRANSIENT ISCHAEMIC ATTACK OR MINOR STROKE? SPECIFICALLY, DOES DUAL ANTIPLATELET THERAPY WITH A COMBINATION OF ASPIRIN AND CLOPIDOGREL LEAD TO A GREATER REDUCTION IN RECURRENT STROKE AND DEATH OVER THE USE OF ASPIRIN ALONE WHEN GIVEN IN THE FIRST 24 HOURS AFTER A HIGH RISK TRANSIENT ISCHAEMIC ATTACK OR MINOR ISCHAEMIC STROKE? AN EXPERT PANEL PRODUCED A STRONG RECOMMENDATION FOR INITIATING DUAL ANTIPLATELET THERAPY WITHIN 24 HOURS OF THE ONSET OF SYMPTOMS, AND FOR CONTINUING IT FOR 10-21 DAYS CURRENT PRACTICE IS TYPICALLY TO USE A SINGLE DRUG." | 3.88 | Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline. ( Agoritsas, T; Booth, B; Fisch, L; Fobuzi, AC; Fraiz, A; Gorthi, SP; Guyatt, G; Hao, Q; Heen, AF; Horton, E; Jusufovic, M; Katragunta, N; Lytvyn, L; Muller, J; O'Donnell, M; Prasad, K; Rochwerg, B; Siemieniuk, J; Siemieniuk, R; Vandvik, PO, 2018) |
| "Prostaglandin-Endoperoxide Synthase 1 (PTGS1) and smoking may play important roles in aspirin nonresponsiveness, but the effect of their interaction on stroke outcomes remains largely unknown." | 3.85 | Association between PTGS1 polymorphisms and functional outcomes in Chinese patients with stroke during aspirin therapy: Interaction with smoking. ( Cai, B; Cai, H; Cao, L; Davis, SM; Guo, H; Liu, X; Sun, L; Sun, W; Yan, B; Zhang, H; Zhang, Z; Zhou, S, 2017) |
| " A substantial proportion of patients with stroke on ASA were "resistant", and the treatment with Clopidogrel was accompanied by even higher rates of unresponsiveness." | 3.85 | Platelet Function Testing in Patients with Acute Ischemic Stroke: An Observational Study. ( Bigliardi, G; Dell'Acqua, ML; Ferraro, D; Lelli, N; Mimmi, S; Nichelli, P; Pentore, R; Picchetto, L; Rosafio, F; Trenti, T; Vandelli, L; Zini, A, 2017) |
| "Our findings indicate a favorable effect of clopidogrel at discharge compared with aspirin in preventing death, recurrent stroke, and CVD events in diabetic patients with a first-ever noncardioembolic AIS." | 3.85 | Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project. ( Elisaf, M; Manios, E; Milionis, H; Ntaios, G; Papavasileiou, V; Spengos, K; Vemmos, K, 2017) |
| "This study is the largest to investigate platelet aggregation in stable coronary artery disease patients receiving aspirin as single antithrombotic therapy." | 3.85 | Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease. ( Grove, EL; Hvas, AM; Kristensen, SD; Larsen, SB; Neergaard-Petersen, S; Würtz, M, 2017) |
| "To investigate the prevalent of aspirin resistance (AR) in stroke and its association with recurrent stroke in 214 patients with ischemic stroke who were receiving aspirin before the stroke onset." | 3.85 | Aspirin resistance are associated with long-term recurrent stroke events after ischaemic stroke. ( Wang, Z; Zhang, N; Zhou, L, 2017) |
| "BACKGROUND To investigate the combination of beraprost sodium (BPS) and aspirin in the treatment of acute ischemic stroke (AIS)." | 3.85 | Beneficial Effect of Beraprost Sodium Plus Aspirin in the Treatment of Acute Ischemic Stroke. ( Chen, S; Chen, W; He, W; Li, S; Wei, D; Xie, S, 2017) |
| "Aspirin and statin are recommended for the treatment of acute ischemic stroke." | 3.85 | Statin and Aspirin Pretreatment Are Associated with Lower Neurological Deterioration and Platelet Activity in Patients with Acute Ischemic Stroke. ( Han, Z; Lin, J; Wang, C; Yi, X; Zhou, Q, 2017) |
| "This study aimed to know how frontline physicians in France, Belgium, and Switzerland implement guidelines regarding the secondary prevention of childhood arterial ischemic stroke and to introduce physicians' point of view on a clinical trial assessing the efficacy of aspirin as a preventive strategy." | 3.85 | Secondary Prevention of Childhood Arterial Ischemic Stroke. ( Bertoletti, L; Chabrier, S; Darteyre, S; Fluss, J; Laporte, S; Renaud, C, 2017) |
| "Active smokers with myocardial infarction were shown to have enhanced benefit with clopidogrel compared with aspirin." | 3.85 | Clopidogrel and ischemic stroke outcomes by smoking status: Smoker's paradox? ( Cao, Q; Dong, K; Feng, W; Hou, C; Huang, X; Ji, X; Ovbiagele, B; Song, H; Wang, M; Wang, Y; Zhang, Q, 2017) |
| " Individuals who underwent coronary stenting and completed 12 months of thienopyridine plus aspirin therapy without ischemic or bleeding events remained on an aspirin regimen and were randomized to continued thienopyridine therapy vs placebo for 18 additional months." | 3.85 | Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study. ( Apruzzese, PK; Cannon, CP; Cohen, DJ; Cutlip, DE; D'Agostino, RB; Kereiakes, DJ; Massaro, JM; Mauri, L; Secemsky, EA; Steg, PG; Yeh, RW, 2017) |
| "Admission National Institutes of Health Stroke Scale (NIHSS) score, ischemic lesion volumes on diffusion-weighted imaging (DWI), and in vitro aspirin resistance, in addition to other pertinent stroke features, were determined in a series of ischemic stroke patients." | 3.83 | The Interplay between Stroke Severity, Antiplatelet Use, and Aspirin Resistance in Ischemic Stroke. ( Agayeva, N; Arsava, EM; Topcuoglu, MA, 2016) |
| "We measured serum levels of proinflammatory/prothrombotic markers P-selectin, CD40L, matrix metalloproteinase 9 (MMP-9), intracellular adhesion molecule 1 (ICAM-1), and interleukin (IL)-6 in ischemic stroke patients, correlating their levels with the results of aspirin (ASA) and clopidogrel antiplatelet responses, using 3 "point of care" platelet function instruments, thromboelastograph (TEG), Accumetrics (ACU), and impedance aggregometer (IMP)." | 3.83 | Relationship between Inflammation and Aspirin and Clopidogrel Antiplatelet Responses in Acute Ischemic Stroke. ( Ambrus, JL; Chichelli, T; Ching, M; Janicke, D; Munschauer, F; Sawyer, R; Sternberg, D; Sternberg, Z; Yu, J, 2016) |
| "Selecting among different antiplatelet strategies when patients experience a new ischemic stroke while taking aspirin is a common clinical challenge, currently addressed by a paucity of data." | 3.83 | Different Antiplatelet Strategies in Patients With New Ischemic Stroke While Taking Aspirin. ( Bae, HJ; Cha, JK; Cho, KH; Cho, YJ; Choi, JC; Choi, KH; Han, MK; Hong, KS; Kang, K; Kim, BJ; Kim, DE; Kim, DH; Kim, JG; Kim, JT; Kim, WJ; Ko, YC; Lee, BC; Lee, J; Lee, JS; Lee, KB; Lee, SJ; Nah, HW; Oh, MS; Park, JM; Park, MS; Park, SS; Park, TH; Ryu, WS; Saver, JL; Shin, DI; Yeo, MJ; Yu, KH, 2016) |
| "The effect of prestroke aspirin use on initial severity, hemorrhagic transformation, and functional outcome of ischemic stroke is uncertain." | 3.83 | Comparative Effectiveness of Prestroke Aspirin on Stroke Severity and Outcome. ( Bae, HJ; Cha, JK; Cho, YJ; Choi, JC; Gorelick, PB; Han, MK; Hong, KS; Kang, K; Kim, DE; Kim, DH; Kim, JT; Ko, Y; Lee, BC; Lee, J; Lee, JS; Lee, KB; Lee, SJ; Park, JM; Park, TH; Yu, KH, 2016) |
| " Among these 397 patients, 69 were receiving monotherapy with clopidogrel prior to stroke, 69 were receiving monotherapy with aspirin and 236 patients were not on any antiplatelet treatment." | 3.83 | Treatment with Clopidogrel Prior to Acute Non-Cardioembolic Ischemic Stroke Attenuates Stroke Severity. ( Angelopoulou, SM; Bouziana, SD; Giampatzis, V; Hatzitolios, AI; Kostaki, S; Papadopoulou, M; Savopoulos, C; Spanou, M; Tsopozidi, M; Tziomalos, K, 2016) |
| "To investigate whether aspirin resistance is associated with initial stroke severity and infarct volume, using diffusion-weighted imaging (DWI) in patients with acute ischemic stroke that occurred while taking aspirin." | 3.83 | Aspirin resistance is associated with increased stroke severity and infarct volume. ( Jang, MU; Jung, S; Kim, C; Lee, BC; Lee, J; Lee, JH; Oh, MS; Yu, KH, 2016) |
| "A higher loading dose of aspirin (160-325 mg) can be beneficial in treating acute ischemic stroke, although there is an increased risk of minor bleeding." | 3.83 | To Load or Not to Load? Aspirin Loading in Acute Ischemic Stroke: A Study of Clinical Outcomes. ( Chan, YL; Lee, JD; Lee, M; Lee, TH; Lin, LC; Su, TH; Wen, YW, 2016) |
| "miR-145 is involved in the anti-proliferation and anti-inflammation effects of aspirin on VSMCs by inhibiting the expression of CD40." | 3.83 | miR-145 mediated the role of aspirin in resisting VSMCs proliferation and anti-inflammation through CD40. ( Chen, M; Guo, R; Guo, X; Peng, X; Wu, T; Yu, L; Zhang, B, 2016) |
| "Aspirin is known to reduce stroke risk; however, its role in reducing severity of ischemic syndrome is not clear." | 3.83 | Antecedent Aspirin Use Is Associated with Less Severe Symptoms on Admission for Ischemic Stroke. ( Cloonan, L; Fitzpatrick, KM; Furie, KL; Kanakis, AS; Nelson, S; Perilla, AS; Rost, NS; Shideler, KI, 2016) |
| "Aspirin resistance has an incidence of 5%-65% in patients with ischemic stroke, who receive the standard dose of aspirin, but the platelet function is inadequately inhibited, thereby leading to thrombotic events." | 3.83 | Associations of MDR1, TBXA2R, PLA2G7, and PEAR1 genetic polymorphisms with the platelet activity in Chinese ischemic stroke patients receiving aspirin therapy. ( Cai, YF; Chen, LY; Chen, XM; Huang, M; Jin, J; Li, JL; Peng, LL; Zhao, M; Zhao, YQ; Zhou, ZY, 2016) |
| "Plasma anticoagulation with warfarin during the early postoperative phase was shown statistically to be inferior to platelet aggregation inhibition by aspirin with regards to postoperative bleeding risk, cerebral ischemic events, and survival." | 3.83 | Anticoagulation After Biological Aortic Valve Replacement: Is There An Optimal Regimen? ( Breuer, M; Fuchs, J; Hüter, L; Kuntze, T; Lauer, B; Owais, T; Rouman, M, 2016) |
| "A significant proportion of ischemic strokes occur while using aspirin and therefore can be considered as clinical aspirin resistance." | 3.81 | Pathophysiologic, rather than laboratory-defined resistance drives aspirin failure in ischemic stroke. ( Agayeva, N; Arsava, EM; Gungor, L; Topcuoglu, MA, 2015) |
| " The aim of this study was to evaluate the protective potential of implanted human umbilical cord mesenchymal stem (hUCMs) cells with/without aspirin (ASA) against focal cerebral ischemia." | 3.81 | Coadministration of the Human Umbilical Cord Matrix-Derived Mesenchymal Cells and Aspirin Alters Postischemic Brain Injury in Rats. ( Eslaminejad, T; Esmaeilpour, K; Nematollahi-Mahani, SN; Shams ara, A; Sheibani, V, 2015) |
| " Therefore, we sought to evaluate the time-dependent changes in platelet reactivity to aspirin during the acute stage after ischemic stroke and the clinical implications of variable patient responses to aspirin in acute ischemic stroke." | 3.81 | Clinical Implications of Changes in Individual Platelet Reactivity to Aspirin Over Time in Acute Ischemic Stroke. ( Cho, KH; Choi, KH; Choi, SM; Heo, SH; Kim, BC; Kim, JT; Kim, MK; Lee, SH; Nam, TS; Park, MS; Saver, JL, 2015) |
| "In patients with ischemic stroke of non-cardioembolic origin, acetylsalicylic acid, clopidogrel, or a combination of acetylsalicylic acid and dipyridamole are recommended for the prevention of a recurrent stroke." | 3.81 | Comparison of antiplatelet regimens in secondary stroke prevention: a nationwide cohort study. ( Carlson, N; Christiansen, CB; Gerds, TA; Gislason, G; Jørgensen, ME; Kristensen, SL; Numé, AK; Olesen, JB; Pallisgaard, J; Torp-Pedersen, C, 2015) |
| "Some patients with a recent ischemic stroke who are being treated with aspirin as an antiaggregant suffer a new ischemic stroke." | 3.80 | Aspirin resistant patients with recent ischemic stroke. ( Castilla-Guerra, L; Fernández-Moreno, MC; Navas-Alcántara, MS, 2014) |
| "We estimated the effectiveness and safety of antiplatelet drugs (aspirin and clopidogrel) for the prevention of recurrent ischemic stroke in end-stage renal disease patients undergoing dialysis during long-term follow-up after first-time ischemic stroke." | 3.80 | Effectiveness and safety of antiplatelet in stroke patients with end-stage renal disease undergoing dialysis. ( Chen, CY; Huang, YB; Lai, WT; Lee, CT; Lee, KT, 2014) |
| "This study was designed to test the pre-treatment doses of guggulipid (50 mg/kg), aspirin (100 mg/kg) per orally and co-administration of both drugs for 28 days followed by middle cerebral artery occlusion - a model of focal cerebral ischemia in rats." | 3.80 | Neuroprotective effect of guggulipid alone and in combination with aspirin on middle cerebral artery occlusion (MCAO) model of focal cerebral ischemia in rats. ( Ahmad, MA; Akhtar, M; Mujeeb, M; Najmi, AK, 2014) |
| "Our objective was to investigate the association between recurrent stroke risk and headache induced by extended-release dipyridamole (ER-DP) when administered alone or with low-dose aspirin (ASA+ER-DP)." | 3.80 | Dipyridamole-induced headache and lower recurrence risk in secondary prevention of ischaemic stroke: a post hoc analysis. ( Bath, PM; Cotton, D; Davidai, G; Diener, HC; Gorelick, P; Lipton, RB; Sacco, R, 2014) |
| "To analyze the potential impact of aspirin therapy for long-term secondary prevention after stroke of undetermined etiology in resource-limited settings without access to neuroimaging to distinguish ischemic stroke from intracerebral hemorrhage (ICH)." | 3.80 | Aspirin for secondary prevention after stroke of unknown etiology in resource-limited settings. ( Berkowitz, AL; Bianchi, MT; Chou, SH; Westover, MB, 2014) |
| "Aspirin resistance is common in the population of patients with hemodynamic cerebral ischemia scheduled for cerebral revascularization." | 3.79 | Aspirin resistance in patients with hemodynamic cerebral ischemia undergoing extracranial-intracranial bypass surgery. ( Horn, P; Jussen, D; Vajkoczy, P, 2013) |
| "A prospective study included 35 patients admitted with ischemic stroke and commenced on 300 mg aspirin." | 3.79 | "Aspirin resistance" in ischemic stroke: insights using short thrombelastography. ( Curzen, N; Englyst, N; Radhakrishnan, A; Sambu, N; Weir, N, 2013) |
| "The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial found no difference between warfarin and aspirin in patients with low ejection fraction in sinus rhythm for the primary outcome: first to occur of 84 incident ischemic strokes (IIS), 7 intracerebral hemorrhages or 531 deaths." | 3.79 | Stroke in heart failure in sinus rhythm: the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial. ( Anker, SD; Di Tullio, MR; Diek, M; Freudenberger, RS; Graham, S; Haddad, H; Homma, S; Labovitz, AJ; Lok, DJ; Mann, DL; Mohr, JP; Ponikowski, P; Pullicino, PM; Qian, M; Sacco, RL; Sanford, AR; Teerlink, JR; Thompson, JL, 2013) |
| "Among patients with stroke, the phenomenon of resistance to treatment with low-dose aspirin acetylsalicylic acid (ASA) is quite common." | 3.79 | Factors influencing multiplate whole blood impedance platelet aggregometry measurements, during aspirin treatment in acute ischemic stroke: a pilot study. ( Chełstowski, K; Clark, J; Jastrzębska, M; Nowacki, P; Siennicka, A; Wódecka, A, 2013) |
| "The prognostic value of occurrence of ischemic stroke in a patient despite aspirin treatment (aspirin treatment failure) is not known." | 3.79 | Aspirin treatment failure and the risk of recurrent stroke and death among patients with ischemic stroke. ( Adams, HP; Cordina, SM; Georgiadis, AL; Lakshminarayan, K; Qureshi, AI; Suri, MF; Tariq, N; Vazquez, G, 2013) |
| "This study evaluated the antiplatelet effects of clopidogrel (CPG) in patients sustaining acute ischemic stroke who were already receiving chronic outpatient aspirin therapy (81-325 mg/day)." | 3.79 | Clopidogrel responsiveness in stroke patients on a chronic aspirin regimen. ( Chichelli, T; Ching, M; Farooq, O; Janicke, D; Li, F; Mehta, B; Munschauer, FE; Radovic, V; Sawyer, RN; Sternberg, Z, 2013) |
| " The patient was subsequently found to have incomplete inhibition of platelet activity despite being on clopidogrel 150 mg and aspirin 81 mg daily and having a normal CYP-2C19 genotype, suggesting that suboptimal antiplatelet inhibition, secondary to morbid obesity, contributed to his in-stent thrombosis." | 3.79 | Obesity and intracranial in-stent thrombosis. ( Koch, S; Reyes-Iglesias, Y; Rose, DZ; Yavagal, DR, 2013) |
| "Of the 82 patients with recurrent cerebral ischemia included in this study, 37 (45%) patients were poor compliant with aspirin." | 3.79 | Clinical and biochemical aspirin resistance in patients with recurrent cerebral ischemia. ( Abu-Hegazy, M; Azzam, H; El-Mitwalli, A; Gomaa, M; Wasel, Y, 2013) |
| "Most ischemic strokes due to TCVI are embolic in nature and occur prior to screening CTA and initiation of treatment with aspirin." | 3.79 | Timing and mechanism of ischemic stroke due to extracranial blunt traumatic cerebrovascular injury. ( Alexandrov, AV; Barlinn, K; Cava, LP; Curé, JK; Fleming, JB; Griessenauer, CJ; Harrigan, MR; Richards, BF; Taylor, T; Younan, DS; Zhao, L, 2013) |
| "Randomized trials suggested superior stroke prevention with extended-release dipyridamole (ERD) in combination with low-dose aspirin than either with aspirin or dipyridamole alone." | 3.78 | Effects of extended-release dipyridamole in vitro on thrombin indices measured by calibrated automated thrombography in poststroke survivors. ( Fong, A; Hanley, D; Pokov, I; Sani, Y; Schevchuck, A; Serebruany, V; Thevathasan, L, 2012) |
| "The widespread use of aspirin-driven vascular prevention strategies does not impede the occurrence of first and recurrent ischemic strokes in numerous subjects." | 3.78 | Ischemic stroke in patients receiving aspirin. ( Ameriso, S; Ameriso, SF; Povedano, GP; Pujol Lereis, VA, 2012) |
| "Aspirin is the most commonly used antiplatelet drug for treatment of a serious vascular event, most notably myocardial infarction and stroke." | 3.78 | Association of C3435T multi drug resistance gene-1 polymorphism with aspirin resistance in ischemic stroke and its subtypes. ( Al-Hazzani, A; Dadheech, S; Jyothy, A; Kaul, S; Munshi, A; Prabha, TS; Rao, PP; Sharma, V, 2012) |
| " In this study, the authors assess the incidence of stroke or transient ischemic attack (TIA) following discontinuation of a 6-week course of clopidogrel in patients with cerebral aneurysms treated with stent-assisted techniques." | 3.78 | Incidence of cerebral ischemic events after discontinuation of clopidogrel in patients with intracranial aneurysms treated with stent-assisted techniques. ( Abel, TJ; Chalouhi, N; Hasan, DM; Jabbour, PM; Kung, DK; Rossen, JD; Thomas, J; Wassef, SN, 2012) |
| "We enrolled patients within 24 h of ischemic stroke and a group of controls taking aspirin who had never suffered a vascular event on therapy." | 3.77 | Aspirin resistance and compliance with therapy. ( Dawson, J; Higgins, P; Lees, KR; Quinn, T; Rafferty, M; Ray, G; Walters, MR, 2011) |
| "A total of 85 patients with acute ischemic stroke on 160mg aspirin daily were prospectively included." | 3.77 | Aspirin non-responder status and early neurological deterioration: a prospective study. ( Bugnicourt, JM; Canaple, S; Garcia, PY; Godefroy, O; Lamy, C; Roussel, B, 2011) |
| "The accuracy of the NHIRD in recording ischemic stroke diagnoses and aspirin prescriptions was high, and the NHIRD appears to be a valid resource for population research in ischemic stroke." | 3.77 | Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. ( Cheng, CL; Kao, YH; Lai, ML; Lee, CH; Lin, SJ, 2011) |
| " The aim of the present study is to investigate the effects of cilostazol and aspirin on endothelial nitric oxide synthase (eNOS) phosphorylation in the cerebral cortex, endothelial function, and infarct size after brain ischemia in spontaneously hypertensive rats (SHR)." | 3.77 | Cilostazol, not aspirin, reduces ischemic brain injury via endothelial protection in spontaneously hypertensive rats. ( Kawamura, M; Kitagawa, K; Omura-Matsuoka, E; Oyama, N; Sasaki, T; Sugiyama, Y; Terasaki, Y; Yagita, Y, 2011) |
| "In AF patients with CHADS(2) score 1, warfarin was better to prevent ischemic stroke than aspirin without increasing the incidence of major bleeding complications." | 3.76 | The effect and safety of the antithrombotic therapies in patients with atrial fibrillation and CHADS score 1. ( Choi, DH; Hwang, ES; Kim, SK; Kim, YH; Kwak, JJ; Lee, BH; Pak, HN; Park, JH; Park, JS, 2010) |
| "Administrative claims from a large, geographically diverse US health plan were used to evaluate acetylsalicylic acid / extended-release dipyridamole (ASA/ERDP) treated and clopidogrel treated patients from November 1, 2002 - December 31, 2005 who had an ischemic stroke requiring hospitalization." | 3.76 | Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors. ( Burke, JP; Henk, H; Sander, S; Shah, H; Zarotsky, V, 2010) |
| "A rapid and sustained reduction in the frequency of aspirin+clopidogrel use in ischemic stroke and transient ischemic attack was observed after publication of the MATCH trial in the absence of MATCH-specific GWTG-Stroke initiatives and preceding an American Heart Association guideline update." | 3.76 | Rapid change in prescribing behavior in hospitals participating in get with the guidelines-stroke after release of the management of atherothrombosis with clopidogrel in high-risk patients (MATCH) clinical trial results. ( Ellrodt, G; Fonarow, GC; Frankel, MR; Hernandez, AF; Labresh, KA; Liang, L; Menon, BK; Schwamm, LH; Smith, EE, 2010) |
| "In patients with AF, all combinations of warfarin, aspirin, and clopidogrel are associated with increased risk of nonfatal and fatal bleeding." | 3.76 | Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. ( Abildstrøm, SZ; Andersen, SS; Clausen, MT; Fog-Petersen, ML; Folke, F; Gadsbøll, N; Gislason, GH; Hansen, ML; Køber, L; Poulsen, HE; Raunsø, J; Schramm, TK; Sørensen, R; Torp-Pedersen, C, 2010) |
| " We replicated the observation of the Atherosclerosis Risk in Communities Study and observed an interaction of rs20417 with aspirin use on myocardial infarction risk (p for interaction=0." | 3.75 | Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke. ( Bis, JC; Heckbert, SR; Lemaitre, RN; Lumley, TS; Marciante, K; Psaty, BM; Rice, K; Smith, NL; Wiggins, KL, 2009) |
| "A considerable proportion of patients discontinue dipyridamole therapy because of headache." | 3.75 | Risk indicators for development of headache during dipyridamole treatment after cerebral ischaemia of arterial origin. ( Algra, A; Halkes, PH; Kappelle, LJ; Koudstaal, PJ; van Gijn, J, 2009) |
| "Encourage men age 45 to 79 years to use aspirin when the potential benefit of a reduction in myocardial infarctions outweighs the potential harm of an increase in gastrointestinal hemorrhage." | 3.75 | Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. ( , 2009) |
| "There are very limited data on the influence of pretreatment with aspirin (ASA) on the etiology of subsequent first-ever ischemic stroke." | 3.75 | Pretreatment with aspirin and etiology of first-ever ischemic stroke in young and middle-aged patients. ( Kouperberg, E; Sprecher, E; Telman, G; Yarnitsky, D, 2009) |
| " We tested the hypothesis that combined pre-treatment with aspirin and clopidogrel is a risk factor for thrombolysis-related symptomatic intracerebral hemorrhage (sICH)." | 3.75 | Combined anti-platelet therapy with aspirin and clopidogrel: risk factor for thrombolysis-related intracerebral hemorrhage in acute ischemic stroke? ( Dzialowski, I; Gahn, G; Hermann, A; Koch, R, 2009) |
| "Aspirin remains the most commonly used antithrombotic agent for the prevention of recurrent stroke among antithrombotic naive patients with a first-ever ischemic stroke in our institution." | 3.75 | The prescribing patterns of antithrombotic agents for prevention of recurrent ischemic stroke. ( Hseuh, IH; Lin, YJ; Po, HL, 2009) |
| " Ischemic stroke was predicted by hypertension, myocardial infarction, low-dose aspirin, comorbidity score, Health Assessment Questionnaire score, and presence of total joint replacement, but not by diabetes, smoking, exercise, or body mass index." | 3.74 | Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. ( Hallenbeck, JM; Michaud, K; Nadareishvili, Z; Wolfe, F, 2008) |
| "Aspirin is an important therapeutic regimen to prevent the recurrent ischemic events or death after acute ischemic stroke." | 3.74 | ADP-induced platelet aggregation in acute ischemic stroke patients on aspirin therapy. ( Cha, JK; Jeon, HW; Kang, MJ, 2008) |
| "Based on the risk-benefit analysis, warfarin prophylaxis for cardioembolic stroke in Chagas' disease is recommended for patients with a score of 4-5 points, in whom the risk of CE overweighs the risk of a major bleeding." | 3.74 | Prevention strategies of cardioembolic ischemic stroke in Chagas' disease. ( Freitas, GR; Hasslocher-Moreno, A; Sousa, AS; Xavier, SS, 2008) |
| "The results suggest that triflusal and aspirin appear to be equally neuroprotective against middle cerebral artery occlusion-induced cerebral ischemia." | 3.74 | Effects of triflusal and aspirin in a rat model of cerebral ischemia. ( Allen, GV; Bayona, NA; Cechetto, DF; Cheng, G; Hachinski, VC; Whitehead, SN, 2007) |
| "To report a case of cerebral ischemia in a patient receiving oral isotretinoin for severe acne." | 3.74 | Cerebral ischemia probably related to isotretinoin. ( Laroche, ML; Macian-Montoro, F; Merle, L; Vallat, JM, 2007) |
| "The present study was carried out to investigate the effect of the combination of an endothelin antagonist TAK-044 and an antiinflammatory agent aspirin in middle cerebral artery (MCA) occlusion model of acute ischemic stroke in rats." | 3.74 | Effect of combination of endothelin receptor antagonist (TAK-044) and aspirin in middle cerebral artery occlusion model of acute ischemic stroke in rats. ( Briyal, S; Gulati, A; Gupta, YK, 2007) |
| "In acute ischemic stroke and transient ischemic attack (TIA), aspirin is recommended to all patients (except immediately following thrombolysis)." | 3.74 | [Antithrombotic therapy in ischemic stroke and transient ischemic attack]. ( Husted, SE; Overgaard, K; Poulsen, TS, 2007) |
| "A total of 88 patients taking aspirin daily for the secondary prevention of stroke were included." | 3.74 | Can aspirin resistance be clinically predicted in stroke patients? ( Bang, OY; Choi, YJ; Huh, K; Joo, IS; Lee, PH; Seok, JI; Yoon, JH, 2008) |
| "We studied 137 patients undergoing antiplatelet therapy with clopidogrel and 336 patients with aspirin for the occurrence of neurological events (ischemic stroke and/or carotid revascularization)." | 3.73 | Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. ( Amighi, J; Brunner, M; Exner, M; Felber, K; Funk, M; Mannhalter, C; Minar, E; Mlekusch, W; Müller, M; Sabeti, S; Schillinger, M; Ziegler, S, 2005) |
| "We aimed to study the timing of aspirin prescription in ischaemic stroke comparing patients admitted to an acute stroke unit (ASU) directly or via a general medical ward." | 3.73 | Timing of aspirin and secondary preventative therapies in acute stroke: support for use of stroke units. ( MacLeod, MJ; Reid, J; Williams, D, 2005) |
| "To study the discontinuation of aspirin therapy as a risk factor for ischemic stroke (IS)." | 3.73 | Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. ( Bezerra, DC; Bogousslavsky, J; Maulaz, AB; Michel, P, 2005) |
| " The antiplatelet drugs acetylsalicylic acid (aspirin) and a thienopyridine derivative (ticlopidine) are commonly used to treat cerebral ischemia but exert different effects on high-shear-stress-induced platelet aggregation (H-SIPA) in the plasma." | 3.73 | Platelets treated with ticlopidine are less reactive to unusually large von Willebrand factor multimers than are those treated with aspirin under high shear stress. ( Fujimura, Y; Iida, J; Ishizashi, H; Kawaguchi, S; Matsumoto, M; Sakaki, T; Yagi, H, 2005) |
| "Our findings do not concur with the hypothesis that aspirin, dipyridamole, or the combination may be especially effective in preventing vascular events in patients with previous cerebral ischemia that was caused by LVD compared with SVD." | 3.73 | Antiplatelet drugs in the secondary prevention after stroke: differential efficacy in large versus small vessel disease? A subgroup analysis from ESPS-2. ( Algra, A; Ariesen, MJ; Kappelle, LJ, 2006) |
| "We studied outpatients of 5 neurological ambulatory centers in an urban city, Valencia, all with a history of ischemic stroke who had received aspirin for at least 6 months." | 3.73 | Adherence to aspirin in secondary prevention of ischemic stroke. ( Ferrer, JM; Lago, A; Pareja, A; Ponz, A; Santos, MT; Tembl, JI; Vallés, J, 2006) |
| "The purpose of this study was to determine safety and tolerability of clopidogrel in children with arterial ischemic stroke (AIS)." | 3.73 | The risks and safety of clopidogrel in pediatric arterial ischemic stroke. ( Allen, A; deVeber, G; Hune, S; MacGregor, D; Rafay, MF; Soman, T, 2006) |
| "Millions of people around the world regularly consume aspirin, but its value in determining stroke severity is still not clear." | 3.73 | Does prior aspirin use reduce stroke mortality? ( Demirkaya, M; Karlikaya, G; Orken, C; Tireli, H; Varlbas, F, 2006) |
| " Bleeding complications occurred in 2 patients receiving aspirin, 1 patient receiving warfarin, and 5 patients who did not receive anticoagulant or antiplatelet therapy." | 3.73 | Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. ( Galor, A; Hoffman, GS; Lee, MS; Smith, SD, 2006) |
| "In the recently published Warfarin Aspirin Recurrent Stroke Study (WARSS), a low-intensity anticoagulation regimen was used because of safety concerns." | 3.72 | Oral anticoagulation in patients after cerebral ischemia of arterial origin and risk of intracranial hemorrhage. ( , 2003) |
| "The authors describe course and outcome of eight patients with ischemic stroke as the first thrombotic manifestation of antiphospholipid syndrome who received low-dose aspirin as prophylactic treatment." | 3.72 | Low dose aspirin after ischemic stroke associated with antiphospholipid syndrome. ( de Groot, PG; Derksen, RH; Kappelle, LJ, 2003) |
| "Of 596 ischemic strokes, 32 percent occurred during warfarin therapy, 27 percent during aspirin therapy, and 42 percent during neither type of therapy." | 3.72 | Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. ( Chang, Y; Go, AS; Henault, LE; Hylek, EM; Jensvold, NG; Selby, JV; Singer, DE, 2003) |
| "To investigate the protective effects and mechanism of action of aspirin on focal cerebral ischemia-reperfusion rats." | 3.72 | [Protective effects and mechanism of action of aspirin on focal cerebral ischemia-reperfusion in rats]. ( Chen, CH; Qiu, LY; Yu, J; Zhou, Y, 2003) |
| "Using the CAPRIE database, we performed multivariate analyses for patients who had symptomatic atherosclerotic disease (ischemic stroke [IS] or myocardial infarction [MI]) in their medical history before enrollment in the Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) trial." | 3.72 | Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. ( Bhatt, DL; Hacke, W; Hirsch, AT; Ringleb, PA; Topol, EJ, 2004) |
| "The results with GP in acute ischemic stroke are promising and further studies should be initiated using especially tirofiban, but with monitoring by cerebral diffusion-weighted MRI before and after treatment." | 3.72 | [Efficacy and safety of treatment of acute ischemic stroke with glycoprotein IIb/IIIa receptor blocker in routine clinical practice]. ( Haerten, K; Krabbe, C; Raiber, M, 2004) |
| "From a consecutive series of AF patients with first-ever ischemic stroke, we evaluated prospectively those with moderate to severe disability (grade 4-5 on the modified Rankin Scale) who were treated during a 5-year follow-up period with either warfarin or aspirin." | 3.72 | Anticoagulation influences long-term outcome in patients with nonvalvular atrial fibrillation and severe ischemic stroke. ( Manios, E; Moulopoulos, SD; Spengos, K; Toumanidis, S; Tsivgoulis, G; Vemmos, KN; Zakopoulos, N, 2004) |
| " The findings also suggest that older patients and those who have used aspirin before stroke are at higher risk of a severe HT on rtPA." | 3.71 | Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). ( Bluhmki, E; Larrue, V; Müller, A; von Kummer R, R, 2001) |
| "The potential neuroprotective effects of the novel nitro-derivate of aspirin (NCX4016) on permanent focal cerebral ischemia in spontaneously hypertensive rats (SHRs) was investigated." | 3.71 | Nitro-aspirin (NCX4016) reduces brain damage induced by focal cerebral ischemia in the rat. ( Ambrosini, MV; Del Soldato, P; Fredduzzi, S; Mariucci, G; Tantucci, M, 2001) |
| "Patients with both patent foramen ovale and atrial septal aneurysm who have had a stroke constitute a subgroup at substantial risk for recurrent stroke, and preventive strategies other than aspirin should be considered." | 3.71 | Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. ( Arquizan, C; Cabanes, L; Coste, J; Derumeaux, G; Lamy, C; Mas, JL; Zuber, M, 2001) |
| "A previous study indicated that diaspirin-crosslinked hemoglobin (DCLHb) decreases cerebral ischemia after subarachnoid hemorrhage." | 3.70 | Subarachnoid molecular hemoglobin after subarachnoid hemorrhage in rats: effect on the area of hypoperfusion. ( Cole, DJ; Cross, LM; Drummond, JC; McKay, LD; Patel, PM, 1998) |
| "Recently developed interventional radiologic techniques, such as embolization with platinum coils, may induce thrombus formation within an aneurysm." | 3.70 | Detection of microemboli distal to cerebral aneurysms before and after therapeutic embolization. ( Berlit, P; Henkes, H; Klötzsch, C; Kühne, D; Nahser, HC, 1998) |
| "Anesthetized swine were randomized to receive SPR, diaspirin cross-linked hemoglobin, or DR after cryogenic brain injury and uncontrolled hemorrhagic shock and studied for 70 minutes after the combined insults." | 3.70 | Comparison of standard and alternative prehospital resuscitation in uncontrolled hemorrhagic shock and head injury. ( Bourguignon, P; Buckingham, S; Nichols, P; Novak, L; Osler, T; Sartorelli, K; Shackford, SR, 1999) |
| "Ischemic event rates were estimated for 12,931 aspirin users drawn from the Saskatchewan Health population between 1990 and 1995 who had an index diagnosis of myocardial infarction, ischemic stroke, or peripheral arterial disease." | 3.70 | Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemi ( Caro, JJ; Migliaccio-Walle, K, 1999) |
| "Large intervention studies suggest that aspirin may reduce mortality when given to patients who present with strokes or transient ischemic attacks." | 3.70 | Does prior use of aspirin affect outcome in ischemic stroke? ( Kalra, L; Perez, I; Smithard, DG; Sulch, D, 2000) |
| "This follow-up study was designed to evaluate whether the use of aspirin either before or after aneurysm rupture affects the occurrence of delayed cerebral ischemia." | 3.69 | Aspirin and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. ( Juvela, S, 1995) |
| "To assess the risk of bleeding complications in patients treated with combination aspirin and heparin for cerebral ischemia." | 3.69 | Safety of combination aspirin and anticoagulation in acute ischemic stroke. ( Fagan, SC; Kertland, HR; Tietjen, GE, 1994) |
| "During a 1-year period, we prospectively studied the mechanism and severity of stroke in 47 patients sustaining a cerebral infarction while taking aspirin." | 3.68 | Mechanism of stroke in patients taking aspirin. ( Chimowitz, MI; Furlan, AJ; Nayak, S; Sila, CA, 1990) |
| "The aggregability of platelets to arachidonic acid (AA) was investigated in 26 control subjects, 40 patients with essential hypertension, 20 patients with ischemic cerebrovascular diseases (CVD) not taking aspirin and 11 patients with CVD taking aspirin." | 3.66 | Platelet aggregation induced by arachidonic acid and thromboxane generation in patients with hypertension or cerebrovascular disease. ( Abe, H; Fujisawa, A; Kimura, K; Kusunoki, M; Matsumoto, M; Matsuyama, T; Uyama, O; Yoneda, S, 1981) |
| "Bleeding was defined using the International Society on Thrombosis and Haemostasis five-level ordered categorical scale: fatal, major, moderate, minor, none." | 3.30 | Bleeding with intensive versus guideline antiplatelet therapy in acute cerebral ischaemia. ( Appleton, JP; Bath, PM; Christensen, H; Dineen, RA; England, TJ; James, M; Krishnan, K; Montgomery, AA; Ranta, A; Robinson, TG; Sprigg, N; Woodhouse, LJ, 2023) |
| "Cerebral small vessel disease is characterized by progressive cerebral white matter changes (WMCs)." | 3.11 | Cilostazol Versus Aspirin on White Matter Changes in Cerebral Small Vessel Disease: A Randomized Controlled Trial. ( Cho, SJ; Choi, SH; Choi, YH; Han, HJ; Jeong, JH; Kim, BC; Kim, EJ; Kim, JH; Kim, S; Lee, JH; Lee, JM; Na, DL; Oh, MS; Park, G; Park, HY; Park, KC; Park, KH; Park, KW; Park, SA; Shim, Y; Yoon, B; Yoon, SJ; Youn, YC, 2022) |
| "Cancer is a frequent finding in ischaemic stroke patients." | 2.94 | Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial. ( Berkowitz, SD; Chamorro, A; Demchuk, A; Hart, RG; Joensuu, H; Kasner, SE; Liu, YY; Marti-Fabregas, J; Martinez-Majander, N; Mundl, H; Ntaios, G; Perera, KS; Prats-Sanchez, L; Rudilosso, S; Saarinen, J; Tatlisumak, T; Themeles, E; Tiainen, M; Ylikotila, P, 2020) |
| "The concept of embolic stroke of undetermined source (ESUS) unifies a subgroup of cryptogenic strokes based on neuroimaging, a defined minimum set of diagnostic tests, and exclusion of certain causes." | 2.94 | Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source: Secondary Analysis of a Randomized Clinical Trial. ( Ameriso, SF; Arauz, A; Berkowitz, SD; Chamorro, Á; Connolly, SJ; Hankey, GJ; Hart, RG; Kasner, SE; Korompoki, E; Lindgren, A; Muir, KW; Mundl, H; Ozturk, S; Pearce, LA; Perera, K; Rudilosso, S; Sharma, M; Shoamanesh, A; Shuaib, A; Tatlisumak, T; Toni, D; Veltkamp, R, 2020) |
| "OBJECTIVE Clinical vasospasm and delayed cerebral ischemia (DCI) are devastating complications of aneurysmal subarachnoid hemorrhage (aSAH)." | 2.87 | Dual antiplatelet therapy in aneurysmal subarachnoid hemorrhage: association with reduced risk of clinical vasospasm and delayed cerebral ischemia. ( Allan, L; Broderick, J; Brown, RD; Chalouhi, N; Chimowitz, M; Derdeyn, CP; Hasan, D; Jabbour, P; Leira, EC; Nagahama, Y; Nakagawa, D; Starke, RM; Torner, JC; Zanaty, M, 2018) |
| "aspirin monotherapy was carried out, to determine optimal peri-operative management with these antiplatelet agents." | 2.82 | Editor's Choice - Peri-Operative Outcomes of Carotid Endarterectomy are Not Improved on Dual Antiplatelet Therapy vs. Aspirin Monotherapy: A Systematic Review and Meta-Analysis. ( Bissacco, D; Chechik, O; Chisci, E; Cusimano, MD; Ku, JC; Larrue, V; Macdonald, RL; Michelagnoli, S; Nasr, N; Pasarikovski, CR; Priola, SM; Rabinovich, Y; Settembrini, PG; Taslimi, S; Yang, VXD; Zuccato, J, 2022) |
| "Acute stroke is the leading cause of disability in the UK and a leading cause of mortality worldwide." | 2.82 | Antiplatelet treatment for acute secondary prevention of non-cardioembolic minor stroke / transient ischaemic attack: an update for the acute physician. ( Appleton, JP; Bath, PM; Dawson, J; England, TJ; Eveson, D; Krishnan, K; Law, ZK; Mavilakandy, A; Minhas, JS; Mistri, A; Robinson, TG; Sprigg, N, 2022) |
| "The primary outcome is IS recurrence." | 2.80 | Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial. ( Hoshino, H; Kimura, K; Minematsu, K; Naritomi, H; Origasa, H; Toyoda, K; Uchiyama, S; Yamaguchi, T, 2015) |
| "60." | 2.79 | Triflusal and aspirin in the secondary prevention of atherothrombotic ischemic stroke: a very long-term follow-up. ( Alvarez-Sabín, J; Maisterra, O; Quintana, M; Santamarina, E, 2014) |
| "Despite improvements in treatment, stroke still carries a high death toll and disability in Asia." | 2.76 | The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial. ( Horie, Y; Ikeda, Y; Uchiyama, S; Urano, Y; Yamaguchi, T, 2011) |
| " These results suggest that administration of aspirin and cilostazol is safe for acute ischemic stroke." | 2.76 | Pilot study of the safety of starting administration of low-dose aspirin and cilostazol in acute ischemic stroke. ( Fujita, K; Higuchi, O; Kamezaki, T; Komatsu, Y; Kujiraoka, Y; Matsumura, A; Sato, N; Suzuki, K, 2011) |
| " It is impossible to exclude that long term administration of warfarin in strategy of sinus rhythm maintenance attenuated advantages of normal rhythm in relation of lowering of stroke risk in AFFIRM study and other similar works." | 2.73 | [Prevention of ischemic stroke in middle aged patients with atrial fibrillation. Effect of sinus rhythm maintenance, aspirin, warfarin, and simvastatin]. ( Kanorskiĭ, SG; Shevelev, VI; Zafiraki, VK; Zingilevskiĭ, KB, 2007) |
| "Patients with minor ischemic stroke or transient ischemic attack represent a high-risk population for recurrent stroke." | 2.72 | Ticagrelor vs Clopidogrel in addition to Aspirin in minor ischemic stroke/ transient ischemic attack-Protocol for a systematic review and network meta-analysis. ( Dhaliwal, S; Dowlatshahi, D; Hutton, B; Lun, R; Roy, DC; Shorr, R; Zitikyte, G, 2021) |
| "Location of stenosis, type of qualifying event, and prior use of antithrombotic medications were not associated with increased risk." | 2.72 | Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis. ( Benesch, CG; Chaturvedi, S; Chimowitz, MI; Cloft, HJ; Frankel, MR; Hertzberg, VS; Howlett-Smith, H; Jovin, TG; Kasner, SE; Levine, SR; Lynn, MJ; Romano, JG; Sila, CA; Stern, BJ, 2006) |
| " There is no study that assessed the effect of age on adverse event rates in cryptogenic stroke patients with PFO." | 2.71 | Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale. ( DiTullio, MR; Homma, S; Mohr, JP; Sacco, RL; Sciacca, RR, 2004) |
| "Both high blood pressure and low blood pressure were independent prognostic factors for poor outcome, relationships that appear to be mediated in part by increased rates of early recurrence and death resulting from presumed cerebral edema in patients with high blood pressure and increased coronary heart disease events in those with low blood pressure." | 2.70 | Blood pressure and clinical outcomes in the International Stroke Trial. ( Bath, PM; Leonardi-Bee, J; Phillips, SJ; Sandercock, PA, 2002) |
| "Aspirin use at entry was also associated with a 4-fold (95% CI, 1." | 2.69 | Aspirin use and incident stroke in the cardiovascular health study. CHS Collaborative Research Group. ( Beauchamp, NJ; Hart, RG; Kronmal, RA; Manolio, TA; Newman, A; Talbert, RL, 1998) |
| "We studied 68 patients with 50% to 99% stenosis of one of the following arteries: intracranial vertebral (n = 31), basilar (n = 28), posterior cerebral (PCA) (n = 6), or posterior inferior cerebellar (PICA) (n = 3)." | 2.69 | Prognosis of patients with symptomatic vertebral or basilar artery stenosis. The Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Study Group. ( , 1998) |
| " Two patients in the 100 mg/kg group had adverse events that were possibly drug related: one suffered fatal brain and pulmonary edema, the other transient renal and pancreatic insufficiency." | 2.69 | Controlled safety study of a hemoglobin-based oxygen carrier, DCLHb, in acute ischemic stroke. ( Carton, H; Hacke, W; Kaste, M; Koudstaal, PJ; Przybelski, RJ; Saxena, R; Stern, KN; Wijnhoud, AD, 1999) |
| "As part of a multicenter treatment trial of vascular dementia, this method was then used to analyze MR films in 13 patients with vascular dementia who all had an MR study at baseline and at 1 year." | 2.68 | Volumetric measurement of multifocal brain lesions. Implications for treatment trials of vascular dementia and multiple sclerosis. ( Broderick, JP; Dhawan, AP; Gaskill, M; Khoury, J; Narayan, S, 1996) |
| "Many clinical trials have evaluated the benefit of long-term use of antiplatelet drugs in reducing the risk of clinical thrombotic events." | 2.68 | A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. ( , 1996) |
| "Only aspirin has been evaluated in the setting of primary prevention and it seems to be ineffective in preventing cerebral infarction." | 2.68 | [Primary and secondary prevention of ischemic cerebrovascular accidents of arteriosclerosis by platelet inhibitors]. ( Canaple, S; Rosa, A, 1996) |
| " This paper reviews the pattern of adverse reactions to AAS and their relationship to the dosage of ASS evaluated." | 2.68 | [Secondary prevention of ischemic strokes: effect of dosage of aspirin]. ( Alvarez-Sabín, J; Calvo, G; Morros, R, 1997) |
| "The subjects were 75 patients with cerebral ischemia and 26 control subjects." | 2.67 | Shear-induced platelet aggregation in cerebral ischemia. ( Fukuyama, M; Handa, M; Ikeda, Y; Itagaki, I; Maruyama, S; Uchiyama, S; Yamazaki, M, 1994) |
| "048), and the frequency of adverse events was not significantly different between the two treatment groups." | 2.67 | The efficacy and safety of ticlopidine and aspirin in non-whites: analysis of a patient subgroup from the Ticlopidine Aspirin Stroke Study. ( Weisberg, LA, 1993) |
| "The number of fatal and non fatal cerebral infarction was 31 in the P group, 17 in the ASA group, and 18 in the ASA + D group." | 2.65 | [The A.I.C.L.A. controlled cooperative trial. Secondary prevention of cerebral ischemic accidents due to atherosclerosis by aspirin and dipyridamole. 3: Results]. ( Bousser, MG; Eschwege, E; Haguenau, M; Lefauconnier, JM; Thibult, N; Touboul, D; Touboul, PJ, 1983) |
| "Recurrent stroke is common immediately following a transient ischemic attack (TIA) or ischemic stroke." | 2.61 | Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials. ( Abdalla, A; Ahmed, S; Al Qasmi, M; Bachuwa, G; Bhatt, DL; Chahine, A; Hassan, M; Haykal, T; Kheiri, B; Osman, M; Swaid, B, 2019) |
| "Stroke is one of the leading causes of death." | 2.55 | Genetic Signatures in Ischemic Stroke: Focus on Aspirin Resistance. ( Chaurasia, P; Munshi, A; Singh, S; Vasudeva, K, 2017) |
| "Performance in patients with cerebral ischemia was poor." | 2.53 | Prediction models for intracranial hemorrhage or major bleeding in patients on antiplatelet therapy: a systematic review and external validation study. ( Algra, A; Greving, JP; Hilkens, NA, 2016) |
| " Cilostazol-based TAPT compared with DAPT is associated with improved angiographic outcomes and decreased risk of TLR and TVR but does not reduce major cardiovascular events and is associated with an increase in minor adverse events." | 2.52 | Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials. ( Bai, J; Chen, J; Chen, P; Eikelboom, JW; Gong, X; Kong, D; Li, C; Liu, J; Meng, H; Xu, L; Yang, Z; Zou, F, 2015) |
| " In addition, the discussion here reviews select acute ischemic stroke intravenous thrombolytic studies, such as the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study and European Cooperative Acute Stroke Studies, select neuroprotectant and endovascular clot retrieval device studies, and large cooperative databases, such as the Virtual International Stroke Trials Archive and Safe Implementation of Treatment in Stroke-International Stroke Thrombolysis Registry, to explore relationships between baseline stroke severity and other possible factors associated with efficacy and safety outcomes." | 2.48 | How baseline severity affects efficacy and safety outcomes in acute ischemic stroke intervention trials. ( Gorelick, PB, 2012) |
| "In acute intracerebral hemorrhage the beneficial effect of recombinant coagulation factor VII found in a small study could not be proved in a large phase III trial." | 2.45 | [Pharmacotherapy of stroke]. ( Bereczki, D, 2009) |
| "Most strokes are caused by a sudden blockage of an artery in the brain (called an ischaemic stroke) that is usually due to a blood clot." | 2.45 | Antiplatelet treatment in ischemic stroke treatment. ( Arnao, V; Di Raimondo, D; Di Sciacca, R; La Placa, S; Licata, G; Miceli, S; Milio, G; Pinto, A; Tuttolomondo, A, 2009) |
| "Stroke is a leading cause of death and the primary cause of serious, long-term disability in the United States." | 2.44 | Combination antiplatelet agents for secondary prevention of ischemic stroke. ( Saseen, JJ; Vande Griend, JP, 2008) |
| "Ischemic stroke is a common complication after CABG." | 2.44 | Prevention of ischemic stroke: surgery. ( Chaturvedi, S; Rajamani, K, 2007) |
| "Twenty-three children had varicella at age 1." | 2.43 | Post-varicella arteriopathy of childhood: natural history of vascular stenosis. ( Armstrong, D; deVeber, G; Domi, T; Lanthier, S, 2005) |
| "Approximately 7000 intracerebral hemorrhages (ICHs) annually in the US are caused by use of antithrombotic therapies." | 2.43 | Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas. ( Hart, RG; Pearce, LA; Tonarelli, SB, 2005) |
| " The optimum doses of antiplatelet drugs depend upon several variables, such as genetic and environmental factors, so that clinical and laboratory response for dosage varies for each patient." | 2.43 | Antiplatelet therapy in ischemic stroke. ( Káposzta, Z; Pongrácz, E, 2005) |
| "About 80% of strokes have ischemic origin." | 2.43 | [Current concepts of the antiplatelet and anticoagulant treatment in the prevention of stroke]. ( Szapáry, L, 2005) |
| "Ischemic stroke is a leading cause of death and disability in the Western world." | 2.43 | Therapy for early reperfusion after stroke. ( Juttler, E; Kohrmann, M; Schellinger, PD, 2006) |
| "Aspirin treatment of erythromelalgia in thrombocythemia patients resulted in the disappearance of the erythromelalgic, thrombotic signs and symptoms, correction of the shortened platelet survival times, and a significant reduction of the increased levels of beta-TG, PF4, TM and urinary TxB2 excretion to normal." | 2.42 | Platelet-mediated microvascular inflammation and thrombosis in thrombocythemia vera: a distinct aspirin-responsive arterial thrombophilia, which transforms into a bleeding diathesis at increasing platelet counts. ( Michiels, JJ, 2003) |
| "The risk of TIA or stroke recurrence reaches 30-45%." | 2.42 | [Stenosis of the carotid arteries]. ( Kaźmierski, MK, 2003) |
| "Ticlopidine is a reserve drug due to its unfavorable side effect profile (neutropenia, TTP)." | 2.42 | [The value of platelet inhibitors in the secondary prophylaxis of stroke -- a review]. ( Jüttler, E; Meyding-Lamadé, UK; Schellinger, PD; Schwark, C, 2004) |
| "Paroxysmal AF is an important cause of brain embolism, that is often difficult to document." | 2.42 | Atrial fibrillation and cardioembolic stroke. ( Ferro, JM, 2004) |
| "Aspirin treatment does not preclude control of underlying and comorbid conditions such as diabetes mellitus, hypertension, and dyslipidemia." | 2.41 | Aspirin in the prophylaxis of coronary artery disease. ( Mehta, P, 2002) |
| "In comparison with transient ischemic attacks in patients with vascular risk factors, the usual neurologic presentation of ET consists of brief attacks of sudden cerebral or visual dysfunction, which can be either well localized or diffuse and entirely nonspecific." | 2.40 | Neurologic and visual symptoms in essential thrombocythemia: efficacy of low-dose aspirin. ( Koudstaal, A; Koudstaal, PJ, 1997) |
| "Four patients presented transient ischemic attacks, one amaurosis fugax, two suffered from a minor stroke, four had non-focalized ischemic cerebral symptoms and two were asymptomatic." | 2.40 | Fibromuscular dysplasia of the internal carotid artery. Personal experience with 13 cases and literature review. ( Limet, R; Sakalihasan, N; Van Damme, H, 1999) |
| " Furthermore, in assessing the potential benefits of long-term use of ASA for prophylactic purposes in these patients, one should also evaluate the side-effects and intolerance related to its chronic use, as well as its potential complications especially from a gastrointestinal perspective." | 2.39 | Aspirin in asymptomatic carotid disease. ( Côté, R, 1994) |
| " Among the anti-aggregant agents, only Aspirin at high dosage (1 to 1." | 2.37 | [The fate of patients with carotid stenosis. Comparative study, based on the literature, of their natural history and evolution under medical treatment or following endarterectomy]. ( Bachet, P; Ninet, J; Pasquier, J, 1985) |
| "The therapeutic outcomes for acute ischemic stroke (AIS) with early neurological deterioration (END) are adverse." | 1.91 | Efficacy and Prognosis of Adjuvant Argatroban Treatment in Acute Ischemic Stroke Patients with Early Neurological Deterioration. ( Wu, T; Xu, S; Xu, Z; Zhang, W; Zhang, Y, 2023) |
| "Aspirin nanoparticles were formulated in this study which may offer better therapeutic advantages over the conventional aspirin tablets in the prevention and management of acute myocardial infarction and ischaemic stroke." | 1.91 | Formulation of aspirin nanoparticles using solvent evaporation method and in vivo evaluation of its antithrombotic effect. ( Alhajj, L; Ovenseri Airemwen, C; Pozharani, LB, 2023) |
| "Acute cerebral ischemia was discovered to be the most common cerebrovascular disease associated with SARS-CoV-2." | 1.72 | Coexistence of SARS-CoV-2 and cerebrovascular diseases: does COVID-19 positivity trigger cerebrovascular pathologies? ( Ates, O; Dogan, M; Ersoz, E; Hacioglu Kasim, FB; Karaarslan, N; Ozbek, H; Yilmaz, I, 2022) |
| "We report a case of ischaemic stroke in a 34-year-old male recreational bodybuilder following a 3-month period of anabolic androgenic steroid (AAS) use and 1-month period of 'post-cycle therapy' (tamoxifen and clomiphene citrate), the latter treatments aimed at restoring normal endogenous testosterone production after initial AAS use." | 1.62 | Anabolic steroid use and ischaemic stroke in a young fitness enthusiast. ( Choulerton, J; Guha, N; Squires, R, 2021) |
| "Platelet thrombosis is the main pathogeny resulting in the low curability of ischemic stroke, a leading cause of mortality and disability worldwide." | 1.56 | Novel potent antiplatelet thrombotic agent derived from biguanide for ischemic stroke. ( Chen, Z; He, Y; Huang, W; Ji, C; Lee, KH; Li, S; Li, Y; Ming, Y; Morris-Natschke, SL; Niu, H; Wei, Z; Xin, G; Xing, Z; Yang, X; Yu, K; Zhang, B; Zhang, J; Zhang, X, 2020) |
| "Neonatal ischemic stroke has a higher incidence than childhood stroke." | 1.56 | Preventive Effects of Neuroprotective Agents in a Neonatal Rat of Photothrombotic Stroke Model. ( Choi, SG; Kang, JW; Kim, DW; Kim, SK; Shin, HJ; Song, HJ; Yi, YY, 2020) |
| "TAT under TEG guidance appears to be a safe antiplatelet strategy in patients undergoing stenting for extracranial and/or intracranial artery stenosis." | 1.51 | The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease. ( Jiang, WJ; Li, C; Liu, AF; Qiu, H; Wang, K; Wu, Z; Zhang, Y; Zhou, J, 2019) |
| "Aspirin use was independently associated with reduced DCI risk (P < ." | 1.51 | Post-treatment Antiplatelet Therapy Reduces Risk for Delayed Cerebral Ischemia due to Aneurysmal Subarachnoid Hemorrhage. ( Darkwah Oppong, M; Deuschl, C; Forsting, M; Gembruch, O; Jabbarli, R; Kaier, K; Kleinschnitz, C; Köhrmann, M; Mönninghoff, C; Pierscianek, D; Sure, U, 2019) |
| "Twenty-and-a-half syndrome is reported for the first time." | 1.51 | Twenty-and-a-half syndrome: a case report. ( Chouksey, D; Dani, R; Dube, M; Dubey, A, 2019) |
| "Post-LVAD strokes are an important cause of morbidity and reduced quality of life." | 1.48 | Cerebrovascular Accidents During Mechanical Circulatory Support: New Predictors of Ischemic and Hemorrhagic Strokes and Outcome. ( Ahmed, FS; Akbik, F; Feske, SK; Givertz, MM; Izzy, S; Renault, S; Rubin, DB; Smallwood, JA; Sylvester, KW; Vaitkevicius, H, 2018) |
| "A 37-year-old woman with idiopathic thrombocytopenic purpura (ITP) suffered from multiple trauma scheduled for open reduction and internal fixation for right tibial and left radius fracture five days after SAE." | 1.48 | Bilateral visual loss and cerebral infarction after spleen embolization in a trauma patient with idiopathic thrombocytopenic purpura: A case report. ( Chen, JY; Hung, KC; Lan, KM; Li, YY; Lin, WC; Sun, CK; Wang, WT, 2018) |
| "The participants were 5,696 adults with COPD with a first myocardial infarction (n = 2,850) or ischemic stroke (n = 3,010) and at least one acute exacerbation from the UK Clinical Practice Research Datalink with linked Hospital Episodes Statistics data." | 1.48 | Myocardial Infarction and Ischemic Stroke after Exacerbations of Chronic Obstructive Pulmonary Disease. ( Connell, O; Douglas, I; Müllerová, H; Pearce, N; Quint, JK; Rothnie, KJ; Smeeth, L, 2018) |
| "The aspirin reaction unit was blindly measured at the following two times: after 3 hours of aspirin loading and on the fifth day of aspirin administration." | 1.48 | Clinical Significance of Acute and Serial Platelet Function Testing in Acute Ischemic Stroke. ( Cho, KH; Choi, KH; Kim, JT; Lee, JS; Park, MS; Saver, JL, 2018) |
| "Cerebral ischemia was induced for 2 h followed by reperfusion for 22 h." | 1.43 | Protective Effect of Guggulipid in High Fat Diet and Middle Cerebral Artery Occlusion (MCAO) Induced Ischemic Cerebral Injury in Rats. ( Ahmad, MA; Akhtar, M; Mujeeb, M; Najmi, AK, 2016) |
| "Rivaroxaban is an oral anticoagulant that acts as a direct, competitive factor Xa inhibitor." | 1.43 | Failure of old and new anticoagulants to prevent ischemic stroke in high-risk atrial fibrillation: a case report. ( Adamo, A; Bilora, F; Pomerri, F; Prandoni, P, 2016) |
| "HPR-aspirin was persistent 75days later in 36% patients." | 1.43 | High platelet reactivity on aspirin in patients with acute ST elevation myocardial infarction. ( Dillinger, JG; Drouet, L; Henry, P; Saeed, A; Sideris, G; Silberman, SM; Sollier, CB; Spagnoli, V; Voicu, S, 2016) |
| "Nineteen patients presented vascular recurrence after stroke, and 19 matched patients did not present vascular recurrence during the first year of follow-up." | 1.43 | PPM1A Methylation Is Associated With Vascular Recurrence in Aspirin-Treated Patients. ( Bin Dukhyil, AA; Carrera, C; Cullell, N; Fernandez-Cadenas, I; Fontana, P; Gallego-Fabrega, C; Krupinski, J; Martí-Fàbregas, J; Montaner, J; Muiño, E; Pera, J; Pezzini, A; Reny, JL; Segura, T; Serrano-Heras, G; Slowik, A, 2016) |
| "Stroke is the second largest cause of death worldwide." | 1.42 | Prospective evaluation of blood coagulability and effect of treatment in patients with stroke using rotational thromboelastometry. ( Evans, PA; Hawkins, K; Lawrence, M; Morris, RH; Potter, JF; Sabra, A; Stanford, SN; Storton, S; Wani, M; Williams, PR, 2015) |
| "Patients with a history of cerebral hemorrhage were excluded." | 1.40 | Associations of durations of antiplatelet use and vascular risk factors with the presence of cerebral microbleeds. ( Hattori, N; Okuma, Y; Tanaka, R; Tanaka, Y; Ueno, Y; Urabe, T; Yamashiro, K, 2014) |
| "Oral anticoagulation is the recommended treatment for stroke prevention in patients with atrial fibrillation." | 1.40 | Atrial fibrillation patients do not benefit from acetylsalicylic acid. ( Friberg, L; Själander, A; Själander, S; Svensson, PJ, 2014) |
| "Routine follow-up has revealed no recurrence of symptoms." | 1.40 | The mystery of recurrent idiopathic cerebrovascular and coronary arterial thrombosis. ( BinBrek, AS; Mahmoud, WE; Murugesan, V; Rajani, AR, 2014) |
| "About 80% of strokes are ischaemic." | 1.39 | Antithrombotic drugs and ischaemic stroke. ( , 2013) |
| "The risk for preeclampsia increased in patients who were positive for multiple antiphospholipid antibodies (aPL) (odds ratio (OR) 3." | 1.38 | Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: an observational study. ( Brinks, R; Fischer-Betz, R; Schneider, M; Specker, C, 2012) |
| "Focal cerebral ischemia was induced by MCA occlusion for 2 hours followed by reperfusion for 22 hours." | 1.37 | Protective effect of irbesartan, an angiotensin II receptor antagonist, alone and in combination with aspirin on middle cerebral artery occlusion model of focal cerebral ischemia in rats. ( Ahmad, SJ; Akhtar, M; Islam, F; Khanam, R; Pillai, KK; Pratap, R, 2011) |
| "The primary outcome was first recurrence of stroke of any type and the secondary outcome was a composite of stroke, myocardial infarction, or death from vascular causes." | 1.37 | Level of systolic blood pressure within the normal range and risk of recurrent stroke. ( Bath, PM; Cotton, D; Diener, HC; Donnan, GA; Martin, RH; Ovbiagele, B; Vinisko, R; Yusuf, S, 2011) |
| "Pretreatment with cilostazol (100 mg/kg) significantly reduced infarct size." | 1.36 | Cilostazol, a phosphodiesterase inhibitor, attenuates photothrombotic focal ischemic brain injury in hypertensive rats. ( Hashimoto, A; Ito, H; Matsumoto, Y; Miyakoda, G; Yao, H, 2010) |
| "We assessed the safety of thrombolysis under APs in 11,865 patients compliant with the European license criteria and recorded between 2002 and 2007 in the Safe Implementation of Treatments in Stroke (SITS) International Stroke Thrombolysis Register (SITS-ISTR)." | 1.36 | Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset. ( Ahmed, N; Diedler, J; Ford, GA; Lees, KR; Luijckx, GJ; Overgaard, K; Ringleb, P; Soinne, L; Sykora, M; Uyttenboogaart, M; Wahlgren, N, 2010) |
| "Women with CHD also had a higher rate of cerebral ischemia than did men (27." | 1.36 | Sex-specific differences in metabolic control, cardiovascular risk, and interventions in patients with type 2 diabetes mellitus. ( Gerhat, D; Handisurya, A; Hudson, S; Kamyar, MR; Kautzky-Willer, A; Lemmens-Gruber, R; Luger, A; Stemer, G, 2010) |
| " In these patients, we recommend use of the combination of aspirin and extended-release dipyridamole (25/200 mg bid) over aspirin (Grade 1A) and suggest clopidogrel over aspirin (Grade 2B), and recommend avoiding long-term use of the combination of aspirin and clopidogrel (Grade 1B)." | 1.35 | Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). ( Albers, GW; Amarenco, P; Easton, JD; Sacco, RL; Teal, P, 2008) |
| "Aspirin (30 mg/kg) treatment also reduced platelet aggregation." | 1.35 | Aspirin attenuates cerebral ischemic injury in diabetic rats. ( Fu, FH; Han, B; Wang, T; Yu, X; Zhang, LM; Zhu, M, 2009) |
| "Moyamoya disease is a progressive, unilateral, or bilateral carotid artery stenosis of unknown etiology." | 1.35 | Moyamoya disease in an 8-year-old boy presenting with weakness. ( Johnson, LH; Tenney, J, 2009) |
| "Neu2000 protected against the effects of middle cerebral artery occlusion, even when delivered 8 h after reperfusion." | 1.34 | Marked prevention of ischemic brain injury by Neu2000, an NMDA antagonist and antioxidant derived from aspirin and sulfasalazine. ( Ahn, YM; Byun, HY; Cho, JY; Cho, SI; Chung, JM; Gwag, BJ; Im, DS; Kim, KW; Ko, SY; Kwon, HJ; Lee, HU; Lee, JY; Lee, MJ; Lee, YA; Lim, HR; Moon, HS; Noh, JH; Park, SM; Son, SJ; Won, SJ; Yoon, SH; Yun, BS, 2007) |
| "Stroke is associated with elevation of several proinflammatory cytokines such as tumor necrosis factor alpha (TNF-alpha) and interleukin (IL)-8 that are correlated with central nervous system (CNS) injury." | 1.34 | TNF-alpha and IL-8 in acute stroke and the modulation of these cytokines by antiplatelet agents. ( Al-Bahrani, A; Bakhiet, M; Shaath, H; Taha, S, 2007) |
| "Aspirin resistance was found in 32% of cases." | 1.33 | Prevalence of aspirin resistance measured by PFA-100. ( Castano, S; Coma-Canella, I; Velasco, A, 2005) |
| "Cerebral ischemia was mechanically induced by 2-hour occlusion of the left middle cerebral artery (MCA) using an intraluminal filament followed by 24-hour reperfusion." | 1.33 | Lack of antiapoptotic effects of antiplatelet drug, aspirin and clopidogrel, and antioxidant, MCI-186, against focal ischemic brain damage in rats. ( Hong, KW; Lee, JH; Lee, WS; Park, SY, 2005) |
| "(2) Aspirin has been tested in several placebo-controlled trials and has a positive risk-benefit balance, preventing about 5 deaths per 1000 patients with ischaemic stroke." | 1.33 | Ischaemic stroke: acute-phase drug therapy. Mostly aspirin and heparin. ( , 2005) |
| " The aim of the monitoring of ASA therapy should be the identification of nonresponders to prevent a long-term intake of the drug without adequate benefit, to justify a dose escalation, or to initiate an alternative antiplatelet drug therapy." | 1.33 | Monitoring acetylsalicylic acid effects with the platelet function analyzer PFA-100. ( Feuring, M; Losel, R; Schultz, A; Wehling, M, 2005) |
| "The metabolic syndrome is present in about half of individuals with symptomatic intracranial atherosclerotic disease and is associated with a substantially higher risk of major vascular events." | 1.33 | Impact of metabolic syndrome on prognosis of symptomatic intracranial atherostenosis. ( Chimowitz, M; Lynn, MJ; Ovbiagele, B; Saver, JL, 2006) |
| "Poststroke recurrence rate was low (7." | 1.32 | Ischaemic stroke in young people: a prospective and long-term follow-up study. ( Carerj, S; Di Perri, R; Epifanio, A; Gallitto, G; Gangemi, S; Granata, A; La Spina, P; Leggiadro, N; Manganaro, A; Musolino, R; Tripodi, F, 2003) |
| "Two of the intracerebral hemorrhages occurred in the site where asymptomatic MBs were found at baseline." | 1.32 | Cerebral microbleeds as a risk factor for subsequent intracerebral hemorrhages among patients with acute ischemic stroke. ( Fan, YH; Lam, WW; Mok, VC; Wong, KS; Zhang, L, 2003) |
| "Hypertension was a more common risk factor in AS patients (69% AS patients vs." | 1.32 | Risk factors and in-hospital outcomes in stroke and myocardial infarction patients. ( Ivanusa, M; Ivanusa, Z, 2004) |
| "Strokes were subtyped according to inferred mechanism." | 1.32 | Thrombin generation in non-cardioembolic stroke subtypes: the Hemostatic System Activation Study. ( Barzegar, S; Bauer, K; Costigan, T; Furie, KL; Kistler, JP; Mohr, JP; Rosenberg, R; Rosner, B; Sciacca, R; Thompson, JL; Thornell, B, 2004) |
| "An 18-year-old Saudi male with systemic lupus erythematosus (SLE) presented with mild right hemiparesis, followed by recurrent ischemic stroke." | 1.31 | Systemic lupus erythematosus associated with moyamoya syndrome. ( Al Rayes, HM; El Ramahi, KM, 2000) |
| "Because brain ischemia has recently been recognized to contribute to the pathogenesis of AD, we studied the effect of focal brain ischemia in 8- and 20-month-old mice overexpressing the 751-amino acid isoform of human APP." | 1.31 | Beta-amyloid precursor protein transgenic mice that harbor diffuse A beta deposits but do not form plaques show increased ischemic vulnerability: role of inflammation. ( Bures, J; Goldsteins, G; Higgins, LS; Kauppinen, RA; Keinänen, R; Kettunen, MI; Koistinaho, J; Koistinaho, M; Liu, D; Ort, M; Salminen, A, 2002) |
| "History of untreated hypertension prior to the initial stroke (RR = 1." | 1.30 | Stroke recurrence among 30 days survivors of ischemic stroke in a prospective community-based study. ( Baranska-Gieruszczak, M; Czlonkowska, A; Hier, DB; Lechowicz, W; Ryglewicz, D, 1997) |
| "Aspirin-treated and non-aspirin-treated patients did not differ in stroke severity." | 1.30 | Does daily aspirin diminish severity of first-ever stroke? ( Bornstein, NM; Hass, Y; Karepov, V; Korczyn, AD, 1997) |
| " Of the 52 with partial inhibition at initial testing, 35 achieved complete inhibition either by ASA dosage escalation (in 325 mg/d increments) or fluctuation of response at the same dosage, but 8 of those 35 (22." | 1.29 | Development of aspirin resistance in persons with previous ischemic stroke. ( Bolin, KM; Brace, LD; Helgason, CM; Hoff, JA; Mangat, A; Tortorice, KL; Winkler, SR, 1994) |
| "The total brain ischemia has been implemented in accordance with an original technique for 17 to 35 min." | 1.28 | [Anti-ischemic protection of the brain using water-soluble form of aspirin-acelisin]. ( Bilenko, MV; Komarov, PG; Morganov, AA; Tel'pukhov, VI; Tikhomirova, AI, 1992) |
| "Eight patients, 3 with systemic lupus erythematosus (SLE) or "SLE-like" disease, 1 with sarcoidosis, and 4 with no connective tissue disease had transient ischemic attacks (TIA) or cerebral infarctions associated with high levels of anticardiolipin antibodies (ACA)." | 1.28 | Cerebral ischemia associated with anticardiolipin antibodies. ( Ernerudh, J; Lindström, F; Olsson, JE; Vrethem, M, 1992) |
| "62 patients with transient ischemic attack (TIA), 60 with reversible ischemic neurologic deficit (RIND) and 57 with stroke with minimum residuum (SMR) were followed, in a retrospective survey, from the first 7 days to the 3rd month of evolution." | 1.27 | Short-term outcome of medically treated patients with transient ischemic attacks, reversible ischemic neurologic deficits and strokes with minimum residuum. ( Calandre, L; Molina, JA, 1985) |
| "Mitral valve prolapse is usually a benign condition, however, serious complications have been reported to be associated with it." | 1.27 | Mitral valve prolapse and thromboembolic disease in pregnancy: a case report. ( Bergh, PA; Breen, JL; Gregori, CA; Hollander, D, 1988) |
| "Vascular dementia is a common and potentially reversible type of dementing illness." | 1.27 | Validation of cognitive and functional assessment instruments in vascular dementia. ( Greenough, PG; Hershey, LA; Jaffe, DF; Yang, SL, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 60 (7.52) | 18.7374 |
| 1990's | 142 (17.79) | 18.2507 |
| 2000's | 232 (29.07) | 29.6817 |
| 2010's | 288 (36.09) | 24.3611 |
| 2020's | 76 (9.52) | 2.80 |
| Authors | Studies |
|---|---|
| Sun, Y | 1 |
| Jiang, J | 1 |
| Zhang, Z | 3 |
| Yu, P | 1 |
| Wang, L | 2 |
| Xu, C | 1 |
| Liu, W | 2 |
| Wang, Y | 22 |
| Wu, J | 2 |
| Ling, J | 1 |
| Wang, X | 4 |
| Li, T | 1 |
| Liu, J | 3 |
| Lai, Y | 1 |
| Ji, H | 2 |
| Peng, S | 1 |
| Tian, J | 1 |
| Zhang, Y | 6 |
| Xin, G | 1 |
| Ming, Y | 1 |
| Ji, C | 1 |
| Wei, Z | 1 |
| Li, S | 3 |
| Morris-Natschke, SL | 1 |
| Zhang, X | 3 |
| Yu, K | 1 |
| Li, Y | 3 |
| Zhang, B | 4 |
| Zhang, J | 1 |
| Xing, Z | 1 |
| He, Y | 3 |
| Chen, Z | 5 |
| Yang, X | 2 |
| Niu, H | 1 |
| Lee, KH | 1 |
| Huang, W | 3 |
| Anand, SS | 2 |
| Hiatt, W | 1 |
| Dyal, L | 1 |
| Bauersachs, R | 1 |
| Berkowitz, SD | 6 |
| Branch, KRH | 1 |
| Debus, S | 1 |
| Fox, KAA | 1 |
| Liang, Y | 1 |
| Muehlhofer, E | 2 |
| Nehler, M | 1 |
| Haskell, LP | 2 |
| Patel, M | 1 |
| Szarek, M | 2 |
| Yusuf, S | 8 |
| Eikelboom, J | 3 |
| Bonaca, MP | 2 |
| Ryu, WS | 3 |
| Schellingerhout, D | 1 |
| Hong, KS | 9 |
| Jeong, SW | 1 |
| Kim, BJ | 7 |
| Kim, JT | 7 |
| Lee, KB | 5 |
| Park, TH | 4 |
| Park, SS | 2 |
| Park, JM | 7 |
| Kang, K | 4 |
| Cho, YJ | 5 |
| Park, HK | 1 |
| Lee, BC | 5 |
| Yu, KH | 6 |
| Oh, MS | 5 |
| Lee, SJ | 7 |
| Kim, JG | 3 |
| Cha, JK | 10 |
| Kim, DH | 4 |
| Lee, J | 12 |
| Han, MK | 4 |
| Park, MS | 6 |
| Choi, KH | 6 |
| Nahrendorf, M | 1 |
| Bae, HJ | 6 |
| Kim, DE | 5 |
| Sundaravadivel, P | 1 |
| Christopher, R | 1 |
| Ramanujam, N | 1 |
| Chandra, SR | 1 |
| Kim, BC | 3 |
| Youn, YC | 1 |
| Jeong, JH | 1 |
| Han, HJ | 1 |
| Kim, JH | 1 |
| Lee, JH | 6 |
| Park, KH | 1 |
| Park, KW | 4 |
| Kim, EJ | 1 |
| Shim, Y | 1 |
| Lee, JM | 2 |
| Choi, YH | 1 |
| Park, G | 1 |
| Kim, S | 2 |
| Park, HY | 1 |
| Yoon, B | 1 |
| Yoon, SJ | 1 |
| Cho, SJ | 1 |
| Park, KC | 1 |
| Na, DL | 1 |
| Park, SA | 1 |
| Choi, SH | 1 |
| Xu, J | 1 |
| Xu, X | 1 |
| Wang, H | 2 |
| He, L | 2 |
| Liu, Q | 3 |
| Du, Y | 1 |
| Wang, J | 5 |
| Yang, Y | 2 |
| Huang, Z | 1 |
| Minhas, JS | 3 |
| Chithiramohan, T | 1 |
| Barnes, SC | 1 |
| Clough, RH | 1 |
| Kadicheeni, M | 1 |
| Beishon, LC | 1 |
| Robinson, T | 1 |
| van der Steen, W | 1 |
| van de Graaf, RA | 1 |
| Chalos, V | 2 |
| Lingsma, HF | 1 |
| van Doormaal, PJ | 1 |
| Coutinho, JM | 1 |
| Emmer, BJ | 1 |
| de Ridder, I | 1 |
| van Zwam, W | 1 |
| van der Worp, HB | 2 |
| van der Schaaf, I | 1 |
| Gons, RAR | 1 |
| Yo, LSF | 1 |
| Boiten, J | 1 |
| van den Wijngaard, I | 1 |
| Hofmeijer, J | 1 |
| Martens, J | 1 |
| Schonewille, W | 1 |
| Vos, JA | 1 |
| Tuladhar, AM | 1 |
| de Laat, KF | 1 |
| van Hasselt, B | 1 |
| Remmers, M | 1 |
| Vos, D | 1 |
| Rozeman, A | 1 |
| Elgersma, O | 1 |
| Uyttenboogaart, M | 2 |
| Bokkers, RPH | 1 |
| van Tuijl, J | 1 |
| Boukrab, I | 1 |
| van den Berg, R | 1 |
| Beenen, LFM | 1 |
| Roosendaal, SD | 1 |
| Postma, AA | 1 |
| Krietemeijer, M | 1 |
| Lycklama, G | 1 |
| Meijer, FJA | 1 |
| Hammer, S | 1 |
| van der Hoorn, A | 1 |
| Yoo, AJ | 1 |
| Gerrits, D | 1 |
| Truijman, MTB | 1 |
| Zinkstok, S | 1 |
| Koudstaal, PJ | 10 |
| Manschot, S | 1 |
| Kerkhoff, H | 1 |
| Nieboer, D | 1 |
| Berkhemer, O | 1 |
| Wolff, L | 1 |
| van der Sluijs, PM | 1 |
| van Voorst, H | 1 |
| Tolhuisen, M | 1 |
| Roos, YBWEM | 1 |
| Majoie, CBLM | 1 |
| Staals, J | 2 |
| van Oostenbrugge, RJ | 1 |
| Jenniskens, SFM | 1 |
| van Dijk, LC | 1 |
| den Hertog, HM | 1 |
| van Es, ACGM | 1 |
| van der Lugt, A | 2 |
| Dippel, DWJ | 1 |
| Roozenbeek, B | 2 |
| Ku, JC | 1 |
| Taslimi, S | 1 |
| Zuccato, J | 1 |
| Pasarikovski, CR | 1 |
| Nasr, N | 1 |
| Chechik, O | 1 |
| Chisci, E | 1 |
| Bissacco, D | 1 |
| Larrue, V | 2 |
| Rabinovich, Y | 1 |
| Michelagnoli, S | 1 |
| Settembrini, PG | 1 |
| Priola, SM | 1 |
| Cusimano, MD | 1 |
| Yang, VXD | 1 |
| Macdonald, RL | 1 |
| Bor, WL | 1 |
| de Veer, AJW | 1 |
| Olie, RH | 1 |
| Rikken, SAOF | 1 |
| Chan Pin Yin, DRPP | 1 |
| Herrman, JPR | 1 |
| Vrolix, M | 1 |
| Meuwissen, M | 1 |
| Vandendriessche, T | 1 |
| van Mieghem, C | 1 |
| Magro, M | 1 |
| Bennaghmouch, N | 1 |
| Hermanides, R | 1 |
| Adriaenssens, T | 1 |
| Dewilde, WJM | 1 |
| Ten Berg, JM | 1 |
| Shah, J | 1 |
| Liu, S | 2 |
| Yu, W | 1 |
| Pan, Y | 7 |
| Meng, X | 8 |
| Chen, W | 4 |
| Jing, J | 7 |
| Lin, J | 8 |
| Jiang, Y | 2 |
| Johnston, SC | 11 |
| Bath, PM | 20 |
| Dong, Q | 4 |
| Xu, AD | 1 |
| Li, H | 10 |
| Feler, J | 1 |
| Chuck, C | 1 |
| Anderson, M | 1 |
| Poggi, J | 1 |
| Sweeney, J | 1 |
| Moldovan, K | 1 |
| Jayaraman, MV | 1 |
| McTaggart, R | 1 |
| Torabi, R | 1 |
| Zhang, K | 1 |
| Liu, T | 1 |
| Niu, X | 1 |
| Clarke, A | 1 |
| Reddin, C | 1 |
| Murphy, R | 1 |
| O'Donnell, MJ | 2 |
| Ajabnoor, AM | 1 |
| Zghebi, SS | 1 |
| Parisi, R | 1 |
| Ashcroft, DM | 1 |
| Rutter, MK | 1 |
| Doran, T | 1 |
| Carr, MJ | 1 |
| Mamas, MA | 2 |
| Kontopantelis, E | 1 |
| Zheng, F | 1 |
| Stavrinou, P | 1 |
| Hu, W | 1 |
| Ates, O | 1 |
| Yilmaz, I | 1 |
| Karaarslan, N | 1 |
| Ersoz, E | 1 |
| Hacioglu Kasim, FB | 1 |
| Dogan, M | 1 |
| Ozbek, H | 1 |
| Lim, ST | 2 |
| Murphy, SJX | 2 |
| Murphy, SM | 2 |
| Coughlan, T | 3 |
| O'Neill, D | 6 |
| Tierney, S | 2 |
| Egan, B | 2 |
| Collins, DR | 2 |
| McCarthy, AJ | 1 |
| Lim, SY | 1 |
| Smith, DR | 1 |
| Cox, D | 3 |
| McCabe, DJH | 2 |
| Krishnan, K | 5 |
| Law, ZK | 2 |
| Robinson, TG | 5 |
| Sprigg, N | 8 |
| Mavilakandy, A | 2 |
| England, TJ | 5 |
| Eveson, D | 2 |
| Mistri, A | 2 |
| Dawson, J | 3 |
| Appleton, JP | 5 |
| Gao, Y | 1 |
| Han, S | 1 |
| Wang, C | 6 |
| Wang, T | 2 |
| Zhao, X | 8 |
| Liu, L | 8 |
| Amarenco, P | 5 |
| Zhao, D | 1 |
| Chen, X | 3 |
| Wang, R | 1 |
| Pang, H | 1 |
| Duan, C | 1 |
| Xiong, Y | 4 |
| Gu, H | 1 |
| Wang, S | 1 |
| Yang, KX | 1 |
| Hao, M | 1 |
| Feng, X | 1 |
| Medina-Rodríguez, M | 1 |
| Moniche, F | 1 |
| de Albóniga-Chindurza, A | 1 |
| Ortega-Quintanilla, J | 1 |
| Ainz-Gómez, L | 1 |
| Pardo-Galiana, B | 1 |
| Cabezas-Rodríguez, JA | 1 |
| Aguilar-Pérez, M | 1 |
| Zamora, A | 1 |
| Delgado-Acosta, F | 1 |
| Jiménez-Gómez, E | 1 |
| Bravo Rey, I | 1 |
| Oteros Fernández, R | 1 |
| Freijo Guerrero, MDM | 1 |
| González Díaz, E | 1 |
| Escudero-Martínez, I | 1 |
| Morales Caba, L | 1 |
| Vielba-Gomez, I | 1 |
| Mosteiro, S | 1 |
| Castellanos Rodrigo, MDM | 1 |
| Amaya Pascasio, L | 1 |
| Hidalgo, C | 1 |
| Fernandez Prudencio, L | 1 |
| Ramirez Moreno, JM | 1 |
| Díaz Pérez, J | 1 |
| Sanz-Fernandez, G | 1 |
| Baena-Palomino, P | 1 |
| Gamero-García, MÁ | 1 |
| Jiménez Jorge, S | 1 |
| Rosso Fernández, C | 1 |
| Montaner, J | 3 |
| González García, A | 1 |
| Zapata-Arriaza, E | 1 |
| Clares de Andrade, JB | 1 |
| Mohr, JP | 10 |
| Lima, FO | 1 |
| de Carvalho, JJF | 1 |
| Maia Barros, LC | 1 |
| Pontes-Neto, OM | 2 |
| de Abreu, GQ | 1 |
| Silva, GS | 1 |
| Kim, JS | 2 |
| Kang, Y | 1 |
| Sohn, SH | 1 |
| Hwang, HY | 1 |
| Xu, S | 1 |
| Zhang, W | 2 |
| Xu, Z | 2 |
| Wu, T | 2 |
| Yuan, B | 2 |
| Xu, A | 3 |
| Xie, X | 4 |
| Jin, A | 1 |
| Suo, Y | 1 |
| Yang, H | 1 |
| Feng, Y | 1 |
| Zhou, Y | 2 |
| Li, X | 1 |
| Liu, B | 1 |
| Zhu, H | 2 |
| Zhao, J | 1 |
| Huang, X | 3 |
| Li, Z | 4 |
| Zhang, ZM | 1 |
| Lin, ZH | 1 |
| Zhu, GL | 1 |
| Klail, T | 1 |
| Sedova, P | 1 |
| Vinklarek, JF | 1 |
| Kovacova, I | 1 |
| Bar, M | 1 |
| Cihlar, F | 1 |
| Cernik, D | 1 |
| Kočí, L | 1 |
| Jura, R | 1 |
| Herzig, R | 1 |
| Husty, J | 1 |
| Kocher, M | 1 |
| Kovar, M | 1 |
| Nevšímalová, M | 1 |
| Raupach, J | 1 |
| Rocek, M | 1 |
| Sanak, D | 1 |
| Sevcik, P | 1 |
| Skoloudik, D | 1 |
| Sramek, M | 1 |
| Vanicek, J | 1 |
| Vaško, P | 1 |
| Vaclavik, D | 1 |
| Tomek, A | 1 |
| Mikulik, R | 3 |
| Zi, W | 2 |
| Song, J | 1 |
| Kong, W | 1 |
| Huang, J | 3 |
| Guo, C | 1 |
| He, W | 2 |
| Yu, Y | 1 |
| Geng, W | 1 |
| Tan, X | 1 |
| Tian, Y | 2 |
| Liu, Z | 1 |
| Cao, M | 1 |
| Cheng, D | 1 |
| Li, B | 1 |
| Wang, P | 1 |
| Yu, Z | 2 |
| Liang, H | 1 |
| Yang, S | 2 |
| Tang, M | 1 |
| Tang, Y | 1 |
| Wu, Y | 3 |
| Yao, L | 1 |
| Shi, Z | 1 |
| He, P | 1 |
| Zhao, H | 2 |
| Luo, J | 1 |
| Wan, Y | 1 |
| Shi, Q | 1 |
| Wang, M | 2 |
| Huang, F | 1 |
| Mu, J | 1 |
| Zheng, J | 1 |
| Xie, S | 2 |
| Cai, T | 1 |
| Peng, Y | 1 |
| Xie, W | 1 |
| Qiu, Z | 2 |
| Liu, C | 1 |
| Yue, C | 1 |
| Li, L | 1 |
| Yang, D | 4 |
| Miao, J | 1 |
| Yang, J | 3 |
| Hu, J | 1 |
| Nogueira, RG | 1 |
| Wang, D | 4 |
| Saver, JL | 9 |
| Li, F | 3 |
| Yang, Q | 1 |
| Chen, C | 5 |
| Ma, F | 1 |
| Wen, X | 1 |
| Liu, X | 5 |
| Tang, Q | 1 |
| Woodhouse, LJ | 4 |
| Christensen, H | 5 |
| Dineen, RA | 3 |
| James, M | 3 |
| Montgomery, AA | 2 |
| Ranta, A | 3 |
| Bykov, VV | 1 |
| Bykova, AV | 1 |
| Motov, VS | 1 |
| Larchenko, VV | 1 |
| Chernysheva, GA | 1 |
| Smol'yakova, VI | 1 |
| Aliev, OI | 1 |
| Khazanov, VA | 1 |
| Vengerovskii, AI | 1 |
| Udut, VV | 1 |
| Alhajj, L | 1 |
| Ovenseri Airemwen, C | 1 |
| Pozharani, LB | 1 |
| Hankey, GJ | 11 |
| Vidyanti, AN | 1 |
| Chan, L | 1 |
| Lin, CL | 1 |
| Muo, CH | 1 |
| Hsu, CY | 2 |
| Chen, YC | 5 |
| Wu, D | 2 |
| Hu, CJ | 2 |
| Majidi, S | 2 |
| Luby, M | 1 |
| Lynch, JK | 1 |
| Hsia, AW | 1 |
| Benson, RT | 1 |
| Kalaria, CP | 1 |
| Nadareishvili, Z | 2 |
| Latour, LL | 1 |
| Leigh, R | 1 |
| Kinsella, JA | 2 |
| Feeley, TM | 1 |
| Walsh, RA | 1 |
| Harbison, JA | 1 |
| Madhavan, P | 1 |
| O'Neill, SM | 1 |
| Colgan, MP | 1 |
| Moran, N | 1 |
| Hamilton, G | 1 |
| Meaney, JF | 1 |
| Kim, SM | 1 |
| Jung, JM | 3 |
| Lee, JS | 9 |
| Kwon, SU | 6 |
| Kimpton, J | 1 |
| Khong, T | 1 |
| Park, JH | 3 |
| Kim, YJ | 2 |
| Wong, LKS | 2 |
| Yu, S | 3 |
| Hwang, YH | 2 |
| Rha, JH | 3 |
| Heo, SH | 4 |
| Ahn, SH | 2 |
| Seo, WK | 2 |
| Kwon, JH | 3 |
| Sohn, SI | 4 |
| Navarro, JC | 2 |
| Kim, HY | 2 |
| Kim, EG | 2 |
| Nam, HS | 1 |
| Kang, DW | 4 |
| Paciaroni, M | 1 |
| Ince, B | 1 |
| Hu, B | 1 |
| Jeng, JS | 1 |
| Kutluk, K | 1 |
| Lou, M | 2 |
| Parfenov, V | 1 |
| Wong, KSL | 1 |
| Zamani, B | 1 |
| Paek, D | 1 |
| Min Han, J | 1 |
| Del Aguila, M | 1 |
| Girotra, S | 1 |
| Zhao, G | 1 |
| Lin, F | 1 |
| Wang, Z | 3 |
| Shao, X | 1 |
| Gong, Y | 1 |
| Zhang, S | 1 |
| Cui, Y | 1 |
| Lei, H | 1 |
| Cheng, Z | 1 |
| Guo, D | 1 |
| Zhang, Q | 3 |
| Kumar, A | 1 |
| Shariff, M | 1 |
| Doshi, R | 1 |
| Rosińska, J | 1 |
| Maciejewska, J | 1 |
| Narożny, R | 1 |
| Kozubski, W | 1 |
| Łukasik, M | 1 |
| Martinez-Majander, N | 1 |
| Ntaios, G | 4 |
| Liu, YY | 1 |
| Ylikotila, P | 1 |
| Joensuu, H | 1 |
| Saarinen, J | 1 |
| Perera, KS | 2 |
| Marti-Fabregas, J | 2 |
| Chamorro, A | 5 |
| Rudilosso, S | 2 |
| Prats-Sanchez, L | 1 |
| Mundl, H | 4 |
| Themeles, E | 2 |
| Tiainen, M | 1 |
| Demchuk, A | 1 |
| Kasner, SE | 5 |
| Hart, RG | 18 |
| Tatlisumak, T | 3 |
| Hočevar, A | 1 |
| Ješe, R | 1 |
| Tomšič, M | 1 |
| Rotar, Ž | 1 |
| Pande, SD | 1 |
| Win, MM | 1 |
| Khine, AA | 1 |
| Zaw, EM | 1 |
| Manoharraj, N | 1 |
| Lolong, L | 1 |
| Tin, AS | 1 |
| Shoji, S | 1 |
| Sawano, M | 1 |
| Sandhu, AT | 1 |
| Heidenreich, PA | 1 |
| Shiraishi, Y | 1 |
| Ikemura, N | 1 |
| Ueno, K | 1 |
| Suzuki, M | 1 |
| Numasawa, Y | 1 |
| Fukuda, K | 1 |
| Kohsaka, S | 1 |
| Elshafei, MN | 1 |
| Imam, Y | 1 |
| Mohamed, MFH | 1 |
| AlSaud, AE | 1 |
| Ahmed, MS | 1 |
| Obeidat, K | 1 |
| Saeid, R | 1 |
| Ali, M | 1 |
| Abdallah, IM | 1 |
| Parray, AS | 1 |
| Danjuma, MI | 1 |
| Yi, YY | 1 |
| Shin, HJ | 1 |
| Choi, SG | 1 |
| Kang, JW | 1 |
| Song, HJ | 1 |
| Kim, SK | 2 |
| Kim, DW | 1 |
| Albay, CEQ | 1 |
| Leyson, FGD | 1 |
| Cheng, FC | 1 |
| Shao, T | 1 |
| Cheng, Y | 2 |
| Jin, J | 2 |
| Huang, L | 1 |
| Luo, C | 1 |
| Han, Z | 4 |
| Ge, W | 1 |
| Xu, Y | 2 |
| Veltkamp, R | 2 |
| Pearce, LA | 5 |
| Korompoki, E | 1 |
| Sharma, M | 3 |
| Toni, D | 7 |
| Ameriso, SF | 4 |
| Lindgren, A | 3 |
| Arauz, A | 3 |
| Ozturk, S | 2 |
| Muir, KW | 4 |
| Perera, K | 1 |
| Shuaib, A | 3 |
| Shoamanesh, A | 3 |
| Connolly, SJ | 6 |
| Wu, B | 1 |
| Shi, L | 1 |
| A van de Graaf, R | 1 |
| C G M van Es, A | 1 |
| M den Hertog, H | 1 |
| van Dijk, L | 1 |
| F M Jenniskens, S | 1 |
| J van Oostenbrugge, R | 1 |
| H van Zwam, W | 1 |
| B W E M Roos, Y | 1 |
| B L M Majoie, C | 1 |
| F Lingsma, H | 1 |
| W J Dippel, D | 1 |
| Lanthier, L | 1 |
| Huard, G | 1 |
| Plourde, ME | 1 |
| Cauchon, M | 1 |
| Chen, Y | 4 |
| Li, J | 1 |
| Ou, Z | 1 |
| Liang, Z | 1 |
| Deng, W | 1 |
| Wu, Z | 2 |
| Jiang, H | 1 |
| Ouyang, F | 1 |
| Xing, S | 1 |
| Zeng, J | 2 |
| Hamilton, F | 1 |
| Arnold, D | 1 |
| Henley, W | 1 |
| Payne, RA | 1 |
| Huang, K | 1 |
| Cheng, CL | 2 |
| Yang, YK | 1 |
| Zhou, H | 1 |
| Shan, B | 1 |
| Fu, J | 1 |
| Feng, Q | 1 |
| Shen, R | 1 |
| Jin, X | 1 |
| Kaushik, A | 1 |
| Deora, S | 1 |
| Choudhary, R | 1 |
| Kargiotis, O | 1 |
| Tsivgoulis, G | 2 |
| Hill, MD | 1 |
| Wong, YS | 1 |
| Tsai, CF | 1 |
| Hsu, YH | 1 |
| Ong, CT | 1 |
| Fu, B | 1 |
| Li, P | 1 |
| Xu, D | 1 |
| Hou, K | 1 |
| Gou, X | 1 |
| Lv, N | 1 |
| Fang, W | 1 |
| de Castro-Afonso, LH | 1 |
| Nakiri, GS | 1 |
| Abud, TG | 1 |
| Monsignore, LM | 1 |
| de Freitas, RK | 1 |
| Abud, DG | 1 |
| Choulerton, J | 1 |
| Guha, N | 1 |
| Squires, R | 1 |
| Kim, SJ | 1 |
| Kwon, OD | 1 |
| Choi, HC | 1 |
| Lee, EJ | 3 |
| Cho, B | 1 |
| Alušík, Š | 1 |
| Paluch, Z | 1 |
| Zitikyte, G | 1 |
| Roy, DC | 1 |
| Dhaliwal, S | 1 |
| Lun, R | 1 |
| Hutton, B | 1 |
| Shorr, R | 1 |
| Dowlatshahi, D | 1 |
| Yaghi, S | 1 |
| de Havenon, A | 1 |
| Rostanski, S | 1 |
| Kvernland, A | 1 |
| Mac Grory, B | 1 |
| Furie, KL | 4 |
| Kim, AS | 3 |
| Easton, JD | 9 |
| Henninger, N | 1 |
| Johnston, C | 1 |
| Wang, A | 2 |
| Olesen, KKW | 1 |
| Heide-Jørgensen, U | 1 |
| Thim, T | 1 |
| Thomsen, RW | 1 |
| Bøtker, HE | 1 |
| Sørensen, HT | 2 |
| Maeng, M | 1 |
| El Otmani, H | 1 |
| Berrada, M | 1 |
| Abdulhakeem, Z | 1 |
| Bellakhdar, S | 1 |
| El Moutawakil, B | 2 |
| Abdoh Rafai, M | 1 |
| Sanderson, NC | 1 |
| Parker, WAE | 1 |
| Storey, RF | 1 |
| Han, M | 1 |
| Kuang, J | 1 |
| Tu, J | 1 |
| Starcevich, K | 1 |
| Gao, P | 1 |
| Peng, C | 1 |
| Yin, S | 1 |
| Chen, J | 2 |
| Jia, W | 1 |
| Yi, Y | 1 |
| Krantz, MJ | 1 |
| Debus, SE | 1 |
| Hsia, J | 1 |
| Patel, MR | 1 |
| Nehler, MR | 1 |
| Hess, CN | 1 |
| Capell, WH | 1 |
| Bracken, T | 1 |
| Mátyás, L | 1 |
| Krievins, DK | 1 |
| Nault, P | 1 |
| Stefanov, S | 1 |
| Hiatt, WR | 1 |
| Bauersachs, RM | 1 |
| Christophe, BR | 1 |
| Mehta, SH | 1 |
| Garton, AL | 1 |
| Sisti, J | 1 |
| Connolly, ES | 2 |
| Wa, D | 1 |
| Zhu, P | 1 |
| Long, Z | 1 |
| Fiolaki, A | 1 |
| Katsanos, AH | 1 |
| Kyritsis, AP | 1 |
| Papadaki, S | 1 |
| Kosmidou, M | 1 |
| Moschonas, IC | 1 |
| Tselepis, AD | 2 |
| Giannopoulos, S | 1 |
| Cai, H | 1 |
| Cai, B | 2 |
| Sun, L | 2 |
| Zhang, H | 1 |
| Zhou, S | 1 |
| Cao, L | 2 |
| Guo, H | 1 |
| Sun, W | 4 |
| Yan, B | 1 |
| Davis, SM | 1 |
| Leon Guerrero, CR | 1 |
| Gandhy, S | 1 |
| Burger, KM | 1 |
| Sigounas, D | 1 |
| Rosafio, F | 1 |
| Lelli, N | 1 |
| Mimmi, S | 1 |
| Vandelli, L | 1 |
| Bigliardi, G | 1 |
| Dell'Acqua, ML | 1 |
| Picchetto, L | 1 |
| Pentore, R | 1 |
| Ferraro, D | 1 |
| Trenti, T | 1 |
| Nichelli, P | 1 |
| Zini, A | 1 |
| Rao, Z | 1 |
| Zheng, H | 1 |
| Wang, F | 1 |
| Dong, K | 2 |
| Cao, Y | 1 |
| Milionis, H | 2 |
| Papavasileiou, V | 1 |
| Spengos, K | 2 |
| Manios, E | 2 |
| Elisaf, M | 1 |
| Vemmos, K | 1 |
| Larsen, SB | 1 |
| Grove, EL | 2 |
| Neergaard-Petersen, S | 1 |
| Würtz, M | 2 |
| Hvas, AM | 1 |
| Kristensen, SD | 1 |
| Han, YF | 1 |
| Dai, QL | 1 |
| Chen, XL | 1 |
| Xiong, YY | 1 |
| Yin, Q | 2 |
| Xu, GL | 1 |
| Zhu, WS | 1 |
| Zhang, RL | 1 |
| Ma, MM | 1 |
| Liu, WH | 1 |
| Liu, XF | 1 |
| Zhang, N | 1 |
| Zhou, L | 1 |
| Choi, MH | 1 |
| Lee, SE | 1 |
| Shin, DH | 1 |
| Hong, JM | 1 |
| Chen, S | 1 |
| Wei, D | 1 |
| Vasudeva, K | 1 |
| Chaurasia, P | 1 |
| Singh, S | 1 |
| Munshi, A | 3 |
| Nagahama, Y | 1 |
| Allan, L | 1 |
| Nakagawa, D | 1 |
| Zanaty, M | 1 |
| Starke, RM | 1 |
| Chalouhi, N | 2 |
| Jabbour, P | 1 |
| Brown, RD | 1 |
| Derdeyn, CP | 2 |
| Leira, EC | 2 |
| Broderick, J | 2 |
| Chimowitz, M | 2 |
| Torner, JC | 1 |
| Hasan, D | 1 |
| Beridze, M | 2 |
| Duley, L | 2 |
| Flaherty, K | 2 |
| Havard, D | 1 |
| Heptinstall, S | 3 |
| Markus, HS | 3 |
| Pocock, SJ | 1 |
| Randall, M | 1 |
| Scutt, P | 2 |
| Venables, GS | 2 |
| Navi, BB | 1 |
| Marshall, RS | 1 |
| Bobrow, D | 1 |
| Singer, S | 1 |
| Stone, JB | 1 |
| DeSancho, MT | 1 |
| DeAngelis, LM | 1 |
| Cappellari, M | 1 |
| Turcato, G | 1 |
| Forlivesi, S | 1 |
| Zivelonghi, C | 1 |
| Bovi, P | 1 |
| Bonetti, B | 1 |
| Antigüedad-Muñoz, J | 1 |
| de la Riva, P | 1 |
| Arenaza Choperena, G | 1 |
| Muñoz Lopetegi, A | 1 |
| Andrés Marín, N | 1 |
| Fernández-Eulate, G | 1 |
| Moreno Valladares, M | 1 |
| Martínez Zabaleta, M | 1 |
| Kumar, S | 1 |
| de Lusignan, S | 1 |
| McGovern, A | 1 |
| Correa, A | 1 |
| Hriskova, M | 1 |
| Gatenby, P | 1 |
| Jones, S | 1 |
| Goldsmith, D | 1 |
| Camm, AJ | 1 |
| Labovitz, DL | 1 |
| Dhamoon, MS | 1 |
| Rahmani, MR | 1 |
| Shamsizadeh, A | 1 |
| Moghadam-Ahmadi, A | 1 |
| Kaeidi, A | 1 |
| Allahtavakoli, M | 1 |
| Schmidt, M | 1 |
| Horváth-Puhó, E | 1 |
| Henderson, VW | 1 |
| Christiansen, CF | 1 |
| Izzy, S | 1 |
| Rubin, DB | 1 |
| Ahmed, FS | 1 |
| Akbik, F | 1 |
| Renault, S | 1 |
| Sylvester, KW | 1 |
| Vaitkevicius, H | 1 |
| Smallwood, JA | 1 |
| Givertz, MM | 1 |
| Feske, SK | 1 |
| Wang, WT | 1 |
| Li, YY | 1 |
| Lin, WC | 1 |
| Chen, JY | 1 |
| Lan, KM | 1 |
| Sun, CK | 1 |
| Hung, KC | 1 |
| Liu, CY | 1 |
| Chen, HC | 1 |
| Rothnie, KJ | 1 |
| Connell, O | 1 |
| Müllerová, H | 1 |
| Smeeth, L | 1 |
| Pearce, N | 1 |
| Douglas, I | 1 |
| Quint, JK | 1 |
| Li, W | 2 |
| Dai, Z | 1 |
| Liu, R | 1 |
| Hao, Y | 1 |
| Han, Y | 1 |
| Xu, G | 2 |
| Farrant, M | 2 |
| Barsan, W | 3 |
| Conwit, RA | 1 |
| Elm, JJ | 2 |
| Lindblad, AS | 2 |
| Palesch, YY | 2 |
| Bangdiwala, SI | 2 |
| Swaminathan, B | 1 |
| Lavados, P | 1 |
| Davalos, A | 6 |
| Shamalov, N | 1 |
| Cunha, L | 3 |
| Lang, W | 1 |
| Czlonkowska, A | 3 |
| Eckstein, J | 1 |
| Gagliardi, RJ | 3 |
| Bereczki, D | 3 |
| Uchiyama, S | 10 |
| Yoon, BW | 3 |
| Brouns, R | 1 |
| Endres, M | 3 |
| Bornstein, N | 2 |
| De Vries Basson, MM | 1 |
| Pare, G | 1 |
| Pater, C | 1 |
| Kirsch, B | 1 |
| Sheridan, P | 2 |
| Peters, G | 2 |
| Weitz, JI | 1 |
| Peacock, WF | 1 |
| Benavente, OR | 1 |
| Joyner, C | 1 |
| Yi, X | 6 |
| Chai, Z | 2 |
| Zhou, Q | 4 |
| Huang, R | 1 |
| Cho, KH | 5 |
| Schmaier, AA | 1 |
| Bhatt, DL | 7 |
| Fyfe, I | 1 |
| Kalantzi, KI | 1 |
| Ntalas, IV | 1 |
| Chantzichristos, VG | 1 |
| Tsoumani, ME | 1 |
| Adamopoulos, D | 1 |
| Asimakopoulos, C | 1 |
| Bourdakis, A | 1 |
| Darmanis, P | 1 |
| Dimitriadou, A | 1 |
| Gkiokas, S | 1 |
| Ipeirotis, K | 1 |
| Kitikidou, K | 1 |
| Klonaris, I | 1 |
| Kostaki, A | 1 |
| Logothetis, D | 1 |
| Mainas, K | 1 |
| Mais, T | 1 |
| Maragiannis, A | 1 |
| Martiadou, K | 1 |
| Mavronasos, K | 1 |
| Michelongonas, I | 1 |
| Mitropoulos, D | 1 |
| Papadimitriou, G | 1 |
| Papadopoulos, A | 1 |
| Papaioakeim, M | 1 |
| Sofillas, K | 1 |
| Stabola, S | 1 |
| Stefanakis, E | 1 |
| Stergiou, D | 1 |
| Thoma, M | 1 |
| Zenetos, A | 1 |
| Zisekas, S | 1 |
| Goudevenos, JA | 1 |
| Panagiotakos, DB | 1 |
| Giustino, G | 1 |
| Redfors, B | 1 |
| Kirtane, AJ | 1 |
| Mehran, R | 1 |
| Dangas, GD | 1 |
| Witzenbichler, B | 1 |
| Neumann, FJ | 1 |
| Weisz, G | 1 |
| Généreux, P | 1 |
| Maehara, A | 1 |
| McAndrew, T | 1 |
| Farhan, S | 1 |
| Rinaldi, MJ | 1 |
| Metzger, DC | 1 |
| Henry, TD | 1 |
| Cox, DA | 1 |
| Duffy, PL | 1 |
| Mazzaferri, EL | 1 |
| Brodie, BR | 1 |
| Stuckey, TD | 1 |
| Gurbel, P | 1 |
| Ben-Yehuda, O | 1 |
| Stone, GW | 1 |
| Leys, D | 8 |
| Moulin, S | 1 |
| Khatri, P | 1 |
| Kleindorfer, DO | 1 |
| Devlin, T | 1 |
| Sawyer, RN | 2 |
| Starr, M | 1 |
| Mejilla, J | 1 |
| Chatterjee, A | 1 |
| Jauch, EC | 1 |
| Levine, SR | 2 |
| Romano, JG | 3 |
| Vagal, A | 1 |
| Purdon, B | 1 |
| Devenport, J | 1 |
| Pavlov, A | 1 |
| Yeatts, SD | 1 |
| Wang, CW | 1 |
| Su, LL | 1 |
| Hua, QJ | 1 |
| Fan, YN | 1 |
| Xi, TT | 1 |
| Liu, YX | 1 |
| Ji, SB | 1 |
| Chen, L | 1 |
| Cao, S | 1 |
| Barlas, RS | 1 |
| Loke, YK | 1 |
| Bettencourt-Silva, JH | 1 |
| Ford, I | 2 |
| Clark, AB | 1 |
| Bowles, KM | 1 |
| Metcalf, AK | 1 |
| Potter, JF | 2 |
| Myint, PK | 1 |
| Liu, AF | 1 |
| Zhou, J | 2 |
| Wang, K | 2 |
| Li, C | 2 |
| Qiu, H | 1 |
| Jiang, WJ | 1 |
| Regenhardt, RW | 1 |
| Biseko, MR | 1 |
| Shayo, AF | 1 |
| Mmbando, TN | 1 |
| Grundy, SJ | 1 |
| Saadi, A | 1 |
| Wibecan, L | 1 |
| Kharal, GA | 1 |
| Parker, R | 1 |
| Klein, JP | 1 |
| Mateen, FJ | 1 |
| Okeng'o, K | 1 |
| Saber, H | 1 |
| Kherallah, RY | 1 |
| Hadied, MO | 1 |
| Kazemlou, S | 1 |
| Chamiraju, P | 1 |
| Narayanan, S | 1 |
| Dalugama, C | 1 |
| Gawarammana, IB | 1 |
| Sanchez-Lopez, J | 1 |
| Fernandez-Travieso, JC | 1 |
| Illnait-Ferrer, J | 1 |
| Fernandez-Dorta, L | 1 |
| Mendoza-Castano, S | 1 |
| Mas-Ferreiro, R | 1 |
| Mesa-Angarica, M | 1 |
| Reyes-Suarez, P | 1 |
| Jia, L | 1 |
| Li, R | 1 |
| Yin, X | 1 |
| Luo, H | 1 |
| Kheiri, B | 1 |
| Osman, M | 1 |
| Abdalla, A | 1 |
| Haykal, T | 1 |
| Swaid, B | 1 |
| Ahmed, S | 2 |
| Chahine, A | 1 |
| Hassan, M | 1 |
| Bachuwa, G | 1 |
| Al Qasmi, M | 1 |
| Ornello, R | 1 |
| Carolei, A | 2 |
| Darkwah Oppong, M | 1 |
| Gembruch, O | 1 |
| Pierscianek, D | 1 |
| Köhrmann, M | 2 |
| Kleinschnitz, C | 1 |
| Deuschl, C | 1 |
| Mönninghoff, C | 1 |
| Kaier, K | 1 |
| Forsting, M | 3 |
| Sure, U | 1 |
| Jabbarli, R | 1 |
| Aguilar-Salinas, P | 1 |
| Agnoletto, GJ | 1 |
| Brasiliense, LBC | 1 |
| Santos, R | 1 |
| Granja, MF | 1 |
| Gonsales, D | 1 |
| Aghaebrahim, A | 1 |
| Sauvageau, E | 1 |
| Hanel, RA | 1 |
| Hao, Q | 2 |
| Tampi, M | 1 |
| O'Donnell, M | 3 |
| Foroutan, F | 1 |
| Siemieniuk, RA | 1 |
| Guyatt, G | 2 |
| Prasad, K | 1 |
| Siemieniuk, R | 1 |
| Lytvyn, L | 1 |
| Heen, AF | 1 |
| Agoritsas, T | 1 |
| Vandvik, PO | 1 |
| Gorthi, SP | 1 |
| Fisch, L | 1 |
| Jusufovic, M | 1 |
| Muller, J | 1 |
| Booth, B | 1 |
| Horton, E | 1 |
| Fraiz, A | 1 |
| Siemieniuk, J | 1 |
| Fobuzi, AC | 1 |
| Katragunta, N | 1 |
| Rochwerg, B | 1 |
| Boucher, AA | 2 |
| Taylor, JM | 2 |
| Luchtman-Jones, L | 1 |
| Dube, M | 1 |
| Dani, R | 1 |
| Dubey, A | 1 |
| Chouksey, D | 1 |
| Lu, BC | 1 |
| Shi, XJ | 1 |
| Liang, L | 2 |
| Dong, N | 1 |
| Liu, ZZ | 1 |
| Jing, Y | 1 |
| Yue, X | 1 |
| Rahman, H | 1 |
| Khan, SU | 1 |
| Nasir, F | 1 |
| Hammad, T | 1 |
| Meyer, MA | 1 |
| Kaluski, E | 1 |
| Kim, D | 1 |
| Nah, HW | 2 |
| Choi, JC | 4 |
| Kim, WJ | 2 |
| Shin, DI | 2 |
| Hong, JH | 1 |
| Gorelick, PB | 4 |
| Laskowitz, DT | 1 |
| Miao, Z | 1 |
| Uchino, K | 1 |
| Tillman, H | 1 |
| Sur, NB | 1 |
| Di Tullio, MR | 6 |
| Gutierrez, CM | 1 |
| Dong, C | 1 |
| Koch, S | 2 |
| Gardener, H | 1 |
| García-Rivera, EJ | 1 |
| Zevallos, JC | 1 |
| Burgin, WS | 1 |
| Rose, DZ | 2 |
| Goldberger, JJ | 1 |
| Sacco, RL | 13 |
| Rundek, T | 1 |
| Gurunathan, A | 1 |
| Ricci, KW | 1 |
| Vadivelu, S | 1 |
| Quinn, CT | 1 |
| Toyoda, K | 3 |
| Yamaguchi, T | 3 |
| Kimura, K | 4 |
| Hoshino, H | 2 |
| Sakai, N | 1 |
| Okada, Y | 2 |
| Tanaka, K | 1 |
| Origasa, H | 2 |
| Naritomi, H | 2 |
| Houkin, K | 1 |
| Yamaguchi, K | 1 |
| Isobe, M | 1 |
| Minematsu, K | 4 |
| Chen, XP | 1 |
| Wei, DC | 1 |
| Chen, SQ | 1 |
| He, WZ | 1 |
| Veltkamp, RC | 1 |
| Coutts, SB | 1 |
| Harima, K | 1 |
| Honda, S | 1 |
| Mikami, K | 1 |
| Kitajima, M | 1 |
| Urushizaka, M | 1 |
| Tomisawa, T | 1 |
| Hagii, J | 1 |
| Metoki, H | 1 |
| Yasujima, M | 1 |
| Osanai, T | 1 |
| Patrono, C | 3 |
| Baigent, C | 1 |
| Podlasek, A | 1 |
| Al Sultan, AA | 1 |
| Assis, Z | 1 |
| Kashani, N | 1 |
| Goyal, M | 1 |
| Almekhlafi, MA | 1 |
| Dharmasaroja, PA | 1 |
| Muengtaweepongsa, S | 1 |
| Sae-Lim, S | 1 |
| Jussen, D | 1 |
| Horn, P | 1 |
| Vajkoczy, P | 1 |
| Yamashiro, K | 1 |
| Tanaka, R | 1 |
| Okuma, Y | 1 |
| Ueno, Y | 1 |
| Tanaka, Y | 2 |
| Hattori, N | 1 |
| Urabe, T | 1 |
| Sorkin, GC | 1 |
| Dumont, TM | 1 |
| Wach, MM | 1 |
| Eller, JL | 1 |
| Mokin, M | 1 |
| Natarajan, SK | 1 |
| Baxter, MS | 1 |
| Snyder, KV | 1 |
| Levy, EI | 1 |
| Hopkins, LN | 1 |
| Siddiqui, AH | 1 |
| Shepankevich, LA | 1 |
| Vostrikova, EB | 1 |
| Pilipenko, PI | 1 |
| Beynon, C | 1 |
| Sakowitz, OW | 1 |
| Unterberg, AW | 1 |
| D'Amelio, M | 1 |
| Terruso, V | 1 |
| Famoso, G | 1 |
| Di Benedetto, N | 1 |
| Realmuto, S | 1 |
| Valentino, F | 1 |
| Ragonese, P | 1 |
| Savettieri, G | 1 |
| Aridon, P | 1 |
| Sambu, N | 1 |
| Radhakrishnan, A | 1 |
| Englyst, N | 1 |
| Weir, N | 1 |
| Curzen, N | 1 |
| Homma, S | 6 |
| Thompson, JL | 6 |
| Sanford, AR | 3 |
| Mann, DL | 4 |
| Levin, B | 4 |
| Pullicino, PM | 4 |
| Freudenberger, RS | 4 |
| Teerlink, JR | 4 |
| Graham, S | 4 |
| Massie, BM | 2 |
| Labovitz, AJ | 4 |
| Gabriel, AP | 2 |
| Lip, GY | 10 |
| Estol, CJ | 3 |
| Lok, DJ | 4 |
| Ponikowski, P | 4 |
| Anker, SD | 4 |
| Qian, M | 2 |
| Haddad, H | 1 |
| Diek, M | 1 |
| Meyer, DM | 1 |
| Compton, P | 1 |
| Eastwood, JA | 1 |
| Gylys, K | 1 |
| Zivin, JA | 1 |
| Sathishkumar, D | 1 |
| George, R | 1 |
| Irodi, A | 1 |
| Thomas, M | 1 |
| Jastrzębska, M | 1 |
| Chełstowski, K | 1 |
| Wódecka, A | 1 |
| Siennicka, A | 1 |
| Clark, J | 1 |
| Nowacki, P | 1 |
| Chabriat, H | 1 |
| Maeder, P | 1 |
| Gass, A | 1 |
| Michel, P | 3 |
| Bracoud, L | 1 |
| Hennerici, M | 1 |
| Lee, M | 3 |
| Rao, NM | 2 |
| Wu, YL | 2 |
| Ovbiagele, B | 5 |
| Själander, S | 1 |
| Själander, A | 1 |
| Svensson, PJ | 1 |
| Friberg, L | 1 |
| Castilla-Guerra, L | 2 |
| Navas-Alcántara, MS | 2 |
| Fernández-Moreno, MC | 1 |
| Nakagawa, I | 1 |
| Wada, T | 1 |
| Park, HS | 1 |
| Nishimura, F | 1 |
| Yamada, S | 1 |
| Nakagawa, H | 1 |
| Kichikawa, K | 1 |
| Nakase, H | 1 |
| Ferreiro, JL | 1 |
| Ueno, M | 1 |
| Bauer, D | 1 |
| Angiolillo, DJ | 1 |
| Nosul, M | 1 |
| Kolb, GF | 1 |
| Lau, YC | 1 |
| Qian, Y | 1 |
| Bi, Q | 1 |
| Arslan, Y | 1 |
| Yoldaş, TK | 1 |
| Zorlu, Y | 1 |
| Nomani, F | 1 |
| Kamal, AK | 4 |
| Kwon, HM | 1 |
| Lee, YS | 2 |
| Fernandez-Moreno, Mdel C | 1 |
| Jimenez-Gonzalo, F | 1 |
| Alvarez-Sabín, J | 4 |
| Quintana, M | 2 |
| Santamarina, E | 1 |
| Maisterra, O | 1 |
| Chen, CY | 1 |
| Lee, KT | 1 |
| Lee, CT | 1 |
| Lai, WT | 1 |
| Huang, YB | 1 |
| Ciccone, A | 2 |
| Motto, C | 2 |
| Abraha, I | 1 |
| Cozzolino, F | 1 |
| Santilli, I | 1 |
| Loidi Pascual, L | 1 |
| Valcayo Peñalba, A | 1 |
| Yerani Ruiz de Azúa Ciria, A | 1 |
| Yanguas Bayona, I | 1 |
| Chi, W | 1 |
| Sandercock, PA | 7 |
| Counsell, C | 3 |
| Tseng, MC | 1 |
| Cecconi, E | 1 |
| Davis, S | 1 |
| Jones, EF | 1 |
| Cohen, AA | 1 |
| Heiss, WD | 2 |
| Kaste, M | 5 |
| Laouénan, C | 1 |
| Young, D | 1 |
| Macleod, M | 1 |
| Donnan, GA | 3 |
| Meng, H | 1 |
| Xu, L | 2 |
| Kong, D | 1 |
| Chen, P | 1 |
| Gong, X | 1 |
| Bai, J | 1 |
| Zou, F | 1 |
| Yang, Z | 1 |
| Eikelboom, JW | 7 |
| Shestakovska, O | 5 |
| Connolly, S | 2 |
| Bai, W | 1 |
| Duan, Z | 1 |
| Cai, Q | 1 |
| Liu, D | 2 |
| Ma, M | 1 |
| Ahmad, MA | 2 |
| Najmi, AK | 2 |
| Mujeeb, M | 2 |
| Akhtar, M | 3 |
| Davidai, G | 1 |
| Cotton, D | 4 |
| Gorelick, P | 3 |
| Lipton, RB | 1 |
| Sacco, R | 2 |
| Diener, HC | 11 |
| Berkowitz, AL | 1 |
| Westover, MB | 1 |
| Bianchi, MT | 1 |
| Chou, SH | 1 |
| Paraskevas, KI | 1 |
| Veith, FJ | 1 |
| Vanassche, T | 1 |
| Lauw, MN | 1 |
| Healey, JS | 1 |
| Alings, M | 1 |
| Avezum, A | 1 |
| Díaz, R | 1 |
| Hohnloser, SH | 1 |
| Lewis, BS | 1 |
| Joly, B | 1 |
| Menard, AL | 1 |
| Ozkul-Wermester, O | 1 |
| Triquenot-Bagan, A | 1 |
| Guegan-Massardier, E | 1 |
| Borg, JY | 1 |
| Le Cam-Duchez, V | 1 |
| Rajani, AR | 1 |
| Mahmoud, WE | 1 |
| Murugesan, V | 1 |
| BinBrek, AS | 1 |
| Lee, HC | 1 |
| Lee, JD | 2 |
| Chang, KC | 1 |
| Wu, CY | 1 |
| Lee, TH | 3 |
| Wang, HH | 1 |
| Stanford, SN | 1 |
| Sabra, A | 1 |
| Lawrence, M | 1 |
| Morris, RH | 1 |
| Storton, S | 1 |
| Wani, M | 1 |
| Hawkins, K | 1 |
| Williams, PR | 1 |
| Evans, PA | 1 |
| Chýlová, M | 1 |
| Moťovská, Z | 1 |
| Osmančík, P | 1 |
| Procházka, B | 1 |
| Kalvach, P | 1 |
| Robson, K | 1 |
| Dineen, R | 1 |
| Pocock, S | 2 |
| Agayeva, N | 2 |
| Gungor, L | 1 |
| Topcuoglu, MA | 2 |
| Arsava, EM | 2 |
| Choi, MJ | 1 |
| Nam, TS | 2 |
| Lee, SH | 3 |
| Kim, MK | 2 |
| Ye, S | 1 |
| Buchsbaum, R | 2 |
| Freitas-Silva, M | 1 |
| Gonçalves, L | 1 |
| Medeiros, R | 1 |
| Nunes, JP | 1 |
| Thompson, DD | 1 |
| Murray, GD | 1 |
| Candelise, L | 2 |
| Whiteley, WN | 1 |
| Liu, F | 1 |
| Tantry, US | 1 |
| Gurbel, PA | 1 |
| Lee, JY | 2 |
| Blann, AD | 1 |
| Skjøth, F | 1 |
| Rasmussen, LH | 1 |
| Larsen, TB | 1 |
| Lahham, S | 1 |
| Nelson, D | 1 |
| Su, Y | 1 |
| Cheng, X | 1 |
| Shams ara, A | 1 |
| Sheibani, V | 1 |
| Esmaeilpour, K | 1 |
| Eslaminejad, T | 1 |
| Nematollahi-Mahani, SN | 1 |
| Choi, SM | 1 |
| Tziomalos, K | 2 |
| Giampatzis, V | 2 |
| Bouziana, SD | 2 |
| Spanou, M | 2 |
| Kostaki, S | 2 |
| Papadopoulou, M | 2 |
| Dourliou, V | 1 |
| Sofogianni, A | 1 |
| Savopoulos, C | 2 |
| Hatzitolios, AI | 2 |
| Fabiaña, N | 1 |
| Ramaswami, AP | 1 |
| Ang, ES | 1 |
| De Silva, DA | 1 |
| Smith, ER | 1 |
| Barinov, EF | 1 |
| Mamedaliyeva, S | 1 |
| Tverdokhleb, TA | 1 |
| Christiansen, CB | 1 |
| Pallisgaard, J | 1 |
| Gerds, TA | 1 |
| Olesen, JB | 1 |
| Jørgensen, ME | 1 |
| Numé, AK | 1 |
| Carlson, N | 1 |
| Kristensen, SL | 1 |
| Gislason, G | 1 |
| Torp-Pedersen, C | 2 |
| Hilkens, NA | 1 |
| Algra, A | 18 |
| Greving, JP | 1 |
| Sternberg, Z | 2 |
| Chichelli, T | 2 |
| Sternberg, D | 1 |
| Sawyer, R | 1 |
| Ching, M | 2 |
| Janicke, D | 2 |
| Ambrus, JL | 1 |
| Yu, J | 2 |
| Munschauer, F | 1 |
| Ko, YC | 1 |
| Yeo, MJ | 1 |
| Ko, Y | 1 |
| Angelopoulou, SM | 1 |
| Tsopozidi, M | 1 |
| Murphy, SJ | 1 |
| Coughlan, CA | 1 |
| Tobin, O | 1 |
| Kinsella, J | 1 |
| Lonergan, R | 1 |
| Gutkin, M | 1 |
| McCabe, DJ | 3 |
| Jung, S | 2 |
| Kim, C | 1 |
| Jang, MU | 1 |
| Davis, K | 1 |
| Dietrich, E | 1 |
| Ishizuka, N | 1 |
| Shimada, K | 1 |
| Teramoto, T | 1 |
| Yamazaki, T | 1 |
| Oikawa, S | 1 |
| Sugawara, M | 1 |
| Ando, K | 1 |
| Murata, M | 1 |
| Yokoyama, K | 1 |
| Matsumoto, M | 3 |
| Ikeda, Y | 3 |
| Rothwell, PM | 2 |
| Norrving, B | 1 |
| Mehta, Z | 1 |
| Bilora, F | 1 |
| Adamo, A | 1 |
| Pomerri, F | 1 |
| Prandoni, P | 1 |
| Liu, P | 1 |
| Fu, C | 1 |
| Domanski, MJ | 1 |
| Dillinger, JG | 1 |
| Saeed, A | 1 |
| Spagnoli, V | 1 |
| Sollier, CB | 1 |
| Sideris, G | 1 |
| Silberman, SM | 1 |
| Voicu, S | 1 |
| Drouet, L | 2 |
| Henry, P | 1 |
| Gallego-Fabrega, C | 1 |
| Carrera, C | 1 |
| Reny, JL | 1 |
| Fontana, P | 1 |
| Slowik, A | 1 |
| Pera, J | 1 |
| Pezzini, A | 2 |
| Serrano-Heras, G | 1 |
| Segura, T | 1 |
| Bin Dukhyil, AA | 1 |
| Muiño, E | 1 |
| Cullell, N | 1 |
| Krupinski, J | 2 |
| Fernandez-Cadenas, I | 1 |
| Su, TH | 1 |
| Chan, YL | 1 |
| Lin, LC | 1 |
| Wen, YW | 1 |
| Guo, X | 1 |
| Yu, L | 1 |
| Chen, M | 1 |
| Peng, X | 1 |
| Guo, R | 1 |
| Chang, DI | 1 |
| Kim, GM | 1 |
| Park, KY | 1 |
| Sohn, CH | 1 |
| Deng, QQ | 1 |
| Tang, J | 1 |
| Markus, H | 1 |
| Huang, YN | 1 |
| Ratanakorn, D | 1 |
| Wong, KS | 4 |
| Fu, JH | 1 |
| Nelson, S | 1 |
| Cloonan, L | 1 |
| Kanakis, AS | 1 |
| Fitzpatrick, KM | 1 |
| Shideler, KI | 1 |
| Perilla, AS | 1 |
| Rost, NS | 1 |
| Peng, LL | 1 |
| Zhao, YQ | 1 |
| Zhou, ZY | 1 |
| Zhao, M | 1 |
| Chen, XM | 1 |
| Chen, LY | 1 |
| Cai, YF | 2 |
| Li, JL | 1 |
| Huang, M | 1 |
| Ho, HH | 1 |
| Mok, KH | 1 |
| Owais, T | 1 |
| Rouman, M | 1 |
| Breuer, M | 1 |
| Hüter, L | 1 |
| Fuchs, J | 1 |
| Lauer, B | 1 |
| Kuntze, T | 1 |
| Pasala, T | 1 |
| Hoo, JS | 1 |
| Lockhart, MK | 1 |
| Waheed, R | 1 |
| Sengodan, P | 1 |
| Alexander, J | 1 |
| Gandhi, S | 1 |
| Darteyre, S | 1 |
| Renaud, C | 1 |
| Fluss, J | 1 |
| Laporte, S | 1 |
| Bertoletti, L | 1 |
| Chabrier, S | 1 |
| Song, H | 1 |
| Hou, C | 1 |
| Cao, Q | 1 |
| Feng, W | 1 |
| Ji, X | 1 |
| Sanchez, J | 1 |
| Illnait, J | 1 |
| Mas, R | 2 |
| Mendoza, S | 1 |
| Fernandez, L | 1 |
| Mesa, M | 1 |
| Vega, H | 1 |
| Fernandez, J | 1 |
| Reyes, P | 1 |
| Ruiz, D | 1 |
| Chen, YT | 1 |
| Chen, HT | 1 |
| Chao, PW | 1 |
| Kuo, SC | 1 |
| Ou, SM | 1 |
| Shih, CJ | 1 |
| Kim, SW | 1 |
| Choi, KJ | 1 |
| Park, JY | 1 |
| Yoon, SH | 2 |
| Lee, JK | 1 |
| Li, XG | 1 |
| Ma, N | 1 |
| Sun, SS | 1 |
| Wang, YJ | 1 |
| Miao, ZR | 1 |
| Zhao, ZG | 1 |
| Secemsky, EA | 1 |
| Yeh, RW | 1 |
| Kereiakes, DJ | 1 |
| Cutlip, DE | 1 |
| Cohen, DJ | 1 |
| Steg, PG | 1 |
| Cannon, CP | 1 |
| Apruzzese, PK | 1 |
| D'Agostino, RB | 1 |
| Massaro, JM | 1 |
| Mauri, L | 1 |
| Belvís, R | 1 |
| Pagonabarraga, J | 1 |
| Santamaría, A | 1 |
| Kulisevsky, J | 1 |
| Li, ZG | 2 |
| Yu, ZC | 1 |
| Wang, DZ | 1 |
| Ju, WP | 1 |
| Zhan, X | 1 |
| Wu, QZ | 2 |
| Wu, XJ | 1 |
| Cong, HM | 1 |
| Man, HH | 1 |
| Sztriha, LK | 2 |
| Vécsei, L | 2 |
| Albers, GW | 5 |
| Teal, P | 3 |
| Karepov, V | 2 |
| Tolpina, G | 1 |
| Kuliczkowski, W | 1 |
| Serebruany, V | 2 |
| Michaud, K | 1 |
| Hallenbeck, JM | 1 |
| Wolfe, F | 1 |
| Ounpuu, S | 1 |
| Lawton, WA | 1 |
| Palesch, Y | 2 |
| Martin, RH | 3 |
| Bath, P | 2 |
| Chan, BP | 1 |
| Chen, ST | 1 |
| Dahlöf, B | 1 |
| De Keyser, J | 3 |
| Estol, C | 2 |
| Gu, V | 1 |
| Hermansson, K | 2 |
| Hilbrich, L | 1 |
| Lu, C | 2 |
| Machnig, T | 1 |
| Pais, P | 1 |
| Roberts, R | 2 |
| Skvortsova, V | 1 |
| Vandermaelen, C | 1 |
| Voigt, T | 1 |
| Weber, M | 1 |
| Vande Griend, JP | 1 |
| Saseen, JJ | 1 |
| Suri, MF | 2 |
| Hussein, HM | 1 |
| Abdelmoula, MM | 1 |
| Divani, AA | 1 |
| Qureshi, AI | 4 |
| Sare, GM | 1 |
| Gray, LJ | 3 |
| Moulin, T | 1 |
| Woimant, F | 1 |
| England, T | 1 |
| Geeganage, C | 1 |
| De Deyn, PP | 3 |
| Ringelstein, EB | 4 |
| Lemaitre, RN | 1 |
| Rice, K | 1 |
| Marciante, K | 1 |
| Bis, JC | 1 |
| Lumley, TS | 1 |
| Wiggins, KL | 1 |
| Smith, NL | 1 |
| Heckbert, SR | 1 |
| Psaty, BM | 1 |
| Jeon, HW | 1 |
| Kang, MJ | 1 |
| Fu, FH | 1 |
| Han, B | 1 |
| Zhu, M | 2 |
| Yu, X | 1 |
| Zhang, LM | 1 |
| Hanhart, J | 1 |
| Koskas, P | 1 |
| Obadia, M | 1 |
| Le Mer, Y | 1 |
| Sahel, JA | 1 |
| Paques, M | 1 |
| Minnerup, J | 1 |
| Schäbitz, WR | 2 |
| Berger, CT | 1 |
| Wolbers, M | 1 |
| Meyer, P | 1 |
| Daikeler, T | 1 |
| Hess, C | 1 |
| Sousa, AS | 1 |
| Xavier, SS | 1 |
| Freitas, GR | 2 |
| Hasslocher-Moreno, A | 1 |
| Chourkani, N | 1 |
| Sibai, M | 1 |
| Moutaouakil, F | 1 |
| Rafai, M | 1 |
| Bourezgui, M | 1 |
| Slassi, I | 1 |
| van den Bergh, WM | 1 |
| Rinkel, GJ | 1 |
| Zytkiewicz, M | 1 |
| Giełwanowska, L | 1 |
| Wojtasińska, E | 1 |
| Psuja, P | 1 |
| Zawilska, K | 1 |
| Park, MK | 1 |
| Smith, PC | 1 |
| Wanserski, G | 1 |
| Neher, JO | 1 |
| Björklund, L | 1 |
| Wallander, MA | 1 |
| Johansson, S | 1 |
| Lesén, E | 1 |
| Hegge, KA | 1 |
| Faxon, DP | 1 |
| Freedman, JE | 1 |
| Pu, F | 1 |
| Motohashi, K | 1 |
| Kaneko, T | 1 |
| Manome, N | 1 |
| Irie, K | 1 |
| Takata, J | 1 |
| Egashira, N | 1 |
| Oishi, R | 1 |
| Okamoto, T | 1 |
| Sei, Y | 1 |
| Yokozawa, T | 1 |
| Mishima, K | 1 |
| Iwasaki, K | 1 |
| Fujiwara, M | 1 |
| Chang, YJ | 1 |
| Ryu, SJ | 2 |
| Chen, JR | 1 |
| Hu, HH | 3 |
| Yip, PK | 1 |
| Chiu, TF | 1 |
| Halkes, PH | 2 |
| van Gijn, J | 6 |
| Kappelle, LJ | 3 |
| Georgiadis, D | 1 |
| Arnold, M | 2 |
| von Buedingen, HC | 1 |
| Valko, P | 1 |
| Sarikaya, H | 1 |
| Rousson, V | 1 |
| Mattle, HP | 2 |
| Bousser, MG | 8 |
| Baumgartner, RW | 2 |
| Balucani, C | 1 |
| Cordonnier, C | 1 |
| Telman, G | 1 |
| Kouperberg, E | 1 |
| Sprecher, E | 1 |
| Yarnitsky, D | 1 |
| Biller, J | 3 |
| Famakin, BM | 1 |
| Chimowitz, MI | 3 |
| Lynn, MJ | 3 |
| Stern, BJ | 3 |
| George, MG | 1 |
| Tenney, J | 1 |
| Johnson, LH | 1 |
| Hermann, A | 1 |
| Dzialowski, I | 1 |
| Koch, R | 1 |
| Gahn, G | 1 |
| De Schryver, EL | 3 |
| Beckman, JA | 1 |
| Penalba, A | 1 |
| García-Bonilla, L | 1 |
| Po, HL | 2 |
| Lin, YJ | 1 |
| Hseuh, IH | 1 |
| Slaviero, F | 1 |
| Annes, RD | 1 |
| Frighetto, L | 1 |
| Schirmer, LM | 1 |
| Vanzin, JR | 1 |
| Fröhlich, AC | 1 |
| Ferraz, J | 1 |
| Azambuja, ND | 1 |
| Bal Dit Sollier, C | 1 |
| Crassard, I | 1 |
| Simoneau, G | 1 |
| Bergmann, JF | 1 |
| Gomez, CR | 1 |
| Ito, H | 1 |
| Hashimoto, A | 1 |
| Matsumoto, Y | 1 |
| Yao, H | 1 |
| Miyakoda, G | 1 |
| Pinto, A | 1 |
| Di Raimondo, D | 1 |
| Tuttolomondo, A | 1 |
| Di Sciacca, R | 1 |
| Arnao, V | 1 |
| La Placa, S | 1 |
| Milio, G | 1 |
| Miceli, S | 1 |
| Licata, G | 1 |
| Zinkstok, SM | 2 |
| Vermeulen, M | 2 |
| Stam, J | 2 |
| de Haan, RJ | 2 |
| Roos, YB | 2 |
| Ha, SW | 1 |
| Guo, JJ | 1 |
| Xu, E | 2 |
| Lin, QY | 1 |
| Zeng, GL | 1 |
| Xie, HF | 1 |
| Meyer, D | 1 |
| Lee, BH | 1 |
| Park, JS | 2 |
| Kwak, JJ | 1 |
| Hwang, ES | 1 |
| Choi, DH | 1 |
| Kim, YH | 1 |
| Pak, HN | 1 |
| Diedler, J | 1 |
| Ahmed, N | 2 |
| Sykora, M | 1 |
| Overgaard, K | 2 |
| Luijckx, GJ | 2 |
| Soinne, L | 1 |
| Ford, GA | 2 |
| Lees, KR | 3 |
| Wahlgren, N | 2 |
| Ringleb, P | 1 |
| Torgano, G | 1 |
| Zecca, B | 1 |
| Monzani, V | 1 |
| Maestroni, A | 1 |
| Rossi, P | 1 |
| Cazzaniga, M | 1 |
| Manganaro, D | 1 |
| Boiti, C | 1 |
| Zilioli, E | 1 |
| Borutti, G | 1 |
| Falaschi, F | 1 |
| Mandelli, C | 1 |
| Laufs, U | 1 |
| Hoppe, UC | 1 |
| Rosenkranz, S | 1 |
| Kirchhof, P | 1 |
| Böhm, M | 1 |
| Grond, M | 2 |
| Hacke, W | 8 |
| Meinertz, T | 1 |
| Röther, J | 1 |
| Dichgans, M | 2 |
| Burke, JP | 1 |
| Sander, S | 1 |
| Shah, H | 1 |
| Zarotsky, V | 1 |
| Henk, H | 1 |
| Pratap, R | 1 |
| Pillai, KK | 1 |
| Khanam, R | 1 |
| Islam, F | 1 |
| Ahmad, SJ | 1 |
| Pan, SL | 1 |
| Lien, IN | 4 |
| Chen, TH | 1 |
| Quinn, T | 1 |
| Rafferty, M | 1 |
| Higgins, P | 1 |
| Ray, G | 1 |
| Walters, MR | 1 |
| Benbassat, J | 1 |
| Baumal, R | 1 |
| Herishanu, Y | 1 |
| Menon, BK | 1 |
| Frankel, MR | 2 |
| Labresh, KA | 1 |
| Ellrodt, G | 1 |
| Hernandez, AF | 1 |
| Fonarow, GC | 1 |
| Schwamm, LH | 2 |
| Smith, EE | 1 |
| Inzitari, D | 1 |
| Piccardi, B | 1 |
| Sarti, C | 1 |
| Lu, N | 1 |
| Liu, G | 1 |
| Lee, SP | 2 |
| Suh, JW | 2 |
| Lee, HY | 2 |
| Kang, HJ | 2 |
| Koo, BK | 2 |
| Chae, IH | 2 |
| Choi, DJ | 2 |
| Rha, SW | 2 |
| Bae, JW | 2 |
| Cho, MC | 2 |
| Kwon, TG | 2 |
| Bae, JH | 2 |
| Kim, HS | 2 |
| Hansen, ML | 1 |
| Sørensen, R | 1 |
| Clausen, MT | 1 |
| Fog-Petersen, ML | 1 |
| Raunsø, J | 1 |
| Gadsbøll, N | 1 |
| Gislason, GH | 1 |
| Folke, F | 1 |
| Andersen, SS | 1 |
| Schramm, TK | 1 |
| Abildstrøm, SZ | 1 |
| Poulsen, HE | 1 |
| Køber, L | 1 |
| Colli, A | 2 |
| D'Amico, R | 2 |
| Mestres, CA | 1 |
| Pomar, JL | 1 |
| Cámara, ML | 1 |
| Ruyra, X | 1 |
| Mulet, J | 1 |
| Pan, J | 1 |
| Xia, Q | 1 |
| Luo, B | 1 |
| Gizewski, ER | 2 |
| Weber, R | 2 |
| Bischoff, A | 1 |
| Venker, C | 1 |
| Stracke, P | 1 |
| Berlit, P | 2 |
| Diehl, RR | 1 |
| Kurre, W | 1 |
| Sorgenfrei, U | 1 |
| Krämer, M | 1 |
| Chapot, R | 1 |
| Zhou, M | 1 |
| Zhang, D | 1 |
| Yang, M | 1 |
| Zhou, D | 1 |
| Shimokhina, NIu | 1 |
| Petrova, MM | 1 |
| Savchenko, AA | 1 |
| Sakata, T | 1 |
| Kario, K | 1 |
| Bugnicourt, JM | 1 |
| Roussel, B | 1 |
| Garcia, PY | 1 |
| Canaple, S | 2 |
| Lamy, C | 2 |
| Godefroy, O | 1 |
| O'Carroll, R | 1 |
| Whittaker, J | 1 |
| Hamilton, B | 1 |
| Johnston, M | 1 |
| Sudlow, C | 2 |
| Dennis, M | 1 |
| Kautzky-Willer, A | 1 |
| Kamyar, MR | 1 |
| Gerhat, D | 1 |
| Handisurya, A | 1 |
| Stemer, G | 1 |
| Hudson, S | 1 |
| Luger, A | 1 |
| Lemmens-Gruber, R | 1 |
| Mas, JL | 3 |
| Brennan, D | 1 |
| Mak, KH | 1 |
| Fox, KA | 1 |
| Topol, EJ | 4 |
| Fedorov, A | 1 |
| Chibisova, Y | 1 |
| Szymaszek, A | 1 |
| Alexandrov, M | 1 |
| Gall, C | 1 |
| Sabel, BA | 1 |
| Cho, YS | 1 |
| Youn, TJ | 1 |
| Naqvi, I | 1 |
| Husain, MR | 1 |
| Khealani, BA | 1 |
| Sani, Y | 1 |
| Pokov, I | 1 |
| Schevchuck, A | 1 |
| Fong, A | 1 |
| Thevathasan, L | 1 |
| Hanley, D | 1 |
| Kao, YH | 1 |
| Lin, SJ | 1 |
| Lee, CH | 1 |
| Lai, ML | 2 |
| Khan, M | 1 |
| Urano, Y | 1 |
| Horie, Y | 1 |
| Halawani, SH | 1 |
| Williams, DJ | 1 |
| Adefurin, A | 1 |
| Webster, J | 1 |
| Greaves, M | 1 |
| Tate, J | 1 |
| Bushnell, C | 1 |
| Adelman, EE | 1 |
| Lisabeth, L | 1 |
| Brown, DL | 1 |
| Lynch, DR | 1 |
| Ueno, H | 1 |
| Koyama, H | 1 |
| Mima, Y | 1 |
| Fukumoto, S | 1 |
| Tanaka, S | 1 |
| Shoji, T | 2 |
| Emoto, M | 1 |
| Nishizawa, Y | 1 |
| Inaba, M | 1 |
| Pujol Lereis, VA | 1 |
| Ameriso, S | 1 |
| Povedano, GP | 1 |
| Feher, A | 1 |
| Pusch, G | 1 |
| Harang, G | 1 |
| Gasztonyi, B | 1 |
| Papp, E | 1 |
| Werling, D | 1 |
| Menyhart, M | 1 |
| Komaromy, H | 1 |
| Szapary, L | 2 |
| Feher, G | 2 |
| Oyama, N | 1 |
| Yagita, Y | 1 |
| Kawamura, M | 1 |
| Sugiyama, Y | 1 |
| Terasaki, Y | 1 |
| Omura-Matsuoka, E | 1 |
| Sasaki, T | 1 |
| Kitagawa, K | 2 |
| Mono, ML | 1 |
| Geister, L | 1 |
| Galimanis, A | 1 |
| Praz, F | 1 |
| Fischer, U | 1 |
| Wolff, S | 1 |
| Findling, O | 1 |
| Windecker, S | 1 |
| Wahl, A | 1 |
| Meier, B | 1 |
| Nedeltchev, K | 1 |
| Duelsner, A | 1 |
| Gatzke, N | 1 |
| Glaser, J | 1 |
| Hillmeister, P | 1 |
| Li, M | 1 |
| Lehmann, K | 1 |
| Urban, D | 1 |
| Meyborg, H | 1 |
| Stawowy, P | 1 |
| Busjahn, A | 1 |
| Nagorka, S | 1 |
| Persson, AB | 1 |
| Buschmann, IR | 1 |
| Georgiadis, AL | 1 |
| Cordina, SM | 1 |
| Vazquez, G | 1 |
| Tariq, N | 1 |
| Lakshminarayan, K | 1 |
| Adams, HP | 5 |
| Greenhalgh, J | 1 |
| Bagust, A | 1 |
| Boland, A | 1 |
| Martin Saborido, C | 1 |
| Oyee, J | 1 |
| Blundell, M | 1 |
| Dundar, Y | 1 |
| Dickson, R | 1 |
| Proudlove, C | 1 |
| Fisher, M | 2 |
| Nakamura, T | 1 |
| Tsuruta, S | 1 |
| Pelegrín, L | 1 |
| Mesquida, M | 1 |
| Rey, A | 2 |
| Sánchez-Dalmau, B | 1 |
| Frohman, L | 1 |
| Bang, OY | 2 |
| Wang, QS | 1 |
| Chen, XY | 1 |
| Han, JH | 1 |
| Soo, Y | 1 |
| Leung, TW | 2 |
| Mok, V | 1 |
| Vinisko, R | 1 |
| Meves, SH | 1 |
| Overbeck, U | 1 |
| Endres, HG | 1 |
| Krogias, C | 1 |
| Neubauer, H | 1 |
| Sharma, V | 2 |
| Kaul, S | 2 |
| Al-Hazzani, A | 2 |
| Prabha, TS | 1 |
| Rao, PP | 1 |
| Dadheech, S | 1 |
| Jyothy, A | 2 |
| Fiorella, D | 1 |
| Fujita, K | 1 |
| Komatsu, Y | 1 |
| Sato, N | 1 |
| Higuchi, O | 1 |
| Kujiraoka, Y | 1 |
| Kamezaki, T | 1 |
| Suzuki, K | 3 |
| Matsumura, A | 1 |
| Radovic, V | 1 |
| Mehta, B | 1 |
| Farooq, O | 1 |
| Munschauer, FE | 1 |
| Weimar, C | 1 |
| Wanke, I | 1 |
| Möller-Hartmann, C | 1 |
| Blatchford, J | 1 |
| Demchuk, AM | 1 |
| Warach, S | 1 |
| Diehl, A | 1 |
| Acelajado, MC | 1 |
| Oparil, S | 1 |
| Del Zotto, E | 1 |
| Ritelli, M | 1 |
| Drera, B | 1 |
| Gamba, M | 1 |
| Giossi, A | 1 |
| Volonghi, I | 1 |
| Costa, P | 1 |
| Barlati, S | 1 |
| Gasparotti, R | 1 |
| Padovani, A | 1 |
| Colombi, M | 1 |
| Geeganage, CM | 1 |
| Dengler, R | 2 |
| Bath, MW | 1 |
| Wiesemann, S | 1 |
| Passlick, B | 1 |
| Johkura, K | 1 |
| Yoshida, TN | 1 |
| Kudo, Y | 1 |
| Nakae, Y | 1 |
| Momoo, T | 1 |
| Kuroiwa, Y | 1 |
| Nolte, CH | 1 |
| Yaemsiri, S | 1 |
| Sen, S | 1 |
| Tinker, L | 1 |
| Rosamond, W | 1 |
| Wassertheil-Smoller, S | 1 |
| He, K | 1 |
| Mazya, M | 1 |
| Egido, JA | 1 |
| Agarwal, S | 1 |
| Hachamovitch, R | 1 |
| Menon, V | 1 |
| Soo, YO | 1 |
| Siu, DY | 1 |
| Abrigo, J | 1 |
| Ng, N | 1 |
| Ahuja, AT | 1 |
| Wong, LK | 1 |
| Bazan, NG | 1 |
| Eady, TN | 1 |
| Khoutorova, L | 1 |
| Atkins, KD | 1 |
| Hong, S | 1 |
| Lu, Y | 1 |
| Zhang, C | 1 |
| Jun, B | 1 |
| Obenaus, A | 1 |
| Fredman, G | 1 |
| Winkler, JW | 1 |
| Petasis, NA | 1 |
| Serhan, CN | 1 |
| Belayev, L | 1 |
| Ammon, SE | 1 |
| Mejia, V | 1 |
| del Valle, ML | 1 |
| Sheu, JS | 1 |
| Liu, HC | 1 |
| Yuan, RY | 2 |
| Yu, JM | 1 |
| Sheu, JJ | 1 |
| Hung, CH | 1 |
| Fischer-Betz, R | 1 |
| Specker, C | 1 |
| Brinks, R | 1 |
| Schneider, M | 1 |
| Chen, ZC | 1 |
| Sun, JZ | 1 |
| Shi, ZH | 1 |
| Richard, S | 1 |
| Toussaint-Hacquard, M | 1 |
| Fay, R | 1 |
| Lacour, JC | 1 |
| Ducrocq, X | 1 |
| Lecompte, T | 1 |
| Futrell, N | 1 |
| Alshatwi, AA | 1 |
| Reyes-Iglesias, Y | 1 |
| Yavagal, DR | 1 |
| Arnarsdottir, L | 1 |
| Hjalmarsson, C | 1 |
| Bokemark, L | 1 |
| Andersson, B | 1 |
| Worthmann, H | 1 |
| Schumacher, H | 1 |
| Schwartz, A | 1 |
| Eisert, WG | 1 |
| Lichtinghagen, R | 1 |
| Weissenborn, K | 1 |
| Rossen, JD | 1 |
| Wassef, SN | 1 |
| Thomas, J | 1 |
| Abel, TJ | 1 |
| Jabbour, PM | 1 |
| Kung, DK | 1 |
| Hasan, DM | 1 |
| Tobin, WO | 1 |
| Collins, R | 2 |
| Murphy, RP | 1 |
| Bausili, M | 1 |
| Abreu, S | 1 |
| Unzueta, MC | 1 |
| García Álvarez, M | 1 |
| Crespí, J | 1 |
| Moral, MV | 1 |
| Simard, JM | 1 |
| Geng, Z | 1 |
| Silver, FL | 1 |
| Sheth, KN | 1 |
| Kimberly, WT | 1 |
| Colucci, M | 1 |
| Gerzanich, V | 1 |
| Coppens, M | 1 |
| Dorian, P | 1 |
| Flaker, GC | 1 |
| Kaatz, S | 1 |
| Budaj, A | 1 |
| Husted, S | 1 |
| Vellimana, AK | 1 |
| Kadkhodayan, Y | 1 |
| Rich, KM | 1 |
| Cross, DT | 1 |
| Moran, CJ | 1 |
| Zazulia, AR | 1 |
| Chicoine, MR | 1 |
| Dacey, RG | 1 |
| Zipfel, GJ | 1 |
| El-Mitwalli, A | 1 |
| Azzam, H | 1 |
| Abu-Hegazy, M | 1 |
| Gomaa, M | 1 |
| Wasel, Y | 1 |
| Wadiwala, MF | 1 |
| Martins, SC | 1 |
| Pieri, A | 1 |
| Moro, CH | 1 |
| Jesus, PA | 1 |
| Longo, A | 1 |
| Evaristo, EF | 1 |
| Carvalho, JJ | 1 |
| Fernandes, JG | 1 |
| Oliveira-Filho, J | 1 |
| Griessenauer, CJ | 1 |
| Fleming, JB | 1 |
| Richards, BF | 1 |
| Cava, LP | 1 |
| Curé, JK | 1 |
| Younan, DS | 1 |
| Zhao, L | 3 |
| Alexandrov, AV | 1 |
| Barlinn, K | 1 |
| Taylor, T | 1 |
| Harrigan, MR | 1 |
| Thomson, RM | 1 |
| Anderson, DC | 2 |
| Nilanont, Y | 1 |
| Nidhinandana, S | 2 |
| Suwanwela, NC | 1 |
| Hanchaiphiboolkul, S | 1 |
| Pimpak, T | 1 |
| Tatsanavivat, P | 1 |
| Saposnik, G | 1 |
| Poungvarin, N | 2 |
| Song, TJ | 1 |
| Suh, SH | 1 |
| Min, PK | 1 |
| Kim, DJ | 1 |
| Kim, BM | 1 |
| Heo, JH | 1 |
| Kim, YD | 1 |
| Lee, KY | 3 |
| Flaker, G | 1 |
| Hart, R | 1 |
| Lanas, F | 1 |
| Xavier, D | 1 |
| Cervera, A | 3 |
| Castillo, J | 2 |
| Aponte, JJ | 1 |
| Planas, AM | 1 |
| deVeber, G | 3 |
| Chan, A | 1 |
| Mehta, P | 1 |
| Gabis, LV | 1 |
| Yangala, R | 1 |
| Lenn, NJ | 1 |
| Bĕlohlávek, J | 1 |
| Aschermann, M | 1 |
| Musolino, R | 1 |
| La Spina, P | 1 |
| Granata, A | 1 |
| Gallitto, G | 1 |
| Leggiadro, N | 1 |
| Carerj, S | 1 |
| Manganaro, A | 1 |
| Tripodi, F | 1 |
| Epifanio, A | 1 |
| Gangemi, S | 1 |
| Di Perri, R | 1 |
| Lorenzo Fernández, P | 1 |
| Grau, AJ | 2 |
| Reiners, S | 1 |
| Lichy, C | 2 |
| Buggle, F | 2 |
| Ruf, A | 1 |
| Kurth, T | 1 |
| Kase, CS | 1 |
| Berger, K | 2 |
| Schaeffner, ES | 1 |
| Buring, JE | 2 |
| Gaziano, JM | 1 |
| Jeong, MH | 1 |
| Lee, KM | 1 |
| Bae, HR | 2 |
| Lim, YJ | 1 |
| Cheon, SM | 1 |
| Hennerici, MG | 1 |
| Berge, E | 2 |
| Sandercock, P | 5 |
| Michiels, JJ | 1 |
| Katsarou, E | 1 |
| Attilakos, A | 1 |
| Fessatou, S | 1 |
| Tsapra, H | 1 |
| Tzavara, V | 1 |
| Dracou, C | 1 |
| Derksen, RH | 1 |
| de Groot, PG | 1 |
| Schmülling, S | 1 |
| Rudolf, J | 1 |
| Strotmann-Tack, T | 1 |
| Schneweis, S | 1 |
| Sobesky, J | 1 |
| Thiel, A | 1 |
| Fan, YH | 1 |
| Zhang, L | 1 |
| Lam, WW | 1 |
| Mok, VC | 1 |
| Hylek, EM | 1 |
| Go, AS | 1 |
| Chang, Y | 1 |
| Jensvold, NG | 1 |
| Henault, LE | 1 |
| Selby, JV | 1 |
| Singer, DE | 1 |
| Uddin, G | 1 |
| Hussain, M | 1 |
| Wang, CX | 1 |
| Todd, KG | 1 |
| Kaźmierski, MK | 1 |
| Griffin, G | 1 |
| Sarma, GR | 1 |
| Roy, AK | 1 |
| Qiu, LY | 1 |
| Chen, CH | 1 |
| Yamazaki, M | 2 |
| Sulter, G | 1 |
| Elting, JW | 1 |
| Maurits, N | 1 |
| Luyckx, GJ | 1 |
| Ringleb, PA | 3 |
| Hirsch, AT | 2 |
| Berger, C | 2 |
| Xia, F | 2 |
| Schwab, S | 2 |
| Grau, A | 1 |
| Ariesen, MJ | 2 |
| van Walraven, C | 2 |
| Jo, WS | 1 |
| Shin, HC | 1 |
| Ho, JM | 1 |
| Kim, JW | 1 |
| Haerten, K | 1 |
| Krabbe, C | 1 |
| Raiber, M | 1 |
| Boddy, AW | 1 |
| Dukovic, DA | 1 |
| Brandt, T | 1 |
| Nesher, G | 1 |
| Berkun, Y | 1 |
| Mates, M | 1 |
| Baras, M | 1 |
| Nesher, R | 1 |
| Rubinow, A | 1 |
| Sonnenblick, M | 1 |
| Sato, H | 1 |
| Koretsune, Y | 1 |
| Fukunami, M | 1 |
| Kodama, K | 1 |
| Yamada, Y | 1 |
| Fujii, K | 1 |
| Hori, M | 1 |
| Schellinger, PD | 4 |
| Jüttler, E | 2 |
| Meyding-Lamadé, UK | 1 |
| Schwark, C | 2 |
| Negri, M | 1 |
| Martignoni, A | 1 |
| Baccheschi, J | 1 |
| Santilli, G | 1 |
| Marchesi, E | 1 |
| Ferro, JM | 1 |
| DiTullio, MR | 1 |
| Sciacca, RR | 1 |
| Ivanusa, M | 1 |
| Ivanusa, Z | 1 |
| Pongrácz, E | 2 |
| Gherli, T | 1 |
| Fragnito, C | 1 |
| Nicolini, F | 1 |
| Borrello, B | 1 |
| Saccani, S | 1 |
| Beghi, C | 1 |
| Lewis, SC | 2 |
| Warlow, CP | 1 |
| Harrison, P | 1 |
| Sidhu, PS | 1 |
| Brown, MM | 1 |
| Machin, SJ | 1 |
| Rosenberg, R | 1 |
| Bauer, K | 1 |
| Rosner, B | 1 |
| Sciacca, R | 1 |
| Barzegar, S | 1 |
| Thornell, B | 1 |
| Costigan, T | 1 |
| Kistler, JP | 2 |
| Serebruany, VL | 2 |
| Malinin, AI | 2 |
| Sane, DC | 1 |
| Jilma, B | 1 |
| Takserman, A | 1 |
| Atar, D | 1 |
| Hennekens, CH | 4 |
| Gage, BF | 1 |
| Pearce, L | 1 |
| Boode, BS | 1 |
| Petersen, P | 2 |
| Bachman, DS | 1 |
| Lucivero, V | 1 |
| Mezzapesa, DM | 1 |
| Petruzzellis, M | 1 |
| Carella, A | 1 |
| Lamberti, P | 1 |
| Federico, F | 1 |
| Leonardi-Bee, J | 4 |
| Guiraud-Chaumeil, B | 1 |
| Sivenius, J | 3 |
| Yatsu, F | 1 |
| Dewey, ME | 1 |
| Yao, CS | 1 |
| Tang, CS | 1 |
| Meng, XL | 1 |
| Ren, B | 1 |
| Huang, SC | 1 |
| Sun, YH | 1 |
| Bao, HQ | 1 |
| Moussouttas, M | 2 |
| Papamitsakis, N | 1 |
| Eriksson, P | 1 |
| Lanthier, S | 1 |
| Armstrong, D | 1 |
| Domi, T | 1 |
| Fletcher, S | 1 |
| Weaver, C | 1 |
| May, J | 1 |
| Fox, S | 1 |
| Willmot, M | 1 |
| Heptinstal, S | 1 |
| Schwaninger, M | 2 |
| Koistinaho, M | 2 |
| Koistinaho, J | 2 |
| Coma-Canella, I | 1 |
| Velasco, A | 1 |
| Castano, S | 1 |
| Di Napoli, M | 1 |
| Cappelli, R | 1 |
| Ceccarelli, E | 1 |
| Di Gianfilippo, G | 1 |
| Donati, C | 1 |
| Emsley, HC | 1 |
| Forconi, S | 1 |
| Hopkins, SJ | 1 |
| Masotti, L | 1 |
| Paciucci, A | 1 |
| Papa, F | 1 |
| Roncacci, S | 1 |
| Sander, D | 1 |
| Sander, K | 1 |
| Smith, CJ | 1 |
| Stefanini, A | 1 |
| Weber, D | 1 |
| McNaughton, H | 1 |
| Barber, PA | 1 |
| Gommans, J | 1 |
| Nowitz, M | 1 |
| Vemmos, KN | 1 |
| Toumanidis, S | 1 |
| Zakopoulos, N | 1 |
| Moulopoulos, SD | 1 |
| Busse, O | 1 |
| Obach, V | 2 |
| Reverter, JC | 1 |
| Torres, F | 1 |
| Ziegler, S | 1 |
| Schillinger, M | 1 |
| Funk, M | 1 |
| Felber, K | 1 |
| Exner, M | 1 |
| Mlekusch, W | 1 |
| Sabeti, S | 1 |
| Amighi, J | 1 |
| Minar, E | 1 |
| Brunner, M | 1 |
| Müller, M | 1 |
| Mannhalter, C | 1 |
| Tonarelli, SB | 1 |
| Reid, J | 1 |
| MacLeod, MJ | 1 |
| Williams, D | 1 |
| Park, SY | 1 |
| Lee, WS | 1 |
| Hong, KW | 1 |
| Weisman, SM | 1 |
| Káposzta, Z | 1 |
| Espinoza, LR | 1 |
| Maulaz, AB | 1 |
| Bezerra, DC | 1 |
| Bogousslavsky, J | 1 |
| Norris, JW | 1 |
| Feuring, M | 1 |
| Schultz, A | 1 |
| Losel, R | 1 |
| Wehling, M | 1 |
| Ziai, W | 1 |
| Pokov, AN | 1 |
| Alberts, MJ | 2 |
| Hanley, DF | 1 |
| Germanakis, I | 1 |
| Sfyridaki, C | 1 |
| Papadopoulou, E | 1 |
| Raissaki, M | 1 |
| Rammos, S | 1 |
| Sarris, G | 1 |
| Kalmanti, M | 1 |
| Kamouchi, M | 1 |
| Fujimoto, S | 1 |
| Ibayashi, S | 1 |
| Inoue, T | 1 |
| Zee, RY | 1 |
| Diehl, KA | 1 |
| Ridker, PM | 2 |
| Kawaguchi, S | 1 |
| Ishizashi, H | 1 |
| Yagi, H | 1 |
| Iida, J | 1 |
| Sakaki, T | 1 |
| Fujimura, Y | 1 |
| Gray, L | 1 |
| Weaver, CS | 1 |
| Howlett-Smith, H | 1 |
| Hertzberg, VS | 1 |
| Chaturvedi, S | 3 |
| Benesch, CG | 1 |
| Sila, CA | 2 |
| Jovin, TG | 1 |
| Cloft, HJ | 1 |
| Pijak, MR | 1 |
| Lago, A | 3 |
| Tembl, JI | 1 |
| Pareja, A | 1 |
| Ponz, A | 1 |
| Ferrer, JM | 1 |
| Vallés, J | 3 |
| Santos, MT | 3 |
| Soman, T | 1 |
| Rafay, MF | 1 |
| Hune, S | 1 |
| Allen, A | 1 |
| MacGregor, D | 1 |
| González-Correa, JA | 1 |
| Arrebola, MM | 1 |
| Cansino, AL | 1 |
| Muñoz-Marín, J | 1 |
| Guerrero, A | 1 |
| Sánchez de la Cuesta, F | 1 |
| De la Cruz, JP | 1 |
| Kirmani, JF | 1 |
| Safdar, A | 1 |
| Sayed, MA | 1 |
| Pande, RU | 1 |
| Ferguson, R | 1 |
| Hershey, LA | 2 |
| Qazi, KJ | 1 |
| Jonas, S | 1 |
| Grieco, G | 1 |
| Hoyos, L | 1 |
| Espinoza, C | 1 |
| Cantú, C | 1 |
| Barinagarrementeria, F | 1 |
| Román, G | 1 |
| Aznar, J | 2 |
| Sanchez, E | 2 |
| Cosin, J | 2 |
| Moscardó, A | 1 |
| Piñón, M | 1 |
| Broekman, MJ | 3 |
| Marcus, AJ | 3 |
| Ricci, S | 1 |
| Lewis, S | 1 |
| Debette, S | 1 |
| Wallaschofski, H | 1 |
| Lohmann, T | 1 |
| Hild, E | 1 |
| Kobsar, A | 1 |
| Siegemund, A | 1 |
| Spilcke-Liss, E | 1 |
| Hentschel, B | 1 |
| Stumpf, C | 1 |
| Daniel, WG | 1 |
| Garlichs, CD | 1 |
| Eigenthaler, M | 1 |
| Chairangsarit, P | 1 |
| Sithinamsuwan, P | 1 |
| Niyasom, S | 1 |
| Udommongkol, C | 1 |
| Suwantamee, J | 1 |
| Flaherty, ML | 1 |
| Kissela, B | 1 |
| Broderick, JP | 3 |
| Késmárky, G | 1 |
| Koltai, K | 1 |
| Horváth, B | 1 |
| Tóth, K | 1 |
| Onizuka, M | 1 |
| Kazekawa, K | 1 |
| Nagata, S | 1 |
| Tsutsumi, M | 1 |
| Aikawa, H | 1 |
| Tomokiyo, M | 1 |
| Iko, M | 1 |
| Kodama, T | 1 |
| Nii, K | 1 |
| Matsubara, S | 1 |
| Tanaka, A | 1 |
| Karlikaya, G | 1 |
| Varlbas, F | 1 |
| Demirkaya, M | 1 |
| Orken, C | 1 |
| Tireli, H | 1 |
| Lee, MS | 1 |
| Smith, SD | 1 |
| Galor, A | 1 |
| Hoffman, GS | 1 |
| Haberl, R | 1 |
| Dalal, PM | 1 |
| Mishra, NK | 1 |
| Bhattacharjee, M | 1 |
| Bhat, P | 1 |
| Gwag, BJ | 1 |
| Lee, YA | 1 |
| Ko, SY | 1 |
| Lee, MJ | 1 |
| Im, DS | 1 |
| Yun, BS | 1 |
| Lim, HR | 1 |
| Park, SM | 1 |
| Byun, HY | 1 |
| Son, SJ | 1 |
| Kwon, HJ | 1 |
| Cho, JY | 1 |
| Won, SJ | 1 |
| Kim, KW | 1 |
| Ahn, YM | 1 |
| Moon, HS | 1 |
| Lee, HU | 1 |
| Noh, JH | 1 |
| Chung, JM | 1 |
| Cho, SI | 1 |
| Derendorf, H | 1 |
| Whitehead, SN | 1 |
| Bayona, NA | 1 |
| Cheng, G | 1 |
| Allen, GV | 1 |
| Hachinski, VC | 1 |
| Cechetto, DF | 1 |
| Einhäupl, K | 1 |
| Al-Bahrani, A | 1 |
| Taha, S | 1 |
| Shaath, H | 1 |
| Bakhiet, M | 1 |
| Chan, MT | 1 |
| Choi, KC | 1 |
| Wong, GK | 1 |
| Poon, WS | 1 |
| Chan, S | 1 |
| Ros, S | 1 |
| You, KY | 1 |
| Nhem, S | 1 |
| Salle, JY | 1 |
| Dudognon, P | 1 |
| Daviet, JC | 1 |
| Kanorskiĭ, SG | 1 |
| Shevelev, VI | 1 |
| Zafiraki, VK | 1 |
| Zingilevskiĭ, KB | 1 |
| Ng, PW | 1 |
| Tsoi, TH | 1 |
| Li, HL | 1 |
| Fong, WC | 1 |
| Yeung, J | 1 |
| Wong, CK | 1 |
| Yip, KK | 1 |
| Gao, H | 1 |
| Wong, HB | 1 |
| Laroche, ML | 1 |
| Macian-Montoro, F | 1 |
| Merle, L | 1 |
| Vallat, JM | 1 |
| Hohlfeld, T | 1 |
| Weber, AA | 1 |
| Junghans, U | 1 |
| Schumacher, M | 1 |
| Boucher, M | 1 |
| Schrör, K | 1 |
| Siebler, M | 1 |
| Liu, CL | 1 |
| Liao, SJ | 1 |
| Zeng, JS | 1 |
| Lin, JW | 1 |
| Li, CX | 1 |
| Xie, LC | 1 |
| Shi, XG | 1 |
| Huang, RX | 1 |
| Briyal, S | 1 |
| Gulati, A | 1 |
| Gupta, YK | 1 |
| Rajamani, K | 1 |
| Okajima, K | 1 |
| Abe, Y | 1 |
| Salameh, MJ | 1 |
| Jin, Z | 1 |
| Boysen, G | 4 |
| Freilinger, T | 1 |
| Riedel, E | 1 |
| Holtmannspötter, M | 1 |
| Peters, N | 1 |
| Poulsen, TS | 1 |
| Husted, SE | 1 |
| Sas, K | 1 |
| Seres, E | 1 |
| Boda, K | 1 |
| Lenti, L | 1 |
| Csifcsak, G | 1 |
| Kovacs, N | 1 |
| Seok, JI | 1 |
| Joo, IS | 1 |
| Yoon, JH | 1 |
| Choi, YJ | 1 |
| Lee, PH | 1 |
| Huh, K | 1 |
| Stauder, A | 1 |
| Sommer, C | 1 |
| Smout, J | 1 |
| Cleanthis, M | 1 |
| Stansby, G | 1 |
| Fu, Y | 1 |
| Guo, JW | 1 |
| You, JS | 1 |
| Wang, LX | 1 |
| Liang, WX | 1 |
| Huang, Y | 2 |
| Huang, PX | 1 |
| Schwammenthal, Y | 1 |
| Tsabari, R | 1 |
| Shenkman, B | 1 |
| Schwartz, R | 1 |
| Matetzky, S | 1 |
| Lubetsky, A | 1 |
| Orion, D | 1 |
| Israeli-Korn, S | 1 |
| Chapman, J | 1 |
| Savion, N | 1 |
| Varon, D | 1 |
| Tanne, D | 1 |
| Reaume, KT | 1 |
| Regal, RE | 1 |
| Dorsch, MP | 1 |
| Adams, RJ | 1 |
| Albers, G | 1 |
| Benavente, O | 1 |
| Furie, K | 1 |
| Goldstein, LB | 3 |
| Halperin, J | 1 |
| Harbaugh, R | 1 |
| Katzan, I | 1 |
| Kelly-Hayes, M | 1 |
| Kenton, EJ | 1 |
| Marks, M | 1 |
| Helgason, CM | 2 |
| Grossi, E | 1 |
| Pandey, D | 1 |
| Valika, A | 1 |
| Cursio, J | 1 |
| Brace, LD | 2 |
| Nielsen, AA | 1 |
| Veien, KT | 1 |
| Jørgensen, LG | 1 |
| Buck, TC | 1 |
| Brandslund, I | 1 |
| Christensen, C | 1 |
| Skliut, M | 1 |
| Jamieson, DG | 1 |
| Hong, Z | 1 |
| Ding, M | 1 |
| Gao, X | 1 |
| Fan, D | 1 |
| Wong, K | 1 |
| Xiao, J | 1 |
| Yao, C | 1 |
| Omura, Y | 1 |
| Agostoni, A | 1 |
| Hinton, RC | 1 |
| Harris, R | 1 |
| Eschwege, E | 3 |
| Haguenau, M | 3 |
| Lefauconnier, JM | 3 |
| Thibult, N | 2 |
| Touboul, D | 3 |
| Touboul, PJ | 3 |
| Ordinas, A | 1 |
| Sherman, DG | 1 |
| Arai, H | 1 |
| Miyakawa, T | 1 |
| Ozaki, K | 1 |
| Sakuragawa, N | 1 |
| Gupta, MC | 1 |
| Dhamija, JP | 1 |
| Mathur, DS | 1 |
| Sharma, BM | 1 |
| Mizuno, Y | 1 |
| Niijima, S | 1 |
| Yoshida, M | 1 |
| Adachi, S | 1 |
| Haga, T | 1 |
| Saudeau, D | 1 |
| Autret, A | 2 |
| Fukatsu, A | 1 |
| Itoh, E | 1 |
| Straub, PW | 1 |
| Hansen, PE | 1 |
| Hansen, JH | 1 |
| Stenbjerg, S | 1 |
| Marshall, M | 1 |
| Todnem, K | 1 |
| Vik-Mo, H | 1 |
| Kusunoki, M | 2 |
| Nagatsuka, K | 1 |
| Isaka, Y | 1 |
| Uyama, O | 2 |
| Yoneda, S | 2 |
| Abe, H | 2 |
| Zabel-Langhennig, R | 1 |
| Ruttmann, B | 1 |
| Schiele, I | 1 |
| Schäfer, W | 1 |
| Aisch, W | 1 |
| Byer, JA | 1 |
| Cauchie, C | 1 |
| Hamberg, M | 1 |
| Svensson, J | 1 |
| Blombäck, M | 2 |
| Mettinger, KL | 2 |
| Fujisawa, A | 1 |
| Matsuyama, T | 1 |
| Croveri, G | 1 |
| Côté, R | 2 |
| Battista, RN | 1 |
| Abrahamowicz, M | 1 |
| Langlois, Y | 1 |
| Bourque, F | 1 |
| Mackey, A | 1 |
| Bonito, AJ | 2 |
| Matchar, DB | 2 |
| Duncan, PW | 2 |
| DeFriese, GH | 1 |
| Oddone, EZ | 1 |
| Paul, JE | 1 |
| Akin, DR | 1 |
| Samsa, GP | 2 |
| Casto, L | 1 |
| Camerlingo, M | 1 |
| Finazzi, G | 1 |
| Censori, B | 1 |
| Barbui, T | 1 |
| Mamoli, A | 1 |
| Juvela, S | 1 |
| Korte, W | 1 |
| Otremba, H | 1 |
| Lutz, S | 1 |
| Flury, R | 1 |
| Schmid, L | 1 |
| Weissert, M | 1 |
| Gans, M | 1 |
| Anderson, D | 1 |
| Cole, DJ | 5 |
| Drummond, JC | 5 |
| Patel, PM | 2 |
| Marcantonio, S | 1 |
| Verry, M | 1 |
| Panak, E | 1 |
| Cazenave, JP | 1 |
| Bolin, KM | 1 |
| Hoff, JA | 1 |
| Winkler, SR | 1 |
| Mangat, A | 1 |
| Tortorice, KL | 1 |
| Schell, RM | 3 |
| Tison, F | 1 |
| Duché, B | 1 |
| Loiseau, P | 1 |
| Fagan, SC | 1 |
| Kertland, HR | 1 |
| Tietjen, GE | 1 |
| Maruyama, S | 3 |
| Handa, M | 1 |
| Fukuyama, M | 1 |
| Itagaki, I | 1 |
| Verhoef, P | 1 |
| Malinow, MR | 1 |
| Kok, FJ | 1 |
| Willett, WC | 1 |
| Stampfer, MJ | 2 |
| Solomon, DH | 1 |
| Rosendaal, FR | 2 |
| Ansell, J | 1 |
| Recht, L | 1 |
| Gaur, SP | 1 |
| Garg, RK | 1 |
| Kar, AM | 1 |
| Srimal, RC | 1 |
| Halperin, JL | 2 |
| Rothlauf, EB | 1 |
| Arruzazabala, ML | 1 |
| Molina, V | 1 |
| Carbajal, D | 1 |
| Valdés, S | 1 |
| Bornstein, NM | 2 |
| Karepov, VG | 1 |
| Aronovich, BD | 1 |
| Gorbulev, AY | 1 |
| Treves, TA | 1 |
| Korczyn, AD | 2 |
| Levy, DE | 2 |
| Brott, TG | 1 |
| Haley, EC | 1 |
| Marler, JR | 1 |
| Sheppard, GL | 1 |
| Weisberg, LA | 1 |
| Miller, VT | 1 |
| Rothrock, JF | 1 |
| Feinberg, WM | 1 |
| Reynolds, L | 1 |
| Bruno, A | 2 |
| Malaterre, HR | 1 |
| Daver, L | 1 |
| Djiane, P | 1 |
| Narayan, S | 1 |
| Gaskill, M | 1 |
| Dhawan, AP | 1 |
| Khoury, J | 1 |
| Barer, D | 1 |
| Marini, C | 1 |
| Motolese, M | 1 |
| Rothwell, P | 1 |
| Frey, JL | 1 |
| Bloom, JM | 1 |
| Roth, GJ | 1 |
| Yamamoto, N | 1 |
| Yokota, K | 1 |
| Yamashita, A | 1 |
| Oda, M | 1 |
| Oláh, L | 1 |
| Misz, M | 1 |
| Fekete, I | 1 |
| Bordánné, JE | 1 |
| Takács, EI | 1 |
| Díez-Tejedor, E | 1 |
| Alonso de Leciñana, M | 1 |
| Díaz-Marín, C | 1 |
| Matías-Guiu, J | 3 |
| Aguilar, M | 1 |
| Bonaventura, I | 1 |
| Martínez, I | 1 |
| Quintana, S | 1 |
| Bendixen, BH | 2 |
| Violi, F | 1 |
| Toplak, H | 1 |
| Bahadori, B | 1 |
| Wascher, TC | 1 |
| Davie, AP | 1 |
| Love, MP | 1 |
| Herroelen, L | 1 |
| De Klippel, N | 1 |
| Cushman, M | 1 |
| Tracy, RP | 1 |
| Rosa, A | 1 |
| Calvo, G | 1 |
| Morros, R | 1 |
| Stiegler, H | 1 |
| Bittar, N | 1 |
| Young, L | 1 |
| Hattemer, CR | 1 |
| Gandhi, AJ | 1 |
| Kemp, SM | 1 |
| Hall, EA | 1 |
| Morton, DJ | 1 |
| Yim, J | 1 |
| Vlasses, PH | 1 |
| Vennervàld, K | 1 |
| Lee, TK | 6 |
| Chan, KW | 1 |
| Huang, ZS | 2 |
| Ng, SK | 1 |
| Lin, RT | 1 |
| Chang, TW | 2 |
| Yan, SH | 1 |
| Deng, JC | 1 |
| Liu, LH | 1 |
| Lie, SK | 1 |
| Sung, SM | 1 |
| Ryglewicz, D | 1 |
| Baranska-Gieruszczak, M | 1 |
| Lechowicz, W | 1 |
| Hier, DB | 1 |
| Koudstaal, A | 1 |
| Członkowska, A | 1 |
| Szpak, GM | 1 |
| Arlien-Søborg, P | 1 |
| Hass, Y | 1 |
| Orberk, E | 1 |
| Killeen, I | 1 |
| Osa, A | 1 |
| Masuhr, F | 1 |
| Busch, M | 1 |
| Einhäupl, KM | 1 |
| Codina, A | 2 |
| Zarranz Imirizaldu, JJ | 1 |
| Hamann, GF | 1 |
| Noth, J | 1 |
| Kosten, TR | 1 |
| Gorter, JW | 1 |
| Pellegrino, TR | 1 |
| Ferguson, JJ | 1 |
| Gonzalez, ER | 1 |
| Kannel, WB | 1 |
| Olin, JW | 1 |
| Raps, EC | 1 |
| Kronmal, RA | 1 |
| Manolio, TA | 1 |
| Talbert, RL | 1 |
| Beauchamp, NJ | 1 |
| Newman, A | 1 |
| Fernández, PL | 1 |
| McKay, LD | 1 |
| Cross, LM | 1 |
| Klötzsch, C | 1 |
| Nahser, HC | 1 |
| Henkes, H | 1 |
| Kühne, D | 1 |
| Büttner, Th | 1 |
| Müller, Th | 1 |
| Hellwig, K | 1 |
| Meves, S | 1 |
| Kuhn, W | 1 |
| Aritzu, E | 1 |
| Piana, A | 1 |
| Saxena, R | 2 |
| Wijnhoud, AD | 2 |
| Man in 't Veld, AJ | 1 |
| van den Meiracker, AH | 1 |
| Boomsma, F | 1 |
| Przybelski, RJ | 3 |
| Lindley, RI | 2 |
| He, J | 1 |
| Whelton, PK | 1 |
| Vu, B | 1 |
| Klag, MJ | 1 |
| Lee, IM | 1 |
| Manson, JE | 1 |
| Forbes, C | 1 |
| Laakso, M | 1 |
| Lowenthal, A | 1 |
| Smets, P | 1 |
| Riekkinen, P | 2 |
| Hartmann, A | 1 |
| Warlow, C | 3 |
| Scott, G | 1 |
| Scott, HM | 1 |
| Bednar, MM | 3 |
| Gross, CE | 3 |
| Sanges, G | 1 |
| Sampaolo, S | 1 |
| Di Iorio, G | 1 |
| Khayyam, N | 1 |
| Thavendiranathan, P | 1 |
| Carmichael, FJ | 1 |
| Kus, B | 1 |
| Jay, V | 1 |
| Burnham, WM | 1 |
| Akyuz, A | 1 |
| Bolayir, E | 1 |
| Dener, S | 1 |
| Topalkara, K | 1 |
| Topaktas, S | 1 |
| Carton, H | 1 |
| Stern, KN | 1 |
| McBride, R | 1 |
| Rothbart, RM | 1 |
| Asinger, RW | 1 |
| van Kooten, F | 1 |
| Ciabattoni, G | 1 |
| Grobbee, DE | 1 |
| Kluft, C | 1 |
| Gubitz, GJ | 1 |
| Zusman, RM | 1 |
| Chesebro, JH | 1 |
| Comerota, A | 1 |
| Hartmann, JR | 1 |
| Massin, EK | 1 |
| Raps, E | 1 |
| Wolf, PA | 1 |
| Van Damme, H | 1 |
| Sakalihasan, N | 1 |
| Limet, R | 1 |
| Novak, L | 1 |
| Shackford, SR | 1 |
| Bourguignon, P | 1 |
| Nichols, P | 1 |
| Buckingham, S | 1 |
| Osler, T | 1 |
| Sartorelli, K | 1 |
| Holm, J | 1 |
| Hillarp, A | 1 |
| Erhardt, L | 1 |
| Berntorp, E | 1 |
| Delanty, N | 1 |
| Jolobe, OM | 1 |
| Caro, JJ | 1 |
| Migliaccio-Walle, K | 1 |
| Kalra, L | 1 |
| Perez, I | 1 |
| Smithard, DG | 1 |
| Sulch, D | 1 |
| Hemphill, JC | 1 |
| Abdelnoor, M | 1 |
| Nakstad, PH | 1 |
| Sandset, PM | 1 |
| Mosso, M | 1 |
| Chen, ZM | 1 |
| Pan, HC | 1 |
| Liu, LS | 1 |
| Xie, JX | 1 |
| Peto, R | 1 |
| Sudlow, CL | 1 |
| Dunbabin, DW | 1 |
| Vila, N | 1 |
| Revilla, M | 1 |
| Ascaso, C | 1 |
| Bergmann, SR | 1 |
| El Ramahi, KM | 1 |
| Al Rayes, HM | 1 |
| Olson, J | 1 |
| von Kummer R, R | 1 |
| Müller, A | 1 |
| Bluhmki, E | 1 |
| Restrepo, L | 1 |
| Fisch, G | 1 |
| Farquhar, D | 1 |
| Fredduzzi, S | 1 |
| Mariucci, G | 1 |
| Tantucci, M | 1 |
| Del Soldato, P | 1 |
| Ambrosini, MV | 1 |
| Kumihashi, K | 1 |
| Uchida, K | 1 |
| Miyazaki, H | 1 |
| Kobayashi, J | 1 |
| Tsushima, T | 1 |
| Machida, T | 1 |
| Jackson, G | 1 |
| Kalashnikova, LA | 1 |
| Nasonov, EL | 1 |
| Aleksandrova, EN | 1 |
| Kosheleva, NM | 1 |
| Reshetniak, TM | 1 |
| Salozhin, KV | 1 |
| De Cristóbal, J | 2 |
| Moro, MA | 2 |
| Leza, JC | 2 |
| Camarero, J | 1 |
| Colado, MI | 1 |
| Lorenzo, P | 2 |
| Lizasoain, I | 2 |
| Howard, DB | 1 |
| Russell, SR | 1 |
| Ellenberger, C | 1 |
| McConnell, JP | 1 |
| Cheryk, LA | 1 |
| Durocher, A | 1 |
| Bang, NU | 1 |
| Fleck, JD | 1 |
| Williams, L | 1 |
| Meschia, JF | 1 |
| Sträter, R | 1 |
| Kurnik, K | 1 |
| Heller, C | 1 |
| Schobess, R | 1 |
| Luigs, P | 1 |
| Nowak-Göttl, U | 1 |
| Masson, C | 1 |
| Arquizan, C | 1 |
| Zuber, M | 1 |
| Cabanes, L | 1 |
| Derumeaux, G | 1 |
| Coste, J | 1 |
| Cárdenas, A | 1 |
| Fernández-Tomé, P | 1 |
| Lazar, RM | 1 |
| Pettigrew, LC | 1 |
| Jackson, CM | 1 |
| Pullicino, P | 1 |
| Powers, WJ | 1 |
| Kettunen, MI | 1 |
| Goldsteins, G | 1 |
| Keinänen, R | 1 |
| Salminen, A | 1 |
| Ort, M | 1 |
| Bures, J | 1 |
| Kauppinen, RA | 1 |
| Higgins, LS | 1 |
| Gibson, JB | 1 |
| Maxwell, RA | 1 |
| Schweitzer, JB | 1 |
| Fabian, TC | 1 |
| Proctor, KG | 1 |
| Hsi, DH | 1 |
| Alaimo, DJ | 1 |
| Pinsky, DJ | 1 |
| Peschon, JJ | 1 |
| Stocking, KL | 1 |
| Fujita, T | 1 |
| Ramasamy, R | 1 |
| Kiss, S | 1 |
| Choudhri, TF | 1 |
| McTaggart, RA | 1 |
| Liao, H | 1 |
| Drosopoulos, JH | 1 |
| Price, VL | 1 |
| Maliszewski, CR | 1 |
| Phillips, SJ | 1 |
| Breddin, K | 1 |
| Bogoiavlenskaia, NM | 1 |
| Armitage, P | 1 |
| Bradley, K | 1 |
| Tel'pukhov, VI | 2 |
| Bilenko, MV | 2 |
| Khokhlov, AV | 1 |
| Komarov, PG | 2 |
| Maggioni, AP | 1 |
| Franzosi, MG | 1 |
| Santoro, E | 1 |
| White, H | 1 |
| Van de Werf, F | 1 |
| Tognoni, G | 1 |
| Tikhomirova, AI | 1 |
| Morganov, AA | 1 |
| Joseph, R | 3 |
| Han, E | 2 |
| Tsering, C | 1 |
| Grunfeld, S | 2 |
| Welch, KM | 2 |
| Vrethem, M | 1 |
| Ernerudh, J | 1 |
| Lindström, F | 1 |
| Olsson, JE | 1 |
| Fogelholm, R | 2 |
| Koop, H | 1 |
| Leblhuber, F | 1 |
| Költringer, P | 1 |
| Reisecker, F | 1 |
| Farrell, B | 1 |
| Godwin, J | 1 |
| Richards, S | 1 |
| de Falco, FA | 1 |
| Montariello, A | 1 |
| Mastroroberto, G | 1 |
| Visconti, OS | 1 |
| Tchen, PH | 1 |
| Chen, CJ | 1 |
| Wu, SC | 1 |
| Heye, N | 1 |
| Campos, A | 1 |
| Kannuki, S | 1 |
| Cervós-Navarro, J | 1 |
| Robertson, W | 1 |
| Raymond, GL | 1 |
| Crompton, JL | 1 |
| Furlan, AJ | 1 |
| Nayak, S | 1 |
| Calandre, L | 2 |
| Molina, JA | 1 |
| Milandre, L | 1 |
| Bonnefoi, B | 1 |
| Aillaud, MF | 1 |
| Sone, R | 1 |
| Nagayama, T | 2 |
| Shibagaki, Y | 1 |
| Kobayashi, I | 2 |
| Kusakabe, K | 1 |
| Chrobocek, J | 1 |
| Kuo, TL | 3 |
| Liu, MC | 2 |
| Slivka, A | 1 |
| Lapinski, RH | 1 |
| Adams, D | 1 |
| Misselwitz, F | 1 |
| Norden, C | 1 |
| Heine, H | 1 |
| Tsutsumi, Y | 1 |
| Ketsa-Ard, K | 1 |
| Caneschi, S | 2 |
| Bonaventi, C | 2 |
| Finzi, F | 2 |
| Tito, P | 1 |
| Bergh, PA | 1 |
| Hollander, D | 1 |
| Gregori, CA | 1 |
| Breen, JL | 1 |
| D'Andrea, G | 1 |
| Oster, SB | 1 |
| Lechner, H | 1 |
| Schmidt, R | 1 |
| Siemes, H | 1 |
| Casaer, P | 1 |
| Picó, M | 1 |
| Monasterio, J | 1 |
| Vilaseca, J | 1 |
| Hsieh, BS | 1 |
| Jaffe, DF | 1 |
| Greenough, PG | 1 |
| Yang, SL | 1 |
| Gomara, S | 1 |
| Ozaita, G | 1 |
| Bermejo, F | 1 |
| Ang, A | 1 |
| Tans, JT | 1 |
| Tulleken, CA | 1 |
| Mehdorn, HM | 1 |
| Long, JB | 1 |
| Lynch, TG | 1 |
| Karanfilian, RG | 1 |
| Hobson, RW | 1 |
| Ninet, J | 1 |
| Bachet, P | 1 |
| Pasquier, J | 1 |
| Boss, AH | 1 |
| Olseen, JS | 1 |
| Rubin, JR | 1 |
| Goldstone, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).[NCT01776424] | Phase 3 | 27,395 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| A Multicenter, Randomized, Double Blind Study to Compare the Efficacy Between Cilostazol and Aspirin on White Matter Changes by Cerebral Small Vessel Disease[NCT01932203] | Phase 4 | 255 participants (Actual) | Interventional | 2013-07-17 | Active, not recruiting | ||
| INdobufen Versus aSpirin in acUte Ischemic stRokE,INSURE[NCT03871517] | Phase 4 | 5,438 participants (Actual) | Interventional | 2019-06-03 | Completed | ||
| A Multicenter, Double Blind, Factorial Design, Phase IV Trial to Compare the Efficacy and Safety of Cilostazol Long-term Treatment With Aspirin in Ischemic Stroke Patients With High Risk of Cerebral Hemorrhage for the Prevention of Cerebral Hemorrhage and[NCT01013532] | Phase 4 | 1,600 participants (Anticipated) | Interventional | 2009-06-30 | Active, not recruiting | ||
| Low-dose Aspirin Therapy in Patients With Non-Cardioembolic Ischemic Stroke and Microbleeds[NCT04504864] | Phase 4 | 400 participants (Anticipated) | Interventional | 2020-10-01 | Recruiting | ||
| Ticagrelor Versus Clopidogrel in Ischemic Stroke. a Randomized Double-blinded Controlled Trial[NCT05553613] | Phase 3 | 900 participants (Actual) | Interventional | 2022-10-01 | Completed | ||
| Ticagrelor Versus Clopidogrel in Large Vessel Ischemic Stroke, a Randomized Controlled Trial[NCT06120725] | Phase 3 | 580 participants (Actual) | Interventional | 2021-09-01 | Completed | ||
| Multicenter, Randomized, Double-blind, Double-dummy, Active-comparator, Event-driven, Superiority Phase III Study of Secondary Prevention of Stroke and Prevention of Systemic Embolism in Patients With a Recent Embolic Stroke of Undetermined Source (ESUS),[NCT02313909] | Phase 3 | 7,213 participants (Actual) | Interventional | 2014-12-23 | Terminated (stopped due to Study halted early due to no efficacy improvement over aspirin at an interim analysis and very little chance of showing overall benefit if study were completed) | ||
| An Investigation Into The Impact Of Enteric Coated Of Aspirin In Patients With Newly Diagnosed Ischemic Stroke. Non-randomized Interventional Controlled Clinical Trial.[NCT04330872] | Phase 4 | 42 participants (Actual) | Interventional | 2019-08-26 | Completed | ||
| A Randomised, Double-Blind, Placebo-Controlled, International, Multicentre, Phase III Study to Investigate the Efficacy and Safety of Ticagrelor and ASA Compared With ASA in the Prevention of Stroke and Death in Patients With Acute Ischaemic Stroke or Tra[NCT03354429] | Phase 3 | 11,016 participants (Actual) | Interventional | 2018-01-22 | Completed | ||
| Clopidogrel With Aspirin in High-risk Patients With Acute Non-disabling Cerebrovascular Events II[NCT04078737] | Phase 3 | 6,412 participants (Actual) | Interventional | 2019-09-23 | Completed | ||
| Randomized,Double-blind Trial Comparing the Effects of a 3-month Clopidogrel Regimen,Combined With ASA During the First 21days,Versus ASA Alone for the Acute Treatment of TIA or Minor Stroke[NCT00979589] | Phase 3 | 5,100 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| The Effect of Cilostazol Compared to Aspirin on Endothelial Function Measured by Flow Mediated Dilatation in Acute Cerebral Ischemia Patients[NCT03116269] | Phase 4 | 80 participants (Actual) | Interventional | 2012-03-01 | Completed | ||
| Stent Implantation Versus Balloon Dilation for Acute Anterior Circulation Tandem Occlusion: A Multicenter, Prospective, Randomized, Open-label, Blinded End-point Trial[NCT05902000] | 222 participants (Anticipated) | Interventional | 2023-06-14 | Recruiting | |||
| Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial[NCT00991029] | Phase 3 | 4,881 participants (Actual) | Interventional | 2010-05-28 | Terminated (stopped due to The trial was halted by the DSMB.) | ||
| Trial of PCSK9 Inhibition in Patients With Acute Stroke and Symptomatic Intracranial Atherosclerosis - a Prospective, Randomized, Open-label, Blinded End-point Study With High-resolution MR Vessel Wall Imaging[NCT05001984] | Phase 2 | 60 participants (Anticipated) | Interventional | 2021-08-01 | Recruiting | ||
| Early Intensive Medical Therapy for the Prevention of Early Neurological Deterioration in Branch Atheromatous Disease[NCT04824911] | Phase 2 | 424 participants (Anticipated) | Interventional | 2021-03-23 | Recruiting | ||
| Comparison of Clopidogrel-based Antiplatelet Therapy Versus Warfarin as Secondary Prevention Strategy for AntiPhospholipid Syndrome-related STROKE (APS-STROKE)[NCT05995600] | Phase 4 | 400 participants (Anticipated) | Interventional | 2023-12-31 | Not yet recruiting | ||
| Genotype Guided Antiplatelet Therapy In Ischemic Stroke[NCT05763862] | 350 participants (Anticipated) | Interventional | 2023-04-24 | Recruiting | |||
| A REAl-life Study on Short-term Dual Antiplatelet Treatment in Patients With Ischemic Stroke or Transient Ischemic Attack[NCT05476081] | 1,067 participants (Anticipated) | Observational [Patient Registry] | 2021-02-03 | Recruiting | |||
| The Origin and Role of Thromboembolism in the Pathogenesis of Ischaemic Stroke[NCT05636748] | 120 participants (Anticipated) | Observational | 2023-02-28 | Recruiting | |||
| Comparison of Triflusal With Aspirin in the Secondary Prevention of Atherothrombotic Events[NCT02616497] | Phase 4 | 1,220 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| Assessment of Dual AntiPlatelet Therapy With Drug Eluting Stents[NCT00638794] | 8,575 participants (Actual) | Observational | 2008-01-31 | Completed | |||
| A Phase IIIB, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Alteplase in Patients With Mild Stroke: Rapidly Improving Symptoms and Minor Neurologic Deficits (PRISMS)[NCT02072226] | Phase 3 | 313 participants (Actual) | Interventional | 2014-05-31 | Terminated (stopped due to The study was terminated due to slow enrollment.) | ||
| Efficacy and Safety of Tirofiban in Patients With Acute Branch Atheromatous Disease (BAD)- Related Stroke (BRANT)[NCT06037889] | Phase 3 | 516 participants (Anticipated) | Interventional | 2023-11-09 | Recruiting | ||
| Disparities in Stroke Outcomes and Care Delivery in Patients With Atrial Fibrillation: FLorida Puerto Rico Atrial Fibrillation Stroke Study (FLiPER-AF)[NCT03627806] | 104,308 participants (Actual) | Observational [Patient Registry] | 2010-01-01 | Completed | |||
| Cilostazol Stroke Prevention Study for Antiplatelet Combination[NCT01995370] | Phase 4 | 1,884 participants (Actual) | Interventional | 2013-12-13 | Completed | ||
| Multicenter Randomized, Double-blind, Placebo-controlled, Clinical Trial of Acetylsalicylic Acid in the Prevention of Severe SARS-CoV2 Pneumonia in Hospitalised Patients (Asperum)[NCT04808895] | Phase 3 | 204 participants (Anticipated) | Interventional | 2021-04-01 | Not yet recruiting | ||
| Clinical Study Evaluating the Gastroprotective Effect of Carvedilol in Patients With Ischemic Heart Disease on Aspirin Therapy[NCT05553717] | 66 participants (Anticipated) | Interventional | 2022-10-31 | Not yet recruiting | |||
| Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial[NCT00041938] | Phase 3 | 2,305 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| Transient Electrocardiogram Assessment in Stroke Evaluation[NCT03301662] | 100 participants (Anticipated) | Observational | 2017-10-09 | Not yet recruiting | |||
| Prevention of New Vascular Events in Patients With Brain Infarction or Peripheral Embolism and Thoracic Aortic Plaques ≥ 4 mm in Thickness in the Aortic Arch or Descending Aortic Upstream to the Embolized Artery[NCT00235248] | Phase 3 | 350 participants (Actual) | Interventional | 2002-02-28 | Completed | ||
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Japanese Primary Prevention Project With Aspirin in the Elderly With One or More Risk Factors of Vascular Events: JPPP[NCT00225849] | Phase 4 | 10,000 participants | Interventional | 2005-03-31 | Recruiting | ||
| A Prospective Multicenter Clinical Study of Aspirin for Prophylaxis in Patients With Hereditary or Acquired Thrombotic Thrombocytopenic Purpura[NCT05568147] | Phase 2/Phase 3 | 100 participants (Anticipated) | Interventional | 2022-10-01 | Not yet recruiting | ||
| COMbination of Clopidogrel and Aspirin for Prevention of REcurrence in Acute Atherothrombotic Stroke Study: Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Trial[NCT00814268] | Phase 4 | 358 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Aspirin Resistance in Obstructive Sleep Apnea Patients (ARISA Trial)[NCT03930875] | 63 participants (Actual) | Observational | 2017-12-12 | Completed | |||
| The Optimal Regimen of Medical Treatment in Endovascular Therapy in Ischemic Cerebrovascular Disease Based on Clopidogrel Resistance[NCT01925872] | 2,000 participants (Anticipated) | Observational | 2013-05-31 | Enrolling by invitation | |||
| A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal S[NCT00977938] | Phase 4 | 25,682 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes: A Double-blind, Active and Placebo Controlled Study of Aggrenox vs. Clopidogrel, With and Without Micardis[NCT00153062] | Phase 4 | 20,332 participants (Actual) | Interventional | 2003-08-31 | Completed | ||
| Clinical and Functional Effects of Cardiac Contractility Modulation in Chagas Heart Disease: a Randomized Study - Contractility - FIX-Chagas[NCT05519046] | 60 participants (Anticipated) | Interventional | 2022-05-06 | Recruiting | |||
| Implantation of CERENOVUS ENTERPRISE 2 Intracranial Stent in Patients With Severe Symptomatic Intracranial Atherosclerotic Stenosis: A Multicenter, Prospective and Single-Arm Study in China[NCT05316311] | 194 participants (Anticipated) | Interventional | 2022-05-24 | Recruiting | |||
| The Predictive Value of Retinal Vascular Signs for Patients With Intracranial Artery Stenosis: A Prospective, Continuity Study, Cross-sectional Study[NCT05270746] | 1,000 participants (Anticipated) | Observational | 2022-02-27 | Not yet recruiting | |||
| Influence of CILostazol-based Triple Anti-platelet Therapy ON Ischemic Complication After Drug-eluting stenT Implantation[NCT00776828] | Phase 4 | 960 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| CHoosing Triple or Double therApy in the Era of nOac for patientS Undergoing PCI: the CHAOS a Multicenter Study.[NCT03558295] | 1,000 participants (Anticipated) | Observational [Patient Registry] | 2018-05-01 | Recruiting | |||
| Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards Valve. A Randomized Study (the ARTE Trial)[NCT02640794] | Phase 4 | 222 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
| Triple Antithrombotic Therapy in Cardiac Patients Requiring Revascularization[NCT03889574] | 84 participants (Actual) | Observational | 2019-02-26 | Completed | |||
| Aspirin Versus Aspirin + ClopidogRel as Antithrombotic Treatment Following Transcatheter Aortic Valve Implantation With the Edwards SAPIEN XT Valve. A Randomized Pilot Study (the ARTE Trial)[NCT01559298] | Phase 4 | 178 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Effect of Tailored Use of Tirofiban in Patients With Non-ST-elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention[NCT03114995] | Phase 4 | 140 participants (Actual) | Interventional | 2012-02-01 | Completed | ||
| A Multi-center, Randomized, Double-blind and Placebo-controlled Clinical Research of 2200 Cases in Improving Curative Effect of Secondary Prevention for Patients With Ischemic Stroke Through Syndrome Differentiation of TCM[NCT02334969] | Phase 4 | 2,200 participants (Actual) | Interventional | 2016-04-30 | Completed | ||
| JASAP: Japanese Aggrenox Stroke Prevention vs. Aspirin Programme, Phase III Study to Compare the Preventive Effect of Recurrent Brain Infarction and Safety of Aggrenox (Combination Drug Containing Sustained-release Dipyridamole 200 mg/Acetylsalicylic Acid[NCT00311402] | Phase 3 | 1,295 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| "PGDT With the Hypotension Prediction Index to Reduce the Number and Duration of Intraoperative Hypotension and the Incidence of Renal Failure in Patients Undergoing Lung Surgery"[NCT04149314] | 142 participants (Actual) | Interventional | 2019-11-20 | Completed | |||
| Prevalence of Low Response to Clopidogrel in Patients After Acute Ischemic Stroke.[NCT01843361] | 159 participants (Actual) | Observational | 2010-07-31 | Completed | |||
| Antiplatelet Therapy in Secondary Prevention for Patient With Silent Brain Infarction[NCT03318744] | 3,400 participants (Anticipated) | Interventional | 2018-01-31 | Not yet recruiting | |||
| A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events: A Pilot Study[NCT01945268] | Phase 4 | 107 participants (Actual) | Interventional | 2015-04-30 | Completed | ||
| Effects of APIXaban on BRAIN Protection in Patients With Sinus Rhythm and Heart Failure: APIXBRAIN-HF Trial[NCT04696120] | Phase 2 | 200 participants (Anticipated) | Interventional | 2021-03-02 | Not yet recruiting | ||
| A Randomized Controlled Trial of Influenza Vaccine to Prevent Adverse Vascular Events[NCT02762851] | Phase 4 | 5,000 participants (Anticipated) | Interventional | 2016-06-30 | Recruiting | ||
| Apixaban Versus Acetylsalicylic Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment: A Randomized Double-blind Trial[NCT00496769] | Phase 3 | 6,421 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Aspirin Discontinuation After Left Atrial Appendage Occlusion in Atrial Fibrillation[NCT03821883] | 1,120 participants (Anticipated) | Interventional | 2020-06-01 | Recruiting | |||
| English: Current Perspective of the Status of Anticoagulation in Clinical Practice in Primare Care. Spanish: Perspectiva Actual de la sitUación de la anticoaguLación en la práctica clínica de Atención Primaria.[NCT02273609] | 1,524 participants (Actual) | Observational | 2014-02-28 | Completed | |||
| A Prospective Randomized Controlled Study of Additonal Left Atrial Appendage Electrical Isolation in Catheter Ablation Combined With Left Atrial Appendage Occlusion of Persistent Atrial Fibrillation[NCT04897204] | 120 participants (Anticipated) | Interventional | 2021-06-01 | Not yet recruiting | |||
| Rehabilitation of Patients With Atrial Fibrillation[NCT03035539] | 58 participants (Actual) | Interventional | 2012-05-31 | Completed | |||
| Patent Foramen Ovale in Cryptogenic Stroke Study[NCT00697151] | Phase 4 | 630 participants (Actual) | Interventional | 1993-06-30 | Completed | ||
| Medical Treatment With or Without Transcatheter Patent Foramen Ovale CloSure for Older Patients With CrypTogenic StrOke and Patent Foramen Ovale. The STOP Trial[NCT05907694] | 714 participants (Anticipated) | Interventional | 2023-12-01 | Active, not recruiting | |||
| "Transcranial Doppler Assessment of Cerebral Embolization During Early Anti-thrombotic Therapy After Bioprosthetic Aortic Valve Replacement: Comparison of High-dose Aspirin Versus Warfarin Plus Low-dose Aspirin"[NCT00465218] | 56 participants (Actual) | Observational | 2007-03-31 | Completed | |||
| Observatory of Anticoagulation After Bioprosthetic Aortic Valve Replacement[NCT01293188] | 434 participants (Actual) | Observational | 2011-01-31 | Completed | |||
| Multicenter Ambispective Study of Clinical Outcomes of the CoreValve™Evolut R™ 34mm System: All Comers Post-market Registry[NCT03621709] | 100 participants (Anticipated) | Observational | 2017-08-01 | Active, not recruiting | |||
| Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF: The CORRAL-AF Study[NCT04684212] | 2,931 participants (Anticipated) | Interventional | 2023-12-01 | Not yet recruiting | |||
| Focal Cerebral Arteriopathy Steroid Trial[NCT06040255] | Phase 4 | 80 participants (Anticipated) | Interventional | 2023-10-01 | Not yet recruiting | ||
| An International Registry of the Wingspan™ Stent System for the Treatment of Intracranial Atherosclerotic Stenosis[NCT00929383] | 82 participants (Actual) | Observational | 2009-02-28 | Completed | |||
| Effects of Task-oriented Progressive Resistance Strength Training and Balance Exercises in Functional Performance on Lower Limb in Individuals With Stroke[NCT04820660] | 18 participants (Actual) | Interventional | 2019-03-01 | Completed | |||
| Cilostazol Stroke Prevention Study-a Randomized, Double Blind, Double Dummy, Parallel Comparative, Multicenter Clinical Trial[NCT00202020] | Phase 3 | 720 participants | Interventional | 2004-05-31 | Completed | ||
| Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.[NCT00222261] | Phase 4 | 1,001 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| Effects of Prolonged Dual Antiplatelet Therapy With Clopidogrel Plus Acetylsalicylic Acid (ASA) After Percutaneous Lower Extremity Revascularization in Patients With Peripheral Arterial Disease[NCT02798913] | Phase 3 | 300 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| Comparative Study of Clinical Efficacy and Safety of Different Clopidogrel Salts in Patients With Cardiovascular Disease. A Multi-center Non-interventional Clinical Trial.[NCT02126982] | 1,500 participants (Actual) | Observational | 2012-10-31 | Completed | |||
| A Multicenter Prospective observationaL Study to evAluate the effecT of Clopidogrel on the prEvention of Major vascuLar Events According to the gEnotype of Cytochrome P450 2C19 in Ischemic Stroke paTients; PLATELET Study[NCT04072705] | 2,927 participants (Actual) | Observational | 2019-09-20 | Completed | |||
| Antiplatelet Therapy in HIV - Antiplatelet and Immune Modulating Effects of Aspirin or Clopidogrel in Subjects With HIV[NCT02559414] | Phase 2 | 55 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| Influence of Rivaroxaban 2.5 mg Two Times a Day for Intermittent Claudication and Exercise Tolerance in Patients With Symptomatic Peripheral Arterial Disease (PAD) - a Randomised Controlled Trial[NCT04305028] | 100 participants (Anticipated) | Observational | 2021-03-10 | Not yet recruiting | |||
| Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312] | 228 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744] | 101 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| [NCT00000500] | Phase 3 | 0 participants | Interventional | 1981-09-30 | Completed | ||
| Gender-Specific Effects of Physiologic GH Administration on Cardiovascular Risk Factors in Women With Growth Hormone Deficiency[NCT00136032] | 63 participants (Actual) | Interventional | 2002-01-31 | Completed | |||
| A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation in High Risk Primary Prevention (Patients With Metabolic Syndrome)[NCT00272311] | Phase 4 | 70 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| A Randomized Trial of Plaque Identifying Toothpaste on Reduction of Plaque and Inflammation[NCT02666508] | 61 participants (Actual) | Interventional | 2015-09-01 | Completed | |||
| Correlation Between Oral Health and Systemic Inflammation (COHESION)[NCT03641989] | 112 participants (Actual) | Interventional | 2018-09-17 | Completed | |||
| A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation & Endothelial Function in Secondary Prevention (Pts w/Chronic Stable Coronary Disease)[NCT00272337] | Phase 4 | 37 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| A Phase III, Randomized, Double-blind, Multicenter Study to Assess the Efficacy and Safety of OCTAPLEX, a Four-factor Prothrombin Complex Concentrate (4F-PCC), Compared to the 4F-PCC Beriplex® P/N (Kcentra), for the Reversal of Vitamin K Antagonist (VKA) [NCT02740335] | Phase 3 | 208 participants (Actual) | Interventional | 2017-06-08 | Completed | ||
| Acute Ischaemic STROKE: From LABoratory to(2) the Patient's BED. Retrospective Study of Blood Biomarkers and Neuroimaging as Predictors of Cerebral Edema, Extension of Ischemic Injury and Functional Outcome[NCT05725694] | 200 participants (Anticipated) | Observational | 2015-10-01 | Enrolling by invitation | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 313 |
| Rivaroxaban 5mg + Aspirin Placebo | 366 |
| Rivaroxaban Placebo + Aspirin 100mg | 378 |
Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 282 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 389 |
| Rivaroxaban 5mg + Aspirin Placebo | 453 |
| Rivaroxaban Placebo + Aspirin 100mg | 516 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 329 |
| Rivaroxaban 5mg + Aspirin Placebo | 397 |
| Rivaroxaban Placebo + Aspirin 100mg | 450 |
Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 379 |
| Rivaroxaban 5mg + Aspirin Placebo | 448 |
| Rivaroxaban Placebo + Aspirin 100mg | 496 |
Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 353 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis." (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 288 |
| Rivaroxaban 5mg + Aspirin Placebo | 255 |
| Rivaroxaban Placebo + Aspirin 100mg | 170 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension" (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 138 |
Major bleeding event (as per ISTH), defined as bleeding event that met at least one of following: fatal bleeding; symptomatic bleeding in a critical area or organ (intraarticular, intramuscular with compartment syndrome, intraocular, intraspinal, pericardial, or retroperitoneal); symptomatic intracranial haemorrhage; clinically overt bleeding associated with a recent decrease in the hemoglobin level of greater than or equal to (>=) 2 grams per decilitre (g/dL) (20 grams per liter [g/L]; 1.24 millimoles per liter [mmol/L]) compared to the most recent hemoglobin value available before the event; clinically overt bleeding leading to transfusion of 2 or more units of packed red blood cells or whole blood. The results were based on classification of events that have been positively adjudicated as major bleeding events. Incidence rate estimated as number of subjects with incident events divided by cumulative at-risk time, where subject is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 1.82 |
| Acetylsalicylic Acid 100 mg OD | 0.67 |
All-cause mortality includes all deaths of participants due to any cause. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 1.88 |
| Acetylsalicylic Acid 100 mg OD | 1.50 |
Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. Cardiovascular death includes death due to hemorrhage and death with undetermined/unknown cause. Systemic embolism is defined as abrupt vascular insufficiency associated with clinical or radiological evidence of arterial occlusion in the absence of other likely mechanisms. The diagnosis of myocardial infarction requires the combination of: 1)evidence of myocardial necrosis (either changes in cardiac biomarkers or post-mortem pathological findings); and 2)supporting information derived from the clinical presentation, electrocardiographic changes, or the results of myocardial or coronary artery imaging. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 6.20 |
| Acetylsalicylic Acid 100 mg OD | 5.85 |
Non-major clinically relevant bleeding was defined as non-major overt bleeding but required medical attention (example: hospitalization, medical treatment for bleeding), and/or was associated with the study drug interruption of more than 14 days. The results were based on the outcome events at or after randomization until the efficacy cut-off date. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 3.52 |
| Acetylsalicylic Acid 100 mg OD | 2.32 |
Intracranial hemorrhage included all bleeding events that occurred in intracerebral, sub arachnoidal as well as subdural or epidural sites. The below table displays results for all randomized participants and the outcomes at or after randomization until the efficacy cut-off date. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 0.70 |
| Acetylsalicylic Acid 100 mg OD | 0.35 |
Life-threatening bleeding was defined as a subset of major bleeding that met at least one of the following criteria: 1) fatal bleeding; 2) symptomatic intracranial haemorrhage; 3) reduction in hemoglobin of at least 5 g/dl (50 g/l; 3.10 mmol/L); 4) transfusion of at least 4 units of packed red cells or whole blood; 5) associated with hypotension requiring the use of intravenous inotropic agents; 6) necessitated surgical intervention. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 1.02 |
| Acetylsalicylic Acid 100 mg OD | 0.43 |
Components of composite efficacy outcome (adjudicated) includes stroke (ischemic, hemorrhagic, and undefined stroke, TIA with positive neuroimaging) and systemic embolism. Incidence rate estimated as number of participants with incident events divided by cumulative at-risk time, where participant is no longer at risk once an incident event occurred. (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) |
|---|---|
| Rivaroxaban 15 mg OD | 5.14 |
| Acetylsalicylic Acid 100 mg OD | 4.78 |
"Disabling stroke is defined as stroke with modified Rankin score (mRS) greater than or equal to (>=) 4 as assessed by investigator. mRS spans 0-6, running from perfect health to death. A score of 0-3 indicates functional status ranging from no symptoms to moderate disability (defined in the mRS as requiring some help, but able to walk without assistance); mRS 4-6 indicates functional status ranging from moderately severe disability (unable to walk or to attend to own bodily needs without assistance)through to death. CV death includes death due to hemorrhage and death with undetermined/unknown cause. Diagnosis of myocardial infarction requires combination of: 1) evidence of myocardial necrosis either changes in cardiac biomarkers or post-mortem pathological findings); 2) supporting information derived from clinical presentation, electrocardiographic changes, or results of myocardial or coronary artery imaging." (NCT02313909)
Timeframe: From randomization until the efficacy cut-off date (median 326 days)
| Intervention | event/100 participant-years (Number) | ||||
|---|---|---|---|---|---|
| Stroke | Ischemic stroke | Disabling stroke | CV death(includes death due to hemorrhage) | Myocardial infarction | |
| Acetylsalicylic Acid 100 mg OD | 4.71 | 4.56 | 0.84 | 0.66 | 0.67 |
| Rivaroxaban 15 mg OD | 5.11 | 4.71 | 1.20 | 0.99 | 0.49 |
Participants with bleeding event that fulfils serious adverse event criteria and is categorised as GUSTO Moderate/Severe. GUSTO is a bleeding scale (GUSTO = Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries). GUSTO Severe bleeding is defined as any of the following: (1) fatal bleeding, (2) intracranial bleeding, or (3) bleeding that caused haemodynamic compromise requiring intervention. GUSTO Moderate bleeding is a bleeding requiring transfusion of whole blood or packed red blood cells without haemodynamic compromise (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 36 |
| PLACEBO | 11 |
Participants with bleeding event that fulfils serious adverse event criteria and is categorised as GUSTO Severe. GUSTO is a bleeding scale (GUSTO = Global Utilization of Streptokinase and Tissue plasminogen activator for Occluded coronary arteries). GUSTO Severe bleeding is defined as any of the following: (1) fatal bleeding, (2) intracranial bleeding, or (3) bleeding that caused haemodynamic compromise requiring intervention (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 28 |
| PLACEBO | 7 |
Participants with subsequent stroke or death (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 303 |
| PLACEBO | 362 |
Participants with ICH or fatal bleeding event (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 22 |
| PLACEBO | 6 |
Number of participants with ischaemic stroke (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 276 |
| PLACEBO | 345 |
The modified Rankin Scale (mRS) is a scale for measuring the degree of disability or dependence in the daily activities of people who have suffered a stroke or other causes of neurological disability. The scale runs from 0-6, running from perfect health without symptoms to death.0 - No symptoms,1 - No significant disability. Able to carry out all usual activities, despite some symptoms. 2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities. 3 - Moderate disability. Requires some help, but able to walk unassisted. 4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted. 5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent. 6 - Dead. (NCT03354429)
Timeframe: Visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 1282 |
| PLACEBO | 1284 |
Participants with premature permanent discontinuation of IP due to bleeding (NCT03354429)
Timeframe: From randomisation (day 1) to visit 3 (day 30-34)
| Intervention | Participants (Count of Participants) |
|---|---|
| TICAGRELOR | 152 |
| PLACEBO | 32 |
Secondary efficacy outcome: Number of participants with ischemic stroke, myocardial infarction, death from ischemic vascular causes, or major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 141 |
| Placebo | 167 |
Primary efficacy outcome: Number of Participants with Ischemic Stroke, Myocardial Infarction, or Death From Ischemic Vascular Causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 121 |
| Placebo | 160 |
Other safety outcome: Number of Participants with Death from any cause (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 18 |
| Placebo | 12 |
Secondary efficacy outcome: Number of participants with Death from ischemic vascular causes (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 6 |
| Placebo | 4 |
Other safety outcome: Number of participants with Hemorrhagic stroke (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 5 |
| Placebo | 3 |
Secondary efficacy outcome: Number of participants with Ischemic or hemorrhagic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 116 |
| Placebo | 156 |
Secondary efficacy outcome:Number of participants with Ischemic stroke (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 112 |
| Placebo | 155 |
Primary safety outcome: Number of Participants with major hemorrhage (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 23 |
| Placebo | 10 |
Other safety outcome: Number of Participants with Major hemorrhage other than intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 17 |
| Placebo | 7 |
Other safety outcome:Number of Participants with Minor hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 40 |
| Placebo | 13 |
Secondary efficacy outcome: Number of participants with Myocardial infarction (NCT00991029)
Timeframe: Up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 10 |
| Placebo | 7 |
Other safety outcome: Number of participants with other symptomatic intracranial hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 0 |
Other safety outcome: Number of participants with Symptomatic intracerebral hemorrhage (NCT00991029)
Timeframe: up to 90 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Clopidogrel | 2 |
| Placebo | 2 |
Reported here is the percentage of participants who died due to any cause during the study. (NCT02072226)
Timeframe: From baseline to Day 90
| Intervention | percentage of participants (Number) |
|---|---|
| Alteplase + Aspirin Placebo | 0.6 |
| Alteplase Placebo + Aspirin | 0 |
Reported here is the percentage of participants who died due to stroke and neurological disorders. (NCT02072226)
Timeframe: From baseline to Day 90
| Intervention | percentage of participants (Number) |
|---|---|
| Alteplase + Aspirin Placebo | 0 |
| Alteplase Placebo + Aspirin | 0 |
mRS score was determined by the investigator. The mRS is a 7 point scale (0-6) with 0: No symptoms at all, 1: No significant disability despite symptoms, able to carry out all usual duties and activities, 2: Slight disability, unable to carry out all previous activities but able to look after own affairs without assistance, 3: Moderate disability requiring some help, but able to walk without assistance, 4: Moderately severe disability, unable to walk without assistance and unable to attend to own bodily needs without assistance, 5: Severe disability, bedridden, incontinent and requiring constant nursing care and attention, 6: death prior to Day 90. Reported is the percentage of participants with scores of 0 or 1 on the mRS. (NCT02072226)
Timeframe: Day 90
| Intervention | percentage of participants (Number) |
|---|---|
| Alteplase + Aspirin Placebo | 78.2 |
| Alteplase Placebo + Aspirin | 81.5 |
An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. (NCT02072226)
Timeframe: From baseline up to Day 90: Non-serious adverse events were collected through the Day 30 visit. Serious adverse events were collected through the end of study at Day 90.
| Intervention | percentage of participants (Number) |
|---|---|
| Alteplase + Aspirin Placebo | 77.3 |
| Alteplase Placebo + Aspirin | 68.0 |
A serious adverse event (SAE) was defined as any experience that suggested a significant hazard, contraindication, side effect, or precaution, and fulfilled any of the following criteria: fatal (resulted in death), life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was medically significant or required intervention to prevent any of the other outcomes listed here. (NCT02072226)
Timeframe: From baseline to Day 90
| Intervention | percentage of participants (Number) |
|---|---|
| Alteplase + Aspirin Placebo | 26.0 |
| Alteplase Placebo + Aspirin | 13.1 |
ICH was considered symptomatic if it was not seen on computed tomography (CT) or magnetic resonance imaging (MRI) scan at baseline and any neurologic decline was attributed to it by the local investigator. To detect intracranial hemorrhage, neuroimaging (CT or MRI) scan was performed at 22 to 36 hours after study drug administration. (NCT02072226)
Timeframe: Within 36 hours after study drug administration on Day 1
| Intervention | percentage of participants (Number) |
|---|---|
| Alteplase + Aspirin Placebo | 3.2 |
| Alteplase Placebo + Aspirin | 0 |
mRS score was determined by the investigator. The mRS is a 7 point scale (0-6) with 0: No symptoms at all, 1: No significant disability despite symptoms, able to carry out all usual duties and activities, 2: Slight disability, unable to carry out all previous activities but able to look after own affairs without assistance, 3: Moderate disability requiring some help, but able to walk without assistance, 4: Moderately severe disability, unable to walk without assistance and unable to attend to own bodily needs without assistance, 5: Severe disability, bedridden, incontinent and requiring constant nursing care and attention, 6: death before Day 90. Reported are the percentages of participants for all scores on the mRS. (NCT02072226)
Timeframe: Day 90
| Intervention | percentage of participants (Number) | |||||
|---|---|---|---|---|---|---|
| mRS at Day 90 - 0 | mRS at Day 90 - 1 | mRS at Day 90 - 2 | mRS at Day 90 - 3 | mRS at Day 90 - 4 | mRS at Day 90 - 5 or 6 (death) | |
| Alteplase + Aspirin Placebo | 44.9 | 33.3 | 11.5 | 2.6 | 5.1 | 2.6 |
| Alteplase Placebo + Aspirin | 50.3 | 31.2 | 11.5 | 3.2 | 2.5 | 1.3 |
To detect ICH, neuroimaging (CT or MRI) scan was performed at 22 to 36 hours after study drug administration. (NCT02072226)
Timeframe: Within 36 hours after study drug administration on Day 1
| Intervention | percentage of participants (Number) | |
|---|---|---|
| Any ICH within 36 hours reported by site | Any ICH within 36 hours reported by central reader | |
| Alteplase + Aspirin Placebo | 7.1 | 7.1 |
| Alteplase Placebo + Aspirin | 2.6 | 3.3 |
Global favorable recovery is an integrated assessment of participants who meet the following: mRS Score 0-1, National Institutes of Health Stroke Scale (NIHSS) Score 0-1, Barthel Index [BI] greater than or equal to 95, and Glasgow Outcome Scale [GOS] equal to 1. mRS Score 0-1: 0= No symptoms at all, 1= No significant disability despite symptoms, able to carry out all usual duties and activities. NIHSS Score 0-1: 0= No stroke symptoms and 1= Minor stroke symptoms. BI is a 10 question index with a total score range of 0-100 with 100 being the best outcome. GOS =1: Good recovery. Reported here are the percentages of participants who achieved a favorable score on each of these scales. (NCT02072226)
Timeframe: Day 90
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| mRS 0 - 1 at Day 90 | NIHSS 0 - 1 at Day 90 | BI >= 95 at Day 90 | GOS = 1 at Day 90 | |
| Alteplase + Aspirin Placebo | 78.2 | 85.0 | 79.3 | 81.5 |
| Alteplase Placebo + Aspirin | 81.5 | 81.7 | 88.7 | 85.6 |
The time, in years, from randomization to the first to occur of ischemic stroke, intracerebral hemorrhage, or death, up to a maximum of 6 years. Event rate per 100 patient years = 100*(number of subjects with event)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization until the date of the first to occur of ischemic stroke, intracerebral hemorrhage, or death, up to 6 years
| Intervention | events per 100 patient-years (Number) |
|---|---|
| Aspirin | 7.93 |
| Warfarin | 7.47 |
Time, in years, from randomization to death component of secondary composite outcome. This measure counts only deaths that were not preceded by heart failure hospitalization, myocardial infarction, ischemic stroke, or intracerebral hemorrhage. Event rate per 100 patient years = 100*(number of subjects who died)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of death component of secondary composite outcome, up to 6 years
| Intervention | events per 100 patient years (Number) |
|---|---|
| Aspirin | 4.41 |
| Warfarin | 4.43 |
Time, in years, from date of randomization to date of heart failure hospitalization, up to 6 years. Includes hospitalizations for heart failure during follow-up that were not preceded by myocardial infarction. Event rate per 100 patient years = 100*(number of subjects with heart failure hospitalization)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of heart failure hospitalization component of secondary composite outcome, up to 6 years
| Intervention | events per 100 patient years (Number) |
|---|---|
| Aspirin | 5.67 |
| Warfarin | 6.79 |
Time, in years, from date of randomization to date of intracerebral hemorrhage component of secondary composite outcome. Includes only intracerebral hemorrhages not preceded by myocardial infarction or heart failure hospitalization. Event rate per 100 patient years = 100*(number of subjects with intracerebral hemorrhage)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of intracerebral hemorrhage component of secondary composite outcome, up to 6 years
| Intervention | events per 100 patient years (Number) |
|---|---|
| Aspirin | 0.06 |
| Warfarin | 0.11 |
Ischemic stroke component of secondary composite endpoint. Includes only ischemic strokes that were not preceded by a myocardial infarction or heart failure hospitalization. The number of ischemic strokes that are components of the secondary outcome does not therefore match the number of ischemic strokes that are components of the primary outcome. Event rate per 100 patient years = 100*(number of subjects with ischemic stroke)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1)of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of ischemic stroke component of secondary composite outcome, up to 6 years
| Intervention | events per 100 patient years (Number) |
|---|---|
| Aspirin | 1.14 |
| Warfarin | 0.57 |
Time, in years, from date of randomization to date of myocardial infarction, up to 6 years. Includes only myocardial infarctions that occurred during follow-up, before any heart failure hospitalization. Event rate per 100 patient years = 100*(number of subjects with myocardial infarction)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of myocardial infarction component of secondary composite outcome, up to 6 years
| Intervention | events per 100 patient years (Number) |
|---|---|
| Aspirin | 0.87 |
| Warfarin | 0.80 |
"The time, in years, from date of randomization to the date of the first to occur of hospitalization for heart failure, myocardial infarction, ischemic stroke, intracerebral hemorrhage, or death, up to 6 years.~Event rate per 100 patient years = 100*(number of subjects with event)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25." (NCT00041938)
Timeframe: From randomization to the first to occur of hospitalization for heart failure, myocardial infarction, ischemic stroke, intracerebral hemorrhage, or death, up to a maximum of 6 years.
| Intervention | events per 100 patient-years (Number) |
|---|---|
| Aspirin | 12.15 |
| Warfarin | 12.70 |
Time, in years, from date of randomization to date of death component of primary composite outcome. Event rate per 100 patient years = 100*(number of subjects who died)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of death component of primary composite outcome, up to 6 years
| Intervention | events per 100 patient-years (Number) |
|---|---|
| Aspirin | 6.52 |
| Warfarin | 6.63 |
Time, in years, from date of randomization to date of intracerebral hemorrhage component of primary composite outcome. Event rate per 100 patient years = 100*(number of subjects with intracerebral hemorrhage)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of intracerebral hemorrhage component of primary composite outcome, up to 6 years
| Intervention | rate per 100 patient years (Number) |
|---|---|
| Aspirin | 0.05 |
| Warfarin | 0.12 |
Time, in years, from date of randomization to date of ischemic stroke component of primary composite outcome, up to 6 years. Event rate per 100 patient years = 100*(number of subjects with ischemic stroke)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization to date of ischemic stroke component of primary composite outcome, up to 6 years
| Intervention | rate per 100 patient years (Number) |
|---|---|
| Aspirin | 1.36 |
| Warfarin | 0.72 |
Rate/100 patient-years of major hemorrhage. Includes all major hemorrhages in any patient. Major hemorrhage was defined as intracerebral, epidural, subdural, subarachnoid, spinal intramedullary, or retinal hemorrhage; any other bleeding causing a decline in the hemoglobin level of more than 2 g per deciliter in 48 hours; or bleeding requiring transfusion of 2 or more units of whole blood, hospitalization, or surgical intervention. Event rate per 100 patient years = 100*(number of major hemorrhage events)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1) of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization until end of scheduled follow-up, up to 6 years
| Intervention | events per 100 patient years (Number) |
|---|---|
| Aspirin | 0.87 |
| Warfarin | 1.78 |
Rate per 100 patient years of minor hemorrhage. Includes all minor hemorrhages. Minor hemorrhage was defined as any non-major hemorrhage. Event rate per 100 patient years = 100*(number of minor hemorrhage events)/patient-years of follow-up. Patient years of follow-up = sum(date of conclusion of follow-up - date of randomization + 1)of all randomized patients / 365.25. (NCT00041938)
Timeframe: From date of randomization until the end of scheduled follow-up, up to 6 years
| Intervention | events per 100 patient-years (Number) |
|---|---|
| Aspirin | 7.34 |
| Warfarin | 11.6 |
Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| Propensity-matched DES | 1.70 |
| Propensity-matched BMS | 2.61 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 0.50 |
| BMS 12-month DAPT | 1.11 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 0.50 |
| BMS 12-month DAPT | 1.11 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 0.69 |
| DES 12-month DAPT | 1.45 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of definite or probable ST within randomized DES ITT patients between 12 and 30 months post procedure. ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 0.40 |
| DES 12-month DAPT | 1.35 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| BMS 30-month DAPT | 2.03 |
| BMS 12-month DAPT | 0.90 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| BMS 30-month DAPT | 2.09 |
| BMS 12-month DAPT | 1.05 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| DES 30-month DAPT | 2.74 |
| DES 12-month DAPT | 1.88 |
The primary safety endpoint was moderate or severe bleeding within randomized DES ITT patients between 12 and 30 months post procedure. Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| DES 30-month DAPT | 2.53 |
| DES 12-month DAPT | 1.57 |
Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| Propensity-matched DES | 11.37 |
| Propensity-matched BMS | 13.24 |
(NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 4.04 |
| BMS 12-month DAPT | 4.69 |
(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 4.68 |
| BMS 12-month DAPT | 5.48 |
(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 5.62 |
| DES 12-month DAPT | 6.49 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of ARC definite or probable stent thrombosis within randomized DES ITT patients between 12 and 30 months post procedure. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 4.34 |
| DES 12-month DAPT | 5.92 |
Number of patients with any of stroke, myocardial infarction, vascular death (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Aspirin + Extended Release Dipyridamole | 1333 |
| Clopidogrel | 1333 |
Number of patients with any of stroke, myocardial infarction, vascular death, or new or worsening congestive heart failure (NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 1367 |
| Placebo | 1463 |
(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Aspirin + Extended Release Dipyridamole | 916 |
| Clopidogrel | 898 |
(NCT00153062)
Timeframe: time since randomization; follow-up period is 1.5 to 4.4 years
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 880 |
| Placebo | 934 |
(NCT00153062)
Timeframe: Randomization to final patient contact
| Intervention | Participants (Number) |
|---|---|
| Telmisartan | 125 |
| Placebo | 151 |
An area under the curve of serial levels of Troponin I and creatine kinase-MB isoenzyme during 36 hours (NCT03114995)
Timeframe: 0,6,12,18,24,30,36 hours
| Intervention | Hours*ng/ml (Median) | |
|---|---|---|
| Troponin I | creatine kinase-MB isoenzyme | |
| Control C1 (High Platelet Reactivity - no Tirofiban) | 38.0 | 92.7 |
| Control C2 (Low Platelet Reactivity - no Tirofiban) | 121.4 | 185.6 |
| Group A (High Platelet Reactivity - Tirofiban) | 197.2 | 252.5 |
"Percentage of participants with periprocedural myonecrosis under the criteria described below.~When the cardiac biomarkers before the procedure were within the 99th percentile upper reference limit (URL), more than a 5-fold elevation in the URL within 12 hours after percutaneous coronary intervention (PCI) was defined as periprocedural myonecrosis. If the cardiac biomarker level was already above the 99th percentile URL before the procedure and the trend was stationary or decreasing, a ≥20% increase compared to the previous level was considered periprocedural myonecrosis. If the trend was still increasing, the levels at the post-6 hour and 12-hour were compared to determine periprocedural myonecrosis." (NCT03114995)
Timeframe: 0,6,12,18,24,30,36 hours
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Troponin I | creatine kinase-MB isoenzyme | |
| Control C1 (High Platelet Reactivity - no Tirofiban) | 15 | 10 |
| Control C2 (Low Platelet Reactivity - no Tirofiban) | 26 | 25 |
| Group A (High Platelet Reactivity - Tirofiban) | 16 | 11 |
ACS contains acute myocardial infarction (MI), unstable angina and sudden cardiac death. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 9 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 16 |
All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 12 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 7 |
This is a composite endpoint of cerebral infarction, brain (cerebral) hemorrhage, subarachnoid haemorrhage and major bleeding. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 71 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 55 |
All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 45 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 32 |
All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 13 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 13 |
This is a composite endpoint of cerebral infarction, transient ischemic attack (TIA), acute myocardial infarction (MI), unstable angina and sudden death attributable to thromboembolism. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 57 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 51 |
This endpoints were defined as pulmonary embolism, retinal vascular disorder, deep vein thrombosis, peripheral artery obstruction and vascular intervention. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 11 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 6 |
This is a composite endpoint of cerebral infarction, brain (cerebral) hemorrhage and subarachnoid haemorrhage. All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 57 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 39 |
All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 0 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 1 |
All events reported by investigators were adjudicated by the independent event assessment committee in a blinded manner. (NCT00311402)
Timeframe: Up to 124 weeks
| Intervention | patients (Number) |
|---|---|
| Aggrenox Capsule | 3 |
| Acetylsalicylic Acid (ASA) 81 mg Tablet | 3 |
Event rate=percent of participants with an event divided by the total participants in the arm. (NCT00496769)
Timeframe: Randomization to efficacy cutoff date of May 28, 2010 (date revised following cessation of study for superior efficacy)
| Intervention | Percentage of events per year (Number) |
|---|---|
| Apixaban, 2.5 or 5 mg Twice Daily | 4.21 |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 6.35 |
Event rate=percent of participants with an event divided by the total participants in the arm. Intended-treatment period=date of randomization to the efficacy cutoff date, which was to be the date on which at least 226 unrefuted original primary efficacy events occurred (date revised to May 28, 2010 following cessation of study for superior efficacy.) (NCT00496769)
Timeframe: Randomization to efficacy cutoff date of May 28, 2010 (date revised following cessation of study for superior efficacy)
| Intervention | Percentage of events (Number) |
|---|---|
| Apixaban, 2.5 or 5 mg Twice Daily | 1.62 |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 3.63 |
Event rate=percent of participants with an event divided by the total participants in the arm. (NCT00496769)
Timeframe: Day 1 to first bleeding event up to efficacy cutoff date of May 28, 2010 (date revised following cessation of study for superior efficacy)
| Intervention | Percentage of events per year (Number) |
|---|---|
| Apixaban, 2.5 or 5 mg Twice Daily | 10.85 |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 8.32 |
Event rate=percent of participants with an event divided by the total participants in the arm. (NCT00496769)
Timeframe: Randomization to efficacy cutoff date of May 28, 2010 (date revised following cessation of study for superior efficacy)
| Intervention | Percentage of events per year (Number) | ||
|---|---|---|---|
| All-cause death (n=111, 140) | Net clinical benefit (n=163, 220) | Vascular death (n=84, 96) | |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 4.42 | 7.13 | 3.03 |
| Apixaban, 2.5 or 5 mg Twice Daily | 3.51 | 5.23 | 2.65 |
Event rate=percent of participants with an event divided by the total participants in the arm. (NCT00496769)
Timeframe: First dose of study drug (Day 1) to the earlier of a patient's discontinuation of double-blind study drug or the attainment of at least 226 primary efficacy events up to May 28, 2010
| Intervention | Percentage of events per year (Number) | ||
|---|---|---|---|
| Major bleeding | Major or CRNM bleeding | All bleeding | |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 0.92 | 3.24 | 8.32 |
| Apixaban, 2.5 or 5 mg Twice Daily | 1.41 | 4.46 | 10.85 |
BL=baseline, LLN=lower limit of normal, ULN=upper limit of normal. Hemoglobin (g/dL), low: BL>2 or value ≤8; hematocrit(%), low: <0.75*BL; erythrocytes (*10^6 cells/μL), low: <0.75*BL; platelet count (*10^9 cells/L),low: <100*10^9 cells/L; leukocytes (*10^3 cells/μL), low if <0.8*BL and BL
Timeframe: First dose of study drug (Day 1) to 30 days after last dose of blinded study drug
| Intervention | Participants (Number) | |||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hemoglobin, low (n=1956, 1893) | Hemoglobin, high (n=1956, 1893) | Hematocrit, low (n=1728, 1687) | Hematocrit, high (n=1728, 1687) | Erythrocytes, low (n=1728, 1687) | Erythrocytes, high (n=1728, 1687) | Platelet count, low (n=2148, 2098) | Platelet count, high (n=2148, 2098) | Leukocytes, low (n=1738, 1698) | Leukocytes, high (n=1738, 1698) | Neutrophils (absolute), low (n=2170, 2138) | Neutrophils (absolute), high (n=2170, 2138) | Eosinophils (absolute), low (n=2170, 2138) | Eosinophils (absolute), high (n=2170, 2138) | Basophils (absolute), low (n=2170, 2138) | Basophils (absolute), high (n=2170, 2138) | Monocytes (absolute), low (n=2170, 2138) | Monocytes (absolute), high (n=2170, 2138) | Lymphocytes (absolute), low (n=2170, 2138) | Lymphocytes (absolute), high (n=2170, 2138) | Alkaline phosphatase (ALP), low (n=2781, 2758) | ALP, high (n=2781, 2758) | Aspartate phosphatase (AST), low (n=2779, 2753) | AST, high (n=2779, 2753) | Alanine aminotransferase (ALT), low (n=2779, 2753) | ALT, high (n=2779, 2753) | Bilirubin (total), low (n=2781, 2758) | Bilirubin (total), high (n=2781, 2758) | Bilirubin (direct), low (n=2773, 2750) | Bilirubin (direct), high (n=2773, 2750) | Blood urea nitrogen (BUN), low (n=2201, 2172) | BUN, high (n=2201, 2172) | Creatinine, low (n=2209, 2178) | Creatinine, high (n=2209, 2178) | |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 120 | 0 | 9 | 0 | 12 | 0 | 10 | 0 | 14 | 18 | 1 | 0 | 0 | 68 | 0 | 0 | 0 | 2 | 62 | 5 | 0 | 27 | 0 | 33 | 0 | 31 | 0 | 43 | 0 | 248 | 0 | 50 | 0 | 71 |
| Apixaban, 2.5 or 5 mg Twice Daily | 131 | 0 | 13 | 0 | 12 | 0 | 7 | 0 | 12 | 14 | 2 | 0 | 0 | 48 | 0 | 0 | 0 | 0 | 52 | 4 | 0 | 34 | 0 | 28 | 0 | 23 | 0 | 30 | 0 | 241 | 0 | 42 | 0 | 67 |
LLN=lower limit of normal; ULN=upper limit of normal; BL=baseline. Sodium, serum (mEq/L):low if <0.95*BL and BL
Timeframe: First dose of study drug (Day 1) to 30 days after last dose of blinded study drug
| Intervention | Participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Sodium (serum), low (n=1768, 1740) | Sodium (serum), high (n=1768, 1740) | Potassium (serum), low (n=1763, 1737) | Potassium (serum), high (n=1763, 1737) | Chloride (serum), low (n=1768, 1740) | Chloride (serum), high (n=1768, 1740) | Calcium (total), low (n=106, 109) | Calcium (total), high (n=106, 109) | Bicarbonate, low (n=1664, 1619) | Bicarbonate, high (n=1664, 1619) | |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 6 | 2 | 8 | 28 | 3 | 1 | 0 | 0 | 0 | 0 |
| Apixaban, 2.5 or 5 mg Twice Daily | 2 | 1 | 6 | 20 | 0 | 0 | 0 | 0 | 0 | 0 |
ULN=upper limit of normal; LLN=lower limit of normal; BL=baseline. Creatine kinase (U/L), high:>5*ULN; protein, total(g/L):low if <0.90*BL when BL
Timeframe: First dose of study drug (Day 1) to 30 days after last dose of blinded study drug
| Intervention | Participants (Number) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Creatine kinase, low (n=2780, 2758) | Creatine kinase, high (n=2780, 2758) | Protein (total), low (n=103, 109) | Protein (total), high (n=103, 109) | Uric acid, low (n=386, 390) | Uric acid, high (n=386, 390) | Glucose (urine), low (n=2, 3) | Glucose (urine), high (n=2, 3) | Protein (urine), low (n=3, 5) | Protein (urine), high (n=3, 5) | Blood (urine), low (n=3, 5) | Blood (urine), high (n=3, 5) | Leukocyte esterase (urine), low (n=3,5) | Leukocyte esterase (urine), high (n=3,5) | Red blood cells (RBC) (urine), low (n=2,2) | RBC (urine), high (n=2,2) | White blood cells (urine), low (n=2,2) | WBC (urine), high (n=2,2) | |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 0 | 25 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Apixaban, 2.5 or 5 mg Twice Daily | 0 | 13 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. (NCT00496769)
Timeframe: First dose of study drug (Day 1) to 30 days after last dose of blinded study drug
| Intervention | Participants (Number) | ||||
|---|---|---|---|---|---|
| AEs | SAEs | Bleeding AEs | Discontinuations due to AE | Deaths | |
| Acetylsalicylic Acid, 81-324 mg Once Daily | 1925 | 804 | 259 | 362 | 115 |
| Apixaban, 2.5 or 5 mg Twice Daily | 1833 | 657 | 281 | 266 | 91 |
"Any stroke or neurological death at NCT00929383)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Patients Treated With a Wingspan Stent | 12 |
The cumulative stroke rate at 12 months (any stroke or neurological death /= 31 days is 15.9% or 13 events per 82 patients (NCT00929383)
Timeframe: 12 months
| Intervention | participants (Number) |
|---|---|
| Patients Treated With a Wingspan Stent | 13 |
The rate of recurrent ischemic stroke from 31 days to 12 months post procedure was 1.3% or 1 event per 77 patients analyzed. (NCT00929383)
Timeframe: 12 Months
| Intervention | participants (Number) |
|---|---|
| Patients Treated With a Wingspan Stent | 1 |
"The rate of restenosis at 12 months was defined as the degree of residual stenosis greater than 50% as determined by the study sites using the WASID method. There was a 10.4% rate of restenosis >50% or 8 patients out of 77 analyzed. The differences in this analysis population N=77 vs. ITT N= 82 populations results from exclusion of N=4 patients with no stent implanted and N=1 patient who died prior to any follow up measures of restenosis.~The WASID method is a standardized protocol for measuring intracranial arterial stenosis.~[1-(Dstenosis/Dnormal)] x100=% stenosis (where D=vessel diameter)" (NCT00929383)
Timeframe: 12 Months
| Intervention | participants (Number) |
|---|---|
| Patients Treated With a Wingspan Stent | 8 |
The number of Wingspan Stents successfully deployed across the target lesion. (NCT00929383)
Timeframe: Peri-procedural
| Intervention | patients w stent implanted (Number) |
|---|---|
| Patients Treated With a Wingspan Stent | 78 |
Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to endothelial function. (NCT02559414)
Timeframe: 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 14.06 |
| Placebo Follow up | 13.84 |
| Aspirin Baseline | 11.18 |
| Aspirin Randomization | 12.11 |
| Clopidogrel Baseline | 13.06 |
| Clopidogrel Randomization | 12.29 |
Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to immune activity (NCT02559414)
Timeframe: 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 15.53 |
| Placebo Follow up | 15.43 |
| Aspirin Baseline | 13.15 |
| Aspirin Follow up | 14.96 |
| Clopidogrel Baseline | 16.03 |
| Clopidogrel Follow up | 14.85 |
Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to inflammation (NCT02559414)
Timeframe: 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 69.45 |
| Placebo Follow up | 80.33 |
| Aspirin Baseline | 82.04 |
| Aspirin Randomization | 62.00 |
| Clopidogrel Baseline | 78.86 |
| Clopidogrel Randomization | 39.88 |
(NCT02559414)
Timeframe: Baseline, 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 69.45 |
| Placebo Follow up | 80.33 |
| Aspirin Baseline | 82.04 |
| Aspirin Randomization | 62.00 |
| Clopidogrel Baseline | 78.86 |
| Clopidogrel Randomization | 39.88 |
The primary objective of these analyses will be to compare the effects of aspirin versus control and clopidogrel versus control for the outcome of platelet activity. Aspirin is expected to decrease arachidonic acid-induced platelet aggregation by 50% versus control. Clopidogrel is expected to decrease ADP-induced platelet aggregation by 50% versus control. (NCT02559414)
Timeframe: Baseline, 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 72.35 |
| Placebo Follow up | 79.11 |
| Aspirin Baseline | 72.79 |
| Aspirin Randomization | 26.77 |
| Clopidogrel Baseline | 71.07 |
| Clopidogrel Randomization | 65.00 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Histamine-2 Receptor Antagonist Group | 106 |
| Placebo Group | 101 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month
| Intervention | participants (Number) |
|---|---|
| Proton Pump Inhibitor Group | 1 |
| Histamine-2 Receptor Antagonist Group | 7 |
Changes in Heme oxygenase (HO-1) a downstream target of nitric oxide (NO) formation. (NCT00272311)
Timeframe: Baseline to 3 Months (90-97 days)
| Intervention | ng/mL (Mean) |
|---|---|
| Arm 1 of 5 Randomized Treatment Arms | 27.6 |
| Arm 2 of 5 Randomized Treatment Arms | 27.0 |
| Arm 3 of 5 Randomized Treatment Arms | 31.4 |
| Arm 4 of 5 Randomized Treatment Arms | 25.7 |
| Arm 5 of 5 Randomized Treatment Arms | 28.3 |
"Measure description mg/L refers to the change in hs-CRP per mg/L from the baseline to the follow-up visit. The follow-up visit occurred between 30 and 60 days post baseline." (NCT02666508)
Timeframe: Baseline to 30 - 60 days post baseline
| Intervention | log(mg/L) (Geometric Mean) |
|---|---|
| Plaque Identifying Toothpaste | 0.04 |
| Non-plaque Identifying Toothpaste | 0.22 |
"Measure description mg/L refers to the change in hs-CRP per mg/L from the baseline to the follow-up visit. The follow-up visit occurred between 30 and 60 days post baseline. -PSS analysis" (NCT02666508)
Timeframe: Baseline to 30-60 days post
| Intervention | log(mg/L) (Geometric Mean) |
|---|---|
| Plaque Identifying Toothpaste | -0.40 |
| Non-plaque Identifying Toothpaste | 0.14 |
"Measure description percentage refers to the change in plaque percentage from the baseline to the follow-up visit. The follow-up visit occurred between 30 and 60 days post baseline." (NCT02666508)
Timeframe: Baseline to 30 - 60 days post baseline
| Intervention | log(percentage) (Geometric Mean) |
|---|---|
| Plaque Identifying Toothpaste | -1.05 |
| Non-plaque Identifying Toothpaste | -0.03 |
"Measure description percentage refers to the change in plaque percentage from the baseline to the follow-up visit. The follow-up visit occurred between 30 and 60 days post baseline for the Pre-Specified Subgroup (PSS)." (NCT02666508)
Timeframe: Baseline to 30-60 days post
| Intervention | log(percentage) (Geometric Mean) |
|---|---|
| Plaque Identifying Toothpaste | -1.05 |
| Non-plaque Identifying Toothpaste | -0.10 |
Heme oxygenase a downstream target of nitric oxide formation (NCT00272337)
Timeframe: Baseline to 3 Months (90-97 days)
| Intervention | ng/mL (Mean) |
|---|---|
| 1 of 5 Randomized Treatment Arms | 10.0 |
| 2 of 5 Randomized Treatment Arms | 11.2 |
| 3 of 5 Randomized Treatment Arms | 10.0 |
| 4 of 5 Randomized Treatment Arms | 11.0 |
| 5 of 5 Randomized Treatment Arms | 9.6 |
"Change in coagulation factor levels from baseline to after the end of infusion using the Hodges-Lehmann Estimator for median differences: o Factor II~The Hodges-Lehmann Estimator is a method of robust estimation. This estimator is used to give an estimate of the difference between the values in two sets of data. If the two sets of data contain m and n data points respectively, m × n pairs of points (one from each set) can be formed and each pair gives a difference of values. The Hodges-Lehmann estimator for the difference is defined as the median of the m × n differences." (NCT02740335)
Timeframe: 30 minutes after the end of infusion
| Intervention | mg/dL (Mean) |
|---|---|
| Octaplex | 49.5 |
| Beriplex P/N (Kcentra) | 51.0 |
"Change in coagulation factor levels from baseline to after the end of infusion using the Hodges-Lehmann Estimator for median differences: o Factor II Factor IX~The Hodges-Lehmann Estimator is a method of robust estimation. This estimator is used to give an estimate of the difference between the values in two sets of data. If the two sets of data contain m and n data points respectively, m × n pairs of points (one from each set) can be formed and each pair gives a difference of values. The Hodges-Lehmann estimator for the difference is defined as the median of the m × n differences." (NCT02740335)
Timeframe: 30 minutes after the end of infusion
| Intervention | m/dL (Mean) |
|---|---|
| Octaplex | 33.0 |
| Beriplex P/N (Kcentra) | 31.5 |
"Change in coagulation factor levels from baseline to after the end of infusion using the Hodges-Lehmann Estimator for median differences: o Factor VII~The Hodges-Lehmann Estimator is a method of robust estimation. This estimator is used to give an estimate of the difference between the values in two sets of data. If the two sets of data contain m and n data points respectively, m × n pairs of points (one from each set) can be formed and each pair gives a difference of values. The Hodges-Lehmann estimator for the difference is defined as the median of the m × n differences." (NCT02740335)
Timeframe: 30 minutes after the end of infusion
| Intervention | mg/dL (Mean) |
|---|---|
| Octaplex | 35.0 |
| Beriplex P/N (Kcentra) | 23.0 |
"Change in coagulation factor levels from baseline to after the end of infusion using the Hodges-Lehmann Estimator for median differences: o Factor X~The Hodges-Lehmann Estimator is a method of robust estimation. This estimator is used to give an estimate of the difference between the values in two sets of data. If the two sets of data contain m and n data points respectively, m × n pairs of points (one from each set) can be formed and each pair gives a difference of values. The Hodges-Lehmann estimator for the difference is defined as the median of the m × n differences." (NCT02740335)
Timeframe: 30 minutes after the end of infusion
| Intervention | mg/dL (Mean) |
|---|---|
| Octaplex | 50.0 |
| Beriplex P/N (Kcentra) | 63.0 |
To demostrate clinical non-inferiority of treatment with Octaplex to treatment with Beriplex P/N (Kcentra) with respect to hemostatic success. Effective hemostatis includes Excellent and Good ratings, while Ineffective hemostasis includes Moderate, None and missing ratings from Global hemostatic efficacy observed by IEAB (NCT02740335)
Timeframe: At the end of surgery
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Effective | Ineffective | |
| Beriplex P/N (Kcentra) | 97 | 6 |
| Octaplex | 99 | 6 |
Hemostatic Efficacy rated by the Independent Endpoint Adjudication Committee based on a 1 to 4 point hemostatic efficacy scale, taking into account blood loss and transfusion requirements in the context of the surgery. Hemostatic efficacy was assessed based on objective criteria in the categories 'excellent', 'good', 'moderate', or 'none'. Ratings of 'excellent' and 'good' were considered as 'effective' hemostasis, while ratings of 'moderate' and 'none' were considered as 'ineffective' hemostasis. (NCT02740335)
Timeframe: At the end of the surgery
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Excellent - 4 | Good - 3 | Moderate - 2 | None - 1 | Effective | Ineffective | |
| Beriplex P/N (Kcentra) | 50 | 47 | 6 | 0 | 97 | 6 |
| Octaplex | 41 | 58 | 6 | 0 | 99 | 6 |
Number of patients with an international normalized ratio (INR) value of less or equal to 1.5 at 30 min (± 15 min) after the end of infusion. (NCT02740335)
Timeframe: 30 minutes after the end of infusion
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| <=1.5 | > 1.5 | Missing | |
| Beriplex P/N (Kcentra) | 74 | 29 | 0 |
| Octaplex | 82 | 23 | 0 |
144 reviews available for aspirin and Brain Ischemia
| Article | Year |
|---|---|
Efficacy and safety of clopidogrel and/or aspirin for ischemic stroke/transient ischemic attack: An overview of systematic reviews and meta-analysis.
Topics: Aspirin; Brain Ischemia; Cerebral Infarction; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Hu | 2021 |
Oral antiplatelet therapy for acute ischaemic stroke.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Stroke; Platelet Aggregation Inhibitors; Randomized Contro | 2022 |
Editor's Choice - Peri-Operative Outcomes of Carotid Endarterectomy are Not Improved on Dual Antiplatelet Therapy vs. Aspirin Monotherapy: A Systematic Review and Meta-Analysis.
Topics: Aspirin; Brain Ischemia; Carotid Stenosis; Endarterectomy, Carotid; Hematoma; Hemorrhage; Hemorrhagi | 2022 |
Contemporary antiplatelet therapy for secondary stroke prevention: a narrative review of current literature and guidelines.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Dipyridamole; Humans; Ischemic Attack, Transient; | 2022 |
Comparison of Aspirin and P2Y
Topics: Aspirin; Brain Ischemia; Hemorrhage; Humans; Ischemic Stroke; Platelet Aggregation Inhibitors; Secon | 2023 |
Does prior use of antiplatelet therapy modify the effect of dual antiplatelet therapy in transient ischaemic attack/minor ischaemic stroke: A systematic review and meta-analysis.
Topics: Aspirin; Brain Ischemia; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; Ischemic Str | 2022 |
Antiplatelet treatment for acute secondary prevention of non-cardioembolic minor stroke / transient ischaemic attack: an update for the acute physician.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; | 2022 |
Antiplatelet treatment for acute secondary prevention of non-cardioembolic minor stroke / transient ischaemic attack: an update for the acute physician.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; | 2022 |
Antiplatelet treatment for acute secondary prevention of non-cardioembolic minor stroke / transient ischaemic attack: an update for the acute physician.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; | 2022 |
Antiplatelet treatment for acute secondary prevention of non-cardioembolic minor stroke / transient ischaemic attack: an update for the acute physician.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; | 2022 |
Clinical Efficacy of the Huo Xue Hua Yu Method Combined with Aspirin in the Treatment of Acute Cerebral Infarction: A Systematic Evaluation and Meta-analysis.
Topics: Acute Disease; Aspirin; Brain Ischemia; Cerebral Infarction; Drugs, Chinese Herbal; Humans; Stroke; | 2023 |
Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Intracranial He | 2019 |
Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Recurrenc | 2019 |
Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Recurrenc | 2019 |
Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Recurrenc | 2019 |
Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Recurrenc | 2019 |
Dual versus mono antiplatelet therapy for acute non- cardio embolic ischemic stroke or transient ischemic attack, an efficacy and safety analysis - updated meta-analysis.
Topics: Aspirin; Brain Ischemia; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack, Transient; | 2020 |
The 2020 breakthroughs in early secondary prevention: dual antiplatelet therapy versus single antiplatelet therapy.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Early Medical Intervention; Hemorrh | 2021 |
Ticagrelor vs Clopidogrel in addition to Aspirin in minor ischemic stroke/ transient ischemic attack-Protocol for a systematic review and network meta-analysis.
Topics: Aspirin; Bayes Theorem; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Dual Anti-Platelet T | 2021 |
Ticagrelor: clinical development and future potential.
Topics: Aspirin; Brain Ischemia; Humans; Platelet Aggregation Inhibitors; Stroke; Ticagrelor | 2021 |
Current and future perspectives on the treatment of cerebral ischemia.
Topics: Aspirin; Brain Ischemia; Fibrinolytic Agents; Humans; Stroke; Thrombolytic Therapy; Tissue Plasminog | 2017 |
Comparative efficacy and safety of antiplatelet agents in cerebral ischemic disease: A network meta-analysis.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Network Meta-Analysis; Odds Ratio; Platelet Aggregatio | 2019 |
High on treatment platelet reactivity to aspirin and clopidogrel in ischemic stroke: A systematic review and meta-analysis.
Topics: Aspirin; Blood Platelets; Brain Ischemia; Clopidogrel; Drug Resistance; Humans; Platelet Aggregation | 2017 |
Genetic Signatures in Ischemic Stroke: Focus on Aspirin Resistance.
Topics: Animals; Aspirin; Brain Ischemia; Drug Resistance; Fibrinolytic Agents; Genome-Wide Association Stud | 2017 |
Antiplatelet therapy and the risk of ischemic and hemorrhagic complications associated with Pipeline embolization of cerebral aneurysms: a systematic review and pooled analysis.
Topics: Adult; Aged; Aspirin; Blood Vessel Prosthesis; Brain Ischemia; Cerebral Hemorrhage; Embolization, Th | 2019 |
Clopidogrel and aspirin after ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized clinical trials.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Hemor | 2019 |
Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Hemorrhage; Humans; Ischemic Attack | 2018 |
Aspirin in childhood acute ischemic stroke: The evidence for treatment and efficacy testing.
Topics: Aspirin; Blood Platelets; Brain Ischemia; Humans; Platelet Aggregation Inhibitors; Practice Guidelin | 2019 |
Optimal Duration of Aspirin Plus Clopidogrel After Ischemic Stroke or Transient Ischemic Attack.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Human | 2019 |
Role of aspirin in primary prevention of cardiovascular disease.
Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Diabetes Complications; Gastrointestinal Hemorrhag | 2019 |
Role of aspirin in primary prevention of cardiovascular disease.
Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Diabetes Complications; Gastrointestinal Hemorrhag | 2019 |
Role of aspirin in primary prevention of cardiovascular disease.
Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Diabetes Complications; Gastrointestinal Hemorrhag | 2019 |
Role of aspirin in primary prevention of cardiovascular disease.
Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Diabetes Complications; Gastrointestinal Hemorrhag | 2019 |
Outcome of intracranial flow diversion according to the antiplatelet regimen used: a systematic review and meta-analysis.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Male; Platelet Aggregation Inhibitors; Prasugr | 2020 |
[New form of a acetylsalicylic acid in the secondary prevention of ischemic stroke].
Topics: Animals; Aspirin; Brain Ischemia; Humans; Secondary Prevention | 2013 |
Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Human | 2013 |
Systematic study of cilostazol on secondary stroke prevention: a meta-analysis.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Disease Progression; Humans; Incidenc | 2013 |
Glycoprotein IIb-IIIa inhibitors for acute ischaemic stroke.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Brain Ischemia; Humans; Immunoglobulin Fab Fragments; In | 2014 |
Oral antiplatelet therapy for acute ischaemic stroke.
Topics: Aspirin; Brain Ischemia; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Randomized Controlle | 2014 |
Efficacy and safety of cilostazol based triple antiplatelet treatment versus dual antiplatelet treatment in patients undergoing coronary stent implantation: an updated meta-analysis of the randomized controlled trials.
Topics: Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; M | 2015 |
Targeting aspirin in acute disabling ischemic stroke: an individual patient data meta-analysis of three large randomized trials.
Topics: Aspirin; Brain Ischemia; Female; Fibrinolytic Agents; Follow-Up Studies; Humans; Intracranial Hemorr | 2015 |
P2Y12 receptor inhibitors for secondary prevention of ischemic stroke.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggre | 2015 |
Edoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial fibrillation. An indirect comparison analysis.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Drug | 2015 |
Dual Antiplatelet Therapy of Clopidogrel and Aspirin in Secondary Prevention of Ischemic Stroke: Evidence and Indications.
Topics: Antiplatyhelmintic Agents; Aspirin; Brain Ischemia; Clopidogrel; Evidence-Based Medicine; Humans; St | 2015 |
Structural causes of ischemic and hemorrhagic stroke in children: moyamoya and arteriovenous malformations.
Topics: Adolescent; Aspirin; Brain Ischemia; Cerebral Angiography; Cerebral Revascularization; Child; Child, | 2015 |
Prediction models for intracranial hemorrhage or major bleeding in patients on antiplatelet therapy: a systematic review and external validation study.
Topics: Algorithms; Anticoagulants; Aspirin; Brain Ischemia; Calibration; Cerebral Hemorrhage; Dipyridamole; | 2016 |
Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Random | 2016 |
Stroke: How good is aspirin for patients with acute brain ischaemia?
Topics: Acute Disease; Aspirin; Brain Ischemia; Humans; Platelet Aggregation Inhibitors; Randomized Controll | 2016 |
Clopidogrel in secondary ischemic stroke prevention.
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Evidence- | 2008 |
Combination antiplatelet agents for secondary prevention of ischemic stroke.
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Therapy, Combinat | 2008 |
Multifunctional actions of approved and candidate stroke drugs.
Topics: Albumins; Animals; Antihypertensive Agents; Aspirin; Brain Ischemia; Clopidogrel; Cytidine Diphospha | 2009 |
What's new in stroke? The top 10 studies of 2006-2008. Part I.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Evidence-Based Medici | 2008 |
FPIN's clinical inquiries. Aspirin in patients with acute ischemic stroke.
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Education, Medical; Evidence-Based Medicine; Fibr | 2009 |
Aspirin in cardiology--benefits and risks.
Topics: Adult; Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Female; Gastrointestinal Diseases; Humans | 2009 |
Antiplatelet agents for prevention of recurrent ischemic stroke.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Practic | 2009 |
Antiplatelet drugs for ischemic stroke prevention.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; | 2009 |
Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Clinical Trials as Topic; | 2009 |
Secondary stroke prevention with antithrombotic drugs.
Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Cyclooxygenase Inhibitors; Dipyridamole; Drug | 2010 |
Antithrombotic therapies in cerebrovascular disease: what should we use as secondary prevention in patients with carotid artery disease?
Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Stenosis; Clopidogrel; Dipyridamole; Drug Therapy, | 2009 |
[Pharmacotherapy of stroke].
Topics: Acute Disease; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Fibrinolytic Agents; Humans; Hungary; N | 2009 |
Antiplatelet treatment in ischemic stroke treatment.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2009 |
Antiplatelets and stroke outcomes: state of the science.
Topics: Arachidonic Acid; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Clopidogrel; Dipy | 2009 |
A critical review of aspirin in the secondary prevention of noncardioembolic ischaemic stroke.
Topics: Aspirin; Brain Ischemia; Drug Therapy, Combination; Endarterectomy, Carotid; Fibrinolytic Agents; Hu | 2010 |
[Actual review of diagnostics and endovascular therapy of intracranial arterial stenoses].
Topics: Angiography, Digital Subtraction; Angioplasty; Aspirin; Brain Infarction; Brain Ischemia; Cerebral A | 2011 |
Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin.
Topics: Asian People; Aspirin; Brain Ischemia; Cause of Death; Cilostazol; Gastrointestinal Hemorrhage; Huma | 2011 |
Pregnancy and stroke risk in women.
Topics: Aspirin; Brain Ischemia; Female; Fibrinolytic Agents; Humans; Hypertension, Pregnancy-Induced; Plate | 2011 |
Gender differences in the primary prevention of stroke with aspirin.
Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Female; Fibrinolytic Agents; Humans; Male; Meta-An | 2011 |
Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Clopidogrel; Cost-Benefit Analysis; Delayed-Ac | 2011 |
Endovascular treatment of intracranial stenosis.
Topics: Angioplasty, Balloon; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Arteries; Constriction, Path | 2011 |
Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Datab | 2012 |
Current trial-associated outcomes with warfarin in prevention of stroke in patients with nonvalvular atrial fibrillation: a meta-analysis.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Brain Ischemia; Clopidogrel; | 2012 |
How baseline severity affects efficacy and safety outcomes in acute ischemic stroke intervention trials.
Topics: Acute Disease; Anticoagulants; Aspirin; Brain Damage, Chronic; Brain Ischemia; Cerebral Hemorrhage; | 2012 |
Does inhibiting Sur1 complement rt-PA in cerebral ischemia?
Topics: Animals; Antioxidants; Aspirin; ATP-Binding Cassette Transporters; Brain Ischemia; Cells, Cultured; | 2012 |
Acute ischemic cerebrovascular events on antiplatelet therapy: what is the optimal prevention strategy?
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Humans; Life S | 2013 |
Aspirin and clopidogrel for prevention of ischemic stroke.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Platel | 2013 |
Aspirin in the prophylaxis of coronary artery disease.
Topics: Aspirin; Brain Ischemia; Coronary Disease; Dipyridamole; Drug Therapy, Combination; Humans; Myocardi | 2002 |
[Antithrombotic therapy for ischemic cerebrovascular accident].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Fibrinolytic Agents; Humans; Recurrenc | 2002 |
Anticoagulants versus antiplatelet agents for acute ischemic stroke.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Heparin; Humans; Odds Ratio; Platelet Aggregation Inhibitor | 2003 |
Platelet-mediated microvascular inflammation and thrombosis in thrombocythemia vera: a distinct aspirin-responsive arterial thrombophilia, which transforms into a bleeding diathesis at increasing platelet counts.
Topics: Aspirin; Blood Platelets; Brain Ischemia; Erythromelalgia; Hemorrhagic Disorders; Humans; Myocardial | 2003 |
[Stenosis of the carotid arteries].
Topics: Angioplasty, Balloon; Aspirin; Brain Ischemia; Carotid Stenosis; Endarterectomy; Humans; Recurrence; | 2003 |
Are anticoagulants better than antiplatelet agents for treatment of acute ischemic stroke?
Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Evidence-Based Medicine; Humans; Plate | 2003 |
Ongoing and planned trials of antiplatelet therapy in the acute and long-term management of patients with ischaemic brain syndromes: setting a new standard of care.
Topics: Aspirin; Brain Ischemia; Disease Management; Humans; Patient Care; Platelet Aggregation Inhibitors; | 2004 |
Risk of intracerebral hemorrhage in patients with arterial versus cardiac origin of cerebral ischemia on aspirin or placebo: analysis of individual patient data from 9 trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arterial Occlusive Diseases; Aspirin; Atrial Fibrillation; | 2004 |
[Anti-platelet agents in neurological practice].
Topics: Aspirin; Atrial Fibrillation; Brain Ischemia; Humans; Neurology; Platelet Aggregation Inhibitors | 2004 |
Risk factors for cranial ischemic complications in giant cell arteritis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Female; G | 2004 |
[The value of platelet inhibitors in the secondary prophylaxis of stroke -- a review].
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Dose-Response Relation | 2004 |
Atrial fibrillation and cardioembolic stroke.
Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Comorbidity; | 2004 |
Selecting patients with atrial fibrillation for anticoagulation: stroke risk stratification in patients taking aspirin.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cohort Studie | 2004 |
Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials.
Topics: Aspirin; Blood Pressure; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Female; Humans; Is | 2005 |
Combination antiplatelet agents in ischemic cerebrovascular disease.
Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Clopidogrel; Dipyridamole; Drug Therapy, Combinati | 2005 |
Post-varicella arteriopathy of childhood: natural history of vascular stenosis.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Artery, Internal; Carotid Stenosis; Cerebral Angiog | 2005 |
Efficacy and costs of secondary prevention with antiplatelets after ischaemic stroke.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Cost-Benefit Analysis; Dipyridamole; Health Care Costs; Humans | 2005 |
Adding aspirin to clopidogrel after TIA and ischemic stroke: benefits do not match risks.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Synergism; Drug Therapy, Combination; Humans; Ischemic At | 2005 |
Interactions between Alzheimer's disease and cerebral ischemia--focus on inflammation.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Aspirin; Brain Ischemia; Humans; Inflamm | 2005 |
Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Brain Ischemia; C-Reactive Prote | 2005 |
Management problems of spontaneous ICH.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Hospitalization; Humans; Magnetic Reso | 2005 |
Avoiding central nervous system bleeding during antithrombotic therapy: recent data and ideas.
Topics: Administration, Oral; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Blood Pressur | 2005 |
Risk of hemorrhagic stroke with aspirin use: an update.
Topics: Adult; Aged; Aged, 80 and over; Angiography; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain | 2005 |
Antiplatelet therapy in ischemic stroke.
Topics: Aspirin; Brain Ischemia; Humans; Platelet Aggregation Inhibitors; Stroke; Thrombolytic Therapy | 2005 |
Antiplatelet agents in secondary prevention of stroke: a perspective.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Brain Ischemia; Clinical Trials | 2005 |
[Current concepts of the antiplatelet and anticoagulant treatment in the prevention of stroke].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; | 2005 |
[Options in the management of persistent foramen ovale after an ischemic stroke].
Topics: Aspirin; Brain Ischemia; Heart Septal Defects, Atrial; Humans; Ischemic Attack, Transient; Platelet | 2006 |
Antithrombotic agents in cerebral ischaemia.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Fibrinolytic Agents; Humans; Risk Assessment; Risk Factors; | 2006 |
Therapy for early reperfusion after stroke.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Circulation; Diffusion Magnetic Resonance I | 2006 |
Dipyridamole with aspirin is better than aspirin alone in preventing vascular events after ischaemic stroke or TIA.
Topics: Aspirin; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Humans; Ischemic Attack, Transient | 2007 |
Prevention of ischemic stroke: surgery.
Topics: Aspirin; Brain Ischemia; Carotid Artery, External; Carotid Artery, Internal; Carotid Stenosis; Coron | 2007 |
Clinical practice. Acute ischemic stroke.
Topics: Acute Disease; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Contraindications; Diag | 2007 |
The PRoFESS trial: future impact on secondary stroke prevention.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; Clopid | 2007 |
Anticoagulants, aspirin and dipyridamole in the secondary prevention of cerebral ischaemia: which is the best for which patient?
Topics: Anticoagulants; Aspirin; Brain Ischemia; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Stro | 2007 |
Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Aspirin; Brain Ischemia; Clopidogrel; Coron | 2008 |
Update on antiplatelet agents, including MATCH, CHARISMA, and ESPRIT.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Coronary Artery Disease; Dipyridamole; Female; Humans; Ischemi | 2008 |
Cardiovascular diseases in the elderly.
Topics: Aged; Aging; Amyloidosis; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Aspirin; Brain Ischemia; Car | 1983 |
[Place of antiplatelet agents in the prevention of cerebral ischemic strokes].
Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Clinical Trials as Topic; Clofib | 1983 |
[Current clinical results of antiplatelet medication].
Topics: Animals; Anticoagulants; Aspirin; Blood Platelets; Brain Ischemia; Coronary Disease; Dipyridamole; D | 1984 |
Aspirin in asymptomatic carotid disease.
Topics: Aspirin; Brain Ischemia; Carotid Artery Diseases; Carotid Stenosis; Cerebrovascular Disorders; Human | 1994 |
Antiplatelet therapy in the prevention of ischaemic stroke.
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Platele | 1994 |
[Vascular hemi-parkinson disease].
Topics: Aged; Aspirin; Benserazide; Brain Ischemia; Drug Therapy, Combination; Female; Functional Laterality | 1993 |
Antithrombotic therapies for stroke prevention.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebrovascular Disorders; Fibrinolyti | 1994 |
Stroke prevention in atrial fibrillation.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebrovascular Disorders; Humans; Ran | 1993 |
Asymptomatic carotid stenosis: surgery's the answer, but that's not the question.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Arteriosclerosis; Aspirin; Brain Ischemia; | 1996 |
Aspirin in ischemic cerebrovascular disease. How strong is the case for a different dosing regimen?
Topics: Aspirin; Brain Ischemia; Cerebrovascular Circulation; Cerebrovascular Disorders; Coronary Circulatio | 1996 |
[Antithrombotic treatment in acute ischemia stroke].
Topics: Acute Disease; Anticoagulants; Aspirin; Brain Ischemia; Heparin; Humans; Platelet Aggregation Inhibi | 1995 |
Ticlopidine or clopidogrel as alternatives to aspirin in prevention of ischemic stroke.
Topics: Aspirin; Brain Ischemia; Cerebrovascular Disorders; Clopidogrel; Humans; Platelet Aggregation Inhibi | 1996 |
[Treatment protocol of cerebral vascular accident].
Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Stenosis; Clinical Protocols; Endarterectomy; Human | 1997 |
Brain attack. Acute therapeutic intervention. Antithrombotic and antiplatelet-aggregating drugs.
Topics: Antibodies, Monoclonal; Aspirin; Brain Ischemia; Clinical Trials as Topic; Fibrinolytic Agents; Hepa | 1997 |
Neurologic and visual symptoms in essential thrombocythemia: efficacy of low-dose aspirin.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Diagnosis, Differential; Erythromelalgia; Headache; Humans; | 1997 |
Low- versus high-dose aspirin in prevention of ischemic stroke.
Topics: Animals; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Human | 1993 |
[Antithrombotic therapy after cerebral ischemia].
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Dose-Response Relationship, Drug; Drug Therapy, | 1997 |
[Anti-aggregation therapy for prevention of cerebral ischemic stroke: a risk benefit analysis].
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Humans; Platelet Aggregation Inhibitors; Risk; Ti | 1997 |
[Acute cerebral infarct: physiopathology and modern therapeutic concepts].
Topics: Acute Disease; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Infarction; Cerebrovascular Circula | 1997 |
Pharmacotherapy of cerebral ischemia in cocaine dependence.
Topics: Aspirin; Brain; Brain Ischemia; Cerebrovascular Circulation; Cocaine; Cocaine-Related Disorders; Cog | 1998 |
[Secondary prevention following cerebral ischemia: is monotherapy with acetylsalicylic acid still first choice?].
Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cerebrovascular Disorders; Clopidogrel | 1998 |
Anticoagulants and antiplatelet agents in acute ischemic stroke.
Topics: Acute Disease; Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Clinical Trials a | 1998 |
Antithrombotic and thrombolytic therapy for ischemic stroke.
Topics: Acute Disease; Anticoagulants; Aspirin; Brain Ischemia; Contraindications; Fibrinolytic Agents; Hepa | 1998 |
Drug therapy for acute ischaemic stroke: risks versus benefits.
Topics: Aspirin; Brain Ischemia; Heparin; Humans; Neuroprotective Agents; Risk Assessment; Thrombolytic Ther | 1998 |
Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials.
Topics: Aspirin; Brain Ischemia; Cerebral Hemorrhage; Humans; Myocardial Infarction; Platelet Aggregation In | 1998 |
[Effects of the results of randomized trials on the tactics of management of patients with acute stroke].
Topics: Acute Disease; Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Fibrinolytic Agen | 1999 |
Antiplatelet therapy in acute cerebral ischemia.
Topics: Acute Disease; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Humans; Platelet Aggregation Inhi | 1999 |
Antithrombotic and thrombolytic therapy for ischemic stroke.
Topics: Aspirin; Brain Ischemia; Fibrinolytic Agents; Humans; Ischemic Attack, Transient; Platelet Aggregati | 1999 |
Aspirin and heparin in acute ischaemic stroke in older patients.
Topics: Acute Disease; Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cerebrovascular D | 1999 |
Antiplatelet therapy in the prevention of ischemic vascular events: literature review and evidence-based guidelines for drug selection.
Topics: Algorithms; Arteriosclerosis; Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Critic | 1999 |
Fibromuscular dysplasia of the internal carotid artery. Personal experience with 13 cases and literature review.
Topics: Aged; Aneurysm; Angioplasty, Balloon; Aspirin; Blindness; Brain Ischemia; Carotid Artery Diseases; C | 1999 |
[Prevention of cerebral ischemia: anti-platelet agents].
Topics: Arteriosclerosis; Aspirin; Atrial Fibrillation; Brain Ischemia; Humans; Intracranial Embolism; Plate | 1999 |
Ischemic stroke. Clinical strategies based on mechanisms and risk factors.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atrial Fibrillation; Brai | 2000 |
[Transient ischemic attacks and prolonged reversible ischemic neurologic deficit. Diagnosis, differential diagnosis and treatment].
Topics: Aspirin; Brain Ischemia; Cerebral Infarction; Diagnosis, Differential; Dipyridamole; Endarterectomy, | 2000 |
Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups.
Topics: Acute Disease; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrha | 2000 |
Thienopyridines or aspirin to prevent stroke and other serious vascular events in patients at high risk of vascular disease? A systematic review of the evidence from randomized trials.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhib | 2000 |
Use of platelet inhibitor drugs in peripheral and cerebral vascular disorders.
Topics: Arterial Occlusive Diseases; Aspirin; Blood Platelets; Brain Ischemia; Cell Survival; Clinical Trial | 1977 |
[The use of drugs that affect thrombocytes in cerebral ischemia].
Topics: Aspirin; Blood Platelets; Brain Ischemia; Dipyridamole; Female; Humans; Male; Ticlopidine | 1990 |
[Value and limits of antiplatelet agents in cerebral ischemic pathology].
Topics: Aspirin; Brain Ischemia; Humans; Intracranial Embolism and Thrombosis; Platelet Aggregation Inhibito | 1988 |
[Platelet antiaggregants in cerebral ischemic pathology].
Topics: Arteriosclerosis; Aspirin; Atrial Fibrillation; Brain Ischemia; Humans; Platelet Aggregation Inhibit | 1989 |
Asymptomatic carotid disease.
Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cerebrovascular Disor | 1985 |
[The fate of patients with carotid stenosis. Comparative study, based on the literature, of their natural history and evolution under medical treatment or following endarterectomy].
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Brain Ischemia; Carotid Artery Diseases; Combined Modalit | 1985 |
194 trials available for aspirin and Brain Ischemia
| Article | Year |
|---|---|
Cilostazol Versus Aspirin on White Matter Changes in Cerebral Small Vessel Disease: A Randomized Controlled Trial.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Small Vessel Diseases; Cilostazol; Double | 2022 |
Safety and efficacy of aspirin, unfractionated heparin, both, or neither during endovascular stroke treatment (MR CLEAN-MED): an open-label, multicentre, randomised controlled trial.
Topics: Adult; Aspirin; Brain Ischemia; Heparin; Humans; Magnetic Resonance Imaging; Stroke; Treatment Outco | 2022 |
Indobufen versus aspirin in acute ischaemic stroke (INSURE): rationale and design of a multicentre randomised trial.
Topics: Aspirin; Brain Ischemia; Hemorrhage; Humans; Ischemic Stroke; Platelet Aggregation Inhibitors; Strok | 2022 |
Rationale and design of a randomised double-blind 2×2 factorial trial comparing the effect of a 3-month intensive statin and antiplatelet therapy for patients with acute mild ischaemic stroke or high-risk TIA with intracranial or extracranial atherosclero
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Atorvastatin; Brain Ischemia; Clopidogrel; | 2023 |
Safety and efficacy of tirofiban in acute ischemic stroke due to tandem lesions undergoing mechanical thrombectomy: A multicenter randomized clinical trial (ATILA) protocol.
Topics: Aspirin; Brain Ischemia; Clinical Trials, Phase IV as Topic; Humans; Ischemic Stroke; Multicenter St | 2023 |
Indobufen versus aspirin in patients with acute ischaemic stroke in China (INSURE): a randomised, double-blind, double-dummy, active control, non-inferiority trial.
Topics: Aspirin; Brain Ischemia; Double-Blind Method; Female; Humans; Ischemic Stroke; Male; Middle Aged; St | 2023 |
Tirofiban for Stroke without Large or Medium-Sized Vessel Occlusion.
Topics: Aspirin; Brain Ischemia; Cerebral Arterial Diseases; Fibrinolytic Agents; Humans; Intracranial Hemor | 2023 |
Bleeding with intensive versus guideline antiplatelet therapy in acute cerebral ischaemia.
Topics: Acute Disease; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female | 2023 |
Cilostazol Versus Aspirin in Ischemic Stroke Patients With High-Risk Cerebral Hemorrhage: Subgroup Analysis of the PICASSO Trial.
Topics: Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Female; Follow-Up Studies; Humans; M | 2020 |
Cilostazol Versus Aspirin in Ischemic Stroke Patients With High-Risk Cerebral Hemorrhage: Subgroup Analysis of the PICASSO Trial.
Topics: Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Female; Follow-Up Studies; Humans; M | 2020 |
Cilostazol Versus Aspirin in Ischemic Stroke Patients With High-Risk Cerebral Hemorrhage: Subgroup Analysis of the PICASSO Trial.
Topics: Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Female; Follow-Up Studies; Humans; M | 2020 |
Cilostazol Versus Aspirin in Ischemic Stroke Patients With High-Risk Cerebral Hemorrhage: Subgroup Analysis of the PICASSO Trial.
Topics: Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Female; Follow-Up Studies; Humans; M | 2020 |
Rivaroxaban versus aspirin for secondary prevention of ischaemic stroke in patients with cancer: a subgroup analysis of the NAVIGATE ESUS randomized trial.
Topics: Aspirin; Brain Ischemia; Double-Blind Method; Factor Xa Inhibitors; Humans; Intracranial Embolism; I | 2020 |
An investigation into the impact of enteric coated of aspirin in patients with newly diagnosed ischemic stroke (ECASIS).
Topics: Adolescent; Adult; Aged; Aspirin; Blood Platelets; Brain Ischemia; Female; Gastrointestinal Hemorrha | 2020 |
A comparison of three platelet function tests in ischemic stroke patients with antiplatelet therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Platelets; Brain Ischemia; Clopidogrel; Drug Therapy, Combin | 2020 |
Characteristics of Recurrent Ischemic Stroke After Embolic Stroke of Undetermined Source: Secondary Analysis of a Randomized Clinical Trial.
Topics: Aged; Aspirin; Brain Ischemia; Double-Blind Method; Embolic Stroke; Factor Xa Inhibitors; Female; Hu | 2020 |
Multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke. The effect of periprocedural medication: acetylsalicylic acid, unfractionated heparin, both, or neither (MR CLEAN-MED). Rationale and study design.
Topics: Adult; Aspirin; Brain Ischemia; Endovascular Procedures; Heparin; Humans; Ischemic Stroke; Multicent | 2020 |
Carotid Stenosis and Recurrent Ischemic Stroke: A Post-Hoc Analysis of the POINT Trial.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Carotid Stenosis; Clopidogrel; Dual Anti-Platelet | 2021 |
Clopidogrel with aspirin in High-risk patients with Acute Non-disabling Cerebrovascular Events II (CHANCE-2): rationale and design of a multicentre randomised trial.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Humans; Platelet Aggregation Inhibi | 2021 |
Personalized antiplatelet therapy based on clopidogrel/aspirin resistance tests in acute ischemic stroke and transient ischemic attack: Study protocol of a multi-center, single-blinded and randomized controlled trial.
Topics: Aftercare; Aspirin; Brain Ischemia; Clopidogrel; Humans; Ischemic Attack, Transient; Ischemic Stroke | 2021 |
Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial.
Topics: Aged; Aspirin; Brain Ischemia; Drug Therapy, Combination; Factor Xa Inhibitors; Humans; Peripheral A | 2021 |
Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: Time course analysis of CHANCE.
Topics: Aspirin; Brain Ischemia; China; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Fibrino | 2017 |
Cilostazol improves endothelial function in acute cerebral ischemia patients: a double-blind placebo controlled trial with flow-mediated dilation technique.
Topics: Adult; Aged; Arginine; Aspirin; Brain Ischemia; C-Reactive Protein; Cilostazol; Dilatation; Double-B | 2017 |
Dual antiplatelet therapy in aneurysmal subarachnoid hemorrhage: association with reduced risk of clinical vasospasm and delayed cerebral ischemia.
Topics: Adult; Aged; Aspirin; Brain Ischemia; Case-Control Studies; Clopidogrel; Embolization, Therapeutic; | 2018 |
Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.
Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Clopidogrel; Denmark; Dipyridamole; Drug Therapy, Comb | 2018 |
Enoxaparin vs Aspirin in Patients With Cancer and Ischemic Stroke: The TEACH Pilot Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Enoxaparin; Female; Fibrinolyti | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2018 |
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source.
Topics: Aged; Aspirin; Brain Ischemia; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intracranial Emboli | 2018 |
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source.
Topics: Aged; Aspirin; Brain Ischemia; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intracranial Emboli | 2018 |
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source.
Topics: Aged; Aspirin; Brain Ischemia; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intracranial Emboli | 2018 |
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source.
Topics: Aged; Aspirin; Brain Ischemia; Factor Xa Inhibitors; Female; Hemorrhage; Humans; Intracranial Emboli | 2018 |
Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial.
Topics: Aged; Antioxidants; Asian People; Aspirin; Brain Ischemia; Cardiovascular Diseases; Cerebral Hemorrh | 2018 |
Comparison of Triflusal with Aspirin in the Secondary Prevention of Atherothrombotic Events; Α Randomised Clinical Trial.
Topics: Aged; Aspirin; Brain Ischemia; Coronary Artery Disease; Cyclooxygenase Inhibitors; Female; Greece; H | 2019 |
Effect of Alteplase vs Aspirin on Functional Outcome for Patients With Acute Ischemic Stroke and Minor Nondisabling Neurologic Deficits: The PRISMS Randomized Clinical Trial.
Topics: Administration, Intravenous; Administration, Oral; Aged; Aspirin; Bayes Theorem; Brain Ischemia; Dou | 2018 |
Aspirin plus clopidogrel may reduce the risk of early neurologic deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Therapy, Combination; Fem | 2018 |
Effects of policosanol in the functional recovery of non-cardioembolic ischemic stroke hypertensive patients.
Topics: Aged; Aspirin; Brain Ischemia; Double-Blind Method; Drug Therapy, Combination; Fatty Alcohols; Femal | 2018 |
Effect of dual versus mono antiplatelet therapy on recurrent stroke modulated by activated partial thromboplastin time.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Female; Humans; Male; Middle | 2019 |
Risk for Major Hemorrhages in Patients Receiving Clopidogrel and Aspirin Compared With Aspirin Alone After Transient Ischemic Attack or Minor Ischemic Stroke: A Secondary Analysis of the POINT Randomized Clinical Trial.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therapy, Combination; Female; | 2019 |
Disparities and Temporal Trends in the Use of Anticoagulation in Patients With Ischemic Stroke and Atrial Fibrillation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Female; Flori | 2019 |
Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Constriction, Pathologic; | 2019 |
Combination therapy with beraprost sodium and aspirin for acute ischemic stroke: a single-center retrospective study.
Topics: Aged; Aspirin; Brain Ischemia; Drug Therapy, Combination; Epoprostenol; Female; Follow-Up Studies; H | 2019 |
Predictors of Recurrent Ischemic Stroke in Patients with Embolic Strokes of Undetermined Source and Effects of Rivaroxaban Versus Aspirin According to Risk Status: The NAVIGATE ESUS Trial.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Double-Blind Method; Factor Xa Inhibitors; Female; Hu | 2019 |
Benefit of warfarin compared with aspirin in patients with heart failure in sinus rhythm: a subgroup analysis of WARCEF, a randomized controlled trial.
Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind | 2013 |
Results of the PERFORM magnetic resonance imaging study.
Topics: Aged; Aged, 80 and over; Aspirin; Brain; Brain Ischemia; Female; Fibrinolytic Agents; Humans; Magnet | 2013 |
Impact of smoking on long-term outcomes in patients with atherosclerotic vascular disease treated with aspirin or clopidogrel: insights from the CAPRIE trial (Clopidogrel Versus Aspirin in Patients at Risk of Ischemic Events).
Topics: Aspirin; Atherosclerosis; Brain Ischemia; Clopidogrel; Female; Humans; Male; Risk Factors; Single-Bl | 2014 |
[Acetylsalicylic acid non-responders after ischemic insult in geriatric patients].
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Female; Humans; Male; Platelet Aggregation Inhibit | 2014 |
Homocysteine as a predictor of early neurological deterioration in acute ischemic stroke.
Topics: Aged; Aspirin; Biomarkers; Brain Ischemia; C-Reactive Protein; Cilostazol; Disease Progression; Doub | 2014 |
Triflusal and aspirin in the secondary prevention of atherothrombotic ischemic stroke: a very long-term follow-up.
Topics: Aged; Aspirin; Brain Ischemia; Dyspepsia; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; | 2014 |
Low-molecular-weight heparin is more effective than aspirin in preventing early neurologic deterioration and improving six-month outcome.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Enoxaparin; Female; Humans; Male; | 2014 |
Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aorta, Thoracic; Aortic Diseases; Aspirin; Brain Ischemia; | 2014 |
Modification of outcomes with aspirin or apixaban in relation to female and male sex in patients with atrial fibrillation: a secondary analysis of the AVERROES study.
Topics: Age Factors; Aged; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; Comorbidity; D | 2014 |
Impacts of COX-1 gene polymorphisms on vascular outcomes in patients with ischemic stroke and treated with aspirin.
Topics: Aged; Alleles; Aspirin; Brain Ischemia; Cohort Studies; Cyclooxygenase 1; Female; Gene Frequency; Ge | 2014 |
Risk of ischaemic stroke according to pattern of atrial fibrillation: analysis of 6563 aspirin-treated patients in ACTIVE-A and AVERROES.
Topics: Aged; Aspirin; Atrial Fibrillation; Brain Ischemia; Double-Blind Method; Embolism; Female; Fibrinoly | 2015 |
Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort study.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Dose-Response Relationship, Drug; Female; Follow-Up Stud | 2014 |
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi | 2015 |
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi | 2015 |
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi | 2015 |
Protocol for Cilostazol Stroke Prevention Study for Antiplatelet Combination (CSPS.com): a randomized, open-label, parallel-group trial.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Humans; Phosphodi | 2015 |
Statistical analysis plan for the 'Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke' (TARDIS) trial.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Double-Blind Method; Female; Humans; Internation | 2015 |
Aspirin resistance in the acute stages of acute ischemic stroke is associated with the development of new ischemic lesions.
Topics: Acute Disease; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Drug Resistan | 2015 |
Quality of anticoagulation control in preventing adverse events in patients with heart failure in sinus rhythm: Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial substudy.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Chi-Square Distribution; Double- | 2015 |
Rationale and design of the PreventIon of CArdiovascular events in iSchemic Stroke patients with high risk of cerebral hemOrrhage (PICASSO) study: A randomized controlled trial.
Topics: Adult; Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Double-Blind Method; Female; | 2015 |
Aspirin for Stroke Prevention in Elderly Patients With Vascular Risk Factors: Japanese Primary Prevention Project.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Comorbidity; Diabetes Mellitus; Dyslipidemias; Fem | 2016 |
Recurrent Ischemic Lesions After Acute Atherothrombotic Stroke: Clopidogrel Plus Aspirin Versus Aspirin Alone.
Topics: Aged; Aspirin; Atherosclerosis; Brain; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug Therap | 2016 |
The curative effect comparison of two kinds of therapeutic regimens on decreasing the relative intensity of microembolic signal in CLAIR trial.
Topics: Aspirin; Brain Ischemia; Carotid Stenosis; Cerebral Arterial Diseases; Clopidogrel; Drug Therapy, Co | 2016 |
Abnormal glucose regulation increases stroke risk in minor ischemic stroke or TIA.
Topics: Aged; Aspirin; Blood Glucose; Brain Ischemia; Clopidogrel; Diabetes Complications; Double-Blind Meth | 2016 |
Baseline characteristics of the 3096 patients recruited into the 'Triple Antiplatelets for Reducing Dependency after Ischemic Stroke' trial.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Female; Humans; | 2017 |
[Long-term effect of policosanol on the functional recovery of non-cardioembolic ischemic stroke patients: a one year study].
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Aspirin; Brain Damage, Chronic; Brain Ischemia; C | 2017 |
Association of multiple infarctions and ICAS with outcomes of minor stroke and TIA.
Topics: Aged; Aspirin; Brain; Brain Infarction; Brain Ischemia; Clopidogrel; Female; Humans; Image Processin | 2017 |
Plasma triglycerides as predictors of platelet responsiveness to aspirin in patients after first ischemic stroke.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; Drug Resistance; Female; Humans; Hypertr | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; | 2008 |
Safety and tolerability of 600 mg clopidogrel bolus in patients with acute ischemic stroke: preliminary experience.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Male; Middle A | 2008 |
The relationship between baseline blood pressure and computed tomography findings in acute stroke: data from the tinzaparin in acute ischaemic stroke trial (TAIST).
Topics: Acute Disease; Aspirin; Blood Pressure; Brain; Brain Ischemia; Causality; Cerebral Hemorrhage; Comor | 2009 |
Magnesium and aspirin treatment in patients with subarachnoid haemorrhage. Comparison of effects after endovascular and neurosurgical aneurysm occlusion.
Topics: Aspirin; Brain Ischemia; Embolization, Therapeutic; Female; Humans; Intracranial Aneurysm; Magnesium | 2009 |
Causes and severity of ischemic stroke in patients with symptomatic intracranial arterial stenosis.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cerebral Arteries; Cerebrovascular Disorde | 2009 |
Causes and severity of ischemic stroke in patients with symptomatic intracranial arterial stenosis.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cerebral Arteries; Cerebrovascular Disorde | 2009 |
Causes and severity of ischemic stroke in patients with symptomatic intracranial arterial stenosis.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cerebral Arteries; Cerebrovascular Disorde | 2009 |
Causes and severity of ischemic stroke in patients with symptomatic intracranial arterial stenosis.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cerebral Arteries; Cerebrovascular Disorde | 2009 |
Triflusal and aspirin have different effects on inflammatory biomarkers measured in patients with acute ischemic stroke.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Aspirin; Biomarkers; Brain Ischemia; Female; Huma | 2009 |
Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Brain Ischemia; Clopidogrel; Double-Blind Method; Drug | 2009 |
Antiplatelet therapy in combination with rt-PA thrombolysis in ischemic stroke (ARTIS): rationale and design of a randomized controlled trial.
Topics: Aspirin; Brain Ischemia; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Intracranial Hemorr | 2010 |
Addition of cilostazol reduces biological aspirin resistance in aspirin users with ischaemic stroke: a double-blind randomized clinical trial.
Topics: Aspirin; Bleeding Time; Brain Ischemia; Cilostazol; Double-Blind Method; Drug Resistance; Drug Thera | 2010 |
Effect of cilostazol on cerebral arteries in secondary prevention of ischemic stroke.
Topics: Aspirin; Blood Flow Velocity; Brain; Brain Ischemia; Cerebral Angiography; Cerebral Arteries; Cerebr | 2009 |
Effect of intravenous tirofiban and aspirin in reducing short-term and long-term neurologic deficit in patients with ischemic stroke: a double-blind randomized trial.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Chi-Square Distribution; Disability Evaluation; Do | 2010 |
Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Female; Fibrinolytic Agents; Humans; Kapla | 2010 |
A randomised controlled trial of antiplatelet therapy in combination with Rt-PA thrombolysis in ischemic stroke: rationale and design of the ARTIS-Trial.
Topics: Aspirin; Brain Ischemia; Drug Administration Schedule; Drug Therapy, Combination; Fibrinolytic Agent | 2010 |
[Changes of plasma fibrinogen level among acute ischemic stroke subtypes according to TOAST criteria and effects of Songling Xuemaikang].
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Drugs, Chinese Herbal; Female; Fibrinogen; Humans; | 2010 |
Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: A multicenter randomized trial evaluating the efficacy of Cilostazol on ischemic vas
Topics: Angioplasty, Balloon, Coronary; Aspirin; Brain Ischemia; Cilostazol; Clinical Protocols; Clopidogrel | 2010 |
Radix/rhizoma notoginseng extract (sanchitongtshu) for ischemic stroke: a randomized controlled study.
Topics: Activities of Daily Living; Aged; Aspirin; Brain Ischemia; Cognition Disorders; Double-Blind Method; | 2011 |
Predictors of adherence to secondary preventive medication in stroke patients.
Topics: Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Attitude to Health; Brain Ische | 2011 |
Effect of clopidogrel plus ASA vs. ASA early after TIA and ischaemic stroke: a substudy of the CHARISMA trial.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Female; Follow-Up Studies; Hu | 2011 |
Non-invasive alternating current stimulation induces recovery from stroke.
Topics: Aged; Aphasia; Aspirin; Brain Ischemia; Clopidogrel; Combined Modality Therapy; Electric Stimulation | 2010 |
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination; | 2011 |
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination; | 2011 |
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination; | 2011 |
Multicenter randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: results of the CILON-T (influence of CILostazol-based triple antiplatelet therapy ON is
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Coronary Disease; Drug Therapy, Combination; | 2011 |
Quality of life after ischemic stroke varies in western countries: data from the tinzaparin in Acute Ischaemic Stroke Trial (TAIST).
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Chi-Square Distribution; Emotions; Europe; Female; | 2012 |
The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial.
Topics: Aged; Asian People; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Delayed-Action | 2011 |
The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial.
Topics: Aged; Asian People; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Delayed-Action | 2011 |
The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial.
Topics: Aged; Asian People; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Delayed-Action | 2011 |
The Japanese aggrenox (extended-release dipyridamole plus aspirin) stroke prevention versus aspirin programme (JASAP) study: a randomized, double-blind, controlled trial.
Topics: Aged; Asian People; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Delayed-Action | 2011 |
Comparison of the effect of cilostazol with aspirin on circulating endothelial progenitor cells and small-dense LDL cholesterol in diabetic patients with cerebral ischemia: a randomized controlled pilot trial.
Topics: Aged; Aspirin; Brain Ischemia; Cholesterol, LDL; Cilostazol; Diabetes Mellitus; Endothelium, Vascula | 2011 |
Aspirin resistance in cerebrovascular patients.
Topics: Aged; Aspirin; Brain Ischemia; Drug Resistance; Female; Follow-Up Studies; Humans; Male; Middle Aged | 2011 |
Cilostazol combined with aspirin prevents early neurological deterioration in patients with acute ischemic stroke: a pilot study.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Drug Therapy, Combination; Female; Humans; Male; Middle A | 2012 |
Low-molecular-weight heparin versus aspirin for acute ischemic stroke with large artery occlusive disease: subgroup analyses from the Fraxiparin in Stroke Study for the treatment of ischemic stroke (FISS-tris) study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Arterial Occlusive Diseases; As | 2012 |
Pilot study of the safety of starting administration of low-dose aspirin and cilostazol in acute ischemic stroke.
Topics: Acute Disease; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cilostazol; Drug Therapy, Combinati | 2011 |
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C | 2012 |
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C | 2012 |
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C | 2012 |
Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; C | 2012 |
Cilostazol versus aspirin therapy in patients with chronic dizziness after ischemic stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Brain Stem; Cerebellum; Cerebrovascular Circulatio | 2012 |
Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score.
Topics: Age Factors; Aged; Aspirin; Body Weight; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Female; F | 2012 |
Risk of intracerebral hemorrhage in patients with cerebral microbleeds undergoing endovascular intervention.
Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Warfarin and aspirin in patients with heart failure and sinus rhythm.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Double-Blind Method; Female; Fol | 2012 |
Association of COX-2 rs20417 with aspirin resistance.
Topics: Adult; Aged; Alleles; Aspirin; Brain Ischemia; Cyclooxygenase 2; Drug Resistance; Female; Follow-Up | 2013 |
Comparative evaluation of treatment with low-dose aspirin plus dipyridamole versus aspirin only in patients with acute ischaemic stroke.
Topics: Aged; Aspirin; Brain Ischemia; Comorbidity; Dipyridamole; Drug Therapy, Combination; Female; Humans; | 2012 |
Monocyte chemotactic protein-1 as a potential biomarker for early anti-thrombotic therapy after ischemic stroke.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Brain Ischemia; Chemokine CCL2; Dipyridamole; D | 2012 |
The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogre | 2013 |
Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; Contraindic | 2012 |
What is better antiplatelet agent to prevent recurrent stroke?
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Brain Ischemia; Clopid | 2012 |
Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study.
Topics: Aged; Aspirin; Atrial Fibrillation; Brain Ischemia; Female; Fibrinolytic Agents; Health Status Indic | 2013 |
Unfractionated heparin is associated with a lower rise of serum vascular cell adhesion molecule-1 in acute ischemic stroke patients.
Topics: Acute Disease; Aged; Anticoagulants; Aspirin; Brain Ischemia; Female; Forecasting; Heparin; Humans; | 2002 |
Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study.
Topics: Antigens, CD; Aspirin; Blood Platelets; Brain Ischemia; Case-Control Studies; Clopidogrel; Cross-Ove | 2003 |
Changes in platelet P-selectin and in plasma C-reactive protein in acute atherosclerotic ischemic stroke treated with a loading dose of clopidogrel.
Topics: Aged; Arteriosclerosis; Aspirin; Blood Platelets; Brain Ischemia; C-Reactive Protein; Clopidogrel; D | 2002 |
Acetylsalicylic acid pretreatment, concomitant heparin therapy and the risk of early intracranial hemorrhage following systemic thrombolysis for acute ischemic stroke.
Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Dose-Response Relationship, Drug; Drug Administration | 2003 |
Dipyridamole in stroke prevention: effect of dipyridamole on blood pressure.
Topics: Aspirin; Blood Pressure; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Female; Follow-Up | 2003 |
Nadroparin plus aspirin versus aspirin alone in the treatment of acute ischemic stroke.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Drug Therapy, Combination; Female; Humans; Injections, Subc | 2003 |
Acetylsalicylic acid and acetaminophen to combat elevated body temperature in acute ischemic stroke.
Topics: Acetaminophen; Acute Disease; Aged; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroida | 2004 |
Leukocyte count as an independent predictor of recurrent ischemic events.
Topics: Aspirin; Biomarkers; Brain Ischemia; Cause of Death; Clopidogrel; Female; Humans; Inflammation; Leuk | 2004 |
Aspirin attenuates the incidence of silent brain lesions in patients with nonvalvular atrial fibrillation.
Topics: Aged; Aspirin; Atrial Fibrillation; Brain; Brain Ischemia; Female; Humans; Incidence; Magnetic Reson | 2004 |
Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Double-Blind M | 2004 |
Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Double-Blind M | 2004 |
Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Double-Blind M | 2004 |
Age as a determinant of adverse events in medically treated cryptogenic stroke patients with patent foramen ovale.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Double-Blind M | 2004 |
Measurement of platelet aggregation during antiplatelet therapy in ischemic stroke.
Topics: Adenosine Diphosphate; Adult; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Collagen; Epinep | 2004 |
Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study.
Topics: Aged; Anticoagulants; Aspirin; Bioprosthesis; Brain Ischemia; Disease-Free Survival; Female; Heart V | 2004 |
Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study.
Topics: Aged; Anticoagulants; Aspirin; Bioprosthesis; Brain Ischemia; Disease-Free Survival; Female; Heart V | 2004 |
Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study.
Topics: Aged; Anticoagulants; Aspirin; Bioprosthesis; Brain Ischemia; Disease-Free Survival; Female; Heart V | 2004 |
Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study.
Topics: Aged; Anticoagulants; Aspirin; Bioprosthesis; Brain Ischemia; Disease-Free Survival; Female; Heart V | 2004 |
Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study.
Topics: Aged; Anticoagulants; Aspirin; Bioprosthesis; Brain Ischemia; Disease-Free Survival; Female; Heart V | 2004 |
Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study.
Topics: Aged; Anticoagulants; Aspirin; Bioprosthesis; Brain Ischemia; Disease-Free Survival; Female; Heart V | 2004 |
Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study.
Topics: Aged; Anticoagulants; Aspirin; Bioprosthesis; Brain Ischemia; Disease-Free Survival; Female; Heart V | 2004 |
Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study.
Topics: Aged; Anticoagulants; Aspirin; Bioprosthesis; Brain Ischemia; Disease-Free Survival; Female; Heart V | 2004 |
Comparing warfarin with aspirin after biological aortic valve replacement: a prospective study.
Topics: Aged; Anticoagulants; Aspirin; Bioprosthesis; Brain Ischemia; Disease-Free Survival; Female; Heart V | 2004 |
Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial.
Topics: Aged; Antigens, CD; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; CD40 Ligand; Di | 2004 |
Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke.
Topics: Adult; Aged; Aspirin; Blood Platelets; Brain Ischemia; Case-Control Studies; Cell Adhesion; Clopidog | 2005 |
The rapid anticoagulation prevents ischemic damage study in acute stroke--final results from the writing committee.
Topics: Aged; Anticoagulants; Aspirin; Brain; Brain Ischemia; Clinical Trials as Topic; Endpoint Determinati | 2005 |
Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial.
Topics: Aged; Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biomarkers; Blood Platelets; Bra | 2005 |
Complement factor H Y402H gene polymorphism, C-reactive protein, and risk of incident myocardial infarction, ischaemic stroke, and venous thromboembolism: a nested case-control study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; beta Carotene; Brain Ischemia; C-Reactive Protein; Cardiova | 2006 |
Effect of aspirin, clopidogrel and dipyridamole on soluble markers of vascular function in normal volunteers and patients with prior ischaemic stroke.
Topics: Adult; Arteriosclerosis; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; C-Reactive Protein; C | 2006 |
Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Circulation; Constriction, Pathologic | 2006 |
Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Circulation; Constriction, Pathologic | 2006 |
Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Circulation; Constriction, Pathologic | 2006 |
Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Circulation; Constriction, Pathologic | 2006 |
Comparison between aspirin combined with dipyridamole versus aspirin alone within 48 hours after ischemic stroke event for prevention of recurrent stroke and improvement of neurological function: a preliminary study.
Topics: Aged; Aspirin; Brain Ischemia; Dipyridamole; Drug Administration Schedule; Drug Therapy, Combination | 2005 |
ESPRIT study design and outcomes--a critical appraisal.
Topics: Aspirin; Biomarkers; Brain Ischemia; Dipyridamole; Drug Therapy, Combination; Fibrinolytic Agents; H | 2007 |
[Prevention of ischemic stroke in middle aged patients with atrial fibrillation. Effect of sinus rhythm maintenance, aspirin, warfarin, and simvastatin].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Drug Therapy, Combination; Echocardiog | 2007 |
Low-molecular-weight heparin compared with aspirin for the treatment of acute ischaemic stroke in Asian patients with large artery occlusive disease: a randomised study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arterial Occlusive Diseases; A | 2007 |
Variable platelet response to aspirin in patients with ischemic stroke.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Biological Availabi | 2007 |
Impact of valvular thickness on stroke recurrence in medically treated patients with stroke.
Topics: Adult; Aged; Aortic Valve; Aspirin; Brain Ischemia; Double-Blind Method; Echocardiography, Transesop | 2007 |
Sex differences in quality of life in stroke survivors: data from the Tinzaparin in Acute Ischaemic Stroke Trial (TAIST).
Topics: Activities of Daily Living; Age Factors; Aged; Aspirin; Brain Ischemia; Double-Blind Method; Female; | 2007 |
[Randomized multicenter control clinical study on acute ischemic stroke treatment with traditional Chinese medicine].
Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Drug Therapy, Combination; Drugs, Chinese Herbal; Fibr | 2007 |
Aspirin responsiveness in acute brain ischaemia: association with stroke severity and clinical outcome.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Brain Ischemia; Female; Fol | 2008 |
Platelet aggregation and recruitment with aspirin-clopidogrel therapy.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Drug Therapy, Combination; Humans; Platelet Ag | 2008 |
Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study.
Topics: Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; China; Cilostazol; Double-Blind Method; Female; | 2008 |
[Place of antiplatelet agents in the prevention of cerebral ischemic strokes].
Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Clinical Trials as Topic; Clofib | 1983 |
[The A.I.C.L.A. controlled cooperative trial. Secondary prevention of cerebral ischemic accidents due to atherosclerosis by aspirin and dipyridamole. 3: Results].
Topics: Aspirin; Brain Ischemia; Cerebral Infarction; Clinical Trials as Topic; Dipyridamole; Drug Therapy, | 1983 |
[The platelet inhibitor problem].
Topics: Aspirin; Blood Transfusion; Brain Ischemia; Clinical Trials as Topic; Female; Humans; Male; Myocardi | 1981 |
["A.I.C.L.A." controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Part I: Protocol (author's transl)].
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Dipyridamole; Drug Therapy, Combination; Humans; | 1981 |
[Controlled cooperative trial. Secondary prevention of atherosclerosis-related cerebral ischemic accidents by aspirin dipyridamole. 2: Description of subjects at the beginning of the trial].
Topics: Aged; Aspirin; Brain Ischemia; Cerebral Infarction; Clinical Trials as Topic; Dipyridamole; Drug The | 1982 |
[5-year controlled therapy study on the prevention of diabetic angiopathy with the platelet-function inhibitor acetylsalicylic acid].
Topics: Adult; Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Coronary Disease; Diabetic Angiopathies | 1982 |
Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Multicentre Acute Stroke Trial--Italy (MAST-I) Group.
Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Confidence Intervals; Drug Therapy, Combination; Femal | 1995 |
[Embolic complications in atrial fibrillation. Data of the Studio Italiano Fibrillation Atriale (SIFA)].
Topics: Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebrovascular Disorders | 1995 |
Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group.
Topics: Aged; Aspirin; Brain Ischemia; Carotid Arteries; Carotid Stenosis; Double-Blind Method; Female; Gast | 1995 |
Shear-induced platelet aggregation in cerebral ischemia.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; beta-Thromboglobulin; Brain Ischemia; Cerebral Infarction; | 1994 |
A prospective study of plasma homocyst(e)ine and risk of ischemic stroke.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alcohol Drinking; Aspirin; beta Carotene; Brain Ischemi | 1994 |
Failure of aspirin treatment after stroke.
Topics: Aged; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Female; | 1994 |
The efficacy and safety of ticlopidine and aspirin in non-whites: analysis of a patient subgroup from the Ticlopidine Aspirin Stroke Study.
Topics: Aged; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Double-Blind Method; Female; Follow-Up Stu | 1993 |
Volumetric measurement of multifocal brain lesions. Implications for treatment trials of vascular dementia and multiple sclerosis.
Topics: Aspirin; Brain; Brain Ischemia; Dementia, Vascular; Double-Blind Method; Female; Humans; Magnetic Re | 1996 |
Multicentre Acute Stroke Trial--Italy.
Topics: Acute Disease; Aspirin; Brain Ischemia; Humans; Italy; Risk Factors; Streptokinase; Thrombolytic The | 1996 |
Multicentre Acute Stroke Trial--Italy.
Topics: Acute Disease; Aspirin; Brain Ischemia; Humans; Italy; Research Design; Risk Factors; Streptokinase; | 1996 |
Multicentre Acute Stroke Trial--Italy.
Topics: Acute Disease; Aspirin; Brain Ischemia; Humans; Italy; Research Design; Risk Factors; Streptokinase; | 1996 |
Multicentre Acute Stroke Trial--Italy.
Topics: Acute Disease; Aspirin; Brain Ischemia; Humans; Italy; Risk Factors; Streptokinase; Thrombolytic The | 1996 |
Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia.
Topics: Aspirin; Brain Ischemia; Dose-Response Relationship, Drug; Humans; Risk Factors | 1996 |
[Low doses of acetylsalicylic acid effectively inhibits thrombocyte aggregation after ischemic stroke].
Topics: Aged; Aged, 80 and over; Aspirin; Blood Coagulation Tests; Brain Ischemia; Cerebrovascular Disorders | 1996 |
Study design of the International Stroke Trial (IST), baseline data, and outcome in 984 randomised patients in the pilot study.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Feasibility | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; C- | 1997 |
[Primary and secondary prevention of ischemic cerebrovascular accidents of arteriosclerosis by platelet inhibitors].
Topics: Arteriosclerosis; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Dipyridamole; Dose-Response Re | 1996 |
[Secondary prevention of ischemic strokes: effect of dosage of aspirin].
Topics: Aspirin; Brain Ischemia; Cerebral Hemorrhage; Dose-Response Relationship, Drug; Humans; Placebos; Pl | 1997 |
Effectiveness of low-dose ASA in prevention of secondary ischemic stroke, the ASA Study Group in Taiwan.
Topics: Aged; Aspirin; Brain Ischemia; Double-Blind Method; Female; Humans; Male; Middle Aged; Platelet Aggr | 1997 |
[Antithrombotic treatment of acute ischemic apoplexy].
Topics: Acute Disease; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Fibrinolytic Agents; Humans; Plat | 1997 |
A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Female; Hemorrhage; Humans; Male; Middle Aged; Platel | 1997 |
[Comparative study of the effect of low-dosage acetylsalicylic acid and triflusal in the prevention of cardiovascular events among young adults with ischemic cerebrovascular disease].
Topics: Adult; Aspirin; Brain Ischemia; Cardiovascular Diseases; Dose-Response Relationship, Drug; Double-Bl | 1997 |
[Prevention of vascular complications following cerebral ischemia of arterial origin; the ESPRIT trial: mild anticoagulant therapy, combination treatment with acetylsalicylic acid plus dipyridamole or treatment with acetylsalicylic acid alone?].
Topics: Adult; Aged; Anticoagulants; Antifibrinolytic Agents; Aspirin; Brain Ischemia; Cerebrovascular Disor | 1998 |
Aspirin use and incident stroke in the cardiovascular health study. CHS Collaborative Research Group.
Topics: Aged; Aspirin; Brain Ischemia; Cardiovascular Diseases; Cerebral Hemorrhage; Cerebrovascular Disorde | 1998 |
Prognosis of patients with symptomatic vertebral or basilar artery stenosis. The Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Study Group.
Topics: Aged; Anticoagulants; Aspirin; Basilar Artery; Brain Ischemia; Cerebellum; Cerebral Arteries; Cerebr | 1998 |
Risk of aspirin use plus thrombolysis after acute ischaemic stroke: a further MAST-I analysis. MAST-I Collaborative Group. Multicentre Acute Stroke Trial--Italy.
Topics: Acute Disease; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Drug Therapy, Combination; Fibrinolytic | 1998 |
Effect of diaspirin cross-linked hemoglobin on endothelin-1 and blood pressure in acute ischemic stroke in man.
Topics: Acute Disease; Aged; Aspirin; Blood Pressure; Blood Substitutes; Brain Ischemia; Dose-Response Relat | 1998 |
Exercise and risk of stroke in male physicians.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; beta Carotene; Brain Ischemia; Cerebral Hemorrhage; Cerebro | 1999 |
Second European Stroke Prevention Study: antiplatelet therapy is effective regardless of age. ESPS2 Working Group.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aspirin; Brain Ischemia; Cerebrovascular Disorders; | 1999 |
[Effects of the results of randomized trials on the tactics of management of patients with acute stroke].
Topics: Acute Disease; Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Fibrinolytic Agen | 1999 |
The effect of aspirin, ticlopidine and their low-dose combination on platelet aggregability in acute ischemic stroke: a short duration follow-up study.
Topics: Acute Disease; Aged; Aspirin; Brain Ischemia; Dose-Response Relationship, Drug; Drug Therapy, Combin | 1999 |
Controlled safety study of a hemoglobin-based oxygen carrier, DCLHb, in acute ischemic stroke.
Topics: Acute Disease; Aged; Aged, 80 and over; Aspirin; Blood Pressure; Blood Substitutes; Brain Ischemia; | 1999 |
Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators.
Topics: Aged; Alcohol Drinking; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebrovascula | 1999 |
Increased thromboxane biosynthesis is associated with poststroke dementia.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; Cerebral Hemorrhage; Chronic Disease; Co | 1999 |
Changes in levels of factor VII and protein S after acute myocardial infarction: effects of low-dose warfarin.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Antigens; Aspirin; Brain Ischemia; Death, Sudden, Ca | 1999 |
Low molecular-weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double-blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; | 2000 |
Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups.
Topics: Acute Disease; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrha | 2000 |
Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators.
Topics: Aspirin; Brain Ischemia; Cause of Death; Clopidogrel; Confidence Intervals; Double-Blind Method; Fem | 2000 |
Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation.
Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Drug Therapy | 2000 |
Comparison of the acute-phase response in patients with ischemic stroke treated with high-dose heparin or aspirin.
Topics: Acute-Phase Reaction; Aged; Analysis of Variance; Aspirin; Brain Ischemia; Female; Fibrinolytic Agen | 2000 |
Urinary 11-dehydro-thromboxane B(2) and coagulation activation markers measured within 24 h of human acute ischemic stroke.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Blood Coagulation; Brain Ischemi | 2001 |
Aspirin versus low-dose low-molecular-weight heparin: antithrombotic therapy in pediatric ischemic stroke patients: a prospective follow-up study.
Topics: Adolescent; Aspirin; Brain Ischemia; Child; Child, Preschool; Fibrinolytic Agents; Follow-Up Studies | 2001 |
A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Double-Blind Method; Female | 2001 |
Blood pressure and clinical outcomes in the International Stroke Trial.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Blood Pressure; Brain Ischemia; Cohort Studies; Fe | 2002 |
Use of platelet inhibitor drugs in peripheral and cerebral vascular disorders.
Topics: Arterial Occlusive Diseases; Aspirin; Blood Platelets; Brain Ischemia; Cell Survival; Clinical Trial | 1977 |
Aspirin for cerebral transient ischemic attacks or minor ischemic strokes.
Topics: Aspirin; Brain Ischemia; Double-Blind Method; Humans; Ischemic Attack, Transient; Myocardial Infarct | 1992 |
Second European Stroke Prevention Study. ESPS-2 Working Group.
Topics: Aspirin; Brain Ischemia; Computer Simulation; Dipyridamole; Double-Blind Method; Drug Administration | 1992 |
Aspirin for cerebral transient ischemic attacks or minor ischemic strokes.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient | 1992 |
The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and The International Study Group.
Topics: Aged; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cerebrovascular Disorders; Drug Therapy, Combina | 1992 |
The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results.
Topics: Aged; Aspirin; Brain Ischemia; Female; Follow-Up Studies; Humans; Ischemic Attack, Transient; Male; | 1991 |
[Clinical efficacy of picotamide].
Topics: Adult; Aged; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Female; Humans; Ischemic Attack, Tr | 1991 |
Secondary prevention of ischemic stroke with low dose acetylsalicylic acid.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Female; Follow-Up Studies; Humans; Male; Middle Ag | 1990 |
Effect of ticlopidine and aspirin on platelet ionized calcium in ischemic stroke.
Topics: Aspirin; Blood Platelets; Brain Ischemia; Calcium; Collagen; Humans; In Vitro Techniques; Platelet A | 1991 |
European Stroke Prevention Study. ESPS Group.
Topics: Age Factors; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cerebrovascular Disorders; Clinical T | 1990 |
Low-dose acetylsalicylic acid (ASA) plus dipyridamole versus dipyridamole alone in the prevention of stroke in patients with reversible ischemic attacks.
Topics: Adult; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Clinical Trials as Topic; Dipyridamole; D | 1987 |
[The extra-intracranial bypass operation: results of an international randomized study].
Topics: Aspirin; Brain Ischemia; Cerebral Angiography; Cerebral Revascularization; Humans; Ischemic Attack, | 1986 |
Asymptomatic carotid disease.
Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cerebrovascular Disor | 1985 |
465 other studies available for aspirin and Brain Ischemia
| Article | Year |
|---|---|
Antioxidative and thrombolytic TMP nitrone for treatment of ischemic stroke.
Topics: Animals; Antioxidants; Brain Ischemia; Fibrinolytic Agents; Nitrogen Oxides; Pyrazines; Rats; Stroke | 2008 |
Discovery of a potential anti-ischemic stroke agent: 3-pentylbenzo[c]thiophen-1(3H)-one.
Topics: Animals; Antioxidants; Brain; Brain Edema; Brain Infarction; Brain Ischemia; Fibrinolytic Agents; Fr | 2012 |
Novel potent antiplatelet thrombotic agent derived from biguanide for ischemic stroke.
Topics: Administration, Oral; Animals; Biguanides; Brain Ischemia; Dose-Response Relationship, Drug; Male; M | 2020 |
Low-dose rivaroxaban and aspirin among patients with peripheral artery disease: a meta-analysis of the COMPASS and VOYAGER trials.
Topics: Aspirin; Brain Ischemia; Drug Therapy, Combination; Factor Xa Inhibitors; Fibrinolytic Agents; Hemor | 2022 |
Relation of Pre-Stroke Aspirin Use With Cerebral Infarct Volume and Functional Outcomes.
Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Cerebral Infarction; Female; Fibr | 2021 |
Serum thromboxane B2 but not soluble P-selectin levels identify ischemic stroke patients with persistent platelet reactivity while on aspirin therapy.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Stroke; P-Selectin; Thromboxane B2 | 2021 |
Dual Antiplatelet Therapy Plus Argatroban Prevents Early Neurological Deterioration in Branch Atherosclerosis Disease.
Topics: Arginine; Aspirin; Atherosclerosis; Brain Ischemia; Clopidogrel; Humans; Pipecolic Acids; Platelet A | 2022 |
Dual versus triple antithrombotic therapy after percutaneous coronary intervention: the prospective multicentre WOEST 2 Study.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Drug Therapy, Combination; Fibrinolyti | 2022 |
Dual antiplatelet use in the management of COVID-19 associated acute ischemic stroke reocclusion.
Topics: Aspirin; Brain Ischemia; COVID-19; Humans; Ischemic Stroke; Middle Aged; Retrospective Studies; SARS | 2023 |
Incidence of nonvalvular atrial fibrillation and oral anticoagulant prescribing in England, 2009 to 2019: A cohort study.
Topics: Administration, Oral; Adolescent; Adult; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemi | 2022 |
Non-vitamin K oral anticoagulant compared with aspirin may not significantly reduce the rate of ischaemic stroke in patients with mixed cardiovascular disease in sinus rhythm.
Topics: Administration, Oral; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cardiovascular D | 2022 |
Coexistence of SARS-CoV-2 and cerebrovascular diseases: does COVID-19 positivity trigger cerebrovascular pathologies?
Topics: Aspirin; Brain Ischemia; Cerebrovascular Disorders; Clopidogrel; COVID-19; Enoxaparin; Humans; Manni | 2022 |
Assessment of on-treatment platelet reactivity at high and low shear stress and platelet activation status after the addition of dipyridamole to aspirin in the early and late phases after TIA and ischaemic stroke.
Topics: Adenosine Diphosphate; Aspirin; Blood Platelets; Brain Ischemia; Dipyridamole; Humans; Ischemic Atta | 2022 |
Determining the chemical profile of Caragana jubata (Pall.) Poir. by UPLC-QTOF-MS analysis and evaluating its anti-ischemic stroke effects.
Topics: Animals; Aspirin; Brain Ischemia; Caragana; Infarction, Middle Cerebral Artery; Ischemic Stroke; Pla | 2023 |
Intravenous thrombolysis versus antiplatelet therapy in minor stroke patients with large vessel occlusion.
Topics: Aspirin; Brain Ischemia; Cerebral Hemorrhage; Fibrinolytic Agents; Humans; Platelet Aggregation Inhi | 2023 |
In-Hospital Aspirin Dose as a Risk Factor for Hemorrhagic Transformation in Patients Not Treated With Thrombolysis.
Topics: Aspirin; Brain Ischemia; Cerebral Hemorrhage; Hospitals; Humans; Ischemic Stroke; Retrospective Stud | 2023 |
Comparative effectiveness of clopidogrel versus aspirin as a maintenance monotherapy 1 year after coronary artery bypass grafting.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Humans; Pla | 2023 |
Efficacy and Prognosis of Adjuvant Argatroban Treatment in Acute Ischemic Stroke Patients with Early Neurological Deterioration.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Stroke; Prognosis; Stroke; Treatment Outcome | 2023 |
Tirofiban in the treatment of cancer-associated ischemic stroke.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Stroke; Neoplasms; Retrospective Studies; Stroke; Tirofiba | 2023 |
Safety and Efficacy of Baseline Antiplatelet Treatment in Patients Undergoing Mechanical Thrombectomy for Ischemic Stroke: Antiplatelets Before Mechanical Thrombectomy.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Intracranial Hemorrhages; Ischemic Stroke; Mechanical | 2023 |
Pharmacological Effects of a New Soluble Guanylate Cyclase Stimulator in Experimental Ischemic Stroke.
Topics: Animals; Aspirin; Brain Ischemia; Cerebral Infarction; Ischemic Stroke; Platelet Aggregation; Platel | 2023 |
Formulation of aspirin nanoparticles using solvent evaporation method and in vivo evaluation of its antithrombotic effect.
Topics: Animals; Antioxidants; Aspirin; Brain Ischemia; Drug Carriers; Fibrinolytic Agents; Nanoparticles; P | 2023 |
Review: After stroke or TIA, adding clopidogrel to aspirin for ≤ 1 month reduces recurrence and MACE.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhib | 2019 |
Aspirin better than clopidogrel on major adverse cardiovascular events reduction after ischemic stroke: A retrospective nationwide cohort study.
Topics: Aged; Aspirin; Brain Ischemia; Cardiovascular Diseases; Cerebral Hemorrhage; Clopidogrel; Female; Ga | 2019 |
MRI-based thrombolytic therapy in patients with acute ischemic stroke presenting with a low NIHSS.
Topics: Aged; Aspirin; Brain Ischemia; Female; Fibrinolytic Agents; Humans; Intracranial Hemorrhages; Magnet | 2019 |
Relationship between 'on-treatment platelet reactivity', shear stress, and micro-embolic signals in asymptomatic and symptomatic carotid stenosis.
Topics: Aged; Aspirin; Blood Platelets; Brain Ischemia; Carotid Stenosis; Female; Humans; Intracranial Embol | 2020 |
Intensive antiplatelet therapy with three agents does not reduce risk of another stroke.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Humans; Platelet Aggregation Inhibitors; Stroke | 2020 |
Dual Antiplatelet Therapy after Intravenous Thrombolysis for Acute Minor Ischemic Stroke.
Topics: Administration, Intravenous; Aged; Aspirin; Brain Ischemia; Clopidogrel; Dual Anti-Platelet Therapy; | 2019 |
Aspirin plus clopidogrel versus aspirin Mono-Therapy for ischemic stroke.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Stroke; Ticlopidine | 2020 |
Association of platelet-derived microvesicles with high on-treatment platelet reactivity in convalescent ischemic stroke patients treated with acetylsalicylic acid
Topics: Aspirin; Blood Platelets; Brain Ischemia; Cell-Derived Microparticles; Humans; Stroke | 2019 |
Risk factors for severe cranial ischaemic complications in giant cell arteritis.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischem | 2020 |
Haemorrhagic transformation following ischaemic stroke: A retrospective study.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Female; Hemorrhage; Humans; Intr | 2020 |
Ischemic and Bleeding Events Among Patients With Acute Coronary Syndrome Associated With Low-Dose Prasugrel vs Standard-Dose Clopidogrel Treatment.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Case-Control Studies; Clo | 2020 |
Preventive Effects of Neuroprotective Agents in a Neonatal Rat of Photothrombotic Stroke Model.
Topics: Animals; Animals, Newborn; Aspirin; Brain Ischemia; Clopidogrel; Disease Models, Animal; Inflammatio | 2020 |
Cost-utility of ticagrelor plus aspirin in diabetic patients with stable coronary artery disease.
Topics: Aspirin; Brain Ischemia; Coronary Artery Disease; Diabetes Mellitus; Humans; Percutaneous Coronary I | 2021 |
[In patient with symptomatic peripheral arterial disease who had undergone lower-extremity revascularization, does rivaroxaban 2.5 mg twice daily plus aspirin reduce the composite risk of acute limb ischemia, major amputation for vascular causes, myocardi
Topics: Amputation, Surgical; Aspirin; Brain Ischemia; Chocolate; Cysts; Humans; Ischemia; Ischemic Stroke; | 2020 |
Safety and efficacy of low-dose aspirin in ischemic stroke patients with different G6PD conditions.
Topics: Aspirin; Brain Ischemia; Cohort Studies; Drug Therapy, Combination; Glucosephosphate Dehydrogenase; | 2021 |
Aspirin reduces cardiovascular events in patients with pneumonia: a prior event rate ratio analysis in a large primary care database.
Topics: Aged; Aspirin; Brain Ischemia; Humans; Platelet Aggregation Inhibitors; Pneumonia; Primary Health Ca | 2021 |
Not all aspirin products have equivalent antiplatelet efficacy-Aspirin formulated with magnesium stearate is less effective in preventing ischemic stroke.
Topics: Aged; Aspirin; Brain Ischemia; Drug Therapy, Combination; Female; Humans; Ischemic Stroke; Male; Pla | 2020 |
Clopidogrel increases risk of pneumonia compared with aspirin in acute ischemic minor stroke patients.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; | 2021 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient; Stroke; Ticagrelor | 2020 |
Ticagrelor and Aspirin or Aspirin Alone in Acute Ischemic Stroke or TIA. Reply.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient; Stroke; Ticagrelor | 2020 |
In acute ischemic stroke or TIA, adding ticagrelor to aspirin reduced stroke or death and increased severe bleeding.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient; Ischemic Stroke; Stroke; Ticagrelor | 2020 |
Efficacy of aspirin, clopidogrel, and ticlopidine in stroke prevention: A population-based case-cohort study in Taiwan.
Topics: Adult; Aged; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Female; Humans; Male; Middle Aged | 2020 |
2019 novel coronavirus disease with secondary ischemic stroke: two case reports.
Topics: Aspirin; Atorvastatin; Brain Ischemia; COVID-19; Fibrinolytic Agents; Humans; Ischemic Stroke; Male; | 2021 |
Pretreatment of Indobufen and Aspirin and their Combinations with Clopidogrel or Ticagrelor Alleviates Inflammasome Mediated Pyroptosis Via Inhibiting NF-κB/NLRP3 Pathway in Ischemic Stroke.
Topics: Animals; Aspirin; Brain Ischemia; Clopidogrel; Inflammasomes; Ischemic Stroke; Isoindoles; NF-kappa | 2021 |
Aspirin monotherapy in the treatment of distal intracranial aneurysms with a surface modified flow diverter: a pilot study.
Topics: Adult; Aged; Aspirin; Brain Ischemia; Embolization, Therapeutic; Endovascular Procedures; Female; Hu | 2021 |
Anabolic steroid use and ischaemic stroke in a young fitness enthusiast.
Topics: Administration, Intravenous; Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agent | 2021 |
Non-persistence with anti-platelet therapy and long-term mortality after ischemic stroke: A nationwide study.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Brain Ischemia; Cardiovascular Diseases; C | 2021 |
Antiplatelet therapy in secondary prevention of non-embolic ischaemic stroke.
Topics: Aspirin; Brain Ischemia; Drug Therapy, Combination; Humans; Ischemic Stroke; Platelet Aggregation In | 2020 |
Statin but not aspirin treatment is associated with reduced cardiovascular risk in patients with diabetes without obstructive coronary artery disease: a cohort study from the Western Denmark Heart Registry.
Topics: Aspirin; Brain Ischemia; Cardiovascular Diseases; Cohort Studies; Coronary Artery Disease; Denmark; | 2022 |
Aspirin withdrawal: A risk factor for ischemic stroke severity.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Stroke; Risk Factors; Stroke | 2021 |
Association between PTGS1 polymorphisms and functional outcomes in Chinese patients with stroke during aspirin therapy: Interaction with smoking.
Topics: Asian People; Aspirin; Brain Ischemia; China; Cyclooxygenase 1; Female; Fibrinolytic Agents; Follow- | 2017 |
Numerous Fusiform and Saccular Cerebral Aneurysms in Central Nervous System Lupus Presenting with Ischemic Stroke.
Topics: Adult; Antihypertensive Agents; Aspirin; Brain Ischemia; Cerebral Angiography; Diffusion Magnetic Re | 2017 |
Platelet Function Testing in Patients with Acute Ischemic Stroke: An Observational Study.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Platelets; Brain Ischemia; Chi-Square Distribution; Clopidog | 2017 |
High On-Treatment Platelet Reactivity to Adenosine Diphosphate Predicts Ischemic Events of Minor Stroke and Transient Ischemic Attack.
Topics: Adenosine Diphosphate; Adult; Aged; Aspirin; Blood Platelets; Brain Ischemia; Clopidogrel; Drug Resi | 2017 |
Aspirin Versus Clopidogrel for Type 2 Diabetic Patients with First-Ever Noncardioembolic Acute Ischemic Stroke: Ten-Year Survival Data from the Athens Stroke Outcome Project.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Chi-Square Distribution; Clopidogrel; Diabetes Mel | 2017 |
Reduced Antiplatelet Effect of Aspirin Does Not Predict Cardiovascular Events in Patients With Stable Coronary Artery Disease.
Topics: Aged; Aspirin; Brain Ischemia; Coronary Artery Disease; Coronary Thrombosis; Drug Resistance; Female | 2017 |
Emergent loading dose of antiplatelets for stenting after IV rt-PA in acute ischemic stroke: a feasibility study.
Topics: Administration, Intravenous; Aged; Aspirin; Brain Ischemia; Clopidogrel; Computed Tomography Angiogr | 2018 |
Aspirin resistance are associated with long-term recurrent stroke events after ischaemic stroke.
Topics: Aged; Aspirin; Brain Ischemia; Drug Resistance; Female; Follow-Up Studies; Humans; Logistic Models; | 2017 |
Beneficial Effect of Beraprost Sodium Plus Aspirin in the Treatment of Acute Ischemic Stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Infarction; Drug Therapy, Combination; Ep | 2017 |
STARTING-SICH Nomogram to Predict Symptomatic Intracerebral Hemorrhage After Intravenous Thrombolysis for Stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Female; Fibrinol | 2018 |
Internal Carotid Artery Web as the Cause of Recurrent Cryptogenic Ischemic Stroke.
Topics: Adult; Aspirin; Atorvastatin; Biopsy; Brain Ischemia; Cardiovascular Agents; Carotid Artery Diseases | 2018 |
Ischaemic stroke, haemorrhage, and mortality in older patients with chronic kidney disease newly started on anticoagulation for atrial fibrillation: a population based study from UK primary care.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; England; Fe | 2018 |
Charting the Course: Risk Scores for Major Bleeding in Transient Ischemic Attack and Ischemic Stroke.
Topics: Aspirin; Brain Ischemia; Hemorrhage; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibi | 2018 |
Monoacylglycerol lipase inhibitor, JZL-184, confers neuroprotection in the mice middle cerebral artery occlusion model of stroke.
Topics: Animals; Aspirin; Behavior, Animal; Benzodioxoles; Brain; Brain Edema; Brain Ischemia; Disease Model | 2018 |
Pre-admission use of platelet inhibitors and short-term stroke mortality: a population-based cohort study.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Denmark; Drug Th | 2018 |
Cerebrovascular Accidents During Mechanical Circulatory Support: New Predictors of Ischemic and Hemorrhagic Strokes and Outcome.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Female; Heart Failure; Heart-Ass | 2018 |
Bilateral visual loss and cerebral infarction after spleen embolization in a trauma patient with idiopathic thrombocytopenic purpura: A case report.
Topics: Adult; Aspirin; Blindness, Cortical; Brain Ischemia; Embolization, Therapeutic; Female; Humans; Magn | 2018 |
Monotherapy of acetylsalicylic acid or warfarin for prevention of ischemic stroke in low-risk atrial fibrillation: A Easter Asian population-based study.
Topics: Adult; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Comparative Effectiveness | 2019 |
Myocardial Infarction and Ischemic Stroke after Exacerbations of Chronic Obstructive Pulmonary Disease.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Disease Progression; Female; Humans; Male; Myocard | 2018 |
Management of acute tandem occlusions: Stent-retriever thrombectomy with emergency stenting or angioplasty.
Topics: Aged; Angioplasty; Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cl | 2018 |
Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; China; Clinical Decision-Making; Clopidogrel; Cyto | 2018 |
Clinical Significance of Acute and Serial Platelet Function Testing in Acute Ischemic Stroke.
Topics: Acute Disease; Aged; Aspirin; Blood Platelets; Brain Ischemia; Clopidogrel; Female; Humans; Male; Pl | 2018 |
Are Patients Getting Their Aspirin's Worth in Ischemic Stroke?
Topics: Aspirin; Brain Ischemia; Humans; Platelet Aggregation Inhibitors; Platelet Function Tests; Stroke | 2018 |
Positive trials in ischaemic stroke reported at ESOC 2018.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Ischemic Attack, Transient; Stroke | 2018 |
Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation: From the ADAPT-DES Study.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; Clopidogrel; Coronary Artery Disease; Dr | 2018 |
What now for embolic stroke of undetermined source?
Topics: Anticoagulants; Aspirin; Brain Ischemia; Clinical Trials as Topic; Humans; Intracranial Embolism; Ri | 2018 |
Aspirin resistance predicts unfavorable functional outcome in acute ischemic stroke patients.
Topics: Aged; Aspirin; Brain Ischemia; Drug Resistance; Female; Follow-Up Studies; Humans; Male; Middle Aged | 2018 |
Argatroban plus aspirin versus aspirin in acute ischemic stroke.
Topics: Arginine; Aspirin; Brain Ischemia; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fema | 2018 |
Effect of Antiplatelet Therapy (Aspirin + Dipyridamole Versus Clopidogrel) on Mortality Outcome in Ischemic Stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combinati | 2018 |
The safety of triple antiplatelet therapy under thromboelastography guidance in patients undergoing stenting for ischemic cerebrovascular disease.
Topics: Aged; Aspirin; Brain Ischemia; Cilostazol; Clopidogrel; Drug Therapy, Combination; Female; Hemorrhag | 2019 |
Opportunities for intervention: stroke treatments, disability and mortality in urban Tanzania.
Topics: Aged; Antihypertensive Agents; Aspirin; Brain Ischemia; Cohort Studies; Deglutition Disorders; Disab | 2019 |
Ischemic stroke following a wasp sting - a rare complication: a case report.
Topics: Aged; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Atorvasta | 2018 |
Antiplatelet Agents in Acute Stroke and TIA.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke | 2018 |
Antiplatelet Agents in Acute Stroke and TIA.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke | 2018 |
Antiplatelet Agents in Acute Stroke and TIA.
Topics: Aspirin; Brain Ischemia; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhibitors; Stroke | 2018 |
Prestroke Aspirin Use is Associated with Clinical Outcomes in Ischemic Stroke Patients with Atherothrombosis, Small Artery Disease, and Cardioembolic Stroke.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atherosclerosis; Biomarkers; Brain Ischemia; | 2019 |
Primary stroke centers: are they worthy of an upgrade?
Topics: Aspirin; Brain Ischemia; Cardiac Resynchronization Therapy; Humans; Stroke; Tissue Plasminogen Activ | 2019 |
Post-treatment Antiplatelet Therapy Reduces Risk for Delayed Cerebral Ischemia due to Aneurysmal Subarachnoid Hemorrhage.
Topics: Adult; Aged; Aspirin; Brain Ischemia; Case-Control Studies; Clopidogrel; Cohort Studies; Female; Hum | 2019 |
Safety and efficacy of cangrelor in acute stenting for the treatment of cerebrovascular pathology: preliminary experience in a single-center pilot study.
Topics: Adenosine Monophosphate; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Drug Therapy, Comb | 2019 |
Dual antiplatelet therapy with aspirin and clopidogrel for acute high risk transient ischaemic attack and minor ischaemic stroke: a clinical practice guideline.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Ischemic Attack, Transient; Platelet Aggregation Inhib | 2018 |
Twenty-and-a-half syndrome: a case report.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atorvast | 2019 |
Platelet Surface CD62p and Serum Vitamin D Levels are Associated with Clopidogrel Resistance in Chinese Patients with Ischemic Stroke.
Topics: Aged; Asian People; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; China; Clopidogrel; Drug R | 2019 |
Association of Aspirin Resistance with Increased Mortality in Ischemic Stroke.
Topics: Aged; Aspirin; Brain Ischemia; Drug Resistance; Female; Humans; Male; Middle Aged; Mortality; Outcom | 2019 |
Dual Versus Mono Antiplatelet Therapy in Large Atherosclerotic Stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Clopidogrel; Dual Anti-Platelet T | 2019 |
Dual Versus Mono Antiplatelet Therapy in Large Atherosclerotic Stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Clopidogrel; Dual Anti-Platelet T | 2019 |
Dual Versus Mono Antiplatelet Therapy in Large Atherosclerotic Stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Clopidogrel; Dual Anti-Platelet T | 2019 |
Dual Versus Mono Antiplatelet Therapy in Large Atherosclerotic Stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Brain Ischemia; Clopidogrel; Dual Anti-Platelet T | 2019 |
Guideline: Starting dual antiplatelet therapy ≤ 24 h after high-risk TIA or minor ischemic stroke is recommended.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Therapy, Combination; Humans; Ischemic Attack, Transient; | 2019 |
Hemoglobin Southampton complicated by cerebral ischemia, moyamoya, and hydroxyurea-induced methemoglobinemia.
Topics: Aspirin; Brain Ischemia; Child; Female; Hemoglobinopathies; Hemoglobins, Abnormal; Humans; Hydroxyur | 2019 |
Collagen-Induced Platelet Aggregates, Diabetes, and Aspirin Therapy Predict Clinical Outcomes in Acute Ischemic Stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; Comorbidity; Cross-Se | 2019 |
Aspirin nonresponders in patients with ischaemic stroke.
Topics: Aspirin; Brain Ischemia; Female; Humans; Male; Middle Aged; Multivariate Analysis; Platelet Aggregat | 2013 |
Aspirin resistance in patients with hemodynamic cerebral ischemia undergoing extracranial-intracranial bypass surgery.
Topics: Adolescent; Adult; Angiography, Digital Subtraction; Aspirin; Blood Coagulation Disorders; Brain Isc | 2013 |
Associations of durations of antiplatelet use and vascular risk factors with the presence of cerebral microbleeds.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Chi-Square Distribution; Como | 2014 |
Carotid artery stenting outcomes: do they correlate with antiplatelet response assays?
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Carotid Stenosis; Cerebral Revascularizatio | 2014 |
Multiple electrode aggregometry in antiplatelet-related intracerebral haemorrhage.
Topics: Adult; Aspirin; Blood Platelets; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Humans; Male; Pla | 2013 |
Early and late mortality of spontaneous hemorrhagic transformation of ischemic stroke.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Cohort Studies; Disease Progressio | 2014 |
"Aspirin resistance" in ischemic stroke: insights using short thrombelastography.
Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Brain Ischemia; Cytokines; Drug Resistance; Female; Hu | 2013 |
Stroke in heart failure in sinus rhythm: the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction trial.
Topics: Anticoagulants; Aspirin; Brain Damage, Chronic; Brain Ischemia; Cerebral Hemorrhage; Heart Failure; | 2013 |
Antiplatelet loading improves behavioral outcome in a rabbit model of stroke.
Topics: Adenosine Diphosphate; Animals; Arachidonic Acid; Aspirin; Blood Platelets; Brain Ischemia; Collagen | 2013 |
PHACES syndrome with moyamoya vasculopathy - a case report.
Topics: Anticonvulsants; Aortic Coarctation; Aspirin; Brain Ischemia; Child, Preschool; Eye Abnormalities; F | 2013 |
Factors influencing multiplate whole blood impedance platelet aggregometry measurements, during aspirin treatment in acute ischemic stroke: a pilot study.
Topics: Adult; Aged; Aspirin; Blood Platelets; Brain Ischemia; C-Reactive Protein; Cholesterol, HDL; Clopido | 2013 |
Atrial fibrillation patients do not benefit from acetylsalicylic acid.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Brain Ischemia; Cohort Studies; Female; Gastr | 2014 |
Aspirin resistant patients with recent ischemic stroke.
Topics: Aged; Aspirin; Brain Ischemia; Drug Resistance; Female; Humans; Platelet Aggregation Inhibitors; Rec | 2014 |
Platelet inhibition by adjunctive cilostazol suppresses the frequency of cerebral ischemic lesions after carotid artery stenting in patients with carotid artery stenosis.
Topics: Aged; Angioplasty; Aspirin; Brain Ischemia; Carotid Stenosis; Cilostazol; Clopidogrel; Diffusion Mag | 2014 |
Acetylsalicylic acid for stroke prevention in atrial fibrillation: a conspiracy that needs to end?
Topics: Aspirin; Atrial Fibrillation; Brain Ischemia; Female; Humans; Male; Platelet Aggregation Inhibitors; | 2014 |
Interaction between vWF levels and aspirin resistance in ischemic stroke patients.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Case-Control Studies; Female; Humans; Male; | 2013 |
LOAD: a pilot study of the safety of loading of aspirin & clopidogrel in acute ischaemic stroke and transient ischaemic attack. Is the loading dose of aspirin and clopidogrel a good alternative for patients with acute ischaemic stroke and TIA? How this wi
Topics: Aspirin; Brain Ischemia; Female; Humans; Ischemic Attack, Transient; Male; Ticlopidine | 2013 |
Antithrombotic drugs and ischaemic stroke.
Topics: Aspirin; Brain Ischemia; Fibrinolytic Agents; Humans; Stroke | 2013 |
Switching from aspirin to clopidogrel in patients with aspirin resistance after an ischemic stroke. Is it a good solution?
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Drug Resistance; Drug Substitution; F | 2014 |
Effectiveness and safety of antiplatelet in stroke patients with end-stage renal disease undergoing dialysis.
Topics: Aged; Aspirin; Brain Ischemia; Clopidogrel; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate | 2014 |
[Bullous hemorrhagic dermatosis induced by heparin: description of 2 new cases].
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Drug Eruptions; Enoxaparin; Hemo | 2014 |
Neuroprotective effect of guggulipid alone and in combination with aspirin on middle cerebral artery occlusion (MCAO) model of focal cerebral ischemia in rats.
Topics: Acetylcholinesterase; Animals; Aspirin; Brain Ischemia; Catalase; Commiphora; Cyclooxygenase Inhibit | 2014 |
Dipyridamole-induced headache and lower recurrence risk in secondary prevention of ischaemic stroke: a post hoc analysis.
Topics: Aged; Aspirin; Brain Ischemia; Delayed-Action Preparations; Dipyridamole; Drug Therapy, Combination; | 2014 |
Aspirin for secondary prevention after stroke of unknown etiology in resource-limited settings.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cost-Benefit Analysis; | 2014 |
Thrombolysis May Reduce the Incidence/Extent of Postprocedural Ischemic Strokes Associated With Carotid Artery Stenting: A Hypothesis.
Topics: Aspirin; Brain Ischemia; Carotid Stenosis; Cerebral Hemorrhage; Fibrinolytic Agents; Humans; Hydroxy | 2015 |
Involvement of Arg306 mutation in factor V gene in two young men with ischemic stroke.
Topics: Anticholesteremic Agents; Arginine; Aspirin; Brain Ischemia; DNA Mutational Analysis; Factor V; Fibr | 2014 |
The mystery of recurrent idiopathic cerebrovascular and coronary arterial thrombosis.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Coronary Thrombosis; Diagnosis, Differential; Electrocardio | 2014 |
Prospective evaluation of blood coagulability and effect of treatment in patients with stroke using rotational thromboelastometry.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Coagulation; Brain Ischemia; Female; Fibrinolytic Agents; Hu | 2015 |
The effect of different doses and different routes of acetylsalicylic acid administration on platelet aggregation in healthy volunteers and ischemic stroke patients.
Topics: Adult; Aged; Aspirin; Brain Ischemia; Dose-Response Relationship, Drug; Drug Administration Routes; | 2015 |
Pathophysiologic, rather than laboratory-defined resistance drives aspirin failure in ischemic stroke.
Topics: Aged; Aspirin; Blood Platelets; Brain Ischemia; Cohort Studies; Drug Resistance; Female; Humans; In | 2015 |
Can the previous therapeutic control of the main risk factors of cerebrovascular disease influence the acetylsalicylic Acid-nonresponsive status in acute ischemic stroke patients? Results from a portuguese prospective cohort study.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Cohort Studies; Female; | 2015 |
Pediatric Acute Ischemic Cerebral Vascular Accidents: A Case Report.
Topics: Aspirin; Brain Ischemia; Child; Diffusion Magnetic Resonance Imaging; Female; Heparin; Humans; Strok | 2017 |
Coadministration of the Human Umbilical Cord Matrix-Derived Mesenchymal Cells and Aspirin Alters Postischemic Brain Injury in Rats.
Topics: Adipogenesis; Analysis of Variance; Animals; Aspirin; Brain Injuries; Brain Ischemia; Cell Different | 2015 |
Clinical Implications of Changes in Individual Platelet Reactivity to Aspirin Over Time in Acute Ischemic Stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Platelets; Brain Ischemia; Female; Follow-Up Studies; Humans | 2015 |
Adequacy of preadmission oral anticoagulation with vitamin K antagonists and ischemic stroke severity and outcome in patients with atrial fibrillation.
Topics: Acenocoumarol; Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibril | 2016 |
Underutilisation of Guideline-based Therapy Primary Prevention among Patients Presenting with AF-related Ischaemic Stroke.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; | 2015 |
[Interaction of the Humoral Agonist During the Platelets Activation in Patients with Chronic Cerebral Ischemia].
Topics: Adenosine Diphosphate; Adult; Aspirin; Blood Platelets; Brain; Brain Ischemia; Chronic Disease; Epin | 2015 |
Comparison of antiplatelet regimens in secondary stroke prevention: a nationwide cohort study.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Cohort Studies; | 2015 |
The Interplay between Stroke Severity, Antiplatelet Use, and Aspirin Resistance in Ischemic Stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Female; Humans; Magnetic Resonance Imaging; Male; | 2016 |
Relationship between Inflammation and Aspirin and Clopidogrel Antiplatelet Responses in Acute Ischemic Stroke.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Biomarkers; Brain Ischemia; CD40 Ligand; Clopidogrel; Femal | 2016 |
Different Antiplatelet Strategies in Patients With New Ischemic Stroke While Taking Aspirin.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Drug Therapy, Combination; Female; Follow-Up Studi | 2016 |
Comparative Effectiveness of Prestroke Aspirin on Stroke Severity and Outcome.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Female; Humans; Intracranial Hemorrhages; Male; Mi | 2016 |
Treatment with Clopidogrel Prior to Acute Non-Cardioembolic Ischemic Stroke Attenuates Stroke Severity.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Chi-Square Distribution; Clopidogrel; Disability E | 2016 |
Continuation and adherence rates on initially-prescribed intensive secondary prevention therapy after Rapid Access Stroke Prevention (RASP) service assessment.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Brain Ischemia; Clopidogrel; Dipyr | 2016 |
Aspirin resistance is associated with increased stroke severity and infarct volume.
Topics: Aged; Aspirin; Brain; Brain Ischemia; Diffusion Magnetic Resonance Imaging; Drug Resistance; Female; | 2016 |
Extended use of clopidogrel and aspirin after ischemic stroke.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Administration Schedule; Humans; Platelet Aggregation Inh | 2016 |
Protective Effect of Guggulipid in High Fat Diet and Middle Cerebral Artery Occlusion (MCAO) Induced Ischemic Cerebral Injury in Rats.
Topics: Animals; Aspirin; Atorvastatin; Brain; Brain Ischemia; Catalase; Commiphora; Diet, High-Fat; Drug Th | 2016 |
Failure of old and new anticoagulants to prevent ischemic stroke in high-risk atrial fibrillation: a case report.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Female; Humans; Rivaroxaban; Str | 2016 |
Antiplatelet drug resistance is associated with early neurological deterioration in acute minor ischemic stroke in the Chinese population.
Topics: Aged; Aged, 80 and over; Asian People; Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Male; M | 2016 |
Dual Antiplatelet Therapy in the Prevention of Recurrent Ischemic Events.
Topics: Aspirin; Brain Ischemia; Drug Therapy, Combination; Humans; Ischemia; Platelet Aggregation Inhibitor | 2016 |
High platelet reactivity on aspirin in patients with acute ST elevation myocardial infarction.
Topics: Acute Disease; Adenosine; Aspirin; Blood Platelets; Brain Ischemia; Cardiovascular Diseases; Clopido | 2016 |
PPM1A Methylation Is Associated With Vascular Recurrence in Aspirin-Treated Patients.
Topics: Aspirin; Brain Ischemia; CpG Islands; DNA Methylation; Follow-Up Studies; Genetic Association Studie | 2016 |
To Load or Not to Load? Aspirin Loading in Acute Ischemic Stroke: A Study of Clinical Outcomes.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cardiovascular Agents; Disability Evaluation; Dise | 2016 |
miR-145 mediated the role of aspirin in resisting VSMCs proliferation and anti-inflammation through CD40.
Topics: Aspirin; Atherosclerosis; Brain Ischemia; CD40 Antigens; Cell Proliferation; Female; Flow Cytometry; | 2016 |
Antecedent Aspirin Use Is Associated with Less Severe Symptoms on Admission for Ischemic Stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Atrial Fibrillation; Biomarkers; Blood Glucose; Blood Pressure; Br | 2016 |
Associations of MDR1, TBXA2R, PLA2G7, and PEAR1 genetic polymorphisms with the platelet activity in Chinese ischemic stroke patients receiving aspirin therapy.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Aged; Asian People; Aspirin; ATP Binding Cassette Tr | 2016 |
Statin and Aspirin Pretreatment Are Associated with Lower Neurological Deterioration and Platelet Activity in Patients with Acute Ischemic Stroke.
Topics: Aged; Aspirin; Brain Ischemia; Disability Evaluation; Drug Therapy, Combination; Female; Humans; Hyd | 2017 |
Successful drug-coated balloon angioplasty and single anti-platelet therapy to treat an ischaemic stroke patient with haemorrhage and acute coronary syndrome.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon; Aspirin; Brain; Brain Ischemia; Coronary Angiography; | 2016 |
Anticoagulation After Biological Aortic Valve Replacement: Is There An Optimal Regimen?
Topics: Aged; Anticoagulants; Aortic Valve; Aspirin; Bioprosthesis; Blood Coagulation; Brain Ischemia; Femal | 2016 |
Aspirin Resistance Predicts Adverse Cardiovascular Events in Patients with Symptomatic Peripheral Artery Disease.
Topics: Aged; Aspirin; Brain Ischemia; Chi-Square Distribution; Disease-Free Survival; Drug Resistance; Fema | 2016 |
Secondary Prevention of Childhood Arterial Ischemic Stroke.
Topics: Aspirin; Belgium; Brain Ischemia; Child; France; Guideline Adherence; Health Care Surveys; Humans; P | 2017 |
Clopidogrel and ischemic stroke outcomes by smoking status: Smoker's paradox?
Topics: Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Infarction; Plat | 2017 |
Dual Antiplatelet Therapy and Clinical Outcomes after Coronary Drug-Eluting Stent Implantation in Patients on Hemodialysis.
Topics: Aged; Aspirin; Brain Ischemia; Case-Control Studies; Clopidogrel; Coronary Artery Disease; Drug Ther | 2017 |
Neuroprotective effect of triflusal and its main metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid (HTB), in the postischemic brain.
Topics: Animals; Anti-Inflammatory Agents; Aspirin; Brain; Brain Ischemia; Cytokines; Infarction, Middle Cer | 2017 |
Association of genetic variant and platelet function in patients undergoing neuroendovascular stenting.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Aspirin; Brain Ischemia; Clopidogrel; Female; Genetic Varia | 2017 |
Mortality Following Cardiovascular and Bleeding Events Occurring Beyond 1 Year After Coronary Stenting: A Secondary Analysis of the Dual Antiplatelet Therapy (DAPT) Study.
Topics: Aged; Aspirin; Brain Ischemia; Coronary Artery Disease; Coronary Thrombosis; Drug Therapy, Combinati | 2017 |
Influence of acetylsalicylate on plasma lysophosphatidic acid level in patients with ischemic cerebral vascular diseases.
Topics: Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; Down-Regulation; Female; Humans; Lysophospholi | 2008 |
Current practice of antithrombotic treatment in ischemic stroke: a survey among Hungarian neurologists.
Topics: Adult; Aged; Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Prescriptions; | 2008 |
Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Evidence-Based Medici | 2008 |
Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; An | 2008 |
Variation in eicosanoid genes, non-fatal myocardial infarction and ischemic stroke.
Topics: Adult; Aged; Arachidonate Lipoxygenases; Aspirin; Brain Ischemia; Case-Control Studies; Cyclooxygena | 2009 |
ADP-induced platelet aggregation in acute ischemic stroke patients on aspirin therapy.
Topics: Acute Disease; Adenosine Diphosphate; Aged; Aspirin; Brain Ischemia; Clopidogrel; Drug Synergism; Dr | 2008 |
Aspirin attenuates cerebral ischemic injury in diabetic rats.
Topics: Animals; Aspirin; Blood Glucose; Brain Ischemia; Cerebral Infarction; Diabetes Mellitus, Experimenta | 2009 |
[Brain hypoperfusion revealed by an ocular ischemic syndrome].
Topics: Antihypertensive Agents; Aspirin; Atorvastatin; Brain Ischemia; Carotid Artery Thrombosis; Ciliary B | 2008 |
High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition.
Topics: Aged; Aged, 80 and over; Aspirin; Blood Platelets; Brain Ischemia; Cell Size; Female; Giant Cell Art | 2009 |
Prevention strategies of cardioembolic ischemic stroke in Chagas' disease.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Chagas Cardiomyopathy; Epidemiologic Methods; Female; Hemor | 2008 |
[Celiac disease and ischemic stroke].
Topics: Adult; Aspirin; Brain Ischemia; Celiac Disease; Female; Humans; Platelet Aggregation Inhibitors; Str | 2009 |
Resistance to acetylsalicylic acid in patients after ischemic stroke.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Brain Ischemia; Drug Resistance; Female; H | 2008 |
Facts and controversies of aspirin and clopidogrel therapy.
Topics: Acute Coronary Syndrome; Aspirin; Atherosclerosis; Blood Platelets; Brain Ischemia; Clopidogrel; Dos | 2009 |
Neuroprotective effects of Kangen-karyu on spatial memory impairment in an 8-arm radial maze and neuronal death in the hippocampal CA1 region induced by repeated cerebral ischemia in rats.
Topics: Animals; Aspirin; Brain Ischemia; Cell Death; Disease Models, Animal; Dose-Response Relationship, Dr | 2009 |
[Guidelines for the general management of patients with acute ischemic stroke].
Topics: Anticoagulants; Aspirin; Brain Ischemia; Fibrinolytic Agents; Humans; Inpatients; Stroke; Taiwan; Ti | 2008 |
Risk indicators for development of headache during dipyridamole treatment after cerebral ischaemia of arterial origin.
Topics: Aged; Aspirin; Brain Ischemia; Cerebral Arteries; Dipyridamole; Drug Therapy, Combination; Female; H | 2009 |
Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement.
Topics: Age Factors; Aged; Aspirin; Brain Ischemia; Cardiovascular Diseases; Cost of Illness; Female; Gastro | 2009 |
Aspirin vs anticoagulation in carotid artery dissection: a study of 298 patients.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Artery, Internal, Dissection; Female; Follow-Up Stu | 2009 |
Pretreatment with aspirin and etiology of first-ever ischemic stroke in young and middle-aged patients.
Topics: Adolescent; Adult; Aged; Aspirin; Brain Ischemia; Female; Humans; Logistic Models; Male; Middle Aged | 2009 |
Moyamoya disease in an 8-year-old boy presenting with weakness.
Topics: Anti-Inflammatory Agents; Aspirin; Attention Deficit Disorder with Hyperactivity; Brain Ischemia; Ch | 2009 |
Combined anti-platelet therapy with aspirin and clopidogrel: risk factor for thrombolysis-related intracerebral hemorrhage in acute ischemic stroke?
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Clopidogrel; Female; Fibrinol | 2009 |
The prescribing patterns of antithrombotic agents for prevention of recurrent ischemic stroke.
Topics: Adult; Aged; Aspirin; Brain Ischemia; Drug Utilization; Female; Fibrinolytic Agents; Humans; Male; M | 2009 |
Köhlmeier-Degos Disease (malignant atrophic papulosis) and neurologic involvement.
Topics: Adult; Aspirin; Brain Ischemia; Female; Fibrinolytic Agents; Humans; Malignant Atrophic Papulosis; T | 2009 |
Medical treatment of patients with intracranial atherosclerotic disease.
Topics: Anticoagulants; Aspirin; Atherosclerosis; Brain Ischemia; Cilostazol; Clopidogrel; Dipyridamole; Emb | 2009 |
Cilostazol, a phosphodiesterase inhibitor, attenuates photothrombotic focal ischemic brain injury in hypertensive rats.
Topics: Animals; Aspirin; Brain Ischemia; Cells, Cultured; Cerebrovascular Circulation; Cilostazol; Clopidog | 2010 |
The effect and safety of the antithrombotic therapies in patients with atrial fibrillation and CHADS score 1.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Female; Fibrinolytic Agents; Fol | 2010 |
Antiplatelet drugs for patients at high cardiovascular risk. Aspirin generally remains the best choice.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Atrial Fibrillation; Brain Ischemia; Clini | 2009 |
Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrh | 2010 |
[Cardiac workup after cerebral ischemia. Consensus paper of the Working Group on Heart and Brain of the German Cardiac Society and German Stroke Society].
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cardiovascular Diseases; Clopidogrel; | 2010 |
Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Fema | 2010 |
Protective effect of irbesartan, an angiotensin II receptor antagonist, alone and in combination with aspirin on middle cerebral artery occlusion model of focal cerebral ischemia in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Aspirin; Biphenyl Compounds; Brain I | 2011 |
Is higher serum total cholesterol level associated with better long-term functional outcomes after noncardioembolic ischemic stroke?
Topics: Aged; Aspirin; Brain Ischemia; Cholesterol; Cohort Studies; Female; Fibrinolytic Agents; Follow-Up S | 2010 |
Aspirin resistance and compliance with therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; Case-Control Studies; | 2011 |
Treatment of acute ischemic stroke in patients with cerebral microbleeds: a decision analysis.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Cerebral | 2011 |
Rapid change in prescribing behavior in hospitals participating in get with the guidelines-stroke after release of the management of atherothrombosis with clopidogrel in high-risk patients (MATCH) clinical trial results.
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; P | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Cohort Studies; Com | 2010 |
Is early antithrombotic therapy necessary after tissue mitral valve replacement?
Topics: Aged; Aged, 80 and over; Animals; Anticoagulants; Aspirin; Bioprosthesis; Brain Ischemia; Cattle; Ch | 2010 |
Effect of enoxaparin and aspirin on hemodynamic disturbances after global cerebral ischemia in rats.
Topics: Animals; Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Circulation; Enoxaparin; Hemodynam | 2010 |
[Reducing blood pressure, giving aspirin... What must (never) be done in V.a. stroke].
Topics: Antihypertensive Agents; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Heparin; Humans; Platelet Agg | 2010 |
[New options in the therapeutic management of acute ischaemic stroke. Good results with combined i. v. and i. a. lysis and mechanical thrombectomy].
Topics: Acute Disease; Adult; Aged; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cerebral Angiography; | 2010 |
[Aggregation activity of platelets in various periods of ischemic stroke].
Topics: Aged; Aspirin; Blood Coagulation Disorders; Blood Coagulation Tests; Brain Ischemia; Female; Humans; | 2010 |
Antiplatelet therapy effectively reduces plasma plasminogen activator inhibitor-1 levels.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Case-Control Studies; Clopidogrel; Down-Reg | 2011 |
Aspirin non-responder status and early neurological deterioration: a prospective study.
Topics: Aged; Aspirin; Brain Ischemia; Cohort Studies; Drug Resistance; Female; Humans; Male; Middle Aged; N | 2011 |
Sex-specific differences in metabolic control, cardiovascular risk, and interventions in patients with type 2 diabetes mellitus.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Antihypertensive Agents; Aspirin; Blood Gluco | 2010 |
Effects of extended-release dipyridamole in vitro on thrombin indices measured by calibrated automated thrombography in poststroke survivors.
Topics: Aged; Aspirin; Brain Ischemia; Delayed-Action Preparations; Dipyridamole; Dose-Response Relationship | 2012 |
Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan.
Topics: Aspirin; Brain Ischemia; Cross-Sectional Studies; Databases, Factual; Drug Prescriptions; Humans; In | 2011 |
What is the best first agent to give to a patient with acute ischaemic stroke? Aspirin, heparin, clopidogrel, cilostazol or dipyridamole?
Topics: Aspirin; Brain Ischemia; Cilostazol; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Evidence-B | 2010 |
Aspirin failure in patients presenting with acute cerebrovascular ischaemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Brain Ischemia; Drug Resistance; | 2011 |
Apixaban in patients with atrial fibrillation.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemi | 2011 |
Ischemic stroke in patients receiving aspirin.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Argentina; Aspirin; Brain Ischemia; Chi-Square Dis | 2012 |
Cilostazol, not aspirin, reduces ischemic brain injury via endothelial protection in spontaneously hypertensive rats.
Topics: Animals; Aspirin; Brain Ischemia; Cerebral Cortex; Cerebrovascular Circulation; Cilostazol; Endothel | 2011 |
Patent foramen ovale may be causal for the first stroke but unrelated to subsequent ischemic events.
Topics: Adult; Aged; Aspirin; Brain Ischemia; Clopidogrel; Female; Follow-Up Studies; Foramen Ovale, Patent; | 2011 |
Acetylsalicylic acid, but not clopidogrel, inhibits therapeutically induced cerebral arteriogenesis in the hypoperfused rat brain.
Topics: Animals; Aspirin; Brain Ischemia; Cell Line; Cerebral Angiography; Cerebrovascular Circulation; Chem | 2012 |
Aspirin treatment failure and the risk of recurrent stroke and death among patients with ischemic stroke.
Topics: Aged; Aspirin; Brain Ischemia; Female; Humans; Male; Middle Aged; Multivariate Analysis; Odds Ratio; | 2013 |
Blind runner.
Topics: Adult; Angiogenesis Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Hum | 2012 |
Low-molecular-weight heparin in atherosclerotic stroke: a surprising resurrection of anticoagulants?
Topics: Antifibrinolytic Agents; Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Female; Humans; Intra | 2012 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Level of systolic blood pressure within the normal range and risk of recurrent stroke.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Benzimidazoles; Benzoates; Blood Pressure; | 2011 |
Dose-dependent effect of early antiplatelet therapy in acute ischaemic stroke.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Body Mass Index; Brain Ischemia; Clopidogrel; Dose-Response | 2012 |
Association of C3435T multi drug resistance gene-1 polymorphism with aspirin resistance in ischemic stroke and its subtypes.
Topics: Adult; Aged; Aspirin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporte | 2012 |
Clopidogrel responsiveness in stroke patients on a chronic aspirin regimen.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Drug Administration Schedule; Drug Re | 2013 |
Antiplatelet therapy for transient ischemic attack.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Clopidogrel; Cognition Disorders; | 2012 |
Clinical, neuroradiological and molecular features of a patient affected by pseudoxhantoma elasticum associated to carotid rete mirabile: case report.
Topics: Adult; Angiography, Digital Subtraction; Aspirin; Brain Ischemia; Carotid Arteries; Carotid Artery D | 2012 |
[Perioperative management of antiplatelet therapy in thoracic surgery. A survey of German hospitals].
Topics: Arterial Occlusive Diseases; Aspirin; Attitude of Health Personnel; Brain Ischemia; Clopidogrel; Com | 2012 |
[Management of acute ischemic stroke].
Topics: Aspirin; Brain Ischemia; Decompressive Craniectomy; Humans; Stroke; Thrombolytic Therapy | 2012 |
Trans fat, aspirin, and ischemic stroke in postmenopausal women.
Topics: Aged; Aspirin; Brain Ischemia; Cohort Studies; Confidence Intervals; Dietary Fats, Unsaturated; Fema | 2012 |
Novel aspirin-triggered neuroprotectin D1 attenuates cerebral ischemic injury after experimental stroke.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Docosahexaenoic Acids; In | 2012 |
Increase of toll-like receptor 4 but decrease of interleukin-8 mRNA expression among ischemic stroke patients under aspirin treatment.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Case-Control Studies; Female; Gene Expression Regu | 2012 |
Pregnancy outcome in patients with antiphospholipid syndrome after cerebral ischaemic events: an observational study.
Topics: Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Brain Ische | 2012 |
Capsular warning syndrome caused by spontaneous middle cerebral artery dissection.
Topics: Angiography, Digital Subtraction; Aspirin; Atorvastatin; Brain Ischemia; Cerebral Angiography; Diffu | 2012 |
Laboratory effect on platelet activity within 24 h of the first 300-mg oral dose of aspirin given in hospital during the acute phase of ischemic cerebral events.
Topics: Acute Disease; Administration, Oral; Aged; Aspirin; Blood Platelets; Brain Ischemia; Female; Humans; | 2012 |
Optimal platelet inhibition following acute ischemic stroke.
Topics: Aspirin; Brain Ischemia; Female; Humans; Male; Platelet Activation; Platelet Aggregation Inhibitors | 2012 |
Obesity and intracranial in-stent thrombosis.
Topics: Abciximab; Angioplasty, Balloon; Antibodies, Monoclonal; Aspirin; Body Mass Index; Brain Ischemia; C | 2013 |
Incidence of cerebral ischemic events after discontinuation of clopidogrel in patients with intracranial aneurysms treated with stent-assisted techniques.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Drug Therapy, Combina | 2012 |
Prevalence of ex vivo high on-treatment platelet reactivity on antiplatelet therapy after transient ischemic attack or ischemic stroke on the PFA-100(®) and VerifyNow(®).
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Aspirin, Dipyridamole Drug Combination; Blood Platelets; Br | 2013 |
[Postoperative cortical blindness after right upper lung lobectomy].
Topics: Anticoagulants; Aspirin; Blindness, Cortical; Brain Ischemia; Cerebellum; Cerebral Angiography; Colo | 2012 |
Symptomatic patients with intraluminal carotid artery thrombus: outcome with a strategy of initial anticoagulation.
Topics: Adult; Aged; Anticoagulants; Aspirin; Brain Ischemia; Carotid Arteries; Carotid Artery Thrombosis; C | 2013 |
Clinical and biochemical aspirin resistance in patients with recurrent cerebral ischemia.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Brain Ischemia; Drug Resistance; Female; Hum | 2013 |
Guidelines for acute ischemic stroke treatment: part II: stroke treatment.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Fibrinolytic Agents; Heparin; Humans; Platelet Aggregation | 2012 |
Timing and mechanism of ischemic stroke due to extracranial blunt traumatic cerebrovascular injury.
Topics: Adult; Angiography, Digital Subtraction; Aspirin; Brain Ischemia; Cerebral Angiography; Cerebral Art | 2013 |
Quality of acute ischemic stroke care in Thailand: a prospective multicenter countrywide cohort study.
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Chi-Square Distribution; Combined Modality Therapy; D | 2014 |
The influence of anti-platelet resistance on the development of cerebral ischemic lesion after carotid artery stenting.
Topics: Aged; Aspirin; Brain Ischemia; Carotid Arteries; Drug Resistance; Female; Humans; Male; Middle Aged; | 2013 |
Aspirin versus low-molecular-weight heparin for ischemic stroke in children: an unanswered question.
Topics: Aspirin; Brain Ischemia; Child; Clinical Trials as Topic; Dose-Response Relationship, Drug; Feasibil | 2002 |
Time lag to diagnosis of stroke in children.
Topics: Adolescent; Age Factors; Aspirin; Brain Ischemia; Child; Emergency Medical Services; Episode of Care | 2002 |
[Acetylsalicylic acid and ACE inhibitors in heart disease--a phenomenon in dogs and cats?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aspirin; Brain Ischemia; Drug Interactions; Human | 2002 |
Ischaemic stroke in young people: a prospective and long-term follow-up study.
Topics: Acenocoumarol; Adolescent; Adult; Anticoagulants; Aspirin; Brain Ischemia; Disability Evaluation; Ec | 2003 |
[Neuroprotection by aspirin in cerebrovascular pathology].
Topics: Adenosine Triphosphate; Algorithms; Amino Acid Transport System X-AG; Animals; Aspirin; Brain Ischem | 2002 |
Smoking and the risk of hemorrhagic stroke in men.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alcohol Drinking; Aspirin; beta Carotene; Body Mass Ind | 2003 |
Oral anticoagulation in patients after cerebral ischemia of arterial origin and risk of intracranial hemorrhage.
Topics: Anticoagulants; Arterial Occlusive Diseases; Asia, Southeastern; Aspirin; Brain Ischemia; Dipyridamo | 2003 |
Editorial comment: Low-dose or moderate-dose anticoagulation: dream or hope for stroke prevention?
Topics: Administration, Oral; Anticoagulants; Aspirin; Brain Ischemia; Clinical Trials as Topic; Dose-Respon | 2003 |
Anti-beta2-glycoprotein I antibodies and ischemic stroke in a 20-month-old boy.
Topics: Antibodies, Anticardiolipin; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Autoantibodies; Bas | 2003 |
Low dose aspirin after ischemic stroke associated with antiphospholipid syndrome.
Topics: Adult; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Brain Ischemia; Female; Follow-Up Studies | 2003 |
Cerebral microbleeds as a risk factor for subsequent intracerebral hemorrhages among patients with acute ischemic stroke.
Topics: Acute Disease; Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Hemorrhage; China; Cohort Stu | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2003 |
ESPRIT: safety and efficacy of oral anticoagulation--a rebuttal.
Topics: Administration, Oral; Anticoagulants; Aspirin; Brain Ischemia; Humans; International Normalized Rati | 2003 |
Acetylsalicylic acid reduces perfusion deficit in ischemic injured brain in rats.
Topics: Animals; Aspirin; Brain Ischemia; Cerebrovascular Circulation; Disease Models, Animal; Fibrinolytic | 2003 |
Should I start all my ischaemic stroke and TIA patients on a statin, an ACE inhibitor, a diuretic, and aspirin today?
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Brain Ischemia; Humans; Hydroxymethylglutaryl-CoA | 2003 |
[Protective effects and mechanism of action of aspirin on focal cerebral ischemia-reperfusion in rats].
Topics: Animals; Aspirin; Brain Ischemia; Disease Models, Animal; Epoprostenol; Male; Malondialdehyde; Neuro | 2003 |
Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study.
Topics: Antigens, CD; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; Clopidogrel; Cross-Over Studies; | 2003 |
Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events.
Topics: Aged; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Databases, Factual; Female; Hospitaliz | 2004 |
High-dose aspirin is neuroprotective in a rat focal ischemia model.
Topics: Animals; Aspirin; Brain Ischemia; Dose-Response Relationship, Drug; Male; Neuroprotective Agents; Ra | 2004 |
Increased platelet CD63 and P-selectin expression persist in atherosclerotic ischemic stroke.
Topics: Adenosine Diphosphate; Aged; Anticoagulants; Antigens, CD; Aspirin; Blood Platelets; Brain Ischemia; | 2004 |
[Efficacy and safety of treatment of acute ischemic stroke with glycoprotein IIb/IIIa receptor blocker in routine clinical practice].
Topics: Adult; Aged; Anticoagulants; Aspirin; Brain; Brain Ischemia; Carotid Arteries; Clopidogrel; Drug The | 2004 |
[Management of stroke in a ward of internal medicine. Limits and prospects].
Topics: Age Factors; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; | 2004 |
Risk factors and in-hospital outcomes in stroke and myocardial infarction patients.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Croa | 2004 |
There is no evidence that the benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events.
Topics: Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Humans; Platelet Aggregation Inhibitors; Pro | 2004 |
Circulating reticulated platelets in the early and late phases after ischaemic stroke and transient ischaemic attack.
Topics: Aged; Aspirin; Blood Platelets; Brain Ischemia; Cell Size; Dose-Response Relationship, Drug; Female; | 2004 |
Thrombin generation in non-cardioembolic stroke subtypes: the Hemostatic System Activation Study.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Biomarkers; Brain Infarction; Brain Ischemia; Coho | 2004 |
Antiplatelet drug discontinuation is a risk factor for ischemic stroke.
Topics: Aspirin; Brain Ischemia; Humans; Platelet Aggregation Inhibitors; Risk Factors; Stroke | 2004 |
Ischaemic stroke in progressive systemic sclerosis.
Topics: Aspirin; Brain Ischemia; Dysarthria; Female; Humans; Infarction, Middle Cerebral Artery; Magnetic Re | 2004 |
[Effects of aspirin on lowering plasma level of lysophosphatidic acid in cerebral ischemic patients].
Topics: Aged; Aspirin; Brain Ischemia; Female; Fibrinolytic Agents; Humans; Infant; Lysophospholipids; Male; | 2004 |
Creative cost-effectiveness analysis of CAPRIE data- dust in our eyes.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Cost-Benefit Analysis; Drug Costs; Humans; Peripheral Vascular | 2005 |
Prevalence of aspirin resistance measured by PFA-100.
Topics: Aged; Aspirin; Brain Ischemia; Cross-Sectional Studies; Drug Resistance; Female; Humans; Male; Middl | 2005 |
Anticoagulation influences long-term outcome in patients with nonvalvular atrial fibrillation and severe ischemic stroke.
Topics: Age Factors; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Female; Follow-Up S | 2004 |
Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease.
Topics: Aged; Alleles; Aspirin; Brain Ischemia; Cerebrovascular Circulation; Clopidogrel; Cohort Studies; Ex | 2005 |
Timing of aspirin and secondary preventative therapies in acute stroke: support for use of stroke units.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Brain Ischemia; Chemopre | 2005 |
Lack of antiapoptotic effects of antiplatelet drug, aspirin and clopidogrel, and antioxidant, MCI-186, against focal ischemic brain damage in rats.
Topics: Animals; Antioxidants; Antipyrine; Aspirin; bcl-2-Associated X Protein; Blotting, Western; Brain Ede | 2005 |
Clinical trials in giant cell arteritis.
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Dose-Response Relationship, Drug; Giant Cell Arte | 2005 |
Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Case-Control Studies; Coronary Artery Disea | 2005 |
Ischaemic stroke: acute-phase drug therapy. Mostly aspirin and heparin.
Topics: Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemo | 2005 |
[Prophylaxis of stroke].
Topics: Age Factors; Aged; Angioplasty, Balloon; Anticoagulants; Antihypertensive Agents; Aspirin; Atrial Fi | 2005 |
Monitoring acetylsalicylic acid effects with the platelet function analyzer PFA-100.
Topics: Aspirin; Atherosclerosis; Blood Platelets; Brain Ischemia; Cardiovascular Diseases; Clinical Trials | 2005 |
Stroke following Glenn anastomosis in a child with inherited thrombophilia.
Topics: Anastomosis, Surgical; Aspirin; Brain Ischemia; Child, Preschool; Fibrinolytic Agents; Heart Bypass, | 2006 |
Antiplatelet therapy contributes to acute deterioration of intracerebral hemorrhage.
Topics: Administration, Oral; Aged; Aspirin; Brain Ischemia; Causality; Cerebral Arteries; Cerebral Hemorrha | 2005 |
Platelets treated with ticlopidine are less reactive to unusually large von Willebrand factor multimers than are those treated with aspirin under high shear stress.
Topics: ADAM Proteins; ADAMTS13 Protein; Adult; Age Factors; Aged; Aspirin; Blood Platelets; Brain Ischemia; | 2005 |
Antiplatelet drugs in the secondary prevention after stroke: differential efficacy in large versus small vessel disease? A subgroup analysis from ESPS-2.
Topics: Aged; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Dipyridamole; Female; Humans; Male; Middle | 2006 |
Rebound inflammation and the risk of ischemic stroke after discontinuation of aspirin therapy.
Topics: Aspirin; Brain Ischemia; C-Reactive Protein; Humans; Inflammation; Platelet Aggregation Inhibitors; | 2006 |
Adherence to aspirin in secondary prevention of ischemic stroke.
Topics: Adult; Aged; Ambulatory Care; Aspirin; Brain Ischemia; Female; Follow-Up Studies; Health Care Survey | 2006 |
The risks and safety of clopidogrel in pediatric arterial ischemic stroke.
Topics: Adolescent; Aspirin; Brain Ischemia; Child; Child, Preschool; Clopidogrel; Cohort Studies; Drug Ther | 2006 |
Effects of aspirin plus alpha-tocopherol on brain slices damage after hypoxia-reoxygenation in rats with type 1-like diabetes mellitus.
Topics: alpha-Tocopherol; Animals; Antioxidants; Aspirin; Brain Ischemia; Cells, Cultured; Diabetes Mellitus | 2006 |
High prevalence of previous antiplatelet drug use in patients with new or recurrent ischemic stroke: Buffalo metropolitan area and Erie County stroke study.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Cross-Sectional Studies; Drug Therapy, Combination; Hospitaliz | 2006 |
Dipyridamole plus aspirin: the best regimen for stroke prevention after noncardioembolic focal cerebral ischemia.
Topics: Aspirin; Brain Ischemia; Delayed-Action Preparations; Dipyridamole; Drug Therapy, Combination; Human | 2006 |
Impact of metabolic syndrome on prognosis of symptomatic intracranial atherostenosis.
Topics: Aged; Aspirin; Brain Ischemia; Cohort Studies; Comorbidity; Disease Progression; Double-Blind Method | 2006 |
Dissection of cervical arteries: Long-term follow-up study of 130 consecutive cases.
Topics: Adult; Anticoagulants; Aspirin; Brain Ischemia; Carotid Artery, Internal, Dissection; Female; Humans | 2006 |
Aspirin therapy for inhibition of platelet reactivity in the presence of erythrocytes in patients with vascular disease.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Brain Ischemia; Collagen; Dose-Response Re | 2006 |
Previous use of aspirin and baseline stroke severity: an analysis of 17,850 patients in the International Stroke Trial.
Topics: Adult; Aged; Aspirin; Brain Ischemia; Cerebral Infarction; Cohort Studies; Confounding Factors, Epid | 2006 |
Long-term outcome in patients with cervical-artery dissections: There is still a lot to know.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Artery, Internal, Dissection; Humans; Platelet Aggr | 2006 |
Enhanced platelet activation by prolactin in patients with ischemic stroke.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Clopidogrel; Female; Humans; Ischemic Attack, Tran | 2006 |
ESPRIT trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Dipyridamole; Drug Interactions; G | 2006 |
ESPRIT trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Brain Ischemia; Dipyridamole; Dose | 2006 |
Viscosity, hemostasis and inflammation in atherosclerotic heart diseases.
Topics: Aged; Aspirin; Blood Viscosity; Brain Ischemia; Clopidogrel; Coronary Artery Disease; Diabetes Compl | 2006 |
The significance of incomplete stent apposition in patients undergoing stenting of internal carotid artery stenosis.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon; Aspirin; Brain Ischemia; Carotid Arteries; Carotid St | 2006 |
Does prior aspirin use reduce stroke mortality?
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Female; Fibrinolytic A | 2006 |
Antiplatelet and anticoagulant therapy in patients with giant cell arteritis.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Dose- | 2006 |
Marked prevention of ischemic brain injury by Neu2000, an NMDA antagonist and antioxidant derived from aspirin and sulfasalazine.
Topics: Animals; Antioxidants; Aspirin; Benzoates; Brain Ischemia; Cells, Cultured; Excitatory Amino Acid An | 2007 |
Clinical trials and dipyridamole formulation selection.
Topics: Aspirin; Brain Ischemia; Chemistry, Pharmaceutical; Delayed-Action Preparations; Dipyridamole; Drug | 2007 |
Effects of triflusal and aspirin in a rat model of cerebral ischemia.
Topics: Animals; Aspirin; Brain Ischemia; Disease Models, Animal; Drug Therapy, Combination; Male; Rats; Rat | 2007 |
Emerging therapies: ESPRIT.
Topics: Aspirin; Brain Ischemia; Cerebral Hemorrhage; Clinical Trials as Topic; Dipyridamole; Drug Therapy, | 2007 |
TNF-alpha and IL-8 in acute stroke and the modulation of these cytokines by antiplatelet agents.
Topics: Acute Disease; Adult; Aged; Aspirin; Brain Ischemia; Cells, Cultured; Clopidogrel; Dipyridamole; Fem | 2007 |
Interaction between magnesium sulfate and acetylsalicylic acid in the MASH trial.
Topics: Aspirin; Brain Ischemia; Central Nervous System Agents; Drug Interactions; Humans; Magnesium Sulfate | 2007 |
[The management of stroke in Phnom Penh, Cambodia].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Calcium Channe | 2007 |
Cerebral ischemia probably related to isotretinoin.
Topics: Adult; Aspirin; Brain Ischemia; Dermatologic Agents; Dipyridamole; Heparin; Humans; Isotretinoin; Ma | 2007 |
dl-3n-butylphthalide prevents stroke via improvement of cerebral microvessels in RHRSP.
Topics: Animals; Aspirin; Benzofurans; Brain; Brain Ischemia; Cerebral Arteries; Cerebrovascular Circulation | 2007 |
Effect of combination of endothelin receptor antagonist (TAK-044) and aspirin in middle cerebral artery occlusion model of acute ischemic stroke in rats.
Topics: Animals; Antioxidants; Aspirin; Brain Ischemia; Disease Models, Animal; Drug Therapy, Combination; E | 2007 |
Ischemic stroke and peripheral arterial thromboembolism in a patient with Crohn's disease: a case presentation.
Topics: Anticoagulants; Aspirin; Blood Cell Count; Blood Coagulation; Bone Marrow; Brain Ischemia; Crohn Dis | 2008 |
[Antithrombotic therapy in ischemic stroke and transient ischemic attack].
Topics: Aspirin; Brain Ischemia; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Fibrinolytic Agents; | 2007 |
Optical platelet aggregometry does not appear useful as a means of assessing the risk of recurrent vascular events in aspirin-treated patients.
Topics: Aged; Aspirin; Brain Ischemia; Drug Resistance; Electronic Data Processing; Female; Humans; Ischemic | 2008 |
Can aspirin resistance be clinically predicted in stroke patients?
Topics: Adult; Aged; Aspirin; Brain Ischemia; Cohort Studies; Drug Resistance; Female; Humans; Male; Middle | 2008 |
Neuroprotection and glutamate attenuation by acetylsalicylic acid in temporary but not in permanent cerebral ischemia.
Topics: Analysis of Variance; Animals; Aspirin; Brain Ischemia; Cerebral Infarction; Disease Models, Animal; | 2008 |
Comment on "hyperresponsiveness of platelets in ischemic stroke" by Fateh-Moghadam et al.
Topics: Adenosine Diphosphate; Arachidonic Acid; Aspirin; Biomarkers; Blood Platelets; Brain Ischemia; Epine | 2008 |
Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack.
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Combinations; Dru | 2008 |
The balance between stroke prevention and bleeding risk in atrial fibrillation: a delicate balance revisited.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Blood Coagulation Factors; Brain Ischemia; Cerebral He | 2008 |
[Antiplatelet treatment after acute and chronic ischemic heart and brain events is insufficient according to recommendations].
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Angina Pectoris; Angina, Unstable; Aspirin; | 2008 |
Cilostazol shows promise as an alternative to aspirin for patients with ischaemic stroke.
Topics: Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cilostazol; Data Interpretation, Statistical; Dose-Res | 2008 |
Effects of an electrical field and its polarity on an abnormal part of the body or organ representation point associated with a diseased internal organ, and its influence on the Bi-Digital O-Ring Test (simple, non-invasive dysfunction localization method)
Topics: Acupuncture Therapy; Adult; Aspirin; Brain Ischemia; Child; Coronary Disease; Electric Stimulation T | 1982 |
[Current status of medical treatment].
Topics: Aminophylline; Animals; Anticoagulants; Aspirin; Barbiturates; Brain Ischemia; Cerebrovascular Disor | 1980 |
Treatment of cerebral ischemia.
Topics: Aspirin; Brain Ischemia; Carotid Arteries; Dicumarol; Dipyridamole; Endarterectomy; Heart Murmurs; H | 1981 |
Diagnosis and management of ischemic stroke. Part I.--Threatened stroke and its management.
Topics: Anticoagulants; Arrhythmias, Cardiac; Aspirin; Brain Ischemia; Carotid Artery Thrombosis; Cerebral A | 1983 |
Changes of the levels of antithrombin III in patients with cerebrovascular diseases.
Topics: Adult; Aged; Antithrombin III; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cerebrovascular Disorde | 1983 |
Role of propranolol and aspirin in decreasing platelet aggregation in occlusive cerebrovascular diseases.
Topics: Aspirin; Brain Ischemia; Humans; Platelet Aggregation; Platelet Count; Propranolol | 1983 |
[Optimal dose of aspirin in ischemic cerebrovascular disorders].
Topics: Adult; Aged; Aspirin; Brain Ischemia; Female; Humans; Male; Middle Aged; Platelet Aggregation | 1983 |
[Preventive medical treatment of cerebral ischemic accidents related to atherosclerosis].
Topics: Arteriosclerosis; Aspirin; Brain Ischemia; Female; Humans; Hypertension; Male; Middle Aged; Platelet | 1984 |
[Fibrinolytic agents, anticoagulants and anti-platelet agents in the management of ischemic cerebrovascular disorders].
Topics: Aspirin; Brain Ischemia; Cerebrovascular Disorders; Endopeptidases; Humans; Ischemic Attack, Transie | 1982 |
Platelet aggregation in focal cerebral ischemia -a clinical study.
Topics: Adult; Aged; Aspirin; Brain Ischemia; Dipyridamole; Female; Humans; Ischemic Attack, Transient; Male | 1982 |
[Platelet function inhibition and anticoagulation in coronary, cerebral and peripheral arterial occlusive disease. 2. Secondary prevention].
Topics: Anticoagulants; Aspirin; Brain Ischemia; Dipyridamole; Female; Humans; Ischemic Attack, Transient; M | 1982 |
[Anti-platelet aggregation therapy and ischaemic cerebral accidents due to atheroma (author's transl)].
Topics: Anticoagulants; Arteriosclerosis; Aspirin; Brain Ischemia; Humans; Platelet Aggregation | 1982 |
[Cerebral ischemia as a complication of mitral valve prolapse].
Topics: Adult; Anticoagulants; Aspirin; Brain Ischemia; Female; Humans; Male; Mitral Valve Prolapse | 1982 |
Platelet hyperaggregability in ischemic cerebrovascular disease and effects of aspirin.
Topics: Arteries; Aspirin; Brain Ischemia; Dose-Response Relationship, Drug; Humans; Ischemic Attack, Transi | 1982 |
Therapy of ischemic cerebrovascular disease.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Arteries; Cerebrovascular Disorders; Endarterectomy | 1980 |
[Ischemic cerebro-vascular accidents: usefulness of anticoagulant and antiaggregating agents (author's transl)].
Topics: Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Dipyridamole; Humans; Plat | 1981 |
Shortened megakaryocyte-platelet regeneration time in patients with ischemic cerebrovascular disease.
Topics: Adult; Aspirin; Blood Platelets; Brain Ischemia; Cerebrovascular Disorders; Humans; Megakaryocytes; | 1981 |
Platelet aggregation induced by arachidonic acid and thromboxane generation in patients with hypertension or cerebrovascular disease.
Topics: Adolescent; Adult; Aged; Arachidonic Acids; Aspirin; Blood Platelets; Brain Ischemia; Female; Humans | 1981 |
[Multicenter studies in the USA and Canada: thrombocyte function inhibitor in ischemic cerebrovascular diseases].
Topics: Aspirin; Blood Platelets; Brain Ischemia; Canada; Female; Humans; Male; Sulfinpyrazone; United State | 1980 |
[Anti-platelet-aggregating drugs. Clinical pharmacology and therapeutic use].
Topics: Aspirin; Blood Platelet Disorders; Brain Ischemia; Clofibrate; Coronary Disease; Dipyridamole; Human | 1980 |
US national survey of physician practices for the secondary and tertiary prevention of ischemic stroke. Design, service availability, and common practices.
Topics: Aspirin; Attitude of Health Personnel; Brain Ischemia; Carotid Arteries; Cerebral Angiography; Cereb | 1995 |
Essential thrombocytemia and ischemic stroke: report of six cases.
Topics: Aged; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Female; Humans; Magnetic Resonance Imaging | 1994 |
Aspirin and delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Cerebral Infarction; Female | 1995 |
Childhood stroke at three years of age with transient protein C deficiency, familial antiphospholipid antibodies and F. XII deficiency--a family study.
Topics: Antibodies, Antiphospholipid; Aspirin; Basal Ganglia; Brain Ischemia; Child, Preschool; Diagnosis, D | 1994 |
Amaurosis fugax: prognosis and the role of acetylsalicylic acid.
Topics: Aged; Aged, 80 and over; Aspirin; Blindness; Brain Ischemia; Cerebrovascular Disorders; Female; Foll | 1994 |
Effects of viscosity and oxygen content on cerebral blood flow in ischemic and normal rat brain.
Topics: Animals; Aspirin; Autoradiography; Blood Volume; Brain Chemistry; Brain Ischemia; Cerebrovascular Ci | 1994 |
Development of aspirin resistance in persons with previous ischemic stroke.
Topics: Adenosine Diphosphate; Arachidonic Acid; Aspirin; Blood Platelets; Brain Ischemia; Cerebrovascular D | 1994 |
Diaspirin crosslinked hemoglobin (DCLHb): effect of hemodilution during focal cerebral ischemia in rats.
Topics: Animals; Aspirin; Blood Substitutes; Blood Volume; Brain Ischemia; Cerebral Infarction; Cerebrovascu | 1994 |
Safety of combination aspirin and anticoagulation in acute ischemic stroke.
Topics: Acute Disease; Aged; Anticoagulants; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Cohort Stud | 1994 |
[20,000 kg aspirin and 45 pages British Medical Journal].
Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Clinical Trials as Topic; Coronary Disease; Hu | 1994 |
Should cerebral ischemic events in cancer patients be considered a manifestation of hypercoagulability?
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Coagulation Disorders; Brain Ischemia; Cerebral Infar | 1994 |
Effect of anti-platelet therapy (aspirin + pentoxiphylline) on plasma lipids in patients of ischaemic stroke.
Topics: Adult; Aged; Aspirin; Blood Chemical Analysis; Brain Ischemia; Drug Therapy, Combination; Female; Hu | 1993 |
Effect of policosanol on cerebral ischemia in Mongolian gerbils: role of prostacyclin and thromboxane A2.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Brain Ischemia; Drug Synergism; Epoprostenol; Fatty | 1993 |
Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke.
Topics: Adult; Age Factors; Aged; Analysis of Variance; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Female | 1994 |
Ischemic stroke in patients with atrial fibrillation: effect of aspirin according to stroke mechanism. Stroke Prevention in Atrial Fibrillation Investigators.
Topics: Aged; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebrovascular Disorders; Female; Humans; Male; | 1993 |
Focal cerebral ischemia in rats. Effect of hypervolemic hemodilution with diaspirin cross-linked hemoglobin versus albumin on brain injury and edema.
Topics: Albumins; Animals; Aspirin; Brain Edema; Brain Injuries; Brain Ischemia; Cross-Linking Reagents; Hem | 1993 |
Ischemic stroke, Part 2: Optimal treatment and prevention.
Topics: Aged; Aspirin; Brain Edema; Brain Ischemia; Cerebral Infarction; Heparin; Humans; Recurrence; Risk F | 1993 |
[Myocardial infarction and cerebrovascular accident complicating papillary elastofibroma of the mitral valve].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Fibroma; Heart Neoplasms; He | 1995 |
Low-molecular-weight heparin for the treatment of acute ischemic stroke.
Topics: Acute Disease; Aspirin; Brain Ischemia; Fibrinolytic Agents; Humans; Nadroparin; Platelet Aggregatio | 1996 |
Effect of KBT-3022, a new cyclooxygenase inhibitor, on experimental brain edema in vitro and in vivo.
Topics: Animals; Arachidonic Acid; Aspirin; Brain; Brain Edema; Brain Ischemia; Cyclooxygenase Inhibitors; G | 1996 |
[Stroke in young people].
Topics: Adolescent; Adult; Aspirin; Brain Ischemia; Child; Dipyridamole; Female; Humans; Male; Middle Aged; | 1996 |
[Antiaggregant treatment for cerebral ischemia: ticlopidine versus aspirin].
Topics: Aged; Aspirin; Brain Ischemia; Carotid Arteries; Female; Humans; Male; Platelet Aggregation Inhibito | 1996 |
US National Survey of Physician Practices for the Secondary and Tertiary Prevention of Ischemic Stroke. Medical therapy in patients with carotid artery stenosis.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Carotid Stenosis; Cerebrovascular Disorders; Data Collectio | 1996 |
CAPRIE trial.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular Diseases; P | 1997 |
CAPRIE trial.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Humans; Myocardial Infarction; Peripheral Vascular Diseases; P | 1997 |
CAPRIE trial.
Topics: Aspirin; Brain Ischemia; Clopidogrel; Drug Costs; Humans; Platelet Aggregation Inhibitors; Randomize | 1997 |
Early outcome in acute ischemic stroke is not influenced by the prophylactic use of low-dose aspirin.
Topics: Aged; Aspirin; Brain Ischemia; Cause of Death; Cerebral Hemorrhage; Cerebrovascular Disorders; Femal | 1997 |
[Dosage of acetylsalicylic acid in cerebral ischemia].
Topics: Aspirin; Brain Ischemia; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Pla | 1997 |
Clinical characteristics and management of acute stroke in patients with atrial fibrillation admitted to US university hospitals.
Topics: Acute Disease; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia | 1997 |
[Anticoagulation in cerebral ischemia?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Brain Ischemia; Humans | 1997 |
Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.
Topics: Aspirin; Brain Ischemia; Cerebrovascular Disorders; Dipyridamole; Humans; Platelet Aggregation Inhib | 1997 |
Stroke recurrence among 30 days survivors of ischemic stroke in a prospective community-based study.
Topics: Aged; Angina Pectoris; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Cohort Studies; Female; F | 1997 |
Interpretation of IST and CAST stroke trials. International Stroke Trial. Chinese Acute Stroke Trial.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Hemorrhage; Heparin; Humans; Platelet Aggregation Inhibitor | 1997 |
Does daily aspirin diminish severity of first-ever stroke?
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Case-Cont | 1997 |
Thrombolytic therapy as early management of ischemic stroke.
Topics: Acute Disease; Aspirin; Brain Ischemia; Cerebral Hemorrhage; Cerebrovascular Disorders; Fibrinolytic | 1998 |
Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocyt
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Brain Ischemia; Cerebrovascular Disorders; | 1998 |
Differences in medical and surgical therapy for stroke prevention between leading experts in North America and Western Europe.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebrovascular Disorders; Endar | 1998 |
[Acetylsalicylic acid in ischemic insult].
Topics: Anticoagulants; Aspirin; Brain Ischemia; Drug Therapy, Combination; Humans; Myocardial Infarction; P | 1998 |
Clinical safety and efficacy of clopidogrel--implications of the Clopidogrel versus Aspirin in Patients at Risk of Ischemic Events (CAPRIE) study for future management of atherosclerotic disease.
Topics: Arteriosclerosis; Aspirin; Atrial Fibrillation; Brain Ischemia; Clopidogrel; Humans; Myocardial Infa | 1998 |
[Neuroprotective action of aspirin].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain; Brain Ischemia; Cerebrovascular Di | 1997 |
Subarachnoid molecular hemoglobin after subarachnoid hemorrhage in rats: effect on the area of hypoperfusion.
Topics: Analysis of Variance; Anesthetics, Inhalation; Animals; Antipyrine; Aspirin; Blood; Blood Substitute | 1998 |
Detection of microemboli distal to cerebral aneurysms before and after therapeutic embolization.
Topics: Aneurysm; Anticoagulants; Aspirin; Basilar Artery; Brain Ischemia; Carotid Artery Diseases; Carotid | 1998 |
Antipyretic therapy in acute stroke.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Heparin; Humans; Pr | 1998 |
NSA supports low-dose aspirin.
Topics: Aspirin; Brain Ischemia; Humans; Platelet Aggregation Inhibitors; United States; United States Food | 1999 |
Cumulative meta-analysis of aspirin efficacy after cerebral ischaemia of arterial origin.
Topics: Aspirin; Brain Ischemia; Humans; Meta-Analysis as Topic; Risk | 1999 |
Treatment of acute ischemic stroke: where are we?
Topics: Animals; Aspirin; Brain Damage, Chronic; Brain Ischemia; Calcium Channel Blockers; Cerebral Hemorrha | 1999 |
Application of the findings of the European Stroke Prevention Study 2 (ESPS-2) to a New Zealand ischaemic stroke cost analysis.
Topics: Aspirin; Brain Ischemia; Costs and Cost Analysis; Dipyridamole; Health Care Costs; Humans | 1997 |
Craniofacial pain followed by scalp necrosis and stroke. An unusual presentation of the primary antiphospholipid syndrome.
Topics: Aged; Antibodies, Antiphospholipid; Anticoagulants; Antiphospholipid Syndrome; Aspirin; Autoimmune D | 1999 |
Neuroprotective effects of acetylsalicylic acid in an animal model of focal brain ischemia.
Topics: Animals; Aspirin; Brain; Brain Ischemia; Cerebral Infarction; Male; Neuroprotective Agents; Rats; Ra | 1999 |
Secondary prevention after cerebral ischaemia of presumed arterial origin: is aspirin still the touchstone?
Topics: Aspirin; Brain Ischemia; Cerebral Arteries; Humans | 1999 |
Aspirin reduces experimental cerebral blood flow in vivo.
Topics: Animals; Aspirin; Brain Ischemia; Cerebrovascular Circulation; Depression, Chemical; Female; Male; R | 1999 |
Comparison of standard and alternative prehospital resuscitation in uncontrolled hemorrhagic shock and head injury.
Topics: Animals; Aspirin; Blood Substitutes; Brain Injuries; Brain Ischemia; Cerebrovascular Circulation; Em | 1999 |
Secondary prevention after cerebral ischaemia of presumed arterial origin: is aspirin still the touchstone.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain; Brain Ischemia; Humans; Secondary Preventio | 1999 |
Secondary prevention after cerebral ischaemia of presumed arterial origin: is aspirin still the touchstone.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain; Brain Ischemia; Enzyme Inhibitors; Humans; | 1999 |
Generalizing the results of clinical trials to actual practice: the example of clopidogrel therapy for the prevention of vascular events. CAPRA (CAPRIE Actual Practice Rates Analysis) Study Group. Clopidogrel versus Aspirin in Patients at Risk of Ischaemi
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; C | 1999 |
Does prior use of aspirin affect outcome in ischemic stroke?
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Case-Control Studies; Female; Humans; Male; Middle | 2000 |
Ask the doctor. Recently I read that aspirin can actually increase a person's risk for a stroke by causing bleeding in the brain. I have atrial fibrillation and my doctor wants me to take a blood thinner - if not warfarin, then at least aspirin. I've alre
Topics: Aspirin; Atrial Fibrillation; Brain Ischemia; Cerebral Hemorrhage; Humans; Platelet Aggregation Inhi | 2000 |
Alert to physicians: possible interaction of aggrenox and adenosine.
Topics: Adenosine; Aspirin; Aspirin, Dipyridamole Drug Combination; Brain Ischemia; Delayed-Action Preparati | 2000 |
Systemic lupus erythematosus associated with moyamoya syndrome.
Topics: Adolescent; Anticoagulants; Aspirin; Brain; Brain Ischemia; Carotid Artery, Internal; Carotid Stenos | 2000 |
Which patients with an ischemic stroke are likely to be helped or harmed by early aspirin treatment?
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischemia; Humans; Randomized Controlle | 2000 |
Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II).
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aspirin; Blood Pressure; Brain Ischemia; Ce | 2001 |
Heparin and aspirin in stroke.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Heparin, Low-Molecular-Weight; Humans | 2001 |
ASA or low-molecular-weight heparin in the initial management of acute ischemic stroke complicating atrial fibrillation?
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Brain I | 2001 |
Nitro-aspirin (NCX4016) reduces brain damage induced by focal cerebral ischemia in the rat.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Aspirin; Astrocytes; Brain; Brain Injur | 2001 |
Acetylsalicylic acid reduces ischemia-induced proliferation of dentate cells in gerbils.
Topics: Animals; Antimetabolites; Aspirin; Brain Ischemia; Bromodeoxyuridine; Carotid Artery, Common; Cell D | 2001 |
CURE--clopidogrel's major advance.
Topics: Aspirin; Brain Ischemia; Clinical Trials as Topic; Clopidogrel; Humans; Myocardial Infarction; Plate | 2001 |
[Antibodies to phospholipids and ischemic disorders of cerebral circulation in young age].
Topics: Adolescent; Adult; Age Factors; Alcohol Drinking; Antibodies, Antiphospholipid; Anticoagulants; Anti | 1997 |
Neuroprotective effect of aspirin by inhibition of glutamate release after permanent focal cerebral ischaemia in rats.
Topics: Adenosine Triphosphate; Animals; Aspirin; Brain; Brain Ischemia; Cerebral Infarction; Excitatory Ami | 2001 |
The effect of vasodilators on aspirin-induced antagonism of t-PA thrombolysis.
Topics: Animals; Antihypertensive Agents; Aspirin; Atenolol; Brain Ischemia; Cerebrovascular Circulation; Dr | 2001 |
[High or middle dose tinzaparin versus aspirin for the treatment of cerebral ischemic accident].
Topics: Aspirin; Brain Ischemia; Fibrinolytic Agents; Heparin, Low-Molecular-Weight; Tinzaparin | 2001 |
Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both.
Topics: Adolescent; Adult; Aspirin; Brain Ischemia; Echocardiography, Transesophageal; Female; Follow-Up Stu | 2001 |
Inhibition of glutamate release via recovery of ATP levels accounts for a neuroprotective effect of aspirin in rat cortical neurons exposed to oxygen-glucose deprivation.
Topics: Adenosine Triphosphate; Animals; Aspirin; Biological Transport; Brain; Brain Ischemia; Cell Death; C | 2002 |
Oral anticoagulant therapy for the prevention of stroke.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Humans; International Normalized Ratio; Platelet Aggregatio | 2001 |
Beta-amyloid precursor protein transgenic mice that harbor diffuse A beta deposits but do not form plaques show increased ischemic vulnerability: role of inflammation.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Aspirin; Blood Pressure; Brain; Brain Is | 2002 |
Resuscitation from severe hemorrhagic shock after traumatic brain injury using saline, shed blood, or a blood substitute.
Topics: Animals; Aspirin; Blood Substitutes; Blood Transfusion; Brain; Brain Injuries; Brain Ischemia; Carbo | 2002 |
Warfarin or aspirin for recurrent ischemic stroke.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Data Interpretation, Statistical; Hemorrhage; Humans; Plate | 2002 |
Warfarin or aspirin for recurrent ischemic stroke.
Topics: Anticoagulants; Aorta; Aspirin; Brain Ischemia; Echocardiography, Transesophageal; Humans; Platelet | 2002 |
Warfarin or aspirin for recurrent ischemic stroke.
Topics: Administration, Oral; Anticoagulants; Aspirin; Brain Ischemia; Hemorrhage; Humans; International Nor | 2002 |
Elucidation of the thromboregulatory role of CD39/ectoapyrase in the ischemic brain.
Topics: Adenosine Triphosphatases; Animals; Antigens, CD; Apyrase; Aspirin; Brain Ischemia; Disease Models, | 2002 |
Warfarin-Aspirin Recurrent Stroke Study (WARSS) trial: is warfarin really a reasonable therapeutic alternative to aspirin for preventing recurrent noncardioembolic ischemic stroke?
Topics: Anticoagulants; Aspirin; Brain Ischemia; Data Interpretation, Statistical; Embolism; Endpoint Determ | 2002 |
[Serotonin content in the thrombocytes and the effect of acetylsalicylic acid on its rate of liberation in ischemic stroke].
Topics: Absorption; Adult; Aged; Aspirin; Blood Platelets; Brain Ischemia; Cerebrovascular Disorders; Dose-R | 1979 |
Trials of antiplatelet drugs: some methodological considerations.
Topics: Aspirin; Brain Ischemia; Cerebrovascular Disorders; Coronary Disease; Drug Therapy, Combination; Fem | 1979 |
Focal cerebral ischemia in rats: effect of hemodilution with alpha-alpha cross-linked hemoglobin on CBF.
Topics: Animals; Aspirin; Brain; Brain Ischemia; Cerebrovascular Circulation; Cross-Linking Reagents; Diseas | 1992 |
[Changes in EEG and higher nervous activity of rats during cerebral anti-ischemic protection by acelysin].
Topics: Animals; Anti-Infective Agents; Aspirin; Brain; Brain Ischemia; Conditioning, Classical; Drug Combin | 1992 |
Why test antiplatelet therapy in acute ischaemic stroke and how can this be done?
Topics: Acute Disease; Aspirin; Brain Ischemia; Clinical Trials as Topic; Heparin; Humans; Platelet Aggregat | 1992 |
[Anti-ischemic protection of the brain using water-soluble form of aspirin-acelisin].
Topics: Animals; Aspirin; Brain Ischemia; Rats; Rats, Inbred Strains; Solubility; Time Factors | 1992 |
Platelet activity and stroke severity.
Topics: Aged; Aspirin; Blood Platelets; Brain Ischemia; Calcium; Cardiovascular Agents; Collagen; Disease Su | 1992 |
Cerebral ischemia associated with anticardiolipin antibodies.
Topics: Adult; Aged; Antiphospholipid Syndrome; Aspirin; Autoantibodies; Brain Ischemia; Cardiolipins; Cereb | 1992 |
[Drug treatment of ischemic disturbances of circulation in the brain].
Topics: Aspirin; Brain Ischemia; Dipyridamole; Humans; Ticlopidine | 1990 |
[Ulcer prevention in therapy with low-dose acetylsalicylic acid?].
Topics: Aspirin; Brain Ischemia; Coronary Disease; Drug Therapy, Combination; Histamine H2 Antagonists; Huma | 1991 |
[Treatment of acute manifestation of hemichorea with aspirin. A case report].
Topics: Aged; Aged, 80 and over; Anesthesia, General; Aspirin; Brain Ischemia; Carotid Stenosis; Chorea; Cor | 1991 |
Effects of triflusal and acetylsalicylic acid on microthrombi formation in experimental brain ischemia.
Topics: Animals; Aspirin; Brain Ischemia; Cerebral Arteries; Intracranial Embolism and Thrombosis; Male; Pla | 1991 |
Spasm of the near reflex associated with cerebrovascular accident.
Topics: Accommodation, Ocular; Aged; Aspirin; Atropine; Brain Ischemia; Cerebral Infarction; Diplopia; Femal | 1990 |
Mechanism of stroke in patients taking aspirin.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Cerebral Infarction; Cerebrovascular Disord | 1990 |
Short-term outcome of medically treated patients with transient ischemic attacks, reversible ischemic neurologic deficits and strokes with minimum residuum.
Topics: Anticoagulants; Aspirin; Brain Ischemia; Dicumarol; Dipyridamole; Drug Therapy, Combination; Female; | 1985 |
Combination therapy with low-dose aspirin and ticlopidine in cerebral ischemia.
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aged; Aged, 80 and over; Aspirin; beta-Thromboglobulin; Blood P | 1989 |
[The effectiveness of antiplatelet therapy in ischemic cerebrovascular attacks in the chronic stage].
Topics: Aspirin; Brain Ischemia; Dipyridamole; Female; Hemiplegia; Humans; Male; Middle Aged; Pentoxifylline | 1989 |
Effect of low dose acetylsalicylic acid upon plasma thromboxane B2 levels and platelet aggregation in ischemic stroke patients.
Topics: Adenosine Diphosphate; Aged; Aspirin; Brain Ischemia; Cerebrovascular Disorders; Female; Humans; Mal | 1989 |
Risk associated with heparin withdrawal in ischaemic cerebrovascular disease.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Drug Therapy, Combination; Female; Heparin; | 1989 |
Individually controlled aspirin in the long-term treatment of patients with chronic arterial diseases.
Topics: Adenosine Diphosphate; Arteriosclerosis; Aspirin; Blood Platelets; Brain Ischemia; Coronary Disease; | 1989 |
[Antiplatelet effects of combination therapy with low-dose aspirin and ticlopidine in cerebral ischemia].
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Drug Therapy, Combination; Female; Humans; | 1989 |
Low dose aspirin and its antithrombotic effect in ischaemic stroke patient.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Drug Administration Schedule; Female; Human | 1989 |
[Ditazol in the therapy of ischemic cerebrovascular diseases. Clinical results and laboratory experiments (22-to-34-month clinical follow-up)].
Topics: Adenosine Diphosphate; Adult; Aged; Aspirin; Brain Ischemia; Collagen; Epinephrine; Female; Humans; | 1985 |
[Ischemic cerebrovascular disease: treatment with various anti-platelet aggregation drugs. Clinical follow-up of 80 patients (22-34 months)].
Topics: Adenosine Diphosphate; Aspirin; Brain Ischemia; Dipyridamole; Female; Humans; Isoxsuprine; Male; Oxa | 1985 |
Mitral valve prolapse and thromboembolic disease in pregnancy: a case report.
Topics: Adult; Aspirin; Brain Ischemia; Contraceptives, Oral; Dipyridamole; Drug Therapy, Combination; Embol | 1988 |
Whole blood platelet function in acute ischemic stroke. Importance of dense body secretion and effects of antithrombotic agents.
Topics: Acute Disease; Adult; Aspirin; Blood Platelets; Brain Ischemia; Cerebrovascular Disorders; Dipyridam | 1989 |
[Pharmacological and therapeutic features of cerebral ischemic conditions].
Topics: Aspirin; Blood Flow Velocity; Blood Viscosity; Brain Ischemia; Cerebrovascular Circulation; Combined | 1988 |
[Alternating hemiplegia in childhood. Clinical report and single photon emission computed tomography study].
Topics: Acetazolamide; Aspirin; Brain Ischemia; Cerebral Cortex; Child, Preschool; Chloral Hydrate; Drug The | 1988 |
Effect of acetylsalicylic acid on urinary excretion of prostaglandin E in stroke patients.
Topics: Arginine Vasopressin; Aspirin; Brain Ischemia; Dose-Response Relationship, Drug; Humans; Inappropria | 1986 |
Validation of cognitive and functional assessment instruments in vascular dementia.
Topics: Aged; Aged, 80 and over; Aspirin; Brain Ischemia; Dementia; Double-Blind Method; Female; Humans; Mal | 1987 |
Comparison of the effect of acetylsalicylic acid on platelet function in male and female patients with ischemic stroke.
Topics: 6-Ketoprostaglandin F1 alpha; Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Brain Ischemia; | 1987 |
[Remote development of transient ischemic attack, reversible ischemic neurologic deficit and infarct with minimum residual damage. Prospective study of 149 patients treated medically].
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Brain Ischemia; Cerebral Infarction; Female | 1987 |
Studies of platelet hyperactivity in patients with ischemic cerebrovascular diseases: IV. Determination of the optimal dosage of aspirin by measuring plasma salicylate level.
Topics: Aged; Aspirin; Blood Platelets; Brain Ischemia; Female; Humans; Male; Middle Aged; Salicylates; Sali | 1987 |
[Extra-intracranial bypass operation. Morphologic studies of the feasibility of intervention and concomitant medication].
Topics: Adult; Aspirin; Blood Vessel Prosthesis; Brain Ischemia; Cerebral Revascularization; Combined Modali | 1986 |
Effect of incremental doses of aspirin on bleeding time, platelet aggregation and thromboxane production in patients with cerebrovascular disease.
Topics: Adult; Aged; Aspirin; Bleeding Time; Brain Ischemia; Cerebrovascular Disorders; Dose-Response Relati | 1985 |
Peripheral vascular disease: treatment and referral of the elderly. Part II.
Topics: Aged; Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Carotid Artery Diseases; Cerebrovascular | 1985 |
[Medical treatment of ischemic cerebrovascular disease].
Topics: Anticoagulants; Aspirin; Brain Ischemia; Cerebral Infarction; Humans; Ischemic Attack, Transient; Pl | 1985 |